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The PI3K/AKT/mTOR (PAM) pathway is a major driver of cell growth, proliferation and 
survival, and is frequently dysregulated in cancer. AKT, a member of the AGC family of 
serine/threonine kinases, is a key signalling node within the PAM pathway, and as such, 
an attractive therapeutic target for the treatment of cancer. AT13148 is an ATP-
competitive inhibitor of AKT, currently in phase 1 clinical trial, which also potently 
inhibits several other clinically relevant AGC kinases, such as ROCK1/2 and p70S6K. 
Acquired resistance to kinase inhibitors has been a barrier to their success, but 
resistance to AT13148 is yet to be defined. Therefore, the aim of this thesis was to 
investigate mechanisms of acquired AT13148 resistance, using preclinical cell line 
models.  
Isogenic AT13148 resistant sub-clones were generated from the A2780 human ovarian 
carcinoma cell line, which harbours mutations in the PAM pathway. In these sub-clones, 
phosphorylation of S6RP (p70S6K substrate) and PRAS40 (AKT substrate) was refractory 
to AT13148 treatment, concurrent with increased ERK 1/2 phosphorylation, when 
compared to the parental A2780 cell line. Two of the resistant sub-clones were 
sensitised to AT13148 on exposure to the ERK inhibitor GDC-0994, with the combination 
of AT13148 and GDC-0994 shown to restore the inhibition of S6RP phosphorylation. This 
implicates ERK 1/2 as a driver of AT13148 resistance, potentially via the reactivation of 
the PAM pathway and suggests ERK inhibition as a strategy to overcome this resistance. 
A loss of DUSP6 expression, an ERK 1/2 phosphatase, was subsequently detected in 
AT13148 resistant sub-clones, but DUSP6 loss alone was not shown to cause a sustained 
increase in ERK 1/2 phosphorylation or confer AT13148 resistance, suggesting other 
factors are required for AT13148 resistance. 
In conclusion, the results presented in this thesis identify ERK 1/2 as a driver of AT13148 
resistance. This discovery has the potential to aid the ongoing clinical development of 
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1. Introduction 
1.1. Introduction to cancer 
Cancer is a major public health problem and is expected to rank as the leading cause of 
death and the most important barrier to increasing life expectancy in the 21st century 
(Bray et al., 2018; Siegel et al., 2019). According to the World Health Organisation (WHO) 
it is estimated that cancer is the 1st or 2nd leading causing of premature death (death 
before 70) in 91 out of 172 countries worldwide (Bray et al., 2018). Furthermore, 
worldwide in 2018, it was estimated that there were 18.1 million new cancer cases and 
9.6 million cancer deaths (Bray et al., 2018). In the UK, it has been predicted that > 50% 
of adults under the age of 65 will be diagnosed with cancer at some point in their 
lifetimes (Ahmad et al., 2015). Therefore, furthering our understanding of cancer; 
improving prevention, diagnosis and treatment, will be key to enhancing quality of life 
and increasing life expectancy in the 21st century.  
Cancer cannot not be defined as a singular disease, but rather a collection of diseases 
that share a similar phenotype of uncontrolled cellular growth and proliferation, with 
invasion into surrounding local tissue, and in many cases, metastasis from primary sites 
to other organs. It is thought that normal cells become cancerous and gain the 
aforementioned phenotype, by the acquisition of several hallmarks of cancer, such as: 
sustained proliferative signalling, evading growth suppressors, resisting cell death, 
inducing angiogenesis and avoiding immune destruction (Hanahan and Weinberg, 2011; 
summarised in Figure 1.1). However, it is worth noting, that cancer cells need not 
acquire all these hallmarks, for example, whilst most tumours induce some form of 
angiogenesis, and require this for their growth, a minority of tumours grow in a purely 
non-angiogenic manner (Bridgeman et al., 2017; Donnem et al., 2018).  
The process in which normal cells become cancerous, acquiring the hallmarks of cancer, 
is known as oncogenesis (also known as tumourigenesis or carcinogenesis). There are 
several theories has to how oncogenesis may occur, but the most prevalent, and widely 
accepted, is the somatic mutation theory (SMT), although other theories do exist such 
as the tissue organisation field theory of cancer, the metabolic theory of cancer and the 
cancer stem cell theory of cancer (Blagosklonny, 2005; Baker, 2015; Seyfried, 2015; 
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Tomasetti and Vogelstein, 2015; Afify and Seno, 2019). SMT states that cancer arises 
from a single somatic cell, from the stepwise accumulation of genetic and epigenetic 
alterations, which liberates cancer cells from the homeostatic mechanisms that govern 
normal cell proliferation (Blagosklonny, 2005). Thus, according to SMT, cancer can be 
described as a Darwinian process, in which oncogenesis is a succession of clonal 
expansions, each triggered by the chance acquisition of an enabling mutant phenotype 
(Hanahan and Weinberg, 2011). Inherited mutations, such as those in the APC and 
BRCA1 genes, found in familial colorectal and breast cancer respectively, may also 
contribute to oncogenesis, in combination with somatic mutations (Stella et al., 1992; 









Figure 1.1: The hallmarks of cancer. Schematic diagram highlighting the “hallmarks of cancer”. Taken 
from Hanahan and Weinberg, 2011 
Due to the requirement of cancer cells to successively accumulate mutations, genomic 
instability (a hallmark of cancer, Figure 1.1) is seen in nearly all types of cancer, and is 
thought to be the main driver of the acquisition of the hallmarks of cancer (Negrini et 
al., 2010; Hanahan and Weinberg, 2011; Seyfried, 2015). Genomic instability can exist in 
a number of different ways in a cell, including chromosomal instability, microsatellite 
DNA instability and increased frequency of base-pair mutations (Negrini et al., 2010). 
However, normal healthy cells have a remarkably low rate of genetic mutation 
(approximately one mutation is introduced into the genome during each division cycle), 
due to the efficiency of DNA repair pathways in detecting and repairing DNA damage 
(Salk et al., 2010; Hanahan and Weinberg, 2011). Therefore, in order for genomic 
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instability to arise, cancer cells often have an increased rate of DNA damage and genetic 
mutation (Negrini et al., 2010; Salk et al., 2010). This can be caused via exposure to 
mutagens, both internal and environmental, such as tobacco smoke, reactive oxygen 
species (ROS), polycyclic aromatic hydrocarbons (PAH) and ultraviolet light, which 
induce DNA damage (Anand et al., 2008; Hanahan and Weinberg, 2011). As mentioned, 
there are cellular mechanisms to repair damaged DNA, but the increased mutational 
burden may prevent this damage from being repaired correctly, prior to cell division. 
Thus, an alteration to the DNA may become permanently fixed into the genome, 
potentially contributing to oncogenesis. Alternatively, defects within DNA repair 
pathways may also contribute to genomic instability, either alone or in combination with 
exposure to mutagens (Hanahan and Weinberg, 2011).  
Mutations in cancer cells which provide a selective growth advantage, promoting 
oncogenesis, are known as driver mutations, whereas mutations that do not are known 
as passenger mutations (Pon and Marra, 2015). It is has been revealed that driver 
mutations are limited to subset of ~140 genes, with a typical tumour containing only 
two to eight “driver gene” mutations, thus the vast majority of mutations in tumours 
are passenger mutations (Vogelstein et al., 2013). These driver gene mutations can be 
sub-categorised into oncogenes and tumour suppressor genes (TSGs). Oncogenes, 
which are referred to as proto-oncogenes in their non-mutated state, are genes which 
when activated by mutation confer a selective growth advantage to the cell, whereas 
TSGs, are genes which when inactivated by mutation confer a selective growth 
advantage (Vogelstein et al., 2013). Oncogenes, tend be activated by focal 
amplifications, which increases protein expression, or by missense mutations, at a 
limited number of codons, which increases protein activity (Pon and Marra, 2015). For 
example, RAS is an oncogene which is activated in ~27% of cancers, often by a missense 
mutation (such as G12V and Q61K), which constitutively activate RAS by causing a loss 
of GTPase activity, leading to sustained proliferative signalling (Prior et al., 2012; Hobbs 
et al., 2016). In contrast, TSGs tend to be inactivated by focal deletions, and splice-site, 
nonsense and frameshift mutations across the entire length of the gene, which decrease 
protein expression or produce a truncated protein, but can also be inactivated by 
missense mutations that produce an inactive protein (Kern and Winter, 2006; Pon and 
Marra, 2015). For example, the TSG TP53, which is an important protein in sensing DNA 
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damage, is frequently mutated in cancer (~50% of cancers) by mutations which cause a 
loss of TP53 function (Rivlin et al., 2011; Perri et al., 2016). Additionally, it should be 
considered that epigenetic mechanisms may also contribute to the respective activation 
and inactivation of oncogenes and TSGs (Kwon and Shin, 2011). The stepwise 
accumulation of activated oncogenes and inactivated TSGs causes healthy somatic cells 
to gradually acquire the hallmarks of cancer (Figure 1.1), which leads to uncontrolled 
growth, invasion, metastasis, and ultimately, in many patients, death.  
1.2. Oncogene addiction and targeted therapies 
Despite the complexity of cancer, through the progressive accumulation of genetic and 
epigenetic abnormalities in genes with diverse functions, it has been observed that the 
removal of one or two of these abnormalities can drastically inhibit the growth of cancer 
cells (Weinstein and Joe, 2008). Much of the initial evidence for this came from cancer 
cell line models where, in many cases, the knockdown in the expression of a singular 
oncogene profoundly decreased cancer cell line growth. For example, Colomer and 
colleagues (Colomer et al., 1994) demonstrated that the knockdown of the oncogene 
ERBB2 caused up to a 60% decrease in the DNA synthesis and growth of ERBB2 amplified 
breast cancer cell lines. A similar phenomenon was observed in pancreatic cancer; 
knockdown of the KRAS gene was shown to exclusively inhibit the growth of pancreatic 
cancer cell lines that expressed a mutated form of KRAS (Aoki et al., 1997). Furthermore, 
the removal of a singular oncogene, via various techniques, was also shown to inhibit 
tumour growth in a number of mouse models (Weinstein and Joe, 2006). 
This led to the concept of “oncogene addiction”, a term created by Dr Bernard Weinstein 
in the early 21st century, which emphasises the apparent dependency of some cancers 
on one or two oncogenes for their growth and survival (Weinstein, 2000, 2002; 
Weinstein and Joe, 2006). The notion that cancers could be dependent on a singular 
oncogene was of immense therapeutic interest, as it suggested that an oncogene-
targeted therapy (targeted therapy) could be used to successfully treat cancer. 
Furthermore, since normal healthy cells are not “oncogene addicted”, it was considered 
that targeted therapies may have a greater therapeutic window, and much lower 
toxicity, when compared to traditional chemotherapeutic agents.  
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This therapeutic potential was realised with the small molecule tyrosine kinase inhibitor 
(TKI) imatinib, which was the first targeted therapy to be clinically approved (in 2001), 
initially used to treat Philadelphia chromosome positive (ph+; a 9:22 chromosomal 
translocation) chronic myeloid leukaemia (CML; Pagliarini, Shao and Sellers, 2015). The 
rationale for the use of imatinib in ph+ CML was based upon pre-clinical data which 
showed that ph+ CML cells were “addicted” to the oncogene BCR-ABL (a fusion protein 
in which the tyrosine kinase ABL is constitutively active), for their growth and survival 
(Daley et al., 1990; Lugo et al., 1990; Huettner et al., 2000). Therefore, imatinib was 
developed to inhibit the tyrosine kinase activity of ABL, exploiting the oncogene 
addiction of ph+ CML cells. Indeed, this proved a successful approach, as ph+ CML 
patients treated with imatinib have an significant increase in survival, when compared 
to the previously established first-line therapy (interferon-α combined with low dose 
cytarabine; Henkes, van der Kuip and Aulitzky, 2008). Subsequently, many targeted 
therapies have now passed through clinical trials, and are currently used in the clinic to 
treat a number of different cancers (Pagliarini et al., 2015). 
In addition to imatinib, many of the targeted therapies that are used in the clinic or 
currently in clinical development, are also small molecule kinase inhibitors (Bhullar et 
al., 2018). As of 2018, 37 kinase inhibitors had received FDA approval for the treatment 
of cancer and 150 kinase-targeted drugs were in clinical trials (Bhullar et al., 2018). 
Kinases have been an attractive therapeutic target for cancer due the availability of ATP 
and co-factor binding pockets within kinases, which small molecule inhibitors can be 
designed to target with relative ease (Roskoski, 2016, 2019). Furthermore, many of the 
oncogenes that cancer cells become “addicted” to are kinases or function within 
signalling pathways which contain kinases (Weinstein and Joe, 2008; Gross et al., 2015). 
The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
pathway (PAM pathway), is one such pathway that is frequently implicated in oncogene 
addiction, and thus targeted by small molecule kinase inhibitors to treat cancer (Martini 
et al., 2013; Fruman et al., 2017; Revathidevi and Munirajan, 2019).  
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1.3. The PAM pathway 
1.3.1. Function and regulation  
As with other signalling pathways, the function of the PAM pathway is to respond to 
extracellular stimuli, and, through intracellular signalling, co-ordinate an adaptive 
cellular response to the external environment in which a cell is situated (Hassan et al., 
2013). Therefore, the PAM pathway is activated by range of extracellular stimuli 
including growth factors, integrins, hormones and neuropeptides, acting through their 
cognate receptors (e.g. receptor tyrosine kinases and G-protein coupled receptors 
;Acosta-Martínez, 2012; Hassan et al., 2013). In responding to extracellular stimuli the 
PAM pathway regulates a diverse array of biological functions such as cell metabolism, 
growth, proliferation, survival, angiogenesis and protein synthesis, many of which 
regulate the hallmarks of cancer (Liu, Cheng, Thomas M Roberts, et al., 2009; Hanahan 
and Weinberg, 2011; Hassan et al., 2013).  
Within the context of cancer, the PAM pathway is often activated by receptor tyrosine 
kinases (RTKs) in response to growth factor stimulation (Liu, Cheng, Thomas M Roberts, 
et al., 2009). Growth factors bind to extracellular regions of RTKs and stimulate RTK 
activation, by inducing RTK dimerization and trans-autophosphorylation of tyrosine 
residues within the intracellular tyrosine kinase domain (TKD) of RTKs (Du and Lovly, 
2018). This facilitates the binding of class 1A phosphoinositide 3-kinases (PI3Ks) to 
activated RTK’s, either directly or mediated via adapter proteins (e.g. insulin receptor 
substrate 1: IRS), inducing PI3K activation (Fruman et al., 2017).  
Class 1A PI3Ks are heterodimers, which consist of a p110 catalytic subunit, of which 
there are three isoforms (p110α, p110β, p110δ; respectively encoded by the genes 
PIK3CA, PIK3CB and PIK3CD) and a p85 regulatory subunit (encoded by the genes PIK3R1, 
PIK3R2 and PIK3R3; Liu et al., 2009). The p85 subunit facilitates binding to phospho-
tyrosine residues on activated RTKs (and adapter proteins) which is mediated by Src 
homology-2 (SH2) domains within p85 subunits. It is binding of p85 to activated RTKs 
that activates PI3K, by relieving inhibitory contacts between p85 and p110 subunits 
(Fruman et al., 2017). Furthermore, p110 catalytic subunits all contain a RAS binding 
domain, which in p110α and p110δ facilitates binding to activated RAS, and in p110β, 
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the binding to activated RAC1/CDC42 (Gupta et al., 2007; Fritsch et al., 2013; Fruman et 
al., 2017). This is thought to be required for the optimal activation of class 1A PI3Ks. 
Upon activation by RTKs, PI3K is localised proximal to the plasma membrane, where it 
phosphorylates PI(4,5)P2 (phosphatidylinositol-3,4-bisphosphate) to PI(3,4,5)P3 
(phosphatidylinositol-3,4,5-triphosphate), which acts as a 2nd messenger, facilitating the 
formation of membrane signalling complexes and activating multiple downstream 
signalling pathways (Figure 1.2; Liu, Cheng, Thomas M. Roberts, et al., 2009; Fruman et 
al., 2017). The phosphorylation of PI(4,5)P2 to PI(3,4,5)P3 can be reversed by  the 
phosphatase and tensin homolog (PTEN), which dephosphorylates PI(3,4,5)P3 to 
PI(4,5)P2, thus acting as a major negative regulator of the PAM pathway and a tumour 
suppressor (Figure 1.2; Chen et al., 2018).  
Crucially, the formation of PI(3,4,5)P3 induces the activation of the serine/threonine 
kinase AKT (of which there are three isoforms: AKT1, AKT2, AKT3), a major signalling 
node within the PAM pathway; AKT contains a pleckstrin homology (PH) domain which 
facilitates binding to PI(3,4,5)P3 and recruitment to the plasma membrane (Manning 
and Toker, 2017). Once localised to the plasma membrane, AKT is phosphorylated by 
phosphoinositide-dependent kinase-1 (PDK1) and mTOR complex 2 (mTORC2), inducing 
the full activation of AKT  (Figure 1.2). Upon activation, AKT can phosphorylate over 100 
substrates, regulating much of the functional output of the PAM pathway (Manning and 
Cantley, 2007; Fruman et al., 2017; Manning and Toker, 2017). Examples of AKT 
substrates include: glycogen synthase kinase 3β (GSK3β) which regulates cell cycle 
progression and metabolism; the Forkhead Box O (FoXO) family of transcription factors, 
Bcl-2 associated death promoter (BAD), and nuclear factor-kappa B (NFκB), which 
regulate cell survival; and the proline rich AKT substrate of 40 kDa (PRAS40) and 
tuberous sclerosis complex 2 (TSC2), which regulate protein synthesis (Figure 1.2; 
Manning and Cantley, 2007; Liu, Cheng, Thomas M Roberts, et al., 2009; Fruman et al., 
2017; Manning and Toker, 2017).  
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Figure 1.2: The PAM pathway. Diagram highlights some the key components of the PAM pathway and 
the cellular functions that they regulate. Black arrows represent positive regulation and block-headed 
arrows represent negative regulation. Image adapted from Liu et al., 2009.  
AKT also induces the activation of mTOR complex 1 (mTORC1), which is mediated by the 
inhibitory phosphorylation of PRAS40 and TSC2; PRAS40 functions as an inhibitory 
subunit of mTORC1 and TSC2 forms a complex with TSC1 (the tuberous sclerosis 
complex), which functions as a GTPase activating protein (GAP) of RAS homolog 
enriched in brain (RHEB), a positive regulator of mTORC1 activation (Figure 1.2; Inoki et 
al., 2002, 2003; Sancak et al., 2007). mTORC1 is a multi-subunit protein, in which kinase 
activity is derived from its mTOR serine/threonine kinase subunit (Laplante and Sabatini, 
2012). Upon activation, mTORC1 phosphorylates numerous substrates that promote 
anabolic metabolism, such as protein synthesis, supporting cell growth and proliferation 
(Fruman et al., 2017). The phosphorylation of p70 ribosomal S6 kinase (p70S6K) and the 
eukaryotic initiation factor-4E (eIF4E)-binding proteins (4E-BPs), by mTORC1, play an 
important role in the regulation of protein synthesis by mTORC1 (Roux and Topisirovic, 
2018). Upon phosphorylation and activation by mTORC1, p70S6K can phosphorylate and 
regulate multiple components of the translational machinery, such as S6 ribosomal 
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protein (S6RP; Figure 1.2; Fenton and Gout, 2011). The phosphorylation of 4E-BPs, by 
mTORC1, prevents 4E-BPs binding to eIF4E, enabling eIF4E to bind to eIF4G and eIF4A, 
forming a cap-binding translation initiation complex (Figure 1.2; Fruman et al., 2017; 
Roux and Topisirovic, 2018). 
1.3.2. PAM pathway activation in cancer      
Due to the role of the PAM pathway in regulating growth, proliferation and survival (as 
well as other hallmarks of cancer), mutations in this pathway are common in cancer, and 
it is considered to be one of the most frequently mutated pathways in cancer (Sanchez-
Vega et al., 2018). Indeed, it was revealed in a meta-analysis of cancer genome studies, 
that PIK3CA and PTEN were respectively the 2nd and 3rd most highly mutated genes in 
human cancers (Lawrence et al., 2014). In general, these mutations act to hyperactivate 
the PAM pathway, liberating it from homeostatic/feedback control mechanisms, driving 
oncogenesis.  
The majority of mutations in PIK3CA (which encodes the catalytic subunit p110α) occur 
within two mutational hotspots: E542K/E454K and H1047R, which act to cause a 
constitutive increase in kinase activity (Liu et al., 2014). E542K/E454K mutations disrupts 
the inhibitory interface between p110α and p85 regulatory subunits, whereas H1047R 
enhances the interaction of p110α with the plasma membrane, independent of 
association with RAS (Liu et al., 2014; Fruman et al., 2017). PIK3CA mutations are 
particularly common in breast and endometrial cancers, where it is  mutated in ~27% 
and ~24% of patients respectively (Liu, Cheng, Thomas M Roberts, et al., 2009). 
Mutations in regulatory subunits and other catalytic subunits, which increase PI3K 
activity and hyperactivate the PAM pathway, also occur, albeit to a lesser extent (Liu, 
Cheng, Thomas M. Roberts, et al., 2009; Fruman et al., 2017). Alternatively, p110 
catalytic subunits may be amplified in cancer, promoting hyperactivation of the PAM 
pathway. For example, the PIK3CA gene has been shown to be amplified in 69% of 
cervical cancer patients (Liu, Cheng, Thomas M Roberts, et al., 2009).  
Since PTEN functions as a major tumour suppressor of the PAM pathway, cancer-
associated mutations of PTEN usually cause a loss of function/expression of PTEN. In 
many cancers there is a loss of heterozygosity (LOH) of PTEN, for example in prostate 
cancer and glioblastoma, where ~30% patients have LOH of PTEN (Liu, Cheng, Thomas 
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M Roberts, et al., 2009). It has also been shown that missense mutations, such as C124S 
and G129E mutations, can abrogate the lipid phosphatase activity of PTEN (Molinari and 
Frattini, 2014). However, it should be noted that PTEN expression is frequently shown 
to be downregulated in cancer in the absence of genetic loss or mutation, suggesting 
that epigenetic, transcriptional and post-transcriptional regulation of PTEN expression 
is involved in loss of PTEN expression, and thus hyperactivation of the PAM pathway 
(Carracedo et al., 2011).  
Hyperactivation of RTKs can also contribute to induction of PAM pathway activity in 
cancer, since, as discussed in section 1.3.1, RTKs are well-known regulators of the PAM 
pathway. A diverse array of mutations can cause RTK hyperactivation, including RTK 
amplification, amplification of growth factor genes (which act as ligands of RTKs) and 
gain-of-function missense mutations in RTKs. For example, the gene ERBB2, which 
encodes human epidermal growth factor receptor 2 (HER2), has been shown to be 
amplified in a number of different cancers including breast and ovarian cancer, where 
15-30% of patients have an ERBB2 amplification (Iqbal and Iqbal, 2014). In addition, the 
epidermal growth factor receptor (EGFR) has been shown to be mutated in ~32% of non-
small cell lung carcinoma (NSCLC) patients, often by gain-of-function mutations 
(Prabhakar, 2015; Zhang et al., 2016). However, the hyperactivation of RTKs does not 
exclusively cause an increase in PAM pathway activity, as RTKs are known to regulate a 
number of signalling pathways, such as the RAS regulated RAF-MEK-ERK pathway (the 
mitogen activated protein kinase [MAPK] pathway) (Kirouac et al., 2016; Du and Lovly, 
2018) 
Mutations that cause the hyperactivation of RTKs and PI3K, or loss of PTEN function, all 
act to hyperactivate the PAM pathway by increasing the cellular pool of PI(3,4,5)P3, thus 
causing an increase in the activation of downstream effector kinases. However, 
mutations may also occur in downstream kinases of the PAM pathway, albeit to a lesser 
extent than upstream regulators (Fruman et al., 2017). For example, AKT1-3 have been 
shown to be mutated in approximately 3-5% of cancers, with the most common being 
an E17K missense mutation (Carpten et al., 2007; Davies et al., 2008; Yi and Lauring, 
2016). This mutation occurs in the PH domain of AKT and causes constitutive localisation 
to the plasma membrane, therefore constitutive phosphorylation and activation, 
independent of PI3K activation (Carpten et al., 2007; Davies et al., 2008; Yi and Lauring, 
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2016). AKT1-3 have also been shown to be amplified in cancer, particularly AKT2, which 
is amplified in ~30% of patients with head and neck squamous cell carcinoma (HNSCC; 
Pedrero et al., 2005). In addition, gain of function missense mutations have also been 
reported in the mTOR gene, MTOR, inducing hyperactive mTORC1 and mTORC2, but 
these mutations are very rare (Grabiner et al., 2014; Murugan et al., 2019).  
Whilst mutations are much rarer in MTOR and AKT, when compared to upstream PAM 
pathway components (e.g. PIK3CA mutations), mTOR and AKT are still found to be 
frequently hyperactivated in tumours. Increased AKT activity has been reported in ~40% 
of breast, ovarian, prostate and gastric cancers, and mTORC1 signalling is thought to be 
deregulated in ~80% of human cancers (Menon and Manning, 2008; Cargnello et al., 
2015; Revathidevi and Munirajan, 2019). This contrast between hyperactivation and 
rarity of activating mutations, is due the aforementioned alterations in upstream 
regulators of the PAM pathway and reflects how AKT and mTORC1 are important 
effector kinases of the PAM pathway. Furthermore, the strikingly high incidence of 
deregulated mTORC1 signalling, also reflects that mTORC1 can integrate non-PAM 
pathway signalling, which is also often deregulated in cancer (Laplante and Sabatini, 
2012).  
1.3.3. Targeting the PAM pathway 
Due to the frequency by which it is mutated and hyperactivated in cancer, the PAM 
pathway has proven to be an attractive therapeutic target in cancer. There are currently 
several PAM pathway inhibitors that have been clinically approved to treat patients, and 
many more that are in clinical trials, most of which are kinase inhibitors (Alzahrani, 2019; 
Yang et al., 2019). In general, PAM pathway inhibitors can be categorised into four 
groups: PI3K inhibitors, dual PI3K/mTOR inhibitors, mTOR inhibitors and AKT inhibitors 
(Alzahrani, 2019; Yang et al., 2019). 
Many of the initial first-generation PI3K inhibitors, such as wortmannin and LY294002, 
were pan-PI3K inhibitors; they showed no selectivity for individual PI3K isoforms, 
inhibiting all class 1 (1A and 1B) PI3Ks (Liu, Cheng, Thomas M Roberts, et al., 2009). 
Whilst these inhibitors helped gain invaluable insight into signalling mediated by PI3K, 
they demonstrated considerable toxicity in animals, thought to be caused by their lack 
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of selectivity for PI3K isoforms and other off-target effects (Marone et al., 2008; Liu, 
Cheng, Thomas M Roberts, et al., 2009). Subsequently, much of the focus, in the 
development of PI3K inhibitors, has been to synthesise isoform specific PI3K inhibitors. 
Indeed, of the four PI3K inhibitors have been clinically approved to treat cancer, two are 
isoform specific, with the other two shown to be dual-isoform specific (Alzahrani, 2019; 
André et al., 2019; Yang et al., 2019). For example, alpelisib, a PI3K-α specific inhibitor, 
has been approved to treat PI3KCA mutated, hormone receptor positive, HER2 negative 
breast cancer patients, in combination with fulvestrant, an estrogen receptor targeted 
therapy (André et al., 2019). In these patients, it was demonstrated in a phase 3 clinical 
trial, that the combination of alpelisib-fulvestrant improved progression free survival 
(PFS) from 5.7 months to 11.0 months, when compared to fulvestrant-placebo (André 
et al., 2019). The other clinically approved PI3K inhibitors are idelalisib: a PI3K-δ 
inhibitor, approved to treat chronic lymphocytic leukaemia (CLL) in combination with 
rituximab; copanlisib, which predominantly targets PI3K-α & δ, and is approved to treat 
adult patients with relapsed follicular lymphoma; and duvelisib, a dual PI3K-δ & γ 
inhibitor, approved to treat adult patients with relapsed CLL (Furman et al., 2014; Flinn 
et al., 2018; Alzahrani, 2019). All clinically approved PI3K inhibitors function as ATP-
competitive kinase inhibitors.  
Due to the importance of both mTORC1 in regulating the PAM pathway, as highlighted 
by 80% of cancers displaying dysregulated mTORC1 signalling, a number of mTOR 
inhibitors have also been developed that selectively target mTORC1. The 1st generation 
of mTOR inhibitors were rapamycin and its analogues (known as rapalogs), which 
function as allosteric inhibitors of mTORC1, by binding to FKBP12 (a subunit specific to 
mTORC1) and forming  a ternary complex with mTOR, preventing substrate recruitment 
by steric hindrance (Meng and Zheng, 2015). The rapalogs, temsirolimus and 
everolimus, were both initially clinically approved for the treatment of metastatic renal 
cell carcinoma (RCC), with everolimus subsequently approved for use in HER2 negative 
breast cancer and pancreatic neuroendocrine tumours (Meng and Zheng, 2015; 
Roskoski, 2019). However, the clinical efficacy of temsirolimus and everolimus has been 
shown to be limited, and as such, both are usually only used as a 2nd or 3rd line therapy 
when treating cancer (Motzer et al., 2010; Meng and Zheng, 2015). In addition, ATP-
competitive mTOR inhibitors are also being developed and currently undergoing clinical 
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trials (Hua et al., 2019). In directly inhibiting mTOR kinase activity, these inhibitors inhibit 
both mTORC1 and mTORC2, which is hoped will lead to greater therapeutic efficacy 
(Laplante and Sabatini, 2012). 
Since PI3K and mTOR share a similar sequence homology in their catalytic cleft (ATP-
binding site), many ATP-competitive PI3K inhibitors that were initially developed, such 
as PI-103, were also found to inhibit mTOR kinase (Schenone et al., 2011). This opened 
up a new avenue in the search for effective inhibitors of the PAM pathway, as it was 
envisaged that the dual targeting of PI3K/mTOR, thus targeting both mTORC1 and 
mTORC2, might provide a greater therapeutic effect, when compared to other PAM 
pathway inhibitors. Indeed, several dual PI3K/mTOR inhibitors have been developed, 
many of which were shown in pre-clinical studies to elicit a greater apoptotic response, 
when compared to rapamycin/rapalogs (Chiarini et al., 2015). As such, several dual 
PI3K/mTOR inhibitors are currently undergoing clinical phase trials including: dactolisib, 
apitolisib and gedatolisib (Yang et al., 2019). 
As discussed in section 1.3.1, AKT is major signalling node within the PAM pathway, 
regulating much of the pathway’s functional output, such as proliferation and survival, 
and is therefore a major effector of the PAM pathway in driving oncogenesis. The critical 
function of AKT within the PAM pathway has made it an attractive therapeutic target, 
with several AKT inhibitors currently going through clinical trials (Revathidevi and 
Munirajan, 2019). One such example is MK-2206, which is an allosteric pan-AKT 
inhibitor, although MK2206 does display ~5-fold greater potency for AKT1 and 2, when 
compared to AKT3 (Hirai et al., 2010). The exact mechanism in which MK-2206 functions 
as an allosteric AKT inhibitor is not fully understood, but it is thought that MK-2206 
binding to AKT induces a closed conformation, that occludes binding sites for activating 
kinases (mTORC2 and PDK1) and AKT substrates (Cherrin et al., 2010). MK-2206 is 
currently in several phase 2 clinical trials, either as a monotherapy or in combination 
with other cancer drugs, to treat a variety of cancers such as advanced breast cancers 
with PAM pathway mutations and advanced colorectal cancers (Prêtre and Wicki, 2018; 
Xing et al., 2019; clinicaltrials.gov). Several other allosteric AKT inhibitors have also been 
developed, which inhibit AKT by disrupting the interaction between PI(3,4,5)P3 and the 
PH domain of AKT (Revathidevi and Munirajan, 2019). Perifosine is an allosteric inhibitor 
which inhibits AKT in this manner and is currently in a phase 3 clinical trial for the 
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treatment of advanced colorectal cancer (Revathidevi and Munirajan, 2019; 
clinicaltrials.gov - identifier: NCT1097018). 
In addition, several ATP-competitive pan-AKT inhibitors have also been developed which 
have progressed to clinical trials (Revathidevi and Munirajan, 2019). Of these, 
capivasertib (AZD5363) and ipatasertib (GDC-0068) are the most advanced, with several 
phase 3 clinical trials currently being conducted with ipatasertib (clinicaltrials.gov – 
identifier: NCT0307228, NCT04060862, NCT04177108, NCT03337724), and a phase 3 
clinical trial recently initiated to treat advanced triple negative breast cancer patients 
with capivasertib in combination with paclitaxel (clinicaltrials.gov – identifier: 
NCT03997123). It should be noted, that due to the similarity of the ATP-binding pocket 
amongst the AGC protein kinase family (of which AKT is a member), ATP-competitive 
AKT inhibitors are prone to also inhibit other AGC kinases. This can be seen with 
capivasertib, which is equipotent against AKT1-3, cAMP dependent protein kinase (PKA) 
and p70S6K, all of which are AGC kinases (Davies et al., 2012). However, the lack of 
selectivity does not seem to have hindered the progression of ATP-competitive AKT 
inhibitors through clinical development, and may actually improve efficacy, since many 
AGC kinases are also involved in oncogenesis (Pearce et al., 2010a; Prêtre and Wicki, 
2018).  
1.4. AGC kinases  
1.4.1. Structure, function and regulation 
The AGC (related to PKA, cGMP-dependent protein kinase [PKG] and protein kinase C 
[PKC]) protein kinase family is family of serine/threonine protein kinases, which 
comprises 60 of the 518 protein kinases which make up the human kinome (Manning et 
al., 2002; Pearce et al., 2010a). As the name suggests, the family is defined as protein 
kinases which share sequence homology in their catalytic domains with PKA, PKC and 
PKG. The AGC protein kinase family mediate a number of diverse and important cellular 
functions, regulating many of the hallmarks of cancer, and as such, their mutation or 
dysregulation can contribute to oncogenesis (Pearce et al., 2010a; Prêtre and Wicki, 
2018). Therefore, many AGC kinases are an attractive therapeutic target, with several 
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inhibitors of AGC kinases (such as AKT inhibitors), currently in clinical phase trials (Prêtre 
and Wicki, 2018). 
AGC kinases all share a similar structure within their catalytic domains, which is that of 
a prototypical kinase fold, consisting of a small amino-terminal lobe (N-lobe) containing 
a conserved β-sheet, and a large mainly α-helical carboxyl-terminal lobe (C-lobe; 
highlighted in Figure 1.3). Between these two lobes is a connecting polypeptide hinge 
region, which forms a binding pocket for one molecule of ATP, the phosphate donor. In 
addition to sharing a similar structure, most AGC kinases share a similar mechanism of 
activation involving the phosphorylation of two highly conserved motifs: the activation 
loop (also known as the activation segment or T-loop) and hydrophobic motif (HM). The 
activation loop, located within the C-lobe, adjacent to the ATP-binding site and 
connected to the N-lobe via an αC helix, contains important catalytic elements, such as 
the DFG (aspartate-phenylalanine-glycine) motif, which positions ATP for phosphoryl 
transfer. The phosphorylation of the activation loop is necessary for catalytic activation, 
as it leads to conformational changes within the αC helix, coordinating a network of 
hydrogen bonds between a Glu residue on the αC helix, a Lys residue on the N-lobe, and 
the phosphates of ATP. This network of hydrogen bonds is required for the catalytic 
activity of AGC kinases. The HM is located within the C-terminal tail of the C-lobe, and 
upon phosphorylation, wraps around the N-lobe to insert two aromatic residues into the 
hydrophobic pocket formed between the N-lobe and αC helix, stabilizing the active 
confirmation of the αC helix. In addition, the turn motif, also located within the C-
terminal tail of the C-lobe, can also be phosphorylated, which stabilises the 
aforementioned interaction between the HM and hydrophobic pocket. The 
phosphorylation of these sites, within AGC kinases, collectively induces kinase activity 
by positioning the αC helix in an active confirmation, enabling efficient catalysis (Figure 
1.3; Pearce et al., 2010a; Taylor and Kornev, 2011; Arencibia et al., 2013).  












Figure 1.3: Conserved structure of the catalytic domain of AGC kinases. Crystal structure of the catalytic 
domain of PKCβ2 bound to a competitive inhibitor of ATP, with turn motif (T641), hydrophobic motif 
(S660) and activation segment (T500) phosphorylation. Key conserved structures and features of AGC 
kinases are highlighted. Image adapted and taken from Pearce et al., 2010a.  
Another common feature amongst AGC kinases, is the phosphorylation of their 
activation loop by PDK1; this is known to occur in 23 AGC kinases including AKT, p70S6K, 
serum and  glucocorticoid regulated kinase (SGK) and p90 ribosomal S6 kinase (RSK) 
(Pearce et al., 2010a). Through this extensive phosphorylation and activation of AGC 
kinases, PDK1 is known as a master regulator of AGC kinases, regulating a diverse array 
of cellular functions (Mora et al., 2004). Interestingly, PDK1 is also an AGC kinase, and is 
constitutively active, due to the intrinsic ability of PDK1 to trans-autophosphorylate its 
own activation loop at Ser241 (Casamayor et al., 1999; Pearce et al., 2010a). PDK1 also 
contains a PH domain which helps regulate the phosphorylation of some of its targets, 
by co-localising to the plasma membrane in response to PI3K activation and the 
formation of PI(3,4,5)P3 (Arencibia et al., 2013). However, most PDK1 substrates do not 
contain a PH domain, therefore phosphorylation by PDK1 is also regulated by another 
mechanism; PDK1 is thought to regulate the phosphorylation of most of its AGC kinase 
substrates through a region in its catalytic domain called the PDK1-interacting fragment 
(PIF) pocket (Balendran et al., 1999; Pearce et al., 2010a). The PIF pocket enables PDK1 
to bind to phosphorylated HMs of AGC kinases, where upon binding it can phosphorylate 
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the activation loop (Arencibia et al., 2013). Therefore, many AGC kinases have a similar 
mechanism of activation, whereby they are initially phosphorylated at their HM, which 
enables PDK1 to then bind via its PIF pocket to the target substrate kinase and 
phosphorylate the activation loop, inducing AGC kinase activation.   
1.4.2. AKT and p70S6K 
AKT and p70S6K are amongst the most well-characterised AGC kinases, and due to their 
role within the PAM pathway (see section 1.3), heavily implicated in oncogenesis, 
particularly AKT. Whilst their function and regulation were discussed in section 1.3.1, it 
is worth considering them in more detail. Both AKT and p70S6K are phosphorylated at 
their activation loop by PDK1, in common with many other AGC kinases, however the 
mechanism by which this process is regulated is distinct between AKT and p70S6K, as is 
HM phosphorylation.  
The binding of AKT to PI(3,4,5)P3 in PI3K activated cells, mediated by the PH domain of 
AKT, is thought to be important for AKT phosphorylation by PDK1 for two reasons: 1) 
when AKT is an unbound state, its PH domain blocks the activation loop of AKT, but when 
bound to PI(3,4,5)P3 a conformational change takes place, making the activation loop 
accessible; 2) PDK1 also has a PH domain, so it can co-localize with AKT at the plasma 
membrane, upon PI3K activation (Stokoe et al., 1997; Arencibia et al., 2013). Therefore, 
by both binding to PI(3,4,5)P3, PDK1 can phosphorylate the activation loop of AKT (in 
AKT1, PDK1 phosphorylates Thr308 in the activation loop). Whilst the PDK1-mediated 
phosphorylation of the activation loop of AKT is required for activation, this only causes 
a partial activation of AKT, with HM phosphorylation necessary for full activation (Pearce 
et al., 2010a). The exact mechanism by which AKT is phosphorylated at its HM is not fully 
understood, but it is generally accepted that mTORC2 phosphorylates the HM of AKT 
(Ser473 in AKT1), in a PI3K dependent manner. Recently, it has been suggested that this 
might be mediated by mTORC2 also binding to PI(3,4,5)P3, via the mammalian stress-
activated MAP kinase-interacting protein 1 (mSin1)  subunit of mTORC2, which contains 
a PH domain (Liu et al., 2015; Yuan and Guan, 2015).  
The phosphorylation of the activation loop of p70S6K requires the prior phosphorylation 
of the HM motif of p70S6K by mTORC1. Once phosphorylated, PDK1 can bind to the HM 
of p70S6K via its PIF pocket domain, and subsequently phosphorylate the activation loop 
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of p70S6K, inducing its activation (Biondi et al., 2001; Arencibia et al., 2013). This 
mechanism, in which prior HM phosphorylation is required for activation loop 
phosphorylation by PDK1, is known as the “PIF pocket mechanism” of AGC  kinase 
activation, and is the mechanism by which most of the 23 AGC kinases, phosphorylated 
by PDK1, become activated (Balzano et al., 2015). Interestingly, it has also been 
suggested that AKT can be activated via the PIF pocket mechanism, although the 
circumstances, and precise mechanism, in which AKT is activated in this manner, is yet 
to be fully established (Bozulic et al., 2008; Arencibia et al., 2013; Balzano et al., 2015).  
Both AKT and p70S6K play a key role in regulating the functional output of the PAM 
signalling pathway, much of which is linked to the hallmarks of cancer. In particular, AKT 
has been shown to regulate proliferation, growth, survival, angiogenesis and 
metabolism (Revathidevi and Munirajan, 2019). This is mediated through the 
phosphorylation of a reported ≥ 100 substrates by AKT, although only 20 of these have 
been comprehensively validated (Cole et al., 2019). For example, AKT phosphorylates 
GSK3α and GSK3β at a conserved amino-terminal motif, at Ser21 and Ser9 respectively, 
which inhibits GSK3 by creating an intramolecular pseudosubstrate, preventing 
substrate accessibility to GSK3 (Manning and Toker, 2017). Many GSK3 phospho-targets 
are pro-survival factors or cell cycle regulators; such as induced myeloid cell 
differentiation protein (MCL-1), c-Myc and cyclin D1; which upon phosphorylation by 
GSK3, are targeted for proteasomal degradation (Diehl et al., 1998; Manning and Toker, 
2017). Therefore, activated AKT can stabilise the expression of these proteins, via 
inhibition of GSK3, mediating survival and cell cycle progression (Manning and Toker, 
2017). Another key substrate of AKT, is the FoXO family of transcription factors; the 
phosphorylation of FoXO proteins by AKT sequesters FoXO proteins in the cytoplasm, 
preventing the transcription of FoXO-induced genes, most of which are involved in the 
negative regulation of survival, proliferation and growth (Zhang et al., 2011; Manning 
and Toker, 2017).  
The role of p70S6K within the PAM pathway is not quite as extensive as AKT. But as 
mentioned in section 1.3.1, p70S6K is a key substrate of mTORC1, regulating multiple 
components of the translational machinery, playing a crucial role in regulating protein 
synthesis, thus supporting cell growth and survival. However, p70S6K can also 
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phosphorylate other substrates, in addition to components of the translational 
machinery, some of which are shared substrates with AKT (Fenton and Gout, 2011; 
Mendoza et al., 2011). For example, p70S6K can impart an inhibitory phosphorylation 
of GSK3β, in similar manner to AKT (Sutherland et al., 1993; Mendoza et al., 2011). In 
addition, p70S6K can phosphorylate the pro-apoptotic protein BAD, which results in BAD 
being sequestered by 14-3-3 (Harada et al., 2001; Mendoza et al., 2011). Hypo-
phosphorylated BAD binds and neutralizes pro-survival B-cell lymphoma 2 (BCL-2) family 
proteins, such as BCL-2 and BCL-XL, thus the phosphorylation of BAD by p70S6K (and 
AKT) liberates pro-survival BCL-2 family proteins, preventing apoptosis (Yang et al., 
1995; Harada et al., 2001). Furthermore,  p70S6K can impart inhibitory phosphorylation 
on insulin receptor substrate 1 (IRS1), rapamycin insensitive companion of mTOR 
(RICTOR) and mTOR, components of the PAM pathway upstream from p70S6K, thus 
playing an important role in feedback regulation of the PAM pathway (Fenton and Gout, 
2011).  
1.4.3. SGK 
Another example of an AGC kinase that linked to cancer is SGK, of which there are three 
isoforms: SGK1-3. SGK’s share a significant degree of homology with AKT, particularly 
within their kinase domains, where they share 55% identity in primary amino acid 
sequence with AKT (Tessier and Woodgett, 2006). As such, SGK and AKT have 
overlapping substrate specificity and have been shown to phosphorylate many of the 
same substrates, such as GSK3β, BAD, FoXO3a and TSC2 (Bruhn et al., 2010). 
Furthermore, in a similar manner to AKT, all isoforms of SGK have been shown to require 
PI3K activation, and activation loop phosphorylation by PDK1, for their activation and 
function (Tessier and Woodgett, 2006). However, unlike AKT, isoforms of SGK do not 
possess a PH domain, and are therefore activated via the “PIF pocket mechanism”, in a 
similar manner to p70S6K; the HM of SGK is initially phosphorylated, which provides a 
docking site for PDK1 to bind to SGK and phosphorylate the activation loop of SGK 
(Biondi et al., 2001; Pearce et al., 2010a). As with AKT, mTORC2 has been shown to be 
responsible for HM phosphorylation in SGK1, and considering the significant homology 
within the HM amongst SGK isoforms, is likely to be responsible for HM phosphorylation 
in SGK2 and SGK3 (García-Martínez and Alessi, 2008; Bruhn et al., 2010). It is through 
these similarities to AKT, both in substrate specificity and mechanism of activation, that 
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SGK has been linked to the hallmarks of cancer. Interestingly, it has been shown that 
some PIK3CA-mutant cancer cell lines are independent of AKT for their growth and 
survival, but dependent upon SGK3, suggesting that there might be some functional 
redundancy amongst AKT and SGK in PAM pathway driven cancers (Gagliardi et al., 
2012).  
1.4.4. ROCK and ROCK pathway signalling 
The Rho-associated coiled-coil containing kinases (ROCK) are also AGC kinases, and act 
as crucial regulators of the actin-myosin cytoskeleton. There are two isoforms of ROCK, 
ROCK1 and ROCK2, which share a very similar structure consisting of an N-terminal 
kinase, a coiled-coil region, a Rho binding domain (RBD) and a C-terminal split PH 
domain, bisected by a C1 domain (Rath and Olson, 2012). Furthermore, ROCK1 and 2 
share 64% identity in their primary amino acid sequence, with the greatest degree of 
homology (92%) seen within their kinase domains (Julian and Olson, 2014). Whilst a few 
studies have shown some isoform specific functions of ROCK1 and 2, they are mostly 
considered to be functionally redundant to one another (Thumkeo et al., 2005; Kümper 
et al., 2016).  
Unlike other AGC kinases, ROCK1 and 2 do not require the phosphorylation of their 
activation loop or HM to induce activation (Pearce et al., 2010a). Instead, ROCK1 and 2 
are activated by the binding of GTP-bound RhoA, RhoB and RhoC, members of the RAS 
superfamily of GTPases (Rath and Olson, 2012). The exact mechanism in which the 
binding of Rho activates ROCK1 and 2 is unknown, but it is thought that Rho binds to the 
RBD of ROCK, causing conformational changes, which disrupts the negative regulatory 
interactions between the N-terminal kinase domain and auto-inhibitory C-terminal 
region of ROCK (Rath and Olson, 2012; Julian and Olson, 2014). However, in contrast to 
RhoA-C, the binding of GTP-bound RhoE to ROCK1, has been shown to negatively 
regulate ROCK1 activation (Riento et al., 2003). Interestingly, PDK1 has also been shown 
to competitively bind to ROCK1 in a similar region to RhoE, antagonizing the negative 
regulation of ROCK1 by RhoE, in a kinase-independent manner (Pinner and Sahai, 2008). 
Furthermore, there is evidence to suggest that ROCK can be activated independently of 
Rho, for example, by caspase-3 or granzyme B mediated cleavage of the auto-inhibitory 
C-terminal of ROCK during apoptosis, or via the binding of arachidonic acid to the PH 
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domain of ROCK (Feng et al., 1999; Sebbagh et al., 2001, 2005; Wen et al., 2008). In 
addition, the activity of ROCK1 and 2 is also known to be modulated by phosphorylation, 
such as the phosphorylation of Tyr722 ROCK2 by Src, which inhibits ROCK2 activation by 
preventing the binding of Rho (Lee et al., 2010; Julian and Olson, 2014).  
As mentioned, upon activation ROCK predominantly regulates the actin-myosin 
cytoskeleton, which is primarily achieved by the phosphorylation of a few key 
substrates. ROCK phosphorylates myosin regulatory light chain 2 (MLC2), a subunit of 
myosin, at Thr18/Ser19, which causes increased actin-myosin contractility by activating 
myosin ATPase, thus promoting the interaction of myosin and F-actin to generate 
contractile force (Figure 1.4; Julian and Olson, 2014). ROCK also acts to increase the 
phosphorylation of MLC2 by negatively regulating MLC phosphatase (MLC-P), a 
phosphatase of MLC2. MLC-P is composed of three subunits, a catalytic protein 
phosphatase 1 subunit and two non-catalytic subunits: myosin phosphatase-targeting 
subunit 1 (MYPT1), a myosin binding subunit; and M20, the function of which is currently 
unknown (Matsumura and Hartshorne, 2008). ROCK negatively regulates MLC-P by 
phosphorylating MYPT1, inhibiting the binding of MLC-P to myosin, therefore preventing 
the dephosphorylation of MLC2 by MLC-P (Figure 1.4; Julian and Olson, 2014). ROCK also 
can promote actin polymerisation, by phosphorylating and activating LIM domain 
kinases (LIMK), which in turn phosphorylate and inactivate the actin severing protein 
cofilin (Figure 1.4; Ohashi et al., 2000; Prunier et al., 2017). In addition, ROCK can 
phosphorylate several other substrates which facilitate regulation of the actin-myosin 
cytoskeleton (e.g. adducin & ezrin/radixin/moesin proteins), as well other substrates 
which regulate the functional output of ROCK independently of the actin-myosin 
cytoskeleton (e.g. beclin1 & PTEN), although these are less well characterised (Riento 
and Ridley, 2003; Amano et al., 2010; Amin et al., 2013; Gurkar et al., 2013). 
 












Figure 1.4: The Rho/ROCK pathway. Diagram depicts the Rho/ROCK pathway, its regulation of the actin-
myosin cytoskeleton, and its functional output within the context of cancer. ROCK is predominantly 
associated with cancer by its regulation of the actin-myosin cytoskeleton, but phosphorylation of other 
substrates (outside the actin-myosin cytoskeleton) may also contribute to cancer. 
Through the regulation of actin-myosin contractility, ROCK has been shown to regulate 
several cellular functions, many of which are associated with the hallmarks of cancer, 
particularly tumour cell invasion and metastasis (Julian and Olson, 2014; Pandya et al., 
2017). For example, ROCK induced actin-myosin contractility has been shown to 
regulate amoeboid migration, a particularly rapid form of cell migration, which is often 
used by cancer cells to invade surrounding tissues (Wyckoff et al., 2006; Krakhmal et al., 
2015). Moreover, ROCK has also been shown to regulate cancer cell extravasation, an 
important step of the metastatic cascade (Stoletov et al., 2010). 
In addition to tumour cell invasion and metastasis, ROCK is being increasingly linked to 
regulation of the cell cycle and proliferation (Street and Bryan, 2011; Rath and Olson, 
2012). Olson and Croft (Croft and Olson, 2006) demonstrated that the activation of ROCK 
in mouse embryonic fibroblasts (MEF) increased cell cycle progression and proliferation, 
and that this was due to modulation in the expression of several cell cycle regulators, 
such as cyclin D1 and cyclin A, both of which were increased by ROCK activation. This 
regulation of the cell cycle, by ROCK activation, was shown to be dependent upon 
increased actin-myosin contractility (Croft and Olson, 2006). A similar phenomenon was 
seen by Kümper and colleagues (Kümper et al., 2016), where MEF cells, in which both 
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ROCK1 and ROCK2 had been genetically deleted, were shown to be defective in 
proliferation, due to cell cycle arrest and the induction of senescence. Using in vivo 
mouse models of melanoma and NSCLC, Kümper and colleagues (Kümper et al., 2016) 
also showed that the expression of ROCK1 and 2 is essential for tumour formation, i.e. 
cancer cells in which ROCK1 and 2 had been genetically deleted could not form tumours 
(Kümper et al., 2016). Furthermore, ROCK1 and 2 have also been implicated in providing 
the contractile strength required for cytokinesis (the physical act of cell division, dividing 
one parental cell into two daughter cells, which occurs at the end of mitosis), with 
genetic depletion of ROCK1 and ROCK2 shown to increase the number of binucleate 
cells, a marker of failed cytokinesis (Matsumura, 2005; Kümper et al., 2016).  
1.4.5. PKA 
In addition to ROCK, other AGC kinases also have a distinctive mechanism of activation, 
such as PKA; PKA is activated by the 2nd messenger cAMP, which is generated by the 
enzyme adenylate cyclase, downstream of G-protein coupled receptors (GPCRs), which 
are stimulated by extracellular stimuli such as cytokines and hormones (Pearce et al., 
2010a). PKA is maintained in an inactive state by the formation of an heterotetrameric 
complex consisting of two catalytic subunits (of which there are three isoforms) and two 
regulatory subunits (of which there are four isoforms), which act as pseudosubstrates 
to the catalytic domains suppressing activity (Pearce et al., 2010a; Sapio et al., 2014). 
The binding of cAMP to these regulatory subunits induces a conformational change that 
releases the catalytic subunits, freeing them to phosphorylate substrates. Additionally, 
PKA also requires activation loop phosphorylation to induce activation, which in 
common with other AGC kinases is mediated by PDK1, although PKA 
autophosphorylation may also contribute (Cheng et al., 1998; Moore et al., 2002). Upon 
activation, PKA regulates a diverse array of cellular functions, such as proliferation, 
survival and migration (Sakamoto and Frank, 2009; Caretta and Mucignat-Caretta, 2011; 
Sapio et al., 2014). 
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1.5. AT13148, an AGC kinase inhibitor  
As discussed in section 1.3, the PAM pathway is frequently dysregulated in cancer and 
is an attractive therapeutic target for cancer therapy. In recent years, there has been an 
increasing focus on developing small molecule inhibitors of AKT, due to the importance 
of AKT within the PAM pathway. Subsequent to the crystal structure of AKT2 being 
resolved in 2002 at the Institute of Cancer Research (ICR) by David Barford and co-
workers, a collaboration was established between the ICR, Cancer Research Technology 
and Astex Pharmaceuticals, to discover and develop potent and selective ATP-
competitive AKT inhibitors, using fragment and structure-based design (Yang et al., 
2002). This led to the discovery of AT13148, which was shown to  potently inhibit AKT1 
and AKT3, with weaker inhibition of AKT2 (Figure 1.5 Yap et al., 2012). However, 
AT13148 was also found to inhibit several related AGC kinases: PKA, ROCK1, ROCK2, 
p70S6K, SGK3 & RSK1; some of which were more potently inhibited by AT13148 than 
AKT1 and AKT3. Specifically, AT13148 displayed moderate potency (IC50 = 10 - 100 nM 
in in vitro kinase assays) against AKT1, AKT3, SGK3 and RSK1, but potently inhibited (≤ 
10 nM IC50 in in vitro kinase assays) PKA, ROCK1, ROCK2 and p70S6K (Figure 1.5; Yap et 
al., 2012). In a pre-clinical study, AT13148 was shown have efficacy in a number of 
human cancer cell lines with PAM pathway mutations (e.g. PIK3CA and PTEN), where 
AT13148 was shown to induce a pro-apoptotic response, as well as efficacy being seen 
in several in vivo mouse human tumour xenograft models (Yap et al., 2012). 











Figure 1.5: Structure and targets of AT13148. Chemical structure of AT13148 and the IC50 of AT13148 
against its targets, as determined via in vitro kinase assays. Adapted from yap et al., 2012. 
Despite the lack of selectivity for AKT, AT13148 was taken forward for further clinical 
development due to its pro-apoptotic cellular phenotype and because many of the 
additional AGC kinases targeted by AT13148 are of therapeutic interest in the treatment 
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of cancer, as discussed in section 1.5 (Yap et al., 2012). In addition, most selective AKT 
inhibitors (selective in comparison to AT13148) have shown limited efficacy in clinical 
trials when used as a monotherapy (Prêtre and Wicki, 2018; Xing et al., 2019). A similar 
phenomenon has been observed with other PAM pathway inhibitors, for example the 
rapalogs temsirolimus and everolimus, which whilst clinically approved, have been 
shown to have limited efficacy when used as monotherapies (Motzer et al., 2010; Meng 
and Zheng, 2015). It has been suggested that PAM pathway inhibitors may have limited 
efficacy, when used as a monotherapy, due to the relief of negative feedback within the 
PAM pathway, which causes reactivation of the PAM pathway (O’Reilly et al., 2006; 
Prêtre and Wicki, 2018; Wang et al., 2019). In targeting several components of the PAM 
pathway (AKT, p70S6K and SGK3), AT13148 may be able to overcome this, causing a 
stronger more durable decrease in PAM pathway activation, thus improving efficacy, 
when compared to more selective PAM pathway inhibitors. It should also be considered 
that targeting kinases outside the PAM pathway (e.g. ROCK and PKA), which are clinically 
relevant in the treatment of cancer, could also contribute to the efficacy of AT13148.  
AT13148 has recently completed a phase 1 clinical trial in patients with advanced solid 
tumours with the full publication of results from this trial currently awaited 
(clinicaltrials.gov – identifier: NCT01585701). However, the results from the initial first 
in human/dose-escalation study (part of the phase 1 clinical trial) were presented at the 
American Society of Clinical Oncology (ASCO) annual meeting in 2015 (the abstract of 
which is publicly available: Papadatos-Pastos et al., 2015), where AT13148 was shown 
to have favourable pharmacokinetics/pharmacodynamics, as well as acceptable 
toxicities. Currently, a specific clinical indication for the use of AT13148, which could be 
evaluated should AT13148 progress to a phase 2 clinical trial, has not been identified, 
but several have been suggested and are currently under investigation.  
Based upon pre-clinical data, in which the efficacy of AT13148 was shown in human 
cancer cell lines with PAM pathway mutations, AT13148 could be used to treat cancers 
in which the PAM pathway is dysregulated. Breast cancers in particular have a high rate 
of PI3KCA and PTEN mutations (27% and 25% of patients respectively), thus breast 
cancer patients could benefit from treatment with AT13148 (Liu, Cheng, Thomas M 
Roberts, et al., 2009). However, a phase 2 clinical trial in which advanced breast cancer 
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patients with PAM pathway mutations were treated with the allosteric AKT inhibitor 
MK2206, showed limited clinical efficacy due the inability of MK2206 to sufficiently 
inhibit PAM pathway signalling (Xing et al., 2019). Nonetheless, as previously discussed, 
in targeting several kinases of the PAM pathway, AT13148 could potentially have 
improved efficacy in treating breast cancer patients, when compared to more selective 
AKT inhibitors such as MK2206.  
It should also be considered that in targeting other clinically relevant AGC kinases, 
AT13148 could potentially be used in treating cancers in which the PAM pathway is not 
dysregulated. For example, since AT13148 can potently inhibit ROCK1 and 2 it has also 
been investigated as an anti-invasive/metastatic drug. Rath and colleagues (Rath et al., 
2018) showed that AT13148 was able to block the invasion of PDAC cells into 
surrounding healthy pancreatic tissue in an in vivo mouse model. They suggested that 
AT13148 could be used in the adjuvant setting to enable surgical resection by 
maintaining separation between tumour and healthy tissue (Rath et al., 2018). 
Moreover, AT13148 has been shown to inhibit melanoma cell motility in vitro and in an 
in vivo mouse model, further highlighting the potential for AT13148 to be used as an 
anti-invasive/metastatic drug (Sadok et al., 2015).  
In addition, the use of other ROCK inhibitors, either as a monotherapy or in combination 
with other cancer therapies, is currently being investigated and showing great promise. 
Smit and colleagues (Smit et al., 2014) used a functional short hairpin RNA (shRNA) 
screen to identify ROCK1 as a potential combinatorial drug target for BRAF mutant 
melanoma. The combination of a ROCK inhibitor with a proteasomal inhibitor (such as 
bortezimib) has also been suggested as a therapy for mutant KRAS NSCLC (Kumar et al., 
2012). Furthermore, the inhibition of ROCK has been shown to be synthetically lethal 
with loss of von Hippel-Lindau (VHL) in renal cell carcinoma (RCC) (Thompson et al., 
2017). Since there currently aren’t any ROCK inhibitors in clinical trial for the treatment 
of cancer, AT13148 could fill this void, and potentially have additional efficacy by the 
targeting of other AGC kinases.  
However, despite the clinical potential of AT13148, the history of targeted therapies and 
other drugs in the treatment of cancer, informs us that, should AT13148 progress to 
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clinical approval, resistance to AT13148 is almost inevitable. Resistance to targeted 
cancer therapies will be focused upon in the following sections. 
1.6. Resistance to targeted cancer therapies  
1.6.1. The challenge of drug resistance  
Drug resistance to targeted therapies, as well as other cancer therapies, is a major 
barrier to the successful treatment of cancer, with drug resistance continuing to be the 
principle limiting factor to achieving cures within cancer patients (Vasan et al., 2019). 
Unfortunately, most patients with advanced cancer ultimately die because some or all 
their cancer cells exhibit or develop resistance to all available therapeutic avenues 
(Garraway and Jänne, 2012). It is thought that the inherent genomic instability and 
heterogeneity within cancer, as well as the plasticity of oncogenic signalling pathways, 
contribute to the near-universality of resistance to cancer therapies (Garraway and 
Jänne, 2012; Konieczkowski et al., 2018). 
Drug resistance can be categorised as intrinsic drug resistance or acquired drug 
resistance. Intrinsic resistance (also known as de novo resistance) can be defined as 
when a tumour shows no initial response to a therapy that should have been effective 
based upon the underlying biology or genetics of the tumour (Garraway and Jänne, 
2012). For example, 10-20% of patients with mutant BRAF V600E melanoma and ~95% 
of patients with mutant BRAF V600E colorectal cancer, show no response to the BRAF 
V600E inhibitor vemurafenib (Flaherty et al., 2010; Chapman et al., 2011; Kopetz et al., 
2015; Griffin et al., 2017). In contrast, acquired resistance can be defined as tumour 
progression in the face of ongoing treatment to which the tumour was initially sensitive 
(Garraway and Jänne, 2012). An example of this can be seen in ph+ CML patients treated 
with imatinib; 20-25% of these patients stop responding to imatinib after initially 
undergoing a complete haematological and/or cytogenic response (Milojkovic and 
Apperley, 2009).  
Due to the prevalence of resistance to targeted therapies, both intrinsic and acquired, 
understanding the molecular mechanisms of resistance may provide opportunities to 
improve patient outcome. For example, in many cases, understanding the molecular 
mechanism of resistance has led to the identification of novel therapeutic strategies to 
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overcome resistance, increasing the magnitude or duration of clinical response. This can 
be seen in imatinib resistant ph+ CML, where the discovery that resistance is often 
driven by secondary mutations in BCR-ABL, has led to the development of 2nd and 3rd 
generation inhibitors that can overcome resistance and increase the duration of clinical 
response (Jabbour et al., 2015). Furthermore, understanding the molecular mechanisms 
of resistance may enable the identification of predictive biomarkers to clinically stratify 
patients, based upon their likelihood of responding to a particular therapy (Cree and 
Charlton, 2017).  
Despite the complexity in the mechanisms of resistance to targeted therapies, it has 
been suggested that they converge on three recognizable patterns of resistance: 1) 
pathway re-activation, 2) pathway by-pass, 3) pathway indifference (Highlighted in 
Figure 1.6; Konieczkowski, Johannessen and Garraway, 2018). These are discussed in the 









Figure 1.6: Converging mechanisms of resistance. Schematic diagram highlights how mechanisms of 
resistance converge on three recognisable patterns, based upon their relationship between drug target 
and downstream pathways: pathway reactivation, pathway bypass and pathway indifference. These are 
discussed in section 1.6.2. Figure adapted from Konieczkowski et al., 2018.  
1.6.2. Mechanisms of drug resistance to targeted therapies 
1.6.2.1. Pathway reactivation  
As discussed in section 1.2, most targeted therapies target oncogenes, and their 
downstream effector pathways, which cancer cells have become dependent on for their 
growth and survival (oncogene addiction). The most common convergent pattern of 
 1. Introduction 
47 
resistance is pathway re-activation; a process in which the core downstream effector 
pathways, downstream of the drug target, become re-engaged/reactivated, causing 
sustained growth and survival in the presence of a targeted therapy (Konieczkowski et 
al., 2018). For example, approximately 70% of BRAF mutant melanoma’s that clinically 
progress after RAF and/or MEK inhibitor treatment, show sustained ERK 1/2 
phosphorylation, indicating re-activation of the MAPK pathway (Konieczkowski et al., 
2018). In general, there are three distinct mechanisms in which pathway reactivation 
can occur: Drug target alterations, activation of parallel effectors, and alterations in 
upstream and downstream effectors.  
Many of the initially identified mechanisms of resistance to targeted therapies entailed 
alterations in the drug target which render the protein target insensitive to the drug 
itself, thus rendering downstream effector pathways refractory to inhibition 
(Konieczkowski et al., 2018). Within the context of kinase inhibitors, especially TKIs, this 
is frequently caused by mutations in the kinase domain, within contact points crucial for 
kinase-inhibitor interaction. Often these mutations are gatekeeper mutations; 
gatekeeper refers to a conserved amino acid residue found in the catalytic cleft of 
tyrosine kinases which is crucial for the binding of many TKI’s (Garraway and Jänne, 
2012; Roskoski, 2016). For example, threonine 315 is the gatekeeper residue of the ABL 
tyrosine kinase domain and is frequently mutated to isoleucine (T315I mutation) in 
imatinib resistance.  This mutation has been detected in 13% of imatinib resistant ph+ 
CML patients and 37% of ph+ acute lymphoblastic leukaemia (ALL) patients, and 
prevents imatinib from inhibiting the BCR-ABL fusion protein (Soverini et al., 2014; Ursan 
et al., 2015). Other examples, of gatekeeper mutations, include erlotinib-resistant EGFR 
mutant NSCLC (T790M mutation) and crizotinib-resistant anaplastic lymphoma kinase 
(ALK) rearranged NSCLC (ALKL1169M; Garraway and Jänne, 2012). The knowledge that 
gatekeeper mutations frequently generate resistance to TKIs has led to the development 
of novel TKIs which can bind and inhibit gatekeeper mutated tyrosine kinases, such as 
ponatinib and osimertinib, which are respectively used to treat ABLT315I positive ph+ 
CML/ALL patients and EGFRT790M positive NSCLC patients (Garnock-Jones, 2016; 
Pavlovsky et al., 2019). 
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In addition, other alterations in the drug target may also confer resistance to a targeted 
therapy such as mutations in non-contact residues which lead to an altered 
confirmation. This has been observed in resistance to type 2 kinase inhibitors, inhibitors 
which bind kinases in their inactive confirmation outside the ATP-site, such as imatinib 
and sunitinib (Garraway and Jänne, 2012; Klug et al., 2018). Many of these mutations 
occur in the activation loop of kinases, inducing a constitutively active confirmation, 
preventing the binding of type 2 inhibitors (Klug et al., 2018). Furthermore, amplification 
of drug target can also confer resistance to targeted therapies, such as amplification of 
BCR-ABL, which has been shown to cause resistance to imatinib in ph+ CML (Gorre et 
al., 2001; Campbell et al., 2002; Garraway and Jänne, 2012).  
Pathway reactivation can also be achieved by effector proteins which act in parallel to 
the targeted protein (Garraway and Jänne, 2012; Konieczkowski et al., 2018). This is a 
common mechanism of resistance to RTK inhibitors, as most RTKs regulate the same 
downstream effector pathways, predominantly the MAPK and PAM pathways, therefore 
gain-of-function mutations in RTKs can compensate for the inhibition of other RTKs, by 
re-engaging the appropiate effector pathways. A study by Yu and colleagues (Yu et al., 
2013), in patients with EGFR-mutant NSCLC with acquired resistance to EGFR TKI 
therapies, demonstrated that MET and HER2 (both RTKs) amplification was seen in 5% 
and 13% of pateints respectively. This has led to the rationale that the combination of 
EGFR TKI with a MET or HER2 inhibitor could be an effective therapeutic strategy to treat 
EGFR-mutant NSCLC patients with acquired resistance to EGFR TKI therapies. Recently, 
a phase 1b/2 clinical trial was conducted, in which capmatinib (a MET TKI) was used in 
combination with gefitinib (EGFR TKI) to treat pateints with EGFR-mutated, MET-
dysregulated NSCLC, which showed promising results (Wu et al., 2018). Interestingly, in 
the case of MET amplification, it has been shown that resistance occurs due to re-
activation of the PAM pathway in an ERBB3-dependent manner (Engelman et al., 2007). 
Since the amplification/activation of other RTKs might also induce EGFR TKI resistance 
in this manner, co-targetting the PAM pathway could also be a potential therapeutic 
avenue.  
Another notable example of pathway reactivation mediated by parallel effectors can be 
found in mutant BRAF melanoma; a small percentage of BRAF inhibitor resistant patients 
have been shown to have gain-of-function mutations in MAP3K8, a gene which encodes 
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COT kinase (Lehmann et al., 2019). As a MAP3K, COT kinase functions in parallel with 
BRAF within the MAPK pathway, phosphorylating and activating MEK 1/2 which 
subsequently phosphorylates and activates ERK 1/2 (Dasi et al., 2005; Johannessen et 
al., 2010). As such, gain-of-function mutations in MAP3K, in mutant BRAF melanoma, 
can re-engage the MAPK pathway in the presence of BRAF inhibition, driving resistance 
(Figure 1.7A; Johannessen et al., 2010; Lehmann et al., 2019).  
In addition, alterations in upstream and downstream effectors of the target protein can 
cause pathway re-activation. Alterations in both upstream and downstream effectors 
are frequent in mutant BRAF melanomas resistant to BRAF inhibition. For example, 
NRAS and KRAS, upstream effectors of BRAF, have been shown to have gain-of-function 
resistance mutations in 20% of mutant BRAF melanoma patients with acquired 
resistance to BRAF inhibition (Johnson et al., 2015). Gain-of-function resistance 
mutations in NRAS and KRAS (e.g. a Q61K or G12V substitution) can re-engage MAPK 
signalling, by activating CRAF and ARAF (alternate RAF isoforms), leading to sustained 
ERK 1/2 phosphorylation in the presence of BRAF inhibition (Figure 1.7; Nazarian et al., 
2010; Dumaz, 2011; Dorard et al., 2017). Furthermore, gain-of-function resistance 
conferring mutations have been idenitifed in MEK 1/2 (e.g. C121S/C125S substitution), 
a downstream effector of BRAF, in 7% of mutant BRAF melanoma patients with acquired 
resistance to BRAF inhibition, which again, drives resistance against BRAF inhibition by 
causing a sustained phosphorylation of ERK 1/2 (Figure 1.7B; Wagle et al., 2011; Van 
Allen et al., 2014; Johnson et al., 2015). Alterations in downstream effectors also 
contributes to resistance to EGFR therapies (cetuximab & panitumumab) in colorectal 
cancer, with resistance-conferring mutations frequently found in KRAS and BRAF, which 
enable sustained MAPK pathway activation in the presence of anti-EGFR therapy (Zhao 
et al., 2017).  
Since 70% of resistance mutations in mutant BRAF melanoma’s converge upon MAPK 
pathway re-activation (including the aformentioned mutations in NRAS, KRAS, MEK 1/2 
and MAP3K8), the combination of BRAF and MEK inhibitors is now used as a 1st line 
therapy in treatment naïve patients with mutant BRAF melanoma’s, to circumvent the 
acquisition of resistance via re-activation of the MAPK pathway (Arozarena and 
Wellbrock, 2017). This has proven to be a successful aproach with phase 3 clincial trials 
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demonstrating improved efficacy when compared to BRAF inhibitor monotherapy 
(Ascierto et al., 2016; Trojaniello et al., 2019).  
Figure 1.7: Mechanisms of MAPK pathway re-activation in resistance to BRAF inhibition in melanoma. 
The MAPK pathway is frequently re-activated in resistance to BRAF inhibition in BRAF mutant melanoma, 
and provides an instructive example of the mechanisms which drive pathway reactivation in resistance to 
targeted therapies: (A) activation of a parallel effector, such as COT kinase; (B) activation of an upstream 
effector, such as RAS; (C) activation of a downstream effector, such as MEK 1/2. Gain-of-function 
mutations are highlighted with a yellow star.  
1.6.2.2. Pathway bypass  
Whilst many resistance mechanisms to targeted therapies converge upon pathway re-
activation, in a minority of cases resistance occurs in the absence of pathway re-
activation; i.e. despite resistance, the targeted pathway is still robustly inhibited in the 
presence of drug (Konieczkowski et al., 2018). However, one must consider that for a 
targeted therapy to be effective, not only is it required that downstream effector 
pathways must be robustly inhibited, so must the oncogenic output regulated by 
downstream effector pathways (e.g. transcriptional or translational output). Within 
cancer there is a significant degree of redundancy amongst signalling pathways that 
control cell proliferation, survival, and many of the other hallmarks of cancer, with these 
pathways shown to engage many of the same oncogenic outputs (Kaelin, 2006; Kitano, 
2007; Konieczkowski et al., 2018). Therefore, one of the ways in which resistance can 
occur to targeted therapies, in the absence of pathway re-activation, is by pathway 
bypass, a process in which targeted oncogenic output is re-engaged via an alternative 
signalling pathway, independent from the downstream effector pathways initially 
targeted (Konieczkowski et al., 2018).  













Figure 1.8: Pathway bypass of the MAPK pathway in BRAF inhibitor resistance in melanoma. Diagram 
summarises how activation of GPCR/cAMP/CREB signalling can drive resistance to BRAF inhibition in BRAF 
mutant melanoma, by bypass of the MAPK pathway. The MAPK pathway and GPCR/cAMP/CREB signalling 
axis have shared oncogenic output, such as the transcription factors MITF and ETV, therefore activation 
of the GPCR/cAMP/CREB signalling axis can compensate for the inhibition of the MAPK pathway. ADCY: 
adenylate cyclase. Figure adapted from Johannessen et al., 2013. 
Pathway bypass has been observed in mutant BRAF melanoma, where a functional 
genetic screen in mutant BRAF melanoma cell lines, by Johannessen and colleagues  
(Johannessen et al., 2013), demonstrated that resistance against MAPK pathway 
inhibitors (e.g. BRAF inhibitor) can be mediated by MAPK pathway bypass. Specifically, 
they showed that overexpression of genes within the GPCR/cAMP/cAMP responsive 
element binding protein (CREB) signalling axis were able to confer resistance, including 
numerous GPCR genes; ADCY9, an adenylate cyclase gene; and PRKACA, a catalytic 
subunit of PKA. They hypothesised that as the MAPK pathway and GPCR/cAMP/CREB 
signalling axis converge upon a core set of transcriptional outputs, such as the 
transcription factors ETV1 and melanoma inducing transcription factor (MITF), 
GPCR/cAMP/CREB signalling could compensate for MAPK pathway inhibition (Figure 
1.8). In other words, GPCR/cAMP/CREB signalling can engage the same oncogenic 
outputs as the MAPK pathway, therefore drive resistance against MAPK pathway 
inhibitors in a MAPK pathway independent manner. A similar approach (functional 
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genetic screen) also revealed that purinergic P2Y receptors (a family of GPCRs) can drive 
resistance against ALK (an RTK) inhibition in ALK-dependent NSCLC cells, independently 
of downstream effectors of ALK, such as the MAPK and PAM pathways. Furthermore, it 
was shown that there was an overlap between the gene signature associated with P2Y 
driven resistance and pathway reactivation-based resistance mechanisms, thus it was 
hypothesised that P2Y receptors induced resistance against ALK inhibition by re-
engaging transcriptional outputs regulated by downstream effectors of ALK. 
1.6.2.3. Pathway indifference 
Pathway re-activation and pathway by-pass represent distinct patterns of resistance to 
targeted therapies, but they nonetheless converge, driving resistance by re-engaging 
the targeted oncogenic output. However, there are some examples of resistance in 
which both targeted downstream effector pathways and oncogenic output continue to 
be robustly inhibited despite the acquisition of resistance. Often, in these 
circumstances, cancer cells have transcended into an alternative malignant cell state 
(transcriptional or otherwise), in which growth, proliferation and survival are completely 
independent of the initially targeted oncogenic dependencies. This is referred to as 
pathway indifference (Konieczkowski et al., 2018).  
Perhaps the best example of resistance caused by pathway indifference is in breast 
cancer patients treated with poly-ADP ribose polymerase (PARP) inhibitors. PARP 
inhibitors (e.g. olaparib) are predominantly used to treat ovarian and breast cancer 
patients with loss-of-function germline mutations in BRCA1 or BRCA2 (proteins critical 
in the repair of double strand DNA breaks), based on the synthetic lethal relationship 
between BRCA1/2 and PARP (Lord and Ashworth, 2017). Remarkably, it has been shown 
that resistance to PARP inhibitors can be mediated by secondary mutations in BRCA1/2, 
which restore the function of BRCA1/2, abolishing the synthetic lethal relationship 
between BRCA1/2 and PARP (Barber et al., 2013; ter Brugge et al., 2016; Gogola et al., 
2019). In effect, due to the importance of BRCA1/2 in DNA repair, the restoration of 
BRCA1/2 function shifts cancer cells from a genome-unstable state to a genome-stable 
state (Konieczkowski et al., 2018).  
Another notable example of pathway-indifferent resistance can be found in EGFR-
mutant NSCLC patients treated with EGFR inhibitors. In a minority of these patients, 
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acquired resistance to EGFR inhibitors is mediated via a histological transformation 
consistent with that of small cell lung carcinoma (SCLC), whilst still maintaining 
expression of mutant EGFR  (Sequist et al., 2011; Yu et al., 2013; Piotrowska et al., 2015). 
In these patients, resistance against EGFR inhibitors seems to have occurred via the 
transformation of their lung cancer from NSCLC to SCLC. Accordingly, a study by 
Piotrowska and colleagues (Piotrowska et al., 2015) demonstrated that three out of four 
EGFR-mutant NSCLC patients that underwent a SCLC transformation, had a marked 
therapeutic response to platinum-etoposide-based chemotherapy, a classic SCLC 
treatment, highlighting the acquisition of an alternate SCLC-associated oncogenic 
output.  
1.7. Overview and aims of this thesis 
The PAM pathway is a key regulator of many of the hallmarks of cancer such as growth, 
proliferation and survival, and as such is an attractive therapeutic target for the 
treatment of cancer. Due to the importance of AKT within the PAM pathway, efforts 
have been made to discover and develop small-molecule AKT inhibitors as a novel 
targeted cancer therapy, of which several are currently in clinical trials for the treatment 
of cancer, showing promising results (Kim et al., 2017; Schmid et al., 2018; Revathidevi 
and Munirajan, 2019). AT13148 is distinct amongst AKT inhibitors as it potently inhibits 
several AGC kinases, both within the PAM pathway (p70S6K and SGK3) and outside 
(ROCK and PKA), that are of therapeutic relevance in the treatment of cancer (Yap et al., 
2012). Therefore, AT13148 may have improved efficacy in treating cancers with 
dysregulated PAM pathway signalling, as well as having a potential clinical use in cancers 
in which the PAM pathway is not dysregulated but in which other AT13148 targets may 
be important such as ROCK1/2 (e.g. PDAC, see section 1.5).  
Despite the clinical potential of AT13148, the history of kinase inhibitors and other drugs 
in the treatment of cancer, informs us that acquired drug resistance is very likely to occur 
in the clinic to AT13148, if not inevitable (Garraway and Jänne, 2012). As was highlighted 
in section 1.6.2, understanding the mechanisms of acquired drug resistance to targeted 
therapies in the clinic, has led to the identification of therapeutic strategies to overcome 
resistance, increasing the magnitude or duration of clinical response. In many of these 
cases, the use of pre-clinical cell line models has enabled the identification of clinically 
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relevant mechanisms of acquired drug resistance, and have been instrumental in 
identifying and validating therapeutic strategies to overcome resistance (Johannessen 
et al., 2010; Nazarian et al., 2010; Garraway and Jänne, 2012). Therefore, pre-clinical cell 
line models provide an effective means of studying acquired drug resistance whilst a 
drug is still in clinical development, such as AT13148. 
With this in mind, a project was instigated to generate resistance to AKT inhibitors, 
including AT13148, in pre-clinical cell line models (Akan, 2015). During this project an 
AT13148 resistance sub-line (A2780-148R) was derived from the human ovarian 
carcinoma cell line A2780, a cell line with dysregulated PAM pathway signalling. The 
aims of this thesis were therefore to investigate the acquired mechanisms of resistance 
to AT13148, using A2780-148R as a pre-clinical cell line model, and identify therapeutic 
strategies to overcome AT13148 resistance. 
Aims and objectives  
 Investigate the mechanisms(s) of resistance to AT13148 in the A2780-148R cell 
line by: 
o Cross-resistance profiling using a range of targeted inhibitors  
o Evaluating the baseline activation of the PAM pathway and other 
AT13148 targeted pathways.  
o Examining the response of the PAM pathway and other AT13148 
targeted pathways to AT13148. 
 Validate identified AT13148 resistance mechanisms using a range of in vitro 
techniques.  
 Devise and validate therapeutic strategies to overcome identified mechanisms 
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2. Materials and Methods 
2.1. Compounds and Materials 
Compounds used on cultured cells, shown in Table 2.1, were prepared and diluted in 
dimethly sulfoxide (DMSO; Sigma-Aldrich, Germany) under sterile conditions and stored 
at -80°C. Unless otherwise stated, all other chemicals and reagents were purchased from 
Sigma-Aldrich (Germany).  
Table 2.1: Summary of compounds used for cell-based experiments. Table lists compounds used for cell-
based experiments, such as SRB cell viability assays. 
Inhibitor/drug Target(s) [Stock] Supplier 
AT13148 AGC kinases 20 mM Astex pharmaceuticals, UK 
AZD4547 FGFR1-3 10 mM Selleck chemicals, USA 
Capiversatib (AZD5363) AKT 20 mM Selleck chemicals, USA 
Selumetinib (AZD6244) MEK 1/2 10 mM Selleck chemicals, USA 
BCI DUSP6 50 mM Sigma-Aldrich, Germany 
GDC-0994 ERK 1/2 20 mM Adooq, USA 
GSK269962 ROCK 20 mM Tocris Bioscience, USA 
GSK429286A ROCK 10 mM Tocris Bioscience, USA 
KX2-391 Src 20 mM Selleck chemicals, USA 
MK2206 AKT 20 mM Selleck chemicals, USA 
NVP-AEW541 IGF-1R 10 mM Selleck chemicals, USA 
PD0325901 MEK 1/2 10 mM Selleck chemicals, USA 
PF4708671 p70S6K 20 mM Tocris Bioscience, USA 
SCH772984 ERK 1/2 1 mM Adooq, USA 
SU6656 Src family kinases 20 mM Selleck chemicals, USA 
WH-4-023 Lck and Src 10 mM Selleck chemicals, USA 
 
2.2. General cell culture 
2.2.1. Cell lines and culture 
A2780 human ovarian carcinoma cells were originally obtained from the health 
protection agency (Salisbury, UK). A2780-148R, an AT13148 resistance sub-line derived 
from A2780 cells, were generated by Dr Denis Akan, whilst in the Garrett laboratory 
(Institute of Cancer Research, London, UK; Akan, 2015). HEK293T cells were a kind gift 
from Dr Tim Fenton (University of Kent, UK), and were provided at passage number 20. 
All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, UK), 
containing 3.7 g/L Glucose and 4 mM L-glutamine, supplemented with 10% (v/v) foetal 
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bovine serum (FBS; Gibco, UK). DMEM supplemented with 10% (v/v) FBS is hereafter 
referred to as complete DMEM.  All cell culture was performed under sterile conditions 
in a class II biological safety cabinet (BSC), and cells grown at 37°C in a humidified 5% 
CO2 incubator, henceforth referred to as standard growth conditions. 
Passaging of cells (sub-culture) was undertaken when cells were approximately 70-90% 
confluent. In T25 flasks, cell culture medium was aspirated off cells and cells rinsed in 
2ml of phosphate-buffered saline (PBS; Oxoid, UK). 0.5ml of 0.25% Trypsin-EDTA 
(ThermoFisher Scientific, USA) was subsequently added to cells and flasks placed in an 
incubator, under standard growth conditions, until cells had detached. If required, flasks 
were gently agitated to ensure that cells had sufficiently detached. Cells were then re-
suspended in complete DMEM, and depending on the split (usually between 1:10 and 
1:40), an appropriate volume added to a new flask. Additional complete DMEM was 
then added to the new flask for a final volume of 5ml. Complete DMEM was also added 
to the remaining cells in the trypsinised flask, to a final volume of 5ml, to keep as a 
backup. For passaging cells in T75 or T175 flasks, the aforementioned volumes were 
multiplied 3 and 7-fold respectively. Cell lines were routinely tested for mycoplasma 
contamination using the VenorGeM® mycoplasma PCR-based detection kit (Minerva 
labs, UK) 
When counting cells to plate for an assay, cells were trypsinised and re-suspended in 
complete DMEM. Re-suspended cells were then diluted between 1:2 – 1:5 in trypan blue 
and 10 µl added to the chambers of a BRAND® haemocytometer, to count the number 
of cells. After counting, re-suspended cells were diluted accordingly in complete DMEM, 
then plated as required for the desired assay.  
In order to prevent genetic drift, cells were passaged for a maximum of 6 months, and 
regularly cryo-preserved and stored in liquid nitrogen. To cryo-preserve, cells were 
routinely cultured in a T75 flask and allowed to grow to 70% confluence. Cells were then 
trypsinised and re-suspended in complete DMEM (as per section 2.2.1), prior to 
centrifugation at X 270g for 5 minutes to generate a cell pellet. Cell culture medium was 
subsequently aspirated from the cell pellet, and cells re-suspended in 3ml of freeze-
down media (complete DMEM + 10% [v/v] DMSO). Cells were then equally aliquoted 
into three cryovials, which were transferred to a Nalgene® Mr frosty container 
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(containing propan-2-ol) and left overnight in a -80°C freezer. The following day, 
cryovials were transferred to a liquid nitrogen container, for long-term storage.  
When required, cryo-preserved cells were thawed by placing cryovials (containing cells) 
in a 37°C water-bath for 2-3 minutes. Once thawed, cells were mixed with a total volume 
of 5ml complete DMEM in a falcon tube, then centrifuged at 270 x g for 5 minutes, to 
generate a cell pellet. Subsequently, cell culture medium was aspirated from the cell 
pellet, and cells re-suspended in 5ml of fresh complete DMEM. Re-suspended cells were 
then transferred into a T25 flask and allowed to grow under standard growth conditions. 
Within 3-5 passages, cells were expanded to grow in a T75 flask and cryo-preserved as 
previously described.  
2.2.2. Generation of AT13148 resistant cell lines  
As mentioned in section 2.2.1, A2780-148R, an AT13148 resistant sub-line derived from 
A2780 cells, was generated by Dr Denis Akan (Akan, 2015). This was accomplished by 
performing AT13148 dose-escalation on A2780 cells. Briefly, A2780 cells were grown 
under standard growth conditions in their half maximal growth inhibitory concentration 
(GI50) of AT13148. Upon reaching ~70% confluency, A2780 cells were passaged and the 
concentration of AT13148 increased by 1x AT13148 GI50 value in A2780 cells. This 
process was repeated over a period of 6-months, from which the A2780-148R cell line 
was generated. A2780-148R cells were routinely sub-cultured in 5.2 µM AT13148 (x 13 
the GI50 of A2780 cells), as described in section 2.2.1. 
Isogenic sub-clones (148R clones) were derived from A2780-148R cells by limiting 
dilution. A2780-148R cells were seeded at 0.5 cells per well in a 96-well plate in 200 µl 
complete DMEM and grown under standard growth conditions. After plating, wells were 
inspected every day under light microscopy to check for visible colonies of cells; single 
colonies were visible 5-15 days after plating. When colonies became visible to the naked 
eye, cell culture medium was carefully aspirated and colonies were incubated with 40 µl 
trypsin-EDTA at 37°C until cells had detached, then resuspended in 200 µl complete 
DMEM and grown under standard growth conditions. This was to evenly to distribute 
cells across each well, to facilitate further growth in a 96-well plate. Upon reaching ~70-
90% confluency, cells were again trypsinised, as previously described, and re-suspended 
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in complete DMEM to a final volume of 200 µl. Re-suspended cells were then transferred 
to a 24-well plate and additional complete DMEM added for a total volume of 500 µl per 
well. Upon reaching ~70-90% confluency, cells were rinsed with 400 µl PBS, prior to 
being incubated in 200 µl trypsin-EDTA at 37°C until cells had detached, then re-
suspended in 800 µl complete DMEM. Re-suspended cells were then transferred to a 6-
well dish and additional complete DMEM added for total volume of 2ml per well. This 
process was repeated to expand cells from a 6-well plate to a T25 flask, using 2 x the 
volumes described for trypsinising cells in 24-well plates. 148R clones were 
subsequently routinely sub-cultured in T25 flasks, as described in section 2.2.1, in 
complete DMEM containing 5.2 µM AT13148.  
A2780-148R cells and 148R clones were removed from AT13148 one week prior to 
plating for an assay into drug-free complete DMEM, unless otherwise stated. 
Furthermore, when A2780-148R cells and 148R clones were thawed from 
cryopreservation (as described in section 2.2.1), cells were initially sub-cultured in drug-
free complete DMEM for 2-3 passages, prior to being routinely sub-cultured in complete 
DMEM containing 5.2 µM AT13148.  
2.3. Cell line growth characterisation  
Cells were plated in seven 96-well plates in 200 µl of complete DMEM at multiple 
densities, as indicated in the text, and allowed to grow under standard growth 
conditions. Over the course of a week, one plate was fixed per day by the addition of 70 
µl 10% (w/v) trichloroacetic acid (TCA), prior to being stained and analysed as described 
for the sulforhodamine B (SRB) cell viability assay (see section 2.4). Cell line growth 
characterisation assays were used to identify optimal seeding densities for subsequent 
SRB cell viability assays.  
2.4. Sulforhodamine B cell viability assay 
The sulforhodamine B (SRB) dye binds to basic to amino acids residues, so therefore can 
provide an estimation of cellular density and be used to measure cell viability (Skehan 
et al., 1990). Cells were plated in a 96-well plate, in 160 µl complete DMEM, at the 
seeding densities indicated in the text, and allowed to grow under standard growth 
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conditions for 48 hours. Cells were not plated in the outer wells of 96-well plates; 200 
µl per well of PBS was added instead. For screening response to compounds, drugs were 
serially diluted and added to cells in 40 µl of complete DMEM per well, at the 
concentrations indicated in the text. For untreated and DMSO-vehicle control wells, 40 
µl per well of complete DMEM alone, or complete DMEM containing DMSO at the 
maximum concentration used for compound serial dilution, was respectively added.  
Cells were then grown under standard growth conditions for 96-hours, prior to being 
fixed with 70 µl per well of 10% (w/v) TCA for 30 minutes and then washed three times 
in water. After fixation, cells were then stained with 70 µl per well of 0.4% (w/v) SRB 
solubilised in 1% (v/v) acetic acid (ThermoFisher Scientific, USA) for 30 minutes and then 
washed three times in 1% (v/v) acetic acid to remove any excess SRB. Plates were 
subsequently dried in a 37°C oven for at least three hours, followed by addition of 100 
µl per well of 10 mM Tris-base (ThermoFisher Scientific, USA) and then placed on a 
microplate shaker for 10 minutes to solubilise protein-bound SRB. Absorbances were 
read at a wavelength of 490 nm using a Victor X4 multi-label plate reader (PerkinElmer 
Life Sciences, USA). Raw absorbances were blank adjusted by subtracting the mean 
absorbance of the outer wells (in which no cells were plated) containing 100 µl Tris-base. 
These values were percentage normalised to the mean absorbance of the untreated 
control wells and GI50 values determined using non-linear regression on GraphPad Prism 
6 (GraphPad Software Inc, USA). 
An adapted SRB cell viability assay was performed in 24-well plates when analysing the 
response of cells to targeted knockdown of gene expression by small interfering RNAs 
(siRNAs; see section 2.6). When performing these assays, cells were fixed, stained and 
solubilized as described, but the volumes were adjusted as follows: 500 µl 10% (w/v) 
TCA, 500 µl 0.4% (w/v) SRB solubilised in 1% (v/v) acetic acid, and 250 µl 10 mM Tris-
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2.5. Cell lysis and western blotting  
2.5.1. Cell lysis 
Lysis buffer (Table 2.2) was prepared in advance and stored in aliquots at -80°C. 
Table 2.2: Components of lysis buffer. Lysis buffer components, concentrations used in lysis buffer, and 
manufacturer are given. HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, DTT: Dithiothreitol.  
Component  Concentration  Manufacturer 
HEPES pH 7.4 50 mM Sigma-Aldrich, Germany 
NaCl 250 mM Sigma-Aldrich, Germany 
Nonidet-P40 substitute 0.1% (v/v) Roche, Switzerland 
DTT 1 mM Melford labs, UK 
EDTA 1 mM FisherScientific, UK 
NaF 1 mM Sigma-Aldrich, Germany 
β-Glycerophosphate 10 mM Sigma-Aldrich, Germany 
Sodium orthovanadate 0.1 mM Sigma-Aldrich, Germany 
Complete™ protease 
inhibitor cocktail 
1 tablet per 50 ml Roche, Switzerland 
 
Cells were plated in 10 cm dishes, 7 cm dishes, 6-well plates or 24-well plates in 
complete DMEM (seeding densities indicated in the text) and allowed to grow for up to 
72 hours under standard growth conditions. If drug treatment was required, cell culture 
medium was removed after 48 hours and replenished with fresh complete DMEM 
containing drug (concentrations indicated in the text), and cells allowed to grow under 
standard growth conditions for an additional 4 hours, unless otherwise stated. To lyse 
cells, cell culture medium was removed and cells washed twice with ice-cold PBS, prior 
to the addition of ice-cold lysis buffer (components shown in Table 2.2). The volume of 
ice-cold lysis buffer added depended on the tissue culture plasticware used: for 10 cm 
dishes 100 µl was added; for 7 cm dishes 50 µl was added; for 6-well plates 20 µl was 
added; and for 24-well plates 10 µl was added. After ice-cold lysis buffer was added, 
cells were immediately manually scraped into lysis buffer, then transferred to pre-chilled 
microcentrifuge tubes and incubated on ice for 30 mins for cell lysis to occur. Lysates 
were then centrifuged at 14,000 x g for 10 mins at 4°C, to clear any insoluble material, 
and cleared lysate transferred to a clean microcentrifuge tube, which was either kept on 
ice for immediate use or snap-frozen on dry ice and stored at -80°C for future use.  
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2.5.2. Determination of protein concentration 
To determine the total protein concentration of cell lysates, a BCA (Bicinchoninic acid) 
assay was performed using a Pierce™ BCA protein assay kit (ThermoFisher Scientific, UK; 
Smith et al., 1985). Cleared lysates (from section 2.5.1) were diluted 10 to 20-fold in 
ddH20 (double distilled water) and 10 µl added in triplicate to a 96-well plate. On each 
plate, 10 µl of bovine serum albumin (BSA) protein standards (diluted 0.1 – 1.0 mg/ml) 
and ddH2O blanks were also added in triplicate. A copper (II) sulfate solution was then 
diluted 1:50 in BCA and 200 µl added to each well. Plates were then placed on a 
microplate shaker for 30 seconds, prior to being incubated at 37 °C for 30 minutes. After 
incubation, absorbances were measured at a wavelength of 560 nm using a Victor X4 
multi-label plate reader (PerkinElmer Life Sciences, USA). Raw absorbances were blank 
subtracted using the mean absorbance of ddH2O blanks, and total protein concentration 
determined by generating a standard curve from BSA protein standards. 
If the total protein concentration of cell lysate was predicted to be low (< 0.1 mg/ml in 
diluted cell lysate), a modified BCA assay was performed, in which BSA standards were 
diluted 5 – 500 µg/ml and 96-well plates were incubated in a 60 °C oven for 30 minutes. 
All data analysis was performed using Microsoft Excel 2016 (Microsoft, USA).  
2.5.3. SDS-PAGE and western blotting  
Protein expression and protein phosphorylation at specific sites was detected using 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
western blot analysis (Towbin et al., 1979; Burnette, 1981). Cell lysates were thawed on 
ice and then normalised to the same protein concentration in lysis buffer and 5x sample 
buffer (0.3M Tris pH6.8, 50% [v/v] glycerol [ThermoFisher Scientific, UK] 25% [v/v] β-
mercaptoethanol, 10% [w/v] SDS [ThermoFisher Scientific, UK] and 0.05% [v/v] 
bromophenol blue). Subsequently, to denature and reduce proteins, samples were 
heated at 95 °C for 5 minutes in a heat block and then briefly centrifuged.  
After sample preparation, proteins were separated by molecular weight using SDS-PAGE 
under denaturing conditions (Laemmli, 1970). Equal amounts of protein (5 – 80 µg) were 
loaded into the wells of an 8%, 10% or 12% Tris-glycine gel (resolving gel), depending on 
the molecular weight of target proteins, containing a 4% stacking gel (components of 
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resolving and stacking gels are shown in Table 2.3). In addition, 7 µl of dual-coloured 
pre-stained protein standards (Bio-Rad, USA) were also loaded to monitor protein 
resolution across Tris-glycine gels. Gel electrophoresis was undertaken using a Hoefer 
SE250 electrophoresis unit (Hoefer, USA) with a Tris-glycine running buffer (25 mM Tris-
base, 192 mM glycine, 0.1% [w/v] SDS) under a constant voltage of 150V. Gel 
electrophoresis was performed until the dye front was approximately 1 cm from the 
bottom edge of the Tris-glycine gel.  
Table 2.3: Summary of the components of Tris-glycine gels. Table lists the concentrations and 
manufacturer of the components used to make Tris-glycine gels. TEMED: Tetramethylethylenediamine, 







Acrylamide/Bis (29:1) 8-12% (v/v) 4% Bio-Rad, USA 
Tris-HCl pH 8.8 0.375 M N/A Sigma-Aldrich, Germany 
Tris-HCl pH 6.8 N/A 0.125 M Sigma-Aldrich, Germany 
SDS 0.1% (v/v) 0.1% (v/v) Sigma-Aldrich, Germany 
TEMED 0.05% (v/v) 0.1% (v/v) Sigma-Aldrich, Germany 
APS 0.05% (w/v) 0.05% (w/v) Bio-Rad, USA 
 
After protein electrophoresis, separated proteins were transferred to a methanol-
activated 0.2 µm pore Immobilon-P polyvinylidene fluoride (PVDF) membrane 
(Millipore, USA), using a wet transfer system. Proteins were transferred for 75 minutes 
in pre-chilled transfer buffer (25 mM Tris-base, 192 mM glycine, 10% [v/v] methanol 
[ThermoFisher Scientific, USA]) under a constant voltage of 100V. After transfer, 
membranes were re-activated in methanol and briefly incubated in a ponceau S solution 
(0.1% [w/v] ponceau S in 5% [v/v] acetic acid), to check for efficient transfer of proteins 
and to aid in cutting PVDF membranes according to the molecular weight of target 
proteins. Membranes were then blocked for one hour in Tris-buffered-saline Tween 
buffer (TBS-T; 50 mM Tris pH 8.0, 150 mM NaCl, 0.1% [v/v] Tween-20) containing 5% 
(w/v) milk (Marvel, UK), on an orbital shaker. TBS-T containing 5% milk is henceforth 
referred to as blocking buffer and all subsequent antibody incubations and wash steps 
were performed using an orbital shaker.  
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Table 2.4: List of antibodies used for western blot analysis. CST: cell signalling technology 
 
After blocking, membranes were incubated overnight at 4°C in blocking buffer 
containing diluted primary antibody (Table 2.4). The next day, membranes were washed 
twice for 10 minutes in TBS-T, prior to incubation for one hour at room temperature (RT) 
with goat anti-rabbit or goat anti-mouse horseradish peroxidase (HRP)-conjugated 
secondary antibody in blocking buffer (Bio-Rad, USA; Table 2.4). Membranes were then 
washed four times for five minutes in TBS-T and detection performed using Clarity™ 
western enhanced chemiluminescence (ECL) substrate (Bio-Rad, USA), according to 
Primary Antibody Supplier 
Catalogue 
number 
Species Dilution  
AKT CST, USA 4691 Rabbit 1:5000 
AKT pS473 CST, USA 4060 Rabbit 1:5000 
DUSP 4 Santa Cruz, USA sc-17821 Mouse 1:200 
DUSP 5 Santa Cruz, USA sc-393801 Mouse 1:100 
DUSP 6 Santa Cruz, USA sc-377070 Mouse 1:500 
Elk-1 Santa Cruz, USA sc-365876 Mouse 1:1000 
Elk-1 pS383 Santa Cruz, USA sc-8406 Mouse 1:200 
ERK 1/2 pThr202/Tyr204 CST, USA 4370 Rabbit 1:4000 
ERK1/2 CST, USA 4696 Mouse 1:8000 
FGFR2 CST, USA 11835 Rabbit 1:1000 
GAPDH Chemicon, USA MAB374 Mouse 1:200000 
GSK3β  CST, USA 9315 Rabbit 1:2000 
GSK3β pS9 CST, USA 5558 Rabbit 1:2000 
IGF-1R β CST, USA 3027 Rabbit 1:1000 
MEK 1/2  CST, USA 9122 Rabbit 1:2000 
MEK 1/2 pS217/221 CST, USA 9154 Rabbit 1:4000 
MYPT1 CST, USA 8574 Rabbit 1:2000 
MYPT1 pT696 CST, USA 5163 Rabbit 1:500 
PRAS40 CST, USA 2691 Rabbit 1:10000 
PRAS40 pT246 CST, USA 2640 Rabbit 1:2000 
ROCK 1 CST, USA 4035 Rabbit 1:1000 
ROCK 2 CST, USA 9029 Rabbit 1:1000 
S6RP CST, USA 2217 Rabbit 1:10000 
S6RP pS235/236 CST, USA 2211 Rabbit 1:8000 
Tubulin α 1B Bio-Rad, USA VPA00172 Rabbit 1:1000 
β-Actin  Santa Cruz, USA sc-47778 Mouse 1:4000 
Secondary Antibody 
    
Anti-mouse HRP 
conjugate 
Bio-Rad, USA 170-6516 Goat 1:10000 
Anti-Rabbit HRP 
conjugate 
Bio-Rad, USA 170-6515 Goat 1:10000 
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manufacturer’s instructions. Bands were visualised by exposure to Hyperfilm ECL (GE 
healthcare, UK) and processed using an Optimax™ 2010 film processor (Protec, 
Germany).  
2.5.4. Membrane stripping 
Antibodies for phosphorylated proteins were stripped from membranes by incubation 
with stripping buffer (50 mM glycine, 1% [w/v] SDS, pH 2.0) for five minutes and then 
twice washed with TBS-T for five minutes. Membranes were then re-blocked in blocking 
buffer for 30 minutes and incubated with primary antibody for total protein overnight, 
as previously described (section 2.5.3). If required, this process was repeated to re-
probe membranes with primary antibodies for loading controls (Table 2.4).  
2.6. Knockdown of gene expression with small interfering RNA 
Small interfering RNAs (siRNAs) were used for the transient knockdown of target gene 
expression in cells, using reverse transfection with Lipofectamine 2000 (ThermoFisher 
Scientific, USA), a lipid-based transfection reagent. Lipofectamine 2000 and siRNA 
oligonucleotides were used at the concentrations indicated in the text. Non-targeting 
control and death control siRNA oligonucleotides were used to establish transfection 
efficiency and toxicity. The sequences of siRNA oligonucleotides and manufacturers are 
shown in Table 2.5.  
Lipofectamine 2000 and siRNA oligonucleotides were appropriately diluted and mixed 
together in Opti-MEM™ reduced serum medium (ThermoFisher Scientific, USA), then 
incubated for 15 minutes at RT to complex. In the meantime, cells were trypsinised, 
counted (as per section 2.2.1), and appropriately diluted in complete DMEM, depending 
on the seeding density required.  
For 96-well SRB assays, 50 µl of lipid/oligonucleotide complex was added per well 
followed by  110 µl of cells in complete DMEM per well (at the seeding densities 
indicated in the text) and allowed to grow for 24 hours under standard growth 
conditions, prior to treatment with inhibitors in 40 µl of complete DMEM (at the 
concentrations indicated in the text). After treatment, cells were grown for an additional 
72 hours under standard growth conditions, and cell viability analysed by SRB assay (as 
per section 2.4). 
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Target sequence (5'-3') Manufacturer 
D-003964-01 DUSP6 GAACUGUGGUGUCUUGGUA Dharmacon, USA 
D-003964-03 DUSP6 UGGGUUACCUUAUGCAGAA Dharmacon, USA 
D-003964-04 DUSP6 GACUGUGGCUUACCUUAUG Dharmacon, USA 
D-003964-05 DUSP6 GCGACUGGAACGAGAAUAC Dharmacon, USA 
SMARTpool DUSP6 




















To assess knockdown of target gene expression by siRNA, western blot analysis was 
performed, in parallel with SRB cell viability assays. Lipid/oligonucleotide complexes and 
cells were prepared as described, and after complexing, 500 µl of lipid/oligonucleotide 
complex was added per well of a 6-well plate, followed by the addition of 1.1 ml of cells, 
at the seeding densities indicated in the text.  Cells were then allowed to grow under 
standard growth conditions for 24-96 hours, depending on the timepoint being 
analysed, prior to cell lysis and western blot analysis (see section 2.5).   
A modified 2-day SRB cell viability was also performed in a 24-well plate, in which 
western blot analysis was performed in parallel in a separate 24-well plate. 
Lipid/oligonucleotide complexes and cells were prepared as described, and after 
complexing, 125 µl of lipid/oligonucleotide complex was added to each well of a 24-well 
plate, prior to the addition of cells at 275 µl per well, at the seeding densities indicated 
in the text. Cells were then incubated for 4 hours under standard growth conditions, 
then treated with inhibitors in 100 µl of complete DMEM, at the concentrations 
indicated in the text, followed by an additional incubation for 48 hours under standard 
growth conditions. Cell viability was subsequently analysed using an SRB assay (see 
section 2.4). For western blot analysis, after the addition of lipid/oligonucleotide 
complex and cells, cells were incubated for 4-52 hours, depending on the timepoint 
being analysed, prior to cell lysis and western blot analysis (see section 2.5).  
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2.7. Plasmid DNA preparation  
2.7.1. Plasmid recovery 
The lentiviral plasmid pLenti-DUSP6-C-Myc-DDK, was a kind gift from Dr Osamu Tetsu 
(University of California, San Francisco, USA; orginal publiation: Phuchareon et al., 
2015), which was provided spotted on a piece of filter paper. Spotted plasmid DNA was 
cut out of the filter paper and placed in a microcentrifuge tube with 200 µl Tris-EDTA 
buffer (TE; 10 mM Tris pH 8.0, 1 mM EDTA), briefly vortexed, and allowed to incubate at 
RT for 10 minutes. Subsequently, 1 µl of recovered plasmid DNA was used to transform 
competent E.coli (see section 2.7.2). The lentiviral plasmids pCMV-dR8.91 and pMD2.G 
were both kind gifts from Dr Tim Fenton (University of Kent, UK) and were provided as 
glycerol stocks of transformed E.coli. These were streaked on lysogeny broth (LB) agar 
plates (1% [w/v] bacto-tryptone, 0.05% [w/v] yeast extract, 0.05% [w/v] NaCl and 1.5% 
[w/v] agar) containing 125 µg/ml ampicillin, and incubated overnight at 37°C. Colonies 
were subsequently picked for overnight growth in LB (see section 2.7.2). 
2.7.2. Transformation of plasmid DNA 
Plasmid DNA was amplified by the transformation of calcium competent DH5α E. coli 
cells (a kind gift from Dr Mark Shepherd, University of Kent). 1 µl of recovered plasmid 
DNA was added to a 50 µl aliquot of freshly thawed competent cells and allowed to 
incubate on ice for 30 minutes. To heat shock competent cells the DNA/E. coli mixture 
was heated in a 42°C water-bath for one minute, prior to being cooled on ice for two 
minutes, followed by addition of 950 µl of lysogeny broth (LB; 1% [w/v] bacto-tryptone, 
0.05% [w/v] yeast extract, 0.05% [w/v] NaCl) and incubation in a 37°C water-bath at 180 
rpm for 45 minutes. Transformed E.coli was then spread on LB agar plates (1% [w/v] 
bacto-tryptone, 0.05% [w/v] yeast extract, 0.05% [w/v] NaCl and 1.5% [w/v] agar), 
containing 125 µg/ml of ampicillin or 34 µg/ml of chloramphenicol, depending on the 
on the antibiotic resistance gene present on plasmids, and incubated overnight in a 37°C 
incubator. Subsequently, colonies were picked and used to inoculate 10 ml or 30 ml of 
LB, containing 125 µg/ml of ampicillin or 34 µg/ml of chloramphenicol, and incubated at 
37°C overnight in a water-bath at 180 rpm. After overnight culture, glycerol stocks were 
prepared by mixing 500 µl of transformed E. coli (from overnight culture) with 500 µl 
50% (v/v) glycerol in a cryovial, which was then stored at -80°C for future use.  
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2.7.3. Extraction of plasmid DNA 
For small-scale purification of plasmid DNA, 1.5 ml of overnight culture from 
transformed E. coli was used (see section 2.7.2). E. coli cells were pelleted by 
centrifugation at 16,000 x g for 30 seconds followed by extraction of plasmid DNA from 
the cell pellet using a Monarch plasmid miniprep kit, according to manufactures 
instructions (New England Biolabs, USA). Plasmid DNA was eluted in a final volume of 40 
µl TE buffer. For mid-scale purification of plasmid DNA, 30ml of overnight culture from 
transformed E. coli was used (see section 2.7.2). E.coli cells were pelleted by 
centrifugation at 4000 x g for 15 minutes followed by extraction of plasmid DNA from 
the cell pellet using a QIAGEN plasmid plus midi kit, according to the manufacturer’s 
instructions (QIAGEN, Germany), plasmid DNA was eluted in a final volume of 200 µl TE 
buffer. Plasmid DNA concentration was determined using a Nanodrop ND-1000 UV/Vis 
spectrophotometer (Nanodrop, USA).  
2.8. Generation of DUSP6 expressing lentivirus 
2.8.1. Co-transfection of lentiviral plasmids into HEK293T cells 
HEK293T cells were plated in complete DMEM at a density of 3.5 x 106 cells per 10 cm 
dish and allowed to adhere and grow overnight under standard growth conditions. After 
overnight growth, cells were between 50-80% confluent and ready for transfection using 
Lipofectamine 2000. A 50µl Opti-MEM™ solution was prepared containing the following 
amount of lentiviral plasmids: 2 µg pLenti-DUSP6-C-Myc-DDK, 1.5 µg pCMV-dR8.91 and 
1.5 µg pMD2.G. This was mixed 1:1 with a 48% (v/v) Lipofectamine 2000 solution (in 
Opti-MEM™) and incubated at room temperature for 20-30 minutes to allow plasmid 
DNA and Lipofectamine 2000 to complex. Cell culture medium was then removed from 
HEK293T cells, replaced with 8ml Opti-MEM™, and 100µl of complexed plasmid 
DNA/lipid added dropwise. Dishes were then gently agitated to ensure equal 
distribution of the complexed plasmid DNA/Lipid, prior to being incubated for 5 hours 
under standard growth conditions, to allow transfection to proceed. After transfection, 
Opti-MEM™ was aspirated and replaced with complete DMEM and cells grown for a 
further 48 hours under standard growth conditions. Cell culture medium containing 
lentivirus (viral supernatant) was then removed from HEK293T cells, transferred to a 
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50ml falcon and centrifuged at 3000 x g for 1 min, to pellet any cells/cell debris. Viral 
supernatant was subsequently removed from any cells/cell debris that had pelleted and 
passed through a 0.44 µM filter using a syringe, then aliquoted and frozen at -80°C, or if 
supernatant was to be purified, stored overnight at 4°C prior to purification the 
following day.  
2.8.2. Polyethylene glycol purification of lentivirus 
For purification of lentivirus, polyethylene glycol (PEG) purification was performed, 
using a protocol adapted from Kutner and colleagues (Kutner et al., 2009). In order to 
purify lentivirus, the following solution was prepared: 40.8ml crude viral supernatant, 
13.9ml 36.5% (w/v) PEG 6000, 4.3ml 4M NaCl and 1ml of PBS, which resulted in final 
concentration of 8.5% PEG 6000 and 0.3M NaCl in a total volume of 60ml. The solution 
was incubated at 4°C for 1.5 hours, being mixed by gentle inversion every 20-30 minutes. 
After incubation, the solution was aliquoted into two 50 ml tubes and centrifuged at 
7000 x g for 10 minutes at 4°C, to pellet precipitated lentivirus. Supernatant was 
subsequently removed and the pellet, containing purified lentivirus, re-suspended in a 
total volume of 480 µl of 50 mM Tris-HCl pH 7.4. Purified lentiviral vector was then 
vortexed for 20-30 seconds, snap-frozen on dry-ice and stored at -80°C for future use.  
2.9. Generation of transient over-expressing cell lines using lentiviral 
transduction 
Cells were plated in a 6-well plate at 5 x 105 cells per well and allowed to grow overnight 
under standard growth conditions. The next day, cells were 50-80% confluent and ready 
for lentiviral transduction. Lentivirus was diluted, as shown in the text, in complete 
DMEM supplemented with 5-10 µg/ml of hexadimethrine bromide (polybrene; Merck, 
USA). Cell culture medium was then removed from 6-well plates and replaced with 1 ml 
per well of diluted lentivirus, or complete DMEM supplemented with 5-10 µg/ml of 
polybrene to use as a control. Plates were then gently agitated, to ensure an even 
distribution of lentiviral particles, and grown under standard growth conditions for 24 
hours. Cell culture medium was then aspirated off and cells washed in PBS, prior to being 
trypsinised and re-suspended in complete DMEM. Cells were then either plated in 6-
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well plates, for western blot time point analysis (see section 2.5), or in 96-cell plates for 
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3. Investigating AT13148 resistance in A2780-148R 
3.1. Introduction  
In 2012, a project was initiated to identify potential mechanisms of acquired resistance 
to AKT inhibitors, including AT13148. This project was conducted at both the ICR and 
University of Kent, the results of which are currently un-published or published as part 
of a doctoral thesis (Akan, 2015). In this project, resistance was generated against 
AT13148 in the human ovarian carcinoma cell line A2780. A2780 was selected as this 
cell line harbours a loss of function PTEN mutation (383-391 deletion), decreasing PTEN 
lipid phosphatase activity, and a gain of function PIK3CA mutation (E365K substitution), 
increasing p110α PI3K activity (Saito et al., 2000; Wee et al., 2008; Hanrahan et al., 2012; 
cancer.sanger.ac.uk - COSMIC: the cataologue of samatic mutations in cancer). 
Together, these mutations cause hyperactive PAM pathway signalling in A2780, a 
potential clinical indication for use of AT13148 (section 1.5). 
Resistance to AT13148 was generated by dose-escalation, a process whereby the 
concentration of AT13148 that A2780 cells were exposed to was incrementally 
increased over a 6-month period. At the end of this process, an A2780 derived AT13148 
resistant cell line was generated, A2780-148R, which was routinely sub-cultured in 5.2 
µM AT13148, 13x the GI50 of parental A2780 cells against AT13148 (0.40 µM, Table 3.1). 
A2780-148R was subsequently used as model to investigate mechanisms of acquired 
resistance to AT13148.  
As part of the project extensive cross-resistance profiling was conducted on A2780-
148R, the results of which are summarised in Table 3.1. One of the most interesting 
findings of cross-resistance profiling was that A2780-148R cells were sensitive to 
linsitinib and NVP-AEW541, both inhibitors of IGF-1R. In addition, IGF-1R was found to 
be over-expressed via microarray analysis, which was later validated at the protein level 
using western blotting. The over-expression of IGF-1R was subsequently investigated as 
a mechanism of resistance to AT13148.  
To this end, A2780 cell line clones stably expressing IGF-1R were generated to assess if 
over-expression of IGF-1R alone could confer resistance to AT13148. However, the level 
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of IGF-1R over-expression was not found to correlate with resistance to AT13148, thus 
suggesting that the over-expression of IGF-1R alone was not sufficient to confer the 
AT13148-resistant phenotype. In addition, the inverse experiment was performed, 
whereby IGF-1R was knocked-down in A2780-148R cells using siRNA. Whilst knockdown 
of IGF-1R did not sensitize A2780-148R cells to AT13148, it did significantly reduce 
viability in untreated A2780-148R cells, but not A2780 cells, pheno-copying the effect of 
IGF-1R inhibition. Together, these data suggested that the over-expression IGF-1R alone 
does not confer resistance AT13148, but that A2780-148R cells have an increased 
dependency on IGF-1R for their growth and survival. Therefore, IGF-1R inhibition may 
still be a valid therapeutic strategy in AT13148 resistant tumours over-expressing IGF-
1R.  
The over-expression of IGF-1R was the only candidate mechanism of resistance that was 
identified and investigated in A2780-148R. However, cross-resistance profiling did 
reveal other notable changes, which could be implicated in resistance. Perhaps the most 
striking was that A2780-148R cells were found to be cross-resistant to two ROCK 
inhibitors: Y-27632 and GSK429286A (Table 3.1). This was of particular interest since 
ROCK1 and 2 are potently inhibited by AT13148 and clinically relevant targets. Cross-
resistance profiling also demonstrated that A2780-148R cells were sensitive to 
AZD4547, an FGFR inhibitor (Table 3.1). This was in parallel with upregulation in the gene 
expression of fibroblast growth factor receptor 1 & 2 (FGFR1 and FGFR2) in A2780-148R, 
which was identified by microarray analysis (Akan, 2015).  
However, whilst the cross-resistance profiling previously performed had been extensive, 
some important targets had been overlooked (Table 3.1). One such target was the Src 
family of kinases (SFKs), a family of non-receptor tyrosine kinases renowned for being 
pleiotropic, interacting with several different pathways (Bromann et al., 2004). In 
particular, SFKs are known to interact with a number of receptor tyrosine kinases (RTKs), 
for example, Src, the founding member of SFK’s, has been shown to phosphorylate 
autophosphorylation sites on IGF-1R, inducing its activation (Peterson et al., 1996; 
Bromann et al., 2004). In addition, Src has also been shown to regulate ROCK signalling 
via its activating tyrosine phosphorylation of p190RhoGAP (GAP: GTPase activating 
protein), which potentiates hydrolysis of GTP to GDP, inactivating Rho and therefore its 
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downstream effectors ROCK1 & 2 (Fincham et al., 1999). Since A2780-148R has been 
shown to have increased sensitivity to IGF-1R inhibition, as well as increased IGF-1R 
expression, and cross-resistance to ROCK inhibition, SFK’s are a worthwhile target for 
cross-resistance profiling.  
In summary, the previous work conducted on acquired resistance to AT13148 in A2780-
148R has helped gain clinically relevant insight into AT13148 resistance, however, a 
bona fide mechanism of resistance has not been identified. Therefore, the aim of this 
chapter was to further investigate mechanisms of acquired resistance to AT13148 using 
A2780-148R as a model. Initially, to ensure A2780-148R was behaving as previously 
described, key findings, such as IGF-1R over-expression and sensitivity to IGF-1R 
inhibition, were validated. In addition, cross-resistance to ROCK inhibition and sensitivity 
to FGFR inhibition were investigated, and cross-resistance profiling extended to include 
SFK inhibitors. Furthermore, the potential contribution of the MAPK pathway to 
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Table 3.1: Summary of previous cross-resistance profiling conducted on A2780-148R. Table summarises 
GI50 and resistance factor (RF; A2780-148R GI50/A2780 GI50) data from cross-resistance profiling. Data 
points are the mean ± SD of all experiments conducted. Cross-resistance (RF ≥ 2.00) was highlighted in 
red and sensitivity (RF ≤ 0.50) in green. Statistical significance calculated using a student’s t-test, * p ≤ 
0.05, ** p ≤0.01, *** p ≤ 0.001. n ≥ 3 independent experiments. Data adapted from a doctoral thesis 






Drug Target GI50  GI50  RF 
5 FdU (nM)  Pyrimidine analogue 51.10 ± 17.00 36.10 ± 3.90  0.71 
AT13148 (µM) AGC kinases 0.40 ± 0.17 3.71 ± 0.68 * 9.25 
AUY-922 (nM) HSP90 5.50 ± 1.00 4.7 ± 0.40 0.85 
AZD2014 (μM)   mTORC1/2 0.03 ± 0.03 0.05 ± 0.04* 1.67 
AZD4547 (µM) FGFR 1-3 0.09 ± 0.05 0.02 ± 0.01* 0.22 
Capiverasertib (µM) AKT 0.72 ± 0.21 0.77 ± 0.19  1.07 
BI-D1870 (µM) p90RSK 2.02 ± 0.19 1.20 ± 0.07** 0.59 
Bleomycin (IU ml-1) DNA 0.10 ± 0.04 0.05 ± 0.02  0.50 
Cisplatin (μM) DNA 1.09 ± 0.42 1.19 ± 0.32  1.09 
Crizotinib (µM) ALK/MET/ROS1 0.24 ± 0.02 0.19 ± 0.02* 0.79 
Doxorubicin (nM)  DNA 8.66 ± 2.86 8.14 ± 3.94  0.94 
Everolimus (nM)  mTORC1 1.43 ± 0.49 3.23 ± 0.99*  2.26 
GDC-0879 (µM) B-RAF 7.19 ± 3.53 5.49 ± 2.93 0.76 
GDC-0941 (μM)   PI3K 0.10 ± 0.03 0.10 ± 0.03 1.00 
GSK2334470 (µM) PDK1 1.01 ± 0.08 0.98 ± 0.38 0.97 
GSK429286A (µM) ROCK 3.98 ± 1.10 40.30 ± 5.70*** 10.13 
H1152 (µM) ROCK 0.78 ± 0.15 1.24 ± 0.45 1.59 
INCB018424 (µM) JAK1/2 15.10 ± 1.20 14.40 ± 1.40 0.95 
Lapatinib (µM) EGFR/HER2 4.71 ± 0.48 6.04 ± 0.16* 1.28 
Linsitinib (μM)   InsR/IGF-1R 5.91 ± 2.61 0.75 ± 0.57* 0.13 
Mitomycin C (nM)  DNA 13.4 ± 6.0 9.8 ± 5.6  0.73 
MK2206 (µM) AKT 0.30 ± 0.25 0.29 ± 0.21  0.97 
Nintedanib (μM)  VEGFR/FGFR/PDGFR 0.40 ± 0.11 0.47 ± 0.15 1.18 
NVP-AEW541 (µM)  IGF1R 3.05 ± 0.35 0.18 ± 0.03*** 0.06 
Paclitaxel (nM)  Tubulin 1.19 ± 0.50 1.95 ± 0.82  1.63 
PD0325901 (µM) MEK 0.069 ± 0.030 0.098 ± 0.049 1.42 
PF4708671 (µM) p70S6K 8.30 ± 1.96 16.70 ± 3.20* 2.01 
PI-103 (μM)   PI3K/mTOR/DNA-PK 0.11 ± 0.04 0.12 ± 0.03  1.09 
PP242 (μM)   mTORC1/2 0.12 ± 0.02 0.12 ± 0.03  1.00 
SB203580 (µM) p38 MAPK 32.3 ± 4.6 37.1 ± 4.6 1.15 
SN38 (nM)  Topoisomerase I 2.30 ± 0.01 1.88 ± 0.13**  0.82 
Y-27632 (µM) ROCK 19.00 ± 3.00 58.70 ± 4.50*** 3.09 
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3.2. Results 
3.2.1. Growth characterisation of A2780 and A2780-148R cells 
Before SRB cell viability assays could be performed, the optimal seeding densities for 
A2780 and A2780-148R cells in a 96-well plate were established. This was to ensure that 
both cell lines were in log phase growth and had similar growth kinetics during the 96-
hour drug treatment window of a standard 6-day SRB cell viability. Therefore, one could 
be confident that results obtained from SRB cell viability assays were due to genuine 
differences in how the cells responded to a drug, rather than an artefact caused by a 
difference in growth kinetics.  
Cells were plated at various densities in 96-well plates, and one plate fixed per day, and 
analysed via SRB assay. Figure 3.1 shows that the optimal seeding density for A2780 and 
A2780-148R was 800 and 1600 cells per well respectively. At these densities, cells were 
at log phase growth between 48 hours and 144 hours, the 96-hour drug treatment 
window in a standard 6-day SRB cell viability assay. In addition, when the optimal 
seeding densities were superimposed on one another, it was shown that they had near 
identical growth (Figure 3.1). The doubling times for A2780 and A2780-148R, when 
plated at their optimal seeding density, was also calculated using the following equation 
(OD: optical density):  
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 =
96 ℎ𝑜𝑢𝑟𝑠 ∗ log(2)
log(𝑂𝐷 𝑎𝑡 144 ℎ𝑜𝑢𝑟𝑠) − log(𝑂𝐷 𝑎𝑡 48 ℎ𝑜𝑢𝑟𝑠)
 
The doubling times were found to be very similar with A2780 having a doubling time of 
23.6 hours and A2780-148R 26.5 hours (Figure 3.1). Taken together, optimal seeding 
densities for A2780 and A2780-148R were established that enabled near-identical 
growth kinetics over the course of a standard 6-day SRB cell viability assay.  
  








Figure 3.1: Characterisation of A2780 and A2780-148R cell line growth in a 96-well plate. Cells were 
plated at the densities indicated, with 6 replicates per density, in 96-well plates. A plate was fixed every 
24 hours and analysed via SRB assay. Growth curves were generated using GraphPad Prism 6 for (A) A2780 
(B) A2780-148R (C) over-lay of selected optimal seeding densities for A2780 and A2780-148R. T=0h and 
T=96h highlight the 96-hour time period in which cells would be treated with drug in a standard 6-day SRB 
cell viability assay. Data points represent the mean ± SD of one representative experiment. (D) Table 
summarises the doubling times of A2780 and A2780-148R in a 96-well plate at their optimal seeding 
densities. Data points represent the mean ± SD from n = 3 independent experiments. 
Doubling time (hours) 
A2780 (800 cells/well) A2780-148R (1600 cells/well) 
23.6 ± 1.4 26.5 ± 1.4 
D 
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3.2.2. Response of A2780 and A2780-148R to AT13148 and DMSO 
After their optimal seeding densities had been established, A2780 and A2780-148R 
could be further characterised by SRB cell viability assays. This was used to generate 
dose-response curves to drugs/tool compounds and identify GI50 values, the 
concentration of drug required to cause a 50% reduction in cell viability in a standard 6-
day SRB cell viability assay. The GI50 values could then be used to calculate a resistance 
factor (RF, equation shown below), a ratio of resistant cell line GI50 to parental cell line 
GI50, a measure of resistance/sensitivity. E.g. an RF value of 2 would indicate 2-fold 
resistance to a drug, whereas an RF value of 0.5 would indicate 2-fold sensitivity.  
 
 
At first, it was crucial to validate the resistance of A2780-148R against AT13148. Figure 
3.2A & C shows that A2780-148R was resistant to AT13148; the GI50 for parental A2780 
cells was 0.27µM, whereas A2780-148R had a GI50 of 1.36µM. This was shown to be 
statistically significant and equated to an RF value of 5.04 (Figure 3.2A & C). This was 
lower than what has been previously described for AT13148 (RF = 9.25, Table 3.1), but 
nonetheless validated the resistance of A2780-148R against AT13148 and its use as a 
model to identify acquired mechanisms of resistance to AT13148. 
Since all the drugs used in chapter 3 were dissolved in DMSO, a polar aprotic solvent 
which can be toxic to cells (Jamalzadeh et al., 2016), DMSO toxicity was assessed in a 
standard 6-day SRB cell viability assay. Figure 3.2B shows that A2780 and A2780-148R 
responded in a similar manner to DMSO. From the dose-response curves it was 
determined that 0.2% was the maximum concentration of DMSO that could be used 
without significantly effecting cell viability in this assay format. Therefore, where 
possible, the highest concentration of DMSO to be used in SRB cell viability assays was 
0.2%. 
  






















Figure 3.2: Dose-response curves for AT13148 and DMSO, and GI50 determination for AT13148, in A2780 
and A2780-148R cells. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard 
growth conditions for 48 hours. They were then treated with a serial dilution of AT13148 or DMSO for 96-
hours, prior to being analysed by an SRB assay. Dose-response graphs were generated for (A) AT13148 
and (B) DMSO using GraphPad Prism 6, curves were fitted using non-linear regression. Dotted line marks 
the GI50 of AT13148 or effect of 0.2% DMSO. Data points represent the mean ± SD from one representative 
experiment. (C) Table summarises AT13148 GI50 and RF, data points are the mean ± SD of all experiments 
conducted. Statistical significance was calculated using a student’s t-test, *** p ≤ 0.001. n = 17 (AT13148) 








Drug GI50 GI50 RF 
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3.2.3. Light microscopy of A2780 and A2780-148R 
Cancer cells exhibit a wide variety of morphologies which are related to their tissue of 
origin, adaptive changes during tumorigenesis, and can also be altered during therapy 
resistance. Therefore, the morphology of A2780 and A2780-148R was investigated 
under light microscopy, to see if any insight could be gained into their response to 
AT13148 and possibly resistance. Figure 3.3 shows that A2780 cells had a similar 
morphology to what has been previously described (Haslehurst et al., 2012); they grew 
as compact ‘pebble-like’ clusters, with cells having a rounded/polygonal morphology, 
consistent with an epithelial phenotype. A2780-148R had a similar morphology, 
displaying an epithelial phenotype, however they appeared slightly larger and grew in a 
less compact manner; growing as large branches of inter-connected cells (Figure 3.3). 
Both A2780 and A2780-148R didn’t appear to undergo contact-inhibition; cells grew on 
top of one another, particularly with A2780 cells (Figure 3.3) 
Cells were also treated with 5.2 µM of AT13148, the concentration that A2780-148R is 
routinely cultured in (maintenance dose of AT13148) and allowed to grow for 48 hours. 
In response to AT13148, A2780 and A2780-148R both developed a “spindle-like 
morphology”, with cells becoming long and thin (Figure 3.3). However, it should be 
noted that the spindle-like morphology was only seen in a subset of the total population 
of cells. A2780 cells also appeared to be undergoing membrane blebbing, suggesting an 
apoptotic response to AT13148, which was not apparent in A2780-148R, both treated 
and untreated, or untreated A2780 cells (Figure 3.3).  
  

















Figure 3.3: Images of untreated and AT13148 treated A2780 and A2780-148R cells under light 
microscopy.  Cells were split into T25 flasks to allow 2-3 days growth, and either left untreated or treated 
with 5.2µM AT13148. After 48 hours, when cells were ~70% confluent, cells were observed under a light 
microscope at (A) x40 or (B) x100 magnification, and images taken. Images representative of two 
independent experiments. 
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3.2.4. Cross-resistance profiling of A2780-148R 
Cross-resistance profiling was undertaken by performing SRB cell viability assays using 
various drugs and tool compounds targeting several different signalling pathways. 
Identifying a differential response (resistance or sensitivity) of A2780-148R, when 
compared to A2780, may provide insight into mechanisms of resistance against 
AT13148.  
3.2.4.1. AKT inhibition 
AT13148 is known to target both AKT1 and AKT3 (Yap et al., 2012), so it’s possible that 
altered signalling within the PAM pathway could contribute towards resistance against 
AT13148. Therefore, A2780 and A2780-148R cells were profiled with the ATP-
competitive pan-AKT inhibitor capiverasertib (AZD5363, Davies et al., 2012). Figure 3.4 
shows A2780 had a GI50 of 0.18 µM, whereas A2780-148R had GI50 of 0.55 µM. This 
difference was statistically significant, resulting in an RF value of 3.06, indicating low-
level cross-resistance (Figure 3.4). However, it should be noted that this was not 










Figure 3.4: Dose-response curves and GI50 determination for capiverasertib in A2780 and A2780-148R 
cells. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard growth 
conditions for 48 hours. They were then treated with a serial dilution of capiverasertib for 96-hours, prior 
to being analysed by SRB assay. Dose-response graphs and non-linear regression curves were generated 
using GraphPad Prism 6. Dotted line marks 50% viability on the y-axis. Data points represent the mean ± 
SD from one representative experiment. Table summarises capiverasertib GI50 and RF, data points 
represent the mean ± SD of all experiments conducted. Statistical significance was calculated using a 
student’s t-test, * p ≤ 0.05. n = 3 independent experiments. 
 
A2780 A2780-148R 
Drug GI50 GI50 RF 
Capiverasertib (µM) 0.18 ± 0.02 0.55 ± 0.013* 3.06 
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3.2.4.2. ROCK inhibition  
Previous work had demonstrated that A2780-148R cells were cross-resistant to ROCK 
inhibition (Table 3.1). In order to validate this, cross-resistance to ROCK inhibition was 
investigated using two ROCK inhibitors: GSK429286A, which A2780-148R had previously 
been shown to be cross-resistant to (Table 3.1), and GSK269962, a more potent ROCK 
inhibitor (Lotz-Jenne et al., 2016). Figure 3.5A & C shows that there was a statistically 
significant difference in the response to GSK429286A; A2780 had a GI50 of 1.89 µM and 
A2780-148R had a GI50 of 40.43 µM. This resulted in an RF value of 21.39, indicating a 
high level of cross-resistance to GSK429286A (Figure 3.5C), and ~2-fold increase 
compared to what had been shown previously (RF = 10.13, Table 3.1). However, the 
cross-resistance to GSK269962 was shown to be even greater; the GI50 of A2780 was 
0.02 µM compared to 1.72 µM in A2780-148R (Figure 3.5B & C). This difference was also 
statistically significant, resulting in an RF value of 86.00, demonstrating a strong level of 
cross-resistance to GSK269962 (Figure 3.5C). Taken together, these data validate cross-
resistance to ROCK inhibition, perhaps suggesting altered ROCK signalling in AT13148 
resistance, which warrants further investigation.  
  

























Figure 3.5: Dose-response curves and GI50 determinations for GSK429286A and GSK269962 in A2780 
and A2780-148R cells. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard 
growth conditions for 48 hours. They were then treated with a serial dilution of GSK429286A or 
GSK269962 for 96-hours, prior to being analysed by SRB assay. Dose-response graphs and non-linear 
regression curves were generated for (A) GSK429286A or (B) GSK269962 using GraphPad Prism 6. Dotted 
lines mark 50% viability on the y-axis. Data points represent the mean ± SD from one representative 
experiment. (C) Table summarises GI50 and RF values, data points represent the mean ± SD of all 
experiments conducted. Statistical significance was calculated using a student’s t-test, * p ≤ 0.05, *** p ≤ 




Drug GI50 GI50 RF 
GSK429286A (µM) 1.89 ± 1.10 40.43 ± 20.96* 21.39 
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3.2.4.3. IGF-1R and FGFR inhibition  
One of the most remarkable findings of the previous work conducted on A2780-148R 
was the overexpression of IGF-1R and sensitivity to IGF-1R inhibition.  In addition, 
A2780-148R was also found to show some sensitivity to FGFR inhibition. This apparent 
dependency on some RTKs was investigated using NVP-AEW541 and AZD4547, IGF-1R 
and FGFR inhibitors respectively.   
Just as was observed previously it was found that A2780-148R was sensitive to both 
NVP-AEW541 and AZD4547 (Figure 3.6A-C). Figure 3.6A, C shows that A2780-148R was 
~7-fold more sensitive to NVP-AEW541 than parental A2780 cells (RF = 0.14); A2780 had 
a GI50 of 1.56 µM compared to 0.22 µM for A2780-148R. However, A2780-148R cells 
were even more sensitive to AZD4547; A2780 had a GI50 of 0.52 µM whereas the GI50 for 
A2780-148R was 0.03 µM, which meant that A2780-148R was ~17-fold more sensitive 
(RF = 0.06) to AZD4547 (Figure 3.6B). The sensitivity to both NVP-AEW541 and AZD4547 
was statistically significant (Figure 3.6A, B). It should be noted that whilst sensitivity to 
NVP-AEW541 and AZD4547 was consistent with previous results (Table 3.1), there were 
some differences in RF values, particularly for AZD4547 (previous RF value in Table 3.1: 
0.22 vs 0.06 in Figure 3.6C) 
 
  






















Figure 3.6: Dose-response curves and GI50 determinations for NVP-AEW541 and AZD4547 in A2780 and 
A2780-148R cells. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard 
growth conditions for 48 hours. They were then treated with a serial dilution of NVP-AEW541 and 
AZD4547 for 96-hours, prior to being analysed by SRB assay. Dose-response graphs and non-linear 
regression curve fits were generated for (A) NVP-AEW541 or (B) AZD4547 using GraphPad Prism 6. Dotted 
lines mark 50% viability on the y-axis. Data points represent the mean ± SD from one representative 
experiment. (C) Table summarising GI50 and RF, data points are the mean ± SD of all experiments 
conducted. Statistical significance was calculated using a student’s t-test, ** p ≤ 0.01, *** p ≤ 0.001. n = 4 





Drug Target GI50 GI50 RF 
NVP-AEW541 (µM) IGF-1R 1.56 ± 0.22 0.22 ± 0.04** 0.14 
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3.2.4.4. SFK inhibitors 
Together, the cross-resistance profiling previously conducted (Table 3.1), and 
undertaken thus far in this chapter (Figure 3.4-Figure 3.6), had provided a broad 
overview of the responsiveness of A2780 and A2780-148R cells to a broad range of drugs 
and tool compounds. However, inhibitors had not been used against SFKs, a family of 
non-receptor tyrosine kinases, which are pleiotropic and known to interact with IGF-1R 
and the ROCK pathway (Peterson et al., 1996; Fincham et al., 1999). As such, cross-
resistance profiling was performed using several inhibitors of the SFK’s. 
Figure 3.7 shows that there was low-level of cross-resistance to WH-4-023, an inhibitor 
of c-Src and lymphocyte-specific protein tyrosine kinase (Lck). A2780 had a GI50 of 0.85 
µM against WH-4-023, compared to a GI50 of 1.82 µM in A2780-148R, a statistically 
significant difference, equating to an RF value of 2.14 (Figure 3.7). In contrast, A2780-
148R was shown to be slightly sensitive to KX2-391, a peptidomimetic c-Src-specific 
inhibitor; A2780-148R had a GI50 of 17.70 µM compared to 25.24 µM in A2780, 
representing an RF value of 0.70, but this was not statistically significant (Figure 3.7). 
SU6656, a broad SFK inhibitor, was also used, but there was no difference in response; 
both A2780 and A2780-148R had a GI50 of 0.66 µM (Figure 3.7). In summary, cross-
resistance profiling using inhibitors of SFK’s did not reveal any substantial differences 
between A2780 and A2780-148R. 
  











Drug Target(s) GI50 GI50 RF 
WH-4-023 (µM) Lck & Src 0.85 ± 0.11 1.82 ± 0.20** 2.14 
KX2-391 (nM) Src 25.24 ± 3.97 17.70 ± 4.48 0.70 
SU-6656 (µM) SFK 0.66 ± 0.22 0.66 ± 0.20 1.00 
 
Figure 3.7: Dose-response curves and GI50 determinations for SFK inhibitors in A2780 and A2780-148R 
cells. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard growth 
conditions for 48 hours. They were then treated with a serial dilution of SFK inhibitors for 96-hours, prior 
to being analysed by SRB assay. Dose-response graphs and non-linear regression curve fits were generated 
for using GraphPad Prism 6. Dotted lines show the GI50. Data points represent the mean ± SD from one 
representative experiment. Table summarising GI50 and RF, data points are the mean ± SD of all 
experiments conducted. Statistical significance was calculated using a student’s t-test, * p ≤ 0.05, ** p ≤ 
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3.2.5. Analysis of basal signalling in A2780 and A2780-148R 
3.2.5.1. Markers of PAM pathway signalling  
AT13148 is known to target both AKT and p70S6K, both of which act within the PAM 
pathway. It was therefore important to understand how this pathway was functioning 
in A2780-148R, compared to parental A2780 cells, as differences could contribute 
towards AT13148 resistance. As such, the expression of markers of the PAM pathway 
were assessed at the basal level. A2780-148R cells were released from AT13148 for one 
week prior to assaying or maintained in 5.2 µM of AT13148 (maintenance dose). 
Figure 3.8 shows that the phosphorylation of S473 AKT was similar between parental 
A2780 cells and released A2780-148R cells. However, there was a marked increase in 
S473 AKT phosphorylation in maintained A2780-148R cells, consistent with what has 
previously been described for ATP-competitive AKT inhibitors (Figure 3.8, Okuzumi et 
al., 2009). The phosphorylation of two direct substrates of AKT, T246 PRAS40 and S9 
GSK3β, was also assessed. T246 PRAS40 phosphorylation was similar in released A2780-
148R cells, when compared to parental A2780 cells, but the phosphorylation of S9 
GSK3β was slightly reduced (Figure 3.8). In maintained A2780-148R cells, the 
phosphorylation of both T246 PRAS40 and S9 GSK3β was decreased, consistent with 
inhibition of AKT by AT13148 (Figure 3.8). Further down the pathway, the 
phosphorylation of S235/236 S6RP, a p70S6K substrate, was also shown to be 
unchanged in released A2780-148R cells, but as expected, substantially lowered in 
maintained A2780-148R cells (Figure 3.8). The total expression of the aforementioned 
proteins was found to be consistent across all cell lines/conditions (Figure 3.8). Taken 
together, these data show that the PAM pathway was mostly unchanged in A2780-148R, 
at basal level, and that AT13148 was still able to reduce PAM pathway activation. 
  






































Figure 3.8: Analysis of the basal expression of markers of the PAM pathway in A2780 and A2780-148R. 
A2780-148R cells were either released (R) from AT13148 one week prior to plating or maintained (M) in 
5.2 µM AT13148. Cells were plated at 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and 
allowed to grow for 72 hours under standard growth conditions, with maintained A2780-148R cells grown 
in the presence of 5.2 µM AT13148. Cells were then lysed prior to western blot analysis. Western blot 
membranes were probed with antibodies for phospho-proteins, stripped, and then re-probed with 




3.2.5.2. Markers of ROCK pathway signalling 
Since both isoforms of ROCK are targeted by AT13148 and cross-resistance to ROCK 
inhibitors was shown (Figure 3.5), basal signalling of the ROCK pathway was assessed in 
parental A2780 cells and released A2780-148R cells. Figure 3.9 shows that the total 
expression of ROCK1 and ROCK2 remained unchanged between A2780 and A2780-148R 
cells. Conversely, there appeared to be a slight reduction in phosphorylation of T696 
MYPT1, a substrate of ROCK, in A2780-148R, whilst the total expression of MYPT1 
remained the same (Figure 3.9). This could indicate lower ROCK pathway activity in 
A2780-148R and possibly a lower dependency on ROCK signalling, which could 
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contribute towards AT13148 resistance. However, this change was only small, and 
investigating the response of the ROCK pathway to AT13148 would provide a much 












Figure 3.9: Analysis of the basal expression of markers of the ROCK pathway in A2780 and A2780-148R. 
A2780-148R cells were released (R) from AT13148 one week prior to plating. A2780 and A2780-148R cells 
were plated at either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and allowed to grow 
for 48 hours under standard growth conditions. Cells were then lysed prior to western blot analysis. 
Western blot membranes were probed with antibodies for phospho-proteins, stripped, and then re-
probed with antibodies for total proteins and loading control (GAPDH). Data are representative of four 
(ROCK1 & 2) or six (MYPT1) independent experiments. 
 
 
3.2.5.3. IGF-1R and FGFR2 expression  
The expression of IGF-1R and FGFR2 was assessed in order to investigate the sensitivity 
to IGF-1R and FGFR inhibition (Figure 3.6A, B). IGF-1R expression was assessed in both 
released and maintained A2780-148R cells, whereas FGFR2 expression was only 
assessed in released A2780-148R cells. As expected, IGF-1R was shown to be 
considerably over-expressed in both released and maintained A2780-148R cells (Figure 
3.10A). However, IGF-1R was expressed at a greater level in maintained A2780-148R 
cells, when compared to released A2780-148R cells, which has previously not been 
identified (Figure 3.10A). Contrary to the previously described microarray data (section 
3.1), FGFR2 was shown to be expressed at the same level both released A2780-148R 
cells and parental A2780 cells (Figure 3.10B).  
 








Figure 3.10: Analysis of the basal expression of IGF-1R and FGFR2 in A2780 and A2780-148R. A2780-
148R cells were either released (R) from AT13148, one week prior to the experiment, or maintained (M) 
in 5.2 µM AT13148. A2780 and A2780-148R cells were plated at either 0.5 x 106 (A2780) or 1 x 106 (A2780-
148R) cells per 10 cm dish and allowed to grow for 72 hours under standard growth conditions, with 
maintained A2780-148R cells grown in the presence of 5.2 µM AT13148. Cells were then lysed prior to 
western blot analysis. Western blot membranes were probed with antibodies for (A) IGF-1R and (B) 
FGFR2, stripped, and then re-probed with an antibody for β-Actin (loading control). Data are 
representative of four (IGF-1R) or five (FGFR2) independent experiments. 
 
3.2.5.4. Markers of the MAPK pathway 
The MAPK pathway was also investigated in A2780 and released A2780-148R cells, as it 
is a major growth factor pathway commonly associated with resistance to a number of 
different cancer therapies (Garraway and Jänne, 2012). Figure 3.11 shows that there was 
a slight increase in the phosphorylation of ERK 1/2 at Thr202/Tyr204 in A2780-148R, 
however, in contrast, there was a small decrease in S217/221 MEK 1/2 phosphorylation 
in A2780-148R (Figure 3.11). Since ERK 1/2 is only known to be phosphorylated by MEK 
1/2 this finding was unexpected; one would usually expect MEK 1/2 phosphorylation to 
be increased if ERK 1/2 phosphorylation was. The total protein expression of both ERK 
1/2 and MEK 1/2 remained the same between parental A2780 cells and A2780-148R 

























Figure 3.11: Analysis of the basal expression of markers of the MAPK pathway in A2780 and A2780-
148R. A2780-148R cells were released (R) from AT13148 one week prior to plating. A2780 and A2780-
148R cells were plated at either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and allowed 
to grow for 72 hours under standard growth conditions. Cells were then lysed prior to western blot 
analysis. Western blot membranes were probed with antibodies for phospho-proteins, stripped, and then 
re-probed with antibodies for total proteins or loading control (β-Actin). Data are representative of four 
(MEK 1/2) or five (ERK 1/2) independent experiments. 
 
3.2.6. Analysis of signalling pathway response to AT13148 
The investigation into the basal activity of several key signalling pathways did not reveal 
any dramatic differences between A2780 and A2780-148R cells, especially in pathways 
targeted by AT13148 (PAM and ROCK pathways). Despite this, these pathways might 
have still exhibited a differential response to AT13148, which could have contributed 
towards AT13148 resistance. Therefore, A2780 and A2780-148R cells were treated with 
a range of AT13148 concentrations, between 0.1 µM – 10 µM, and the response of key 
signalling pathways assessed via western blot analysis. 
3.2.6.1. Biomarkers of AT13148 target inhibition 
Initially, the response of substrates downstream of AKT and p70S6K, targets of AT13148, 
was investigated, in order to assess if AT13148 was still able to effectively inhibit the 
PAM pathway in A2780-148R. Figure 3.12 shows that the phosphorylation of PRAS40 
decreased in a similar manner in both A2780 and A2780-148R; T246 PRAS40 
phosphorylation was unaffected at 0.1 µM – 1µM of AT13148, but almost completely 
lost at ≥ 5 µM (Figure 3.12). Phosphorylation of S6RP was similarly unchanged but 
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appeared to be more potently affected by AT13148 than PRAS40 phosphorylation; in 
both A2780 and A2780-148R, only 0.5-1 µM of AT13148 was required to cause a 
reduction in S235/236 S6RP phosphorylation, and at ≥ 5 µM there was little signal 
remaining (Figure 3.12). The total protein expression of PRAS40 and S6RP appeared to 
be unaffected by AT13148 in both A2780 and A2780-148R (Figure 3.12). 
The response of the ROCK pathway to AT13148 was also evaluated by measuring the 
phosphorylation of MYPT1, a substrate of ROCK1 and 2. Just as with the PAM pathway, 
the ROCK pathway had a near-identical response to AT13148 in A2780 and A2780-148R 
(Figure 3.12). In both cell lines, 0.1 µM of AT13148 caused sharp reduction in the 
phosphorylation of MYPT1 at T696, however, increasing the concentration of AT13148 
beyond 0.1 µM did not seem to have any additional affect (Figure 3.12). The total 
expression of MYPT1 also appeared to be mostly unaffected by AT13148 in both A2780 
and A2780-148R (Figure 3.12). Taken together, these data show that the PAM and ROCK 
















Figure 3.12: Analysis of markers of the PAM and ROCK pathways in response to AT13148. Cells were 
plated at either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and allowed to grow for 48 
hours under standard growth conditions. Cells were then treated with AT13148, as shown (0 µM = 
untreated), or D: DMSO vehicle control for 4 hours prior to being lysed for western blot analysis. Western 
blot membranes were probed with antibodies for phospho-proteins, stripped, and then re-probed with 
antibodies for total proteins or loading control (GAPDH or β-Actin) Data are representative of four 
(PRAS40 & S6RP) or three (MYPT1) independent experiments. 
 
3.2.6.2. Markers of the MAPK pathway 
AT13148 is not known to directly target the MAPK pathway, however, it was shown in 
Figure 3.11 that there was slight increase in ERK 1/2 phosphorylation in A2780-148R. 
This could possibly indicate that the MAPK pathway is affected by AT13148 and that it 
was altered in A2780-148R, contributing towards AT13148 resistance. The response of 
the MAPK pathway to AT13148 was therefore assessed, using ERK 1/2 phosphorylation 
as a biomarker of MAPK pathway activation. Figure 3.13 shows that the MAPK pathway 
responded to AT13148, in both A2780 and A2780-148R, but in a distinctive manner from 
one another. In A2780, the phosphorylation of ERK 1/2 at Thr202/Tyr204 was decreased 
with 0.1 µM AT13148, but there was an increase with ≥ 0.5 µM, with a peak in 
Thr202/Tyr204 ERK 1/2 phosphorylation at 5–10 µM AT13148 (Figure 3.13). In A2780-
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148R, concentrations of AT13148 between 0.1 µM and 1 µM didn’t have a great effect 
on Thr202/Tyr204 ERK 1/2 phosphorylation, although it did appear that there was a 
slight reduction (Figure 3.13). However, ≥ 5 µM AT13148 elevated the phosphorylation 
of Thr202/Tyr204 ERK 1/2 in A2780-148R cells (Figure 3.13). Interestingly, the 
phosphorylation of Thr202/Tyr202 ERK 1/2 was greater in A2780-148R, when compared 
to parental A2780 cells, both at a basal level (0 µM AT13148), to a much greater extent 
than in Figure 3.11, and across all AT13148 concentrations used (Figure 3.13). The 
response of the MAPK pathway to AT13148, in A2780 and A2780-148R, warrants further 
investigation as it has the potential to contribute towards resistance and to be exploited 
therapeutically.  
 
Figure 3.13: Analysis of markers of the MAPK pathway in response to AT13148. Cells were plated at 
either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and allowed to grow for 48 hours 
under standard growth conditions. Cells were then treated with AT13148, as shown (0 µM = untreated), 
or D: DMSO vehicle control for 4 hours prior to being lysed for western blot analysis. Western blot 
membranes were probed with antibodies for phospho-proteins, stripped, and then re-probed with 
antibodies for total proteins or loading control (β-Actin). (S): short exposure to hyperfilm, (L): long 
exposure to hyperfilm. Data are representative three independent experiments. 
 
3.2.7. Analysis of the response of signalling pathways to ROCK inhibition 
One of the main findings from cross-resistance profiling presented in this chapter, was 
cross-resistance to ROCK inhibition (Figure 3.5). Therefore, the response of the ROCK 
pathway to the ROCK inhibitor GSK269962 was assessed, in order to investigate the 
potential mechanism of ROCK cross-resistance. Figure 3.14 shows that GSK269962 was 
able to potently inhibit the ROCK pathway in A2780; 0.02 µM GSK269962 was able to 
cause a drastic decrease in the phosphorylation of T696 MYPT1. However, as was seen 
with AT13148 in Figure 3.12, increasing the concentration of GSK269962 beyond 0.02 
µM did not cause any further reductions in T696 MYPT1 phosphorylation (Figure 3.14). 
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In comparison, the phosphorylation of T696 MYPT1 in A2780-148R was shown to be 
partially refractory to GSK269962; ≥ 2.5 µM GSK269962 was required to cause a 
substantial reduction in T696 MYPT1 phosphorylation (Figure 3.14). The total protein 
expression of MYPT1 did not show any response to GSK269962 in either cell line. Taken 
together, these data suggest that there was a partial maintenance of the ROCK pathway 
in response to GSK269962 in A2780-148R.  
 
Figure 3.14: Analysis of markers of the ROCK pathway in response to GSK269962. Cells were plated at 
either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and allowed to grow for 48 hours 
under standard growth conditions. Cells were then treated with GSK269962, as shown, or D: DMSO 
vehicle control for 4 hours prior to being lysed for western blot analysis. Western blot membranes were 
probed with antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total 
proteins or loading control (GAPDH). Data are representative of three independent experiments. 
The response of the MAPK pathway to GSK269962 was also assessed, to investigate if 
the inhibition of ROCK1 & 2 contributed to the MAPK pathway response to AT13148 
seen in Figure 3.13. Figure 3.15 shows that the MAPK pathway did respond to 
GSK269962 in A2780 but not in A2780-148R. In A2780, 0.02 µM GSK269962 caused a 
decrease in Thr202/Tyr204 ERK 1/2 phosphorylation but increasing the GSK269962 
concentration further did not cause any additional decreases (Figure 3.15). This was in 
stark contrast to what was seen in A2780-148R, where none of the concentrations of 
GSK269962 effected Thr202/Tyr204 ERK 1/2 phosphorylation (Figure 3.15). Whilst, in 
both A2780 and A2780-148R, ERK 1/2 total protein did not respond to GSK269962, there 
was a lower expression of total ERK 1/2 protein across all GSK269962 concentrations in 
A2780-148R, when compared to parental A2780 cells (Figure 3.15). In addition, 
Thr202/Tyr204 ERK 1/2 phosphorylation was greater in A2780-148R, when compared to 
A2780, across all concentrations of GSK269962 and in the DMSO vehicle control (Figure 
3.15). In summary, these data show that the activation the MAPK pathway decreased in 
 3. Investigating AT13148 resistance in A2780-148R 
98 



















Figure 3.15: Analysis of markers of the MAPK pathway in response to GSK269962. Cells were plated at 
either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and allowed to grow for 48 hours 
under standard growth conditions. Cells were then treated with GSK269962, as shown, or D: DMSO 
vehicle control for 4 hours prior to being lysed for western blot analysis. Western blot membranes were 
probed with antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total 
proteins or loading control (β-Actin) Data are representative of two independent experiments. 
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3.3. Discussion 
The main aim of this chapter was to investigate the mechanism of acquired resistance 
to AT13148 using A2780-148R as a model. Before this could be undertaken, the 
resistance of A2780-148R to AT13148 was validated. Reassuringly, A2780-148R was 
shown have ~5-fold resistance to AT13148 and could therefore be used as a model to 
investigate acquired mechanisms of AT13148 resistance (Figure 3.2). Subsequently, to 
try and gain insight into AT13148 resistance, the morphology of A2780 and A2780-148R 
was assessed in untreated cells and in response to AT13148 (Figure 3.3). Whilst there 
were some differences between untreated A2780 and A2780-148R cells, these weren’t 
significant, with both morphologies consistent with an epithelial phenotype. In response 
to AT13148 both cell lines exhibited a similar response; cells developed a “spindle-like” 
morphology where they extended long-processes, making the cells become long and 
thin. This response is indicative of inhibition of ROCK1 and 2 and has been previously 
described; Kümper and colleagues (Kümper et al., 2016) described this phenotype in 
mouse embryonic fibroblasts (MEF) with a conditional knockout of ROCK1 and 2, as well 
as in response to the ROCK inhibitor H1152. Furthermore, Rath and colleagues (Rath et 
al., 2018) observed a similar response in PDAC cells treated with AT13148, and showed 
that, in regards to cell morphology, AT13148 pheno-copied ROCK-selective inhibitors. 
Therefore, this “spindle-like” morphology in response to AT13148 in A2780 and A2780-
148R, is likely caused by the inhibition ROCK1 and 2 by AT13148, although the impact of 
the inhibition of other AT13148 targets can’t be discounted. However, this response was 
not ubiquitous in A2780 and A2780-148R, only being observed in sub-set of the total 
population of cells, perhaps highlighting a heterogenous response to AT13148, at least 
in morphology.  
It is also worth noting that some A2780 cells exhibited a morphology indicative of 
apoptosis (membrane blebbing) in response to AT13148 (Saraste and Pulkki, 2000). This 
response was less apparent in A2780-148R, which was interesting considering that 
AT13148 has previously been shown to induce an apoptotic phenotype in cancer cells 
(Yap et al., 2012). It’s possible that A2780-148R cells have been able to overcome this, 
although a more thorough investigation of the apoptotic response would be required to 
ascertain this.  
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In addition, cross-resistance profiling was performed on A2780-148R where it was 
shown that A2780-148R cells were cross-resistant to the AKT inhibitor capiversatib 
(Figure 3.4). Since capiversatib also inhibits p70S6K, as well as AKT, both members of the 
PAM pathway as well as targets of AT13148, this might suggest altered PAM pathway 
signalling in A2780-148R (Davies et al., 2012; Yap et al., 2012). However, the level of 
cross-resistance was relatively low (~3-fold), and capiversatib is also known to target 
kinases outside the PAM pathway, including PKA and ROCK2 (Davies et al., 2012). 
Therefore, it’s difficult to draw any strong conclusions from cross-resistance to 
capiversatib, perhaps a more selective AKT inhibitor, such as MK2206, could be used in 
future (Hirai et al., 2010).  
A2780-148R was also shown to have substantial cross-resistance to ROCK inhibition with 
cross-resistance seen against two ROCK inhibitors: GSK429286A and GSK269962 (Figure 
3.5). Including the previously established cross-resistance to Y-27632, shown in Table 
3.1, cross-resistance has now been observed with three ROCK inhibitors, where, as 
shown in Table 3.2, the level of cross-resistance appears to correlate with the potency 
against ROCK1 and 2, thus giving a high-level of confidence that ROCK cross-resistance 
is genuine. This cross-resistance to ROCK inhibition was of particular interest, since 
AT13148 potently targets ROCK1 & 2 and could potentially be used in the clinic as a 
ROCK inhibitor (Rath et al., 2018). It suggests that the inhibition of ROCK1 & 2 is 
important for the effect of AT13148 in A2780 cells, and therefore, to become resistant 
to AT13148, A2780-148R cells have had to overcome this.  
Table 3.2: Summary of the IC50 against ROCK1 and 2 for different ROCK inhibitors as determined from 
biochemical assays. Table adapted from Lotz-Jenne et al., 2016; ROCK IC50 data was generated using in 




Cross-resistance profiling also validated the previously identified sensitivity to NVP-
AEW541, an IGF-1R inhibitor, and AZD4547, an FGFR inhibitor, in A2780-148R (Figure 
3.6). However, the sensitivity to AZD4547 was much greater than what had been seen 
ROCK inhibitor ROCK1 IC50  ROCK2 IC50 RF 
Y-27632 (nM) 2273.0 1585.0 3.091 
GSK429286A (nM) 46.7 55.3 21.392 
GSK269962 (nM) 7.0 1.2 86.002 
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previously: ~17-fold sensitivity in Figure 3.6 vs ~4.5-fold sensitivity in Table 3.1 
(highlighted in Table 3.3). Whilst there were some differences between data in this 
chapter and that which has been shown previously, this was perhaps the most dramatic, 
warranting an explanation. One potential explanation is that a different batch of FBS 
would have been used, and that FBS is known to have batch to batch variation in the 
concentration of growth factors (Zheng et al., 2008). If the FBS used in this chapter had 
more FGF’s (fibroblast growth factors), than the FBS used previously, then it could lead 
to a greater activation of FGFR signalling and possibly increased dependency. However, 
one wouldn’t expect batch to batch variation to cause such a notable difference, other 
factors should also be considered. Cancer cell lines are known to be heterogenous, due 
to the existence of pre-existing sub-populations, as well as inherent genomic instability 
(Ben-David et al., 2018). Over time with continuous cell culture this can cause genetic 
and population drift, altering drug response, which could have played a role in the 
altered response to AZD4547. Nonetheless, in both datasets sensitivity was seen to IGF-
1R and FGFR inhibition, and this could potentially be applied to patients with resistance 
to AT13148.  
Table 3.3: Comparison of datasets generated for AZD4547 in A2780 and A2780-148R. 1data generated in 
this chapter (Figure 3.6) 2data from previous work (Table 3.1). Statistical significance was calculated using 




A number of drugs/tool compounds targeting SFK’s were also used in cross-resistance 
profiling, as they had previously not been screened for (Figure 3.7). As mentioned in 
section 3.1, SFK’s are known to regulate the activation of IGF-1R as well as negatively 
regulating ROCK signalling, and as such one might expect an altered response to SFK 
inhibition in A2780-148R (Peterson et al., 1996; Fincham et al., 1999). Whilst there was 
low-level cross-resistance to the Src and Lck inhibitor WH-4-023 (~2-fold), none of the 
SFK inhibitors used showed any substantial cross-resistance or sensitivity in A2780-
148R. This would seem to suggest that signalling via SFK’s is unchanged between A2780 
and A2780-148R, and that they are not responsible for IGF-1R sensitivity, ROCK cross-
resistance, or resistance to AT13148.   
 
A2780 A2780-148R 
Drug GI50 GI50 RF 
AZD45471 (µM) 0.52 ± 0.11 0.03 ± 0.01*** 0.06 
AZD45472 (µM) 0.09 ± 0.05 0.02 ± 0.01* 0.22 
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To follow up on cross-resistance profiling, PAM pathway activation was investigated, 
initially at a basal level (Figure 3.8). The activation of the PAM pathway appeared to be 
similar across A2780 and A2780-148R cells, with the phosphorylation of AKT; its 
substrates, PRAS40 and GSK3β; and S6RP, a p70S6K substrate, all shown to be 
unchanged. A2780-148R was also maintained in 5.2 µM AT13148 (maintenance dose of 
AT13148), which was shown to cause a striking increase in the phosphorylation of AKT. 
Due to inhibition of AKT by AT13148, one would intuitively not expect this, but this has 
been previously established to occur in response to AT13148 and not affect the 
phosphorylation of AKT substrates (Yap et al., 2012). This response is common in other 
ATP-competitive AKT inhibitors, such as capiversatib and A-443654, which again, despite 
inhibitor induced AKT phosphorylation, are still able to function as AKT inhibitors 
(Okuzumi et al., 2009; Davies et al., 2012). Okuzumi and colleagues (Okuzumi et al., 
2009) provided a mechanistic explanation for this by showing that A-443634 still induced 
phosphorylation of kinase-dead AKT, demonstrating that relief of negative feedback 
downstream of AKT is not a cause of inhibitor-induced AKT phosphorylation (Okuzumi 
et al., 2009). They suggest a kinase intrinsic mechanism, such as a conformational 
change in AKT decreasing the access of AKT phosphatases (Okuzumi et al., 2009). 
Therefore, as expected, maintained A2780-148R cells had decreased phosphorylation of 
substrates downstream of AKT and p70S6K, despite increased AKT phosphorylation. 
Thus, indicating that AT13148 was still able to inhibit the PAM pathway in A2780-148R, 
but dose-response assays were better able to evaluate this.  
The activation of the ROCK pathway was also assessed at a basal level; as previously 
described, A2780-148R had significant cross-resistance to ROCK inhibition, and this 
could have possibly indicated altered signalling via ROCK1 and 2, targets of AT13148 
(Figure 3.9). Indeed, whilst both isoforms of ROCK had similar expression in A2780 and 
A2780-148R, there was a slight reduction of the phosphorylation of the ROCK substrate 
MYPT1. In isolation, it is difficult to interpret the implication of a reduction in the 
phosphorylation of MYPT1 on the activation of the ROCK pathway. A more 
comprehensive analysis of the pathway would be required to assess this, looking at 
multiple substrates of ROCK. This was attempted by western blotting for the ROCK 
substrates MLC2 and LIMK, but they proved difficult to consistently detect (data not 
shown). However, the decrease in the phosphorylation of MYPT1 could indeed indicate 
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that there was reduced activation of the ROCK pathway in A2780-148R. This could 
explain the cross-resistance to ROCK inhibition; perhaps the ROCK pathway has been by-
passed in A2780-148R.  
The over-expression of IGF-1R was also observed in A2780-148R, validating previous 
results and re-affirming that IGF-1R expression could potentially be used as a biomarker 
for sensitivity to IGF-1R inhibition in AT13148 resistant patients (Figure 3.10A; Akan, 
2015). However, there was a marked difference between A2780-148R released from 
AT13148 and A2780-148R maintained; IGF-1R expression was much greater in 
maintained A2780-148R, suggesting that AT13148, to a certain extent, induces the 
expression of IGF-1R. This could be caused by the relief of negative feedback in the PAM 
pathway, due to the inhibition of AKT by AT13148. Chandarlapaty and colleagues 
(Chandarlapaty et al., 2011) showed that AKT inhibition increases the expression of IGF-
1R in a FoXO dependent manner, in a number of cancer cell lines. A similar effect was 
also seen by Zorea and colleagues (Zorea et al., 2018) in PI3K-driven ovarian cancer cells 
treated with the PI3K inhibitor taselisib. It would be interesting to see if the expression 
of IGF-1R is further decreased when released for a longer period from AT13148 and 
whether this impacts sensitivity to IGF-1R. 
Despite sensitivity to FGFR inhibition, and previous microarray analysis showing an 
increase in FGFR2 mRNA expression, FGFR2 had a similar protein expression in A2780 
and A2780-148R (Figure 3.10B). This was disappointing as it was hoped that FGFR2 could 
potentially be used as a biomarker for FGFR sensitivity in AT13148 resistant patients, 
and its overexpression a possible candidate driver of resistance. However, there are four 
isoforms of FGFR (three targeted by AZD4547, FGFR1-3) which could have altered 
expression in A2780-148R. In addition, it’s also possible that FGFR expression was 
unchanged, but that phosphorylation and activation was increased, causing a 
dependency on FGFR signalling, thus increased sensitivity to AZD4547 and possibly 
resistance to AT13148. This has been seen in EGFR-dependent head and neck squamous 
cell carcinoma (HNSCC) and NSCLC cell lines, where a constitutively active FGFR3 fusion 
protein (FGFR3-TACC3) has been shown to cause resistance to combined EGFR/ERBB3 
blockade, via the maintenance of MAPK signalling (Daly et al., 2017). In addition, 
increased phosphorylation of FGFR signalling, has been shown to drive resistance to 
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BRAF (V600E) inhibition in BRAF mutant melanoma cell lines (Yadav et al., 2012). 
Therefore, FGFR signalling warrants further investigation in A2780-148R.  
The basal signalling of the MAPK pathway was also evaluated, where some changes were 
identified; the phosphorylation of ERK 1/2 shown to be slightly increased, but MEK 1/2 
phosphorylation slightly decreased (Figure 3.11). Since MEK 1/2 is upstream of ERK 1/2 
in the MAPK pathway one would usually expect the phosphorylation of ERK 1/2 to be 
decreased if MEK 1/2 phosphorylation was decreased. However, ERK 1/2 is known to 
impart inhibitory phosphorylations on RAF, the kinase upstream from MEK, and thus 
provides an explanation as to how increased phosphorylation of ERK 1/2 can lead to 
decreased MEK 1/2 phosphorylation (Dougherty et al., 2005; Ritt et al., 2010). It should 
also be noted that ERK1/2 phosphorylation was shown to be increased in untreated cells 
in dose-response assays; the phosphorylation of ERK 1/2 was greater in untreated 
A2780-148R cells than untreated A2780 cells in both AT13148 and GSK269962 dose-
response western blots, however, to a much greater extent than was seen in basal 
western blots (Figure 3.13 & Figure 3.16). This difference, between basal and dose-
response western blots, could be due to the presence of distinct sub-populations of cells 
in A2780-148R that were selected for over time/under different cell culture conditions.  
Whilst investigating basal signalling provided a broad overview of the differences 
between A2780 and A2780-148R in several different pathways, it didn’t provide any 
information on how these pathways responded in the presence of AT13148. To this end, 
dose-response western blot assays were performed with AT13148. Broadly speaking, 
these assays revealed that the PAM and ROCK pathways, two key pathways targeted by 
AT13148, were equally inhibited by AT13148 in A2780 and A2780-148R (Figure 3.12). By 
assessing these two pathways, the response of most AT13148 targets was evaluated 
including: AKT1, AKT3, ROCK1, ROCK2, p70S6K, and to a certain extent SGK3, since it has 
overlapping substrate specificity with AKT (Bruhn et al., 2013). The only major AT13148 
target for which inhibition was not assessed at all, was PKA. The PKA substrate 
vasodilator-stimulated phosphoprotein (VASP) was blotted for but proved difficult to 
detect (data not shown). Nonetheless, since the PAM pathway is hyperactivated in 
A2780 cells (due to PTEN and PIK3CA mutations), and A2780-148R cells have cross-
resistance to ROCK inhibition, the fact that both the PAM and ROCK pathways responded 
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in a similar manner, in A2780 and A2780-148R, suggests that the mechanism of 
resistance to AT13148 was caused by the by-pass of these pathways (Figure 3.16). In 
other words, another pathway is compensating for the inhibition of PAM and ROCK 
signalling by AT13148, driving resistance (Figure 3.16).  An example of this can been seen 
in BRAF mutant melanoma, where signalling through platelet-derived growth factor 
receptor (PDGFR) has been shown to by-pass the MAPK pathway, driving resistance to 
BRAF (V600E) inhibition (Nazarian et al., 2010).  
 
Figure 3.16: By-pass of AT13148 targets as a potential mechanism of resistance to AT13148. Resistance 
to AT13148 might be driven by the upregulation of a by-pass pathway, which circumvents the inhibition 
of the PAM (AKT and p70S6K) and ROCK (ROCK 1/2) pathways by AT13148, driving growth and survival 
independently of AT13148 targeted pathways. 
Due to the differences identified in the MAPK pathway at a basal level, the response of 
the MAPK pathway to AT13148 was also investigated in A2780 and A2780-148R (Figure 
3.13). In parental A2780 cells there was a remarkable response in the phosphorylation 
of ERK 1/2 to AT13148. Lower doses decreased ERK 1/2 phosphorylation, but higher 
doses increased phosphorylation, this can be characterised as a bi-directional dose-
response. This response was present in A2780-148R, but to a lesser extent, and as 
mentioned earlier, the phosphorylation of ERK 1/2 was at a higher level when untreated, 
compared to A2780. This response was not anticipated as AT13148 is not known to 
inhibit any members of the MAPK pathway. However, several targets of AT13148 are 
known to regulate the MAPK pathway. For example, PKA and AKT are known to 
positively regulate the expression of dual-specificity MAPK phosphatases (MKP’s or 
DUSP’s), and both impart inhibitory phosphorylations on RAF proteins (Zimmermann 
and Moelling, 1999; Guan et al., 2000; Pursiheimo et al., 2002; Phuchareon et al., 2015; 
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Figure 3.17A). Consequently, inhibition of PKA and AKT by AT13148 could increase the 
phosphorylation of ERK 1/2 (Figure 3.17A). In contrast, inhibition of ROCK has been 
shown to decrease the activation of the MAPK pathway, via an undefined mechanism 
which seems to be dependent upon the regulation of actin-myosin contractility by ROCK 
(Croft and Olson, 2006; Chang et al., 2018; Figure 3.17B). Interestingly, as discussed 
below, in A2780 cells ERK 1/2 phosphorylation did decrease in response to inhibition of 
ROCK by GSK269962 (Figure 3.15). Therefore, the opposing effects of AT13148 targets 
on the MAPK pathway could explain the response of ERK 1/2 phosphorylation to 
AT13148 (Figure 3.17A & B). 
Figure 3.17: Potential mechanisms of AT13148 mediated regulation of the MAPK pathway. (A) Both AKT 
and PKA can negatively regulate the MAPK pathway by inhibitory phosphorylation’s of RAF, or by 
mediating transcription of DUSP proteins, which de-phosphorylate ERK 1/2. Inhibition of AKT and PKA, by 
AT13148, might therefore be responsible for increased ERK 1/2 phosphorylation seen in response to some 
concentrations of AT13148. (B) ROCK has been shown to positively regulate MAPK pathway activation, by 
an undefined mechanism(s). Consequently, inhibition of ROCK1 & 2 by AT13148, may be responsible for 
decreased ERK 1/2 phosphorylation seen in response to some concentrations of AT13148. 
To further investigate the response of the MAPK pathway to AT13148, in particular the 
contribution of ROCK1 and 2 inhibition by AT13148, the response of ERK 1/2 
phosphorylation to the ROCK inhibitor GSK269962 was evaluated (Figure 3.15). 
Remarkably, GSK269962 was able to cause a decrease in the phosphorylation of ERK 1/2 
in parental A2780 cells but had no effect in A2780-148R. Again, just as with AT13148, 
GSK269962 is not known to target the MAPK pathway, so this result was quite 
unexpected. However, as previously mentioned, it has been reported in the literature 
that ROCK inhibition can affect the MAPK pathway. In melanoma cell lines, Chang and 
colleagues (Chang et al., 2018) showed that the inhibition of ROCK exhibited a variable 
A B 
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response on cell proliferation and the activation of the MAPK and PAM pathways, and 
that this seemed to correlate with BRAF status. In BRAF wild-type (WT) melanoma cells, 
ROCK inhibition decreased proliferation and ERK 1/2 phosphorylation, but AKT 
phosphorylation was mostly unaffected; whereas in mutant BRAF V600E melanoma 
cells, ROCK inhibition increased proliferation, whilst having little effect on ERK 1/2 
phosphorylation (there was a slight increase), but induced a notable increase in AKT 
phosphorylation (Chang et al., 2018). 
This could explain the difference in response to GSK269962; A2780 cells had lower basal 
ERK 1/2 phosphorylation, which decreased in response to GSK269962, and were 
sensitive to GSK269962; therefore, parental A2780 cells pheno-copy BRAF WT 
melanoma cells. In contrast, A2780-148R cells pheno-copy BRAF V600E melanoma cells; 
they had increased basal ERK 1/2 phosphorylation, which was unaffected by GSK269962, 
and whilst GSK269962 did not increase proliferation, A2780-148R cells were shown to 
be cross-resistant. It would be interesting to see if AKT phosphorylation was also 
increased in A2780-148R cells, in response to GSK269962. This divergence in the 
response of the MAPK pathway to ROCK inhibition, between A2780 and A2780-148R 
cells, may explain why A2780-148R cells were cross-resistant to ROCK inhibition. It also 
suggests that the ability of lower concentrations of AT13148 to cause a decrease in ERK 
1/2 phosphorylation might be due to the inhibition of ROCK1 and 2 by AT13148. 
In addition, the response of the ROCK pathway to the ROCK inhibitor GSK269962 was 
also assessed. Interestingly, in A2780-148R the ROCK pathway was shown to be partially 
refractory to inhibition by GSK269962, shown by a maintenance in the phosphorylation 
of the ROCK substrate MYPT1. This could suggest that the ROCK pathway is altered in 
some way to maintain the activity of the pathway in the presence of a ROCK inhibitor, 
which, in addition to ERK 1/2 phosphorylation also being refractory to ROCK inhibition 
in A2780-148R, may contribute to ROCK cross-resistance. This is contrary to the AT13148 
response where, as previously described, the ROCK pathway responded in a similar 
manner in A2780 and A2780-148R (Figure 3.12). However, GSK269962 is a far more 
selective ROCK inhibitor, so perhaps the broader activity of AT13148 means that it is 
able to overcome possible changes within the ROCK pathway in A2780-148R that make 
it partially refractory to GSK269962. 
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It is worth noting that there were some issues in using the phosphorylation of T696 
MYPT1 as a marker of ROCK pathway inhibition in A2780 and A2780-148R; in response 
to both AT13148 and GSK269962 the phosphorylation of T696 MYPT1 was never 
completely abolished (Figure 3.12 & Figure 3.15). This is likely to be caused by another 
kinase, not targeted by AT13148 and GSK269962, phosphorylating MYPT1 T696. For 
example, it has been shown that both ROCK1 & 2 and myotonic dystrophy kinase-related 
CDC42-binding kinase (MRCK), a CDC42 effector kinase, are required for the 
phosphorylation of T696 MYPT1, and, to a certain extent, can compensate for one 
another (Wilkinson et al., 2005). Consequently, the use of T696 MYPT1 phosphorylation 
alone may not give an accurate reflection of ROCK pathway inhibition, and the use of 
other ROCK substrates should be considered. However, Kumper and colleagues (Kümper 
et al., 2016) showed that inhibition of ROCK only leads to transient reduction in the 
phosphorylation of its downstream substrates, indicating that alternative mechanisms 
of phosphorylation exist for many ROCK substrates. Therefore, other ROCK substrates 
would likely have similar issues to T696 MYPT1, when used as a marker of ROCK pathway 
inhibition.  
In summary, the work conducted in this chapter has validated A2780-148R as a model 
of resistance to AT13148. A2780-148R cells have been shown to be sensitive to IGF-1R 
and FGFR inhibitors, which provides a potential therapeutic strategy in AT13148 
resistant patients. In addition, ROCK and PAM pathways were shown to be equally 
responsive to AT13148 in A2780 and A2780-148R, highlighting the by-pass of AT13148 
targets as a potential mechanism of resistance. By-pass of the ROCK pathway is likely to 
be of particular importance, due the strong cross-resistance exhibited to ROCK inhibitors 
in A2780-148R. Furthermore, ERK 1/2 phosphorylation was shown to respond to 
AT13148 and GSK269962 in A2780 and A2780-148R, as well as being increased at the 
basal level in A2780-148R cells, the extent of which varied across experiments, 
suggesting the existence of sub-populations within A2780-148R. The following chapters 
will investigate the possible contribution of the by-pass of AT13148 targets and 
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4. Identification of candidate drivers of AT13148 resistance in 
A2780-148R isogenic clones 
4.1. Introduction  
One of the defining features of cancer, as a disease, is the wide range of heterogeneity 
that it displays. This heterogeneity can be seen on a number of different levels (inter-
patient, inter-tumour and intra-tumour) but for the purposes of the work presented 
here intra-tumour heterogeneity (ITH) is the most relevant. Perhaps the clearest 
definition of ITH in its modern usage is from Heppner (Heppner, 1984) who described 
ITH as where “tumour cell differences are believed to be due to differences in cell 
lineage, i.e. due to the presence of distinctly different sub-populations capable of 
breeding true”. In other words, the differences are due to genetic or epigenetic 
alterations and are transmissible to daughter cells. These tumour cell differences 
encompass differences in proliferation, progression through the cell cycle, antigen 
expression, membrane composition and response to therapy, to name a few (Heppner, 
1984). It should be noted that these differences can exist between cells of the same 
tumour but occur independently of differences in cell lineage. Factors such as oxygen 
concentration, growth factor concentration, matrix biophysical properties; which show 
spatial variation across a tumour, and stochastic variation can contribute towards cell to 
cell variation within a tumour, but are not considered to be ITH (Heppner, 1984; Welch, 
2016).  
Much of the initial work on ITH focused on isolating sub-populations (also referred to as 
sub-clones) within a tumour and subsequently culturing them as individual cell lines 
(Heppner, 1984). Whilst some insight was gained into ITH from these studies, 
differences between isolated sub-populations could not be reliably stated to be caused 
by ITH alone, as the process of isolation of cells from a population can be a stimuli for 
new phenotypes in itself (Heppner, 1984). It was not until the advent of new sequencing 
technologies, such as single cell sequencing and deep sequencing, that the full depth of 
ITH was able to be grasped (Navin et al., 2011; Gerlinger et al., 2012). These studies have 
shown the extent of ITH within tumours and enabled cancer to be understood as an 
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evolutionary process in which: individual variation exists across the population, this 
variability is heritable, and individual variation leads to differences in cell survival 
(Gerlinger and Swanton, 2010). Furthermore, several clinical implications of ITH have 
been identified such as tumour sampling bias, therapy induced ITH and the impact of 
ITH upon therapy response and resistance (Swanton, 2012). 
With regards to therapy resistance, studies on ITH have made it increasingly clear that 
sub-populations harbouring resistance conferring mutations frequently exist in tumours 
prior to treatment and are subsequently positively selected for upon treatment, driving 
acquired drug resistance (Burrell and Swanton, 2014; highlighted in Figure 4.1). An 
example of this can be seen in lung cancers which are treated with EGFR TKIs, such as 
gefitinib and erlotinib, in which resistance is commonly caused by a secondary T790M 
mutation in EGFR. Several studies have shown that T790M mutated cells are present in 
treatment naïve tumours and are selected for during treatment, leading to the rapid 
generation of resistance, and poor clinical outcome (Su et al., 2012; Burrell and Swanton, 
2014). In contrast, resistant sub-populations are not always detected in pre-treatment 
samples, and whilst this could be a limitation of the current sequencing technologies, it 
is likely that some resistance conferring mutations arise de novo during treatment 
(Burrell and Swanton, 2014).  
In addition, studies have shown that, whether resistance develops from pre-existing 
mutated resistant sub-populations, de novo mutations, or a combination of the two, 
resistance is often polyclonal (Burrell and Swanton, 2014, highlighted in Figure 4.1). This 
means that several sub-populations conferring distinct resistance mutations, to a single 
therapy, can co-exist within the same tumour. One such example can be seen in a study 
by Liegl and colleagues (Liegl et al., 2008) on resistance mechanisms to KIT/PDGFR TKIs 
in gastrointestinal stromal tumours (GIST), where it was demonstrated that three 
patients had two distinct resistance conferring secondary mutations in KIT, within the 
same lesion. A similar phenomenon has also been seen in BRAF V600E mutant 
melanoma, where Van Allen and colleagues (Van Allen et al., 2014) identified a patient 
with co-existing MEK1 and NRAS mutations, within the same tumour, that conferred 
resistance against BRAF inhibitors. These mutations represent two distinct mechanisms 
of resistance, as NRAS is upstream of BRAF and MEK1 is downstream. 

















Figure 4.1: The impact of ITH upon the development of acquired polyclonal drug resistance. (A) Shows 
how resistance can develop via de novo mutations or by therapy induced selection of pre-existing mutated 
resistant sub-populations. (B) De novo resistance mutations, pre-existing resistant sub-populations, or 
combination of the two, can interact to generate polyclonal drug resistance. Figure adapted from 
Swanton, 2012.  
As to be expected, since they are derived from singular tumours, human cancer cell lines 
have also been shown to have extensive heterogeneity. Much of the evidence for this 
seems to have come from isolating sub-populations from cancer cell lines, however, the 
use of modern sequencing technologies has also been used to map heterogeneity within 
cancer cell lines. For example, Ben-David and colleagues (Ben-David et al., 2018) used 
deep sequencing to analyse 27 strains of the MCF-7 human breast cancer cell line, all of 
which were found to be sub-clonal, the extent of which varied across strains. In terms 
of the work conducted here, the heterogeneity within the A2780 human ovarian 
carcinoma cell line has not been mapped, but one can assume that it is heterogeneous 
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due to the near universality of ITH, which has been documented within ovarian cancer 
(Blagden, 2015). It is also possible that heterogeneity also exists within A2780-148R, and 
that resistance to AT13148 is polyclonal; i.e. there are two or more sub-populations 
within A2780-148R with distinct mechanisms of resistance to AT13148. There was some 
evidence of this shown in chapter 3, which was discussed in section 3.3, where the 
phosphorylation of ERK 1/2 in A2780-148R was shown to be increased at a basal level, 
however the extent of this was variable across experiments (Figure 3.11, Figure 3.13 & 
Figure 3.15). This variability could be caused by the presence of distinct sub-populations 
within A2780-148R which are selected for over time due subtle variations within cell 
culture conditions and experimental set-up. 
Whilst the possibility of A2780-148R polyclonal resistance is interesting, as several 
distinct mechanisms of resistance to AT13148 could be identified, it does present some 
issues. Aside for the variability in results, polyclonal drug resistance may make it difficult 
to distinguish and validate mechanisms of resistance. For example, if a sub-population, 
that was present at a frequency of 5% of the total A2780-148R population, had attained 
resistance by direct re-activation of an AT13148 targeted pathway, this might be masked 
by the rest of the population that retained an AT13148 responsive pathway. 
Furthermore, when attempting to validate such a mechanism of resistance, by 
abolishing the resistance mechanism within A2780-148R (e.g. via pharmacological 
inhibition), the low frequency of the resistant sub-population would likely lead to a false-
negative result.  
To overcome these issues many studies on resistance to cancer therapies employ the 
use of isogenic sub-clones (Garraway and Jänne, 2012). This is often undertaken by using 
limiting dilution, where resistant cell lines are plated at ≤ 1 cell/well in a 96-well plate to 
isolate separate resistant sub-populations (isogenic sub-clones). Whilst, as previously 
mentioned, the effect of isolating sub-populations does have its limitations, the use of 
isogenic sub-clones has proved an effective way of identifying mechanisms of resistance, 
often with clinical relevance. Engelman and colleagues (Engelman et al., 2007) 
generated resistance to the EGFR inhibitor gefitinib in the EGFR mutant NSCLC cell line 
HCC827 using dose-escalation and subsequent isogenic sub-cloning. They found that 
resistance was driven by increased MET expression (via an increase in copy number) and 
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that combination with PHA665752, a MET inhibitor, could re-sensitise resistant isogenic 
sub-clones to gefitinib. In addition, it was shown that MET amplification was present in 
tumours from resistant patients. It’s interesting to note that the increase in MET copy 
number was not identified in the original ‘polyclonal’ resistant cell line (generated from 
dose-escalation alone, not isogenic sub-cloning), which highlights the importance of 
deriving resistant isogenic sub-clones; i.e. without isogenic sub-cloning it would have 
been difficult to identified MET amplification as a mechanism of resistance. Similar 
approaches have been used to identify mechanisms of resistance to vemurafenib & 
crizotinib, to name a few, many of which have been clinically validated (Nazarian et al., 
2010; Katayama et al., 2011). Most studies employing the use of isogenic sub-clones 
tend to focus on one isogenic sub-clone, and therefore only identify one mechanism of 
resistance. However, Gowrishankar and colleagues (Gowrishankar et al., 2012) used 
several isogenic sub-clones (derived from the same polyclonal resistant cell line) to 
identify distinct mechanisms of resistance to dabrafenib (a BRAF V600E inhibitor) in a 
BRAF V600E melanoma cell line, including activating NRAS mutations and increased 
expression of COT1 kinase. This highlights how the use of isogenic sub-clones can enable 
the identification of several distinct mechanisms of resistance to the same therapy. 
Taking into account the likelihood of resistance to AT13148 within A2780-148R being 
polyclonal, the aim of this chapter was to generate isogenic sub-clones from A2780-
148R to investigate AT13148 resistance. Initially, the focus was to screen these sub-
clones based on the key findings of chapter 3, such as cross-resistance to ROCK inhibition 
and sensitivity to IGF-1R inhibition. The results from this were then used to select sub-
clones for further characterisation to identify putative candidate drivers of resistance. 
  




4.2.1. Determination of AT13148 resistance and cross-resistance profiling in 148R 
clones  
In total, 10 isogenic sub-clones (henceforth referred to as 148R clones) were derived 
from A2780-148R by limiting dilution that were able to undergo routine sub-culture 
(Figure 4.2). Subsequently, AT13148 resistance was determined, and cross-resistance 
profiling performed to compare 148R clones to A2780 and A2780-148R cells. This was 
conducted so that resistance to AT13148 could be validated, and 148R clones with the 
most unique phenotypes, which might be indicative of a distinct mechanism of 
resistance, could be identified and selected for further characterisation and 
investigation of AT13148 resistance. The drugs used in cross-resistance profiling were 
drugs that A2780-148R had been shown to have strong resistance or sensitivity to in 
chapter 3: GSK269962, NVP-AEW541 and AZD4547. It should be noted that 148R clones 
were originally plated at 1600 cells/well (the optimal seeding density for A2780-148R, 
Figure 3.1), but that this was changed for some clones based on observations during SRB 
assays. In addition, to maximise their chance of survival, 148R clones were initially 
cultured in the absence of 5.2 µM AT13148 (the maintenance dose of AT13148). 
4.2.1.1. AT13148 
Figure 4.2 shows that all 148R clones, except for 148R-I (RF = 1.86, not statistically 
significant), were shown to have greater than 2-fold resistance to AT13148 (RF ≥ 2.00), 
with this being statistically significant in all but two clones (148R-G and 148R-U). A2780-
148R was also shown to be resistant to AT13148; the GI50 for A2780-148R was 0.94 µM 
compared to 0.22 µM in A2780, a statistically significant difference giving an RF value of 
4.27, consistent with the result in chapter 3 (Figure 4.2, previous result Figure 3.2). 
However, 148R clones exhibited differing levels of resistance when compared to one 
another and A2780-148R (Figure 4.2). Some 148R clones exhibited lower resistance than 
what was seen in A2780-148R, such as 148R-K and 148R-P which had GI50 values of 0.76 
µM and 0.62 µM respectively, resulting in an RF of ~3 (Figure 4.2). In contrast, 148R-J 
and 148R-N had GI50 values of 2.51 µM (RF = 11.41) and 2.04 µM (RF = 9.27) respectively, 
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much higher than was seen with A2780-148R (Figure 4.2). Taken together, the majority 
of 148R clones were shown to be resistant to AT13148, but there was variation in the 




































Figure 4.2: Summary of GI50 and RF values for AT13148 in A2780, A2780-148R and 148R clones. Graph 
and table summarise the GI50 and RF values for AT13148 in A2780, A2780-148R and 148R clones, as 
determined from a standard 6-day SRB cell viability assay. Graph was generated using GraphPad Prism 6. 
Bars and table data points depict the mean GI50 ± SD from all experiments conducted. The red line on the 
y-axis of the graph marks A2780 GI50. Statistical significance was calculated using a student’s t-test, * p ≤ 
0.05, ** p ≤ 0.01, *** p ≥ 0.001, n ≥ 3 independent experiments.  
 
 
Cell line GI50 (µM) RF 
A2780 0.22 ± 0.06 N/A 
A2780-148R 0.94 ± 0.20*** 4.27 
148R-G 1.15 ± 1.11 5.23 
148R-I 0.41 ± 0.19 1.86 
148R-J 2.51 ± 0.45** 11.41 
148R-K 0.76 ± 0.21** 3.45 
148R-M 0.84 ± 0.24** 3.82 
148R-N 2.04 ± 0.40* 9.27 
148R-P 0.62 ± 0.19* 2.82 
148R-S 1.46 ± 0.37** 6.64 
148R-T 0.94 ± 0.23* 4.27 
148R-U 1.22 ± 0.44 5.55 




The response of 148R clones to the ROCK inhibitor GSK269962 was assessed to 
investigate if they were cross-resistant to ROCK inhibition, as was seen with A2780-148R 
in chapter 3 (Figure 3.5). All 148R clones had RF values of > 10.00, indicating strong cross-
resistance to GSK269962 (Figure 4.3A). This was shown to be statistically significant in 
all 148R clones except 148R-G, T & U. Also, as previously shown in chapter 3, A2780-
148R was cross-resistant to GSK269962; A2780-148R had GI50 of 1.310 µM compared to 
0.026 µM in A2780, a statistically significant difference equating to a RF of 50.38 for 
A2780-148R, consistent with the previous result (Figure 4.3A, previous result Figure 3.5). 
As with AT13148, there was a large degree of variation in response to GSK269962 
amongst 148R clones, with some clones having a lower GI50 than A2780-148R and some 
higher. The lowest GI50 was seen in 148R-I, which had a GI50 of 0.287 µM (RF = 11.42), 
substantially lower than the GI50 for A2780-148R (Figure 4.3A). Conversely, the highest 
GI50 was seen in 148R-J, which had a GI50 of 4.388 µM (RF = 168.77), which was greater 
than A2780-148R and 15-fold higher than 148R-I (Figure 4.3B). Other 148R clones, such 
as 148R-N (GI50: 1.662, RF = 63.92), were not too dissimilar from A2780-148R (Figure 
4.3A). 
It was interesting to note that 148R clones with the highest and lowest GI50 for 
GSK269962, 148R-J and 148R-I respectively, corresponded to what was seen with 
AT13148, i.e. 148R-J had the highest AT13148 GI50 and 148R-I the lowest (Figure 4.2 & 
Figure 4.3). To investigate if there was any correlation between the GI50 of AT13148 and 
GSK269962 amongst 148R clones, A2780-148R, and A2780, Pearson correlation 
coefficient analysis was performed (Figure 4.3B). This gave a statistically significant R 
value of 0.89 and an R2 value of 0.79, indicating that there was strong positive correlation 
between the GI50 values of AT13148 and GSK269962 in 148R clones, A2780-148R and 
A2780 (Figure 4.3B). In summary, the majority of 148R clones were cross-resistant to 
the ROCK inhibitor GSK269962, but there was large variation in the level of cross-
resistance. In addition, the strong positive correlation between AT13148 and 
GSK269962 GI50 suggests AT13148 resistance is dependent upon overcoming the 
inhibition of ROCK by AT13148. 





























Figure 4.3: Summary of GI50 and RF values for GSK269962 and correlation with AT13148 in A2780, 
A2780-148R and 148R clones. (A) Graph and table summarise the GI50 and RF values for GSK269962 in 
A2780, A2780-148R and 148R clones, as determined from a standard 6-day SRB cell viability assay. Graph 
was generated using GraphPad Prism 6. Bars and table datapoints depict the mean GI50 ± SD from all 
experiments conducted. The red line on the y-axis of the graph highlights A2780 GI50. Statistical 
significance was calculated using a student’s t-test, * p ≤ 0.05, ** p ≤ 0.01, *** p ≥ 0.001, n ≥ 3 independent 
experiments. (B) Graph displays the correlation between AT13148 and GSK269962 GI50 values. Data points 
represent the mean GI50 for an individual cell line (A2780, A2780-148R or 148R clones). Pearson’s 
correlation coefficient and statistical significance were calculated using GraphPad Prism 6. n ≥ 3 
independent experiments. 
Cell line GI50 (µM) RF 
A2780 0.026 ± 0.012 N/A 
A2780-148R 1.310 ± 0.655*** 50.38 
  148R-G 1.301 ± 1.060 50.04 
148R-I 0.297 ± 0.098* 11.42 
148R-J 4.388 ± 0.746** 168.77 
 148R-K 0.918 ± 0.609* 35.31 
148R-M 0.711 ± 0.138** 27.35 
148R-N 1.662 ± 0.228*** 63.92 
148R-P 0.901 ± 0.226* 34.65 
148R-S 2.363 ± 1.069* 90.88 
148R-T 0.611 ± 0.393 23.50 
148R-U 2.374 ± 1.106 91.31 
A 
B 




Since A2780-148R had been shown to be sensitive to the IGF-1R inhibitor NVP-AEW541 
(Figure 3.6), when compared to parental A2780 cells, the response of 148R clones to 
NVP-AEW541 was investigated. The response amongst the 148R clones was again 
diverse, but remarkably none of them had a strong level of sensitivity to NVP-AEW541, 
with only three clones; 148R-I, P and S, shown to have a greater than 2-fold sensitivity 
(RF ≤ 0.50) to NVP-AEW541 (Figure 4.4A, B). A2780 had GI50 of 1.72 µM compared to 
0.63 µM in 148R-I, 0.76 µM in 148R-P and 0.78 µM in 148R-S, equating to RF values of 
0.37, 0.44 and 0.45 respectively, which were all statistically significant (Figure 4.4A, B).  
In contrast, 148R-N and 148R-U had statistically significant low-level cross-resistance 
against NVP-AEW541; 148R-N and 148R-U had GI50 values of 4.11 µM (RF = 2.39) and 
3.87 µM (RF = 2.25) respectively (Figure 4.4A, B).  
Unexpectedly, A2780-148R was not shown to be sensitive to NVP-AEW541; A2780-148R 
had a GI50 of 1.09 µM, which although statistically significant, only equated to an RF 
value of 0.63 (Figure 4.4A, B). This contradicts what was seen in chapter 3, where A2780-
148R was shown to have an RF value of 0.14, indicating sensitivity to NVP-AEW541 
(Figure 3.6). Upon closer inspection, the loss of sensitivity seemed to have been caused 
by an increase in the GI50 of A2780-148R (0.22 µM in Figure 3.6 vs 1.09 µM in Figure 
4.4A, B), rather than a decrease in the GI50 of A2780 (1.56 µM in Figure 3.6 vs 1.72 µM 
in Figure 4.4A, B). This might explain why 148R clones did not have a high degree of 
sensitivity to NVP-AEW541; they were derived from A2780-148R cells that had already 
lost sensitivity/were in the process of losing sensitivity to NVP-AEW541. Indeed, Figure 
4.4C shows the gradual increase in A2780-148R GI50 against NVP-AEW541 over the 
course of successive SRB assays that were conducted during the time in which 148R 
clones were isolated from A2780-148R and initially characterised. For example, the GI50 
for NVP-AEW541 in A2780-148R cells increased from 0.25 µM on the 28Nov16, when 
A2780-148R cells were plated for limiting dilution, to 1.84 µM on 18Jan17 (Figure 4.4C).  
Taken together, these data suggest that 148R clones have lost most of their sensitivity 
to NVP-AEW541, with many clones showing no sensitivity and some even cross-
resistance. This is likely to be explained by the loss of sensitivity to NVP-AEW541 in 
A2780-148R, from which 148R clones were derived.  





















Date GI50 (µM) GI50 (µM) RF 
28-Nov-16 1.39 0.25 0.18 
18-Dec-16 1.41 0.51 0.36 
10-Jan-17 1.30 0.62 0.48 
11-Jan-17 2.16 0.99 0.46 
17-Jan-17 1.64 1.31 0.80 





Figure 4.4: Summary of GI50 and RF values for NVP-AEW541 in A2780, A2780-148R and 148R clones. 
(A, B) Summary of the GI50 and RF values for NVP-AEW541 in A2780, A2780-148R and 148R clones, as 
determined from a standard 6-day SRB cell viability assay. Graph was generated using GraphPad Prism 6. 
Bars depict the mean GI50 ± SD of all experiments conducted. Red line on the y-axis of the graph highlights 
A2780 GI50. Table summarises NVP-AEW541 GI50 and RF, GI50 data points represent the mean ± SD of all 
experiments conducted. Statistical significance was calculated using a student’s t-test, * p ≤ 0.05, ** p ≤ 
0.01, *** p ≥ 0.001, n ≥ 3 independent experiments. (C) Table summarises GI50 and RF values for NVP-
AEW541 in A2780 and A2780-148R over time. GI50 and RF values were taken from individual experiments.  
 
 
Cell line GI50 (µM) RF 
A2780 1.72 ± 0.34 N/A 
A2780-148R 1.09 ± 0.43** 0.63 
148R-G 1.25 ± 0.55 0.73 
148R-I 0.63 ± 0.13*** 0.37 
148R-J 1.21 ± 0.07* 0.70 
148R-K 0.97 ± 0.28** 0.56 
148R-M 1.34 ± 0.64 0.78 
148R-N 4.11 ± 0.07*** 2.39 
148R-P 0.76 ± 0.37** 0.44 
148R-S 0.78 ± 0.42* 0.45 
148R-T 2.56 ± 0.67 1.49 
148R-U 3.87 ± 0.17*** 2.25 
B C 
A 




The response of 148R clones to the FGFR inhibitor AZD4547 was also assessed to see if 
they maintained sensitivity to AZD4547, which was shown in A2780-148R in chapter 3 
(Figure 3.6). Figure 4.5 shows that A2780-148R had statistically significant sensitivity to 
AZD4547, compared to parental A2780 cells; A2780-148R had a GI50 of 0.034 µM 
compared to 0.378 µM in A2780, which equated to a RF of 0.089 (11-fold sensitivity). 
This was mirrored in 148R clones, which were all shown to have statistically significant 
sensitivity to AZD4547, except for 148R-N (Figure 4.5). However, just as was seen with 
other compounds used in cross-resistance profiling, the response to AZD4547 was 
diverse amongst 148R clones. 148R-M had a GI50 of 0.001 µM which was the lowest GI50 
observed and equated to an RF value of 0.003 (~378-fold sensitivity), 148R-M was 
therefore considerably more sensitive than A2780-148R (Figure 4.5). Contrary to this, 
148R-N had a GI50 of 1.113 µM, which whilst just shy of being statistically significant (p 
= 0.06, data not shown), indicated low-level cross-resistance, which 148R-N also 
displayed to NVP-AEW541 (Figure 4.4 & Figure 4.5). Other 148R clones had a similar GI50 
to A2780-148R, such as 148R-T and 148R-U, which had GI50 values of 0.037 µM (RF = 
0.098) and 0.032 µM (RF = 0.085) respectively (Figure 4.5). In summary, these data show 
that whilst there was considerable variation in response to AZD4547 amongst 148R 





























































Figure 4.5: Summary of GI50 and RF values for AZD4547 in A2780, A2780-148R and 148R clones. Graph 
and table summarise the GI50 and RF values for AZD4547 in A2780, A2780-148R and 148R clones, as 
determined from a standard 6-day SRB cell viability assay. Graph was generated using GraphPad Prism 6. 
Bars and table datapoints depict the mean GI50 ± SD of all experiments conducted. The red line on the 
graph y-axis highlights A2780 GI50. Statistical significance was calculated using a student’s t-test, *** p ≥ 






Cell line GI50 (µM) RF 
A2780 0.378 ± 0.196 N/A 
A2780-148R 0.034 ± 0.011*** 0.089 
148R-G 0.009 ± 0.005*** 0.024 
148R-I 0.004 ± 0.002*** 0.011 
148R-J 0.024 ± 0.014*** 0.063 
148R-K 0.004 ± 0.003*** 0.011 
148R-M 0.001 ± 0.001*** 0.003 
148R-N 1.113 ± 0.287 2.94 
148R-P 0.002 ± 0.001*** 0.005 
148R-S 0.008 ± 0.004*** 0.021 
148R-T 0.037 ± 0.014*** 0.098 
148R-U 0.032 ± 0.026*** 0.085 
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4.2.2. Analysis of basal signalling in 148R clones 
Markers of pathways directly targeted by AT13148 (PAM and ROCK pathways), as well 
as IGF-1R expression (shown to be upregulated in A2780-148R, Figure 3.10), were 
investigated at basal level via western blotting in 148R clones. Figure 4.6 shows all 148R 
clones, as well as A2780-148R, over-expressed IGF-1R when compared to parental 
A2780 cells, but just as was seen with cross-resistance profiling, there was a high degree 
of variation in the level of IGF-1R expression amongst 148R clones (Figure 4.6). Some 
148R clones, such 148R-J and 148R-T, had much higher expression of IGF-1R than A2780-
148R (Figure 4.6). On the other hand, other 148R clones, such  as 148R-K, S & U, had a 
lower expression of IGF-1R versus A2780-148R (Figure 4.6). 
Figure 4.6 also shows that there was little difference in AKT S473 and PRAS40 T246 
phosphorylation in A2780-148R when compared to A2780, although S473 AKT 
phosphorylation appeared marginally lower in A2780-148R. This was similar in most 
148R clones; the phosphorylation of S473 AKT and T246 PRAS40 was the same or slightly 
decreased when compared to A2780, however, these markers were increased in some 
clones (Figure 4.6). 148R-N had a slight increase in the phosphorylation of S473 AKT and 
a more notable increase in T246 PRAS40 phosphorylation, whereas in 148R-J, G and T, 
S473 AKT phosphorylation was unaltered/slightly decreased but T246 PRAS40 
phosphorylation was increased (Figure 4.6). Further downstream the PAM pathway 
there were also changes seen within the phosphorylation of S235/236 S6RP, a p70S6K 
substrate (Figure 4.6). Many clones had decreased S235/236 S6RP phosphorylation, 
with this being most notable in 148R-K, M and S (Figure 4.6). This appeared to be 
independent of the changes in AKT and PRAS40 phosphorylation, for example, 148R-N 
had increased AKT and PRAS40 phosphorylation but decreased S235/236 S6RP 
phosphorylation (Figure 4.6).  
The phosphorylation of T696 MYPT1 was also assessed as a marker of the ROCK 
pathway. T696 MYPT1 phosphorylation was shown to be relatively unaltered amongst 
A2780, A2780-148R and 148R clones (Figure 4.6). However, there were a few exceptions 
to this, with T696 MYPT1 phosphorylation being notably decreased in 148R-G and 148R-
P (Figure 4.6). Taken together, these data showed that there was some variation in the 
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basal signalling in pathways assessed amongst 148R clones, with this being most 
prominent with IGF-1R expression. Some of these changes, particularly within the PAM 





Figure 4.6: Analysis of the basal expression of IGF-1R and markers of the PAM and ROCK pathways in 
A2780, A2780-148R and 148R clones. Cells were plated at either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R 
and 148R clones) cells per 10 cm dish and allowed to grow for 48 hours under standard growth conditions. 
Cells were then lysed prior to western blot analysis. Western blot membranes were probed with 
antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total proteins and 
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4.2.3. Selection of 148R clones for further characterisation  
The initial characterisation of 148R clones gained insight into the resistance generated 
against AT13148. In particular, the diverse response amongst the 148R clones to the 
cross-resistance profiling suggested that there was a degree of heterogeneity within 
A2780-148R, and therefore the possible existence of several sub-populations with 
distinct mechanisms of resistance to AT13148. In order to investigate this, three 148R 
clones: 148R-K, 148R-N and 148R-S, were selected for further, more detailed, 
characterisation. The rationale for this is highlighted in Table 4.1. Briefly, these clones 
were selected as they all had robust resistance to AT13148 but represented the range 
of resistance to AT13148 seen amongst clones in Figure 4.2 (RF value of the three clones 
was between ~3 and ~9). It was important to have this range represented amongst the 
selected 148R clones, as different levels of resistance to AT13148 may require distinct 
mechanisms. Additionally, 148R-K and 148R-S were selected as they were sensitive to 
AZD4547, with 148R-S also sensitive to NVP-AEW541. In contrast, 148R-N was selected 
as it appeared to be the most unique clone, displaying cross-resistance to NVP-AEW541 
and AZD4547 and displayed markers that indicated altered signalling within the PAM 
pathway (Figure 4.6, e.g. increased PRAS40 phosphorylation). 
Table 4.1: Summary of cross-resistance profiling in 148R clones. Table gives an overview of cross-
resistance profiling (Figure 4.2-Figure 4.5), the results of which were used to justify the selection of 148R 
clones for further characterisation.  and  respectively indicate a positive or negative result for the 
attribute outlined (e.g. AT13148 resistance). An increasing number of ticks indicates greater 
resistance/sensitivity. Results that were not statistically significant are marked with a ^. The threshold for 
resistance/cross-resistance was RF ≥ 2.00 and sensitivity RF ≤ 0.50. Clones that were selected for further 












148R-G ^ ^  
148R-I    
148R-J    
148R-K    
148R-M    
148R-N    (Cross-resistant)  (Cross-resistant^)
148R-P    
148R-S    
148R-T  ^  
148R-U ^ ^  (Cross-resistant) 
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4.2.4. Light microscopy of selected 148R clones 
As with A2780-148R cells in chapter 3, the morphology of selected 148R clones was 
evaluated under light microscopy, both untreated and treated with 5.2 µM AT13148 
(maintenance dose of AT13148), and compared to parental A2780 cells, as well as one 
another. Figure 4.7 shows that untreated parental A2780 cells displayed a similar 
morphology as was previous described in chapter 3 (Figure 3.3), growing as ‘pebble-like’ 
clusters; having a rounded/polygonal morphology, consistent with an epithelial 
phenotype, and not undergoing contact inhibition. In general, the morphology of 
untreated 148R clones was similar to one another and parental A2780 cells; 148R clones 
retained an epithelial phenotype and did not appear to undergo contact inhibition, as 
had been previously described for A2780-148R cells in chapter 3 (Figure 3.3 & Figure 
4.7). However, there were some subtle differences in morphology amongst 148R clones. 
Both 148R-K and 148R-S cells grew as distinct compact colonies, not too dissimilar from 
the ‘pebble-like’ colonies of A2780, but 148R-N cells grew less compact, as large 
interconnected ‘branches’ of cells, in similar manner to A2780-148R cells as described 
in chapter 3 (Figure 3.3 & Figure 4.7). In addition, 148R-S cells appeared smaller and had 
more of a rounded morphology, when compared to 148R-K and 148R-N, which had more 
of a polygonal morphology and appeared larger, particularly 148R-N (Figure 4.7).  
The morphology of parental A2780 cells treated with AT13148 was also consistent with 
what was previously described in chapter 3; a subset of cells were either undergoing 
membrane blebbing, indicative of apoptosis, or had developed a ‘spindle-like’ 
morphology, becoming long and thin (Figure 3.3 & Figure 4.7). This ‘spindle-like’ 
morphology was also seen in all 148R clones, but again only in subset of cells, not the 
total population. As discussed in section 3.3, this ‘spindle-like’ morphology likely due to 
the inhibition of ROCK1 and 2 by AT13148, although the effect of other AT13148 targets 
cannot be discounted. 
Taken together, these data show that 148R-K, N and S, despite some subtle differences, 
have similar morphologies to one another, consistent with an epithelial phenotype, and 
morphologically respond to AT13148 in similar manner to parental A2780 cells, 




































Figure 4.7: Light microscopy images of untreated and AT13148 treated A2780 cells and 148R clones. Cells were split into T25 flasks to allow 2-3 days growth, and either left 
untreated or treated with 5.2µM AT13148. After 48 hours, when cells were ~70% confluent, cells were observed under a light microscope at x40 or x100 magnification and images 
taken. Images are representative of two independent experiments.
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4.2.5. Growth characterisation of selected 148R clones 
As previously mentioned, since growth characterisation assays had not been performed, 
the seeding densities used for 148R clones (Figure 4.2-Figure 4.5) were determined via 
trial and error over successive SRB assays. Therefore, prior to the additional 
characterisation of selected 148R clones, growth characterisation assays were 
performed to determine the optimal seeding density for 148R clones in a standard 6-
day SRB cell viability assay. The optimal seeding density for A2780 and 148R-N was 
determined to be 800 cells/well and 3200 cells/well respectively (Figure 4.8). This was 
consistent with the established optimal seeding density for A2780 in chapter 3 and 
seeding density that had been used for 148R-N in Figure 4.2-Figure 4.5. It was difficult 
to determine the optimal seeding density for 148R-K and 148R-S as they appeared to be 
log-phase growth when plated at both 1600 cells/well and 3200 cells/well (Figure 4.8). 
However, at 3200 cells/well 148R-K cells appeared to be more consistently in log-phase 
growth, whereas 148R-S abruptly stopped growing at T = 144h (Figure 4.8). This could 
indicate that the growth of 148R-S cells slowed towards the end of the 96-hour drug 
treatment window when plated at 3200 cells/well (Figure 4.8). Therefore, the optimal 
seeding densities selected for 148R-K and 148R-S were 3200 cells/well and 1600 
cells/well respectively. 148R-K cells had been plated at 1600 cells/well in Figure 4.2-
Figure 4.5. 
The doubling times for 148R clones and A2780 cells (when plated at their optimal 
seeding densities) were also calculated (as shown in shown in section 3.2.1). Whilst 
there were some differences between the doubling times of A2780, 148R-K and 148R-S 
(25.9, 32.8 and 30.0 hours respectively), they weren’t too dissimilar (Figure 4.9). 
However, 148R-N had a doubling time of 42.5 hours which was longer than A2780, 148R-
K and 148R-S (Figure 4.9). This was also seen when the optimal seeding densities were 
superimposed on the same graph; A2780, 148R-K and 148R-S were indistinguishable 
from one another, but 148R-N was more distinctive, albeit not too dissimilar; the curve 
for 148R-N appeared to be more shallow and the growth for 148R-N plateaued between 
144 and 168 hours (Figure 4.9). Taken together, optimal seeding densities for A2780 and 
148R clones were established that enabled near-identical growth kinetics over the 
course of an SRB cell viability assay.  




Figure 4.8: Characterisation of the growth of A2780 and 148R clones in a 96-well plate. Cells were plated 
in 96-well plates at the densities indicated, with 6 replicates per density. A plate was fixed every 24 hours 
and analysed via SRB assay. Growth curves were generated using GraphPad Prism 6. T = 0h and T = 96h 
highlights the 96-hour drug treatment window in a standard 6-day SRB cell viability assay. Data points 


















Cell line Density (Fig 4.2-4.5) Optimal density (cells/well) Doubling time (hrs) 
A2780 800 800 25.9 ± 2.8 
148R-K 1600 3200 32.8 ± 0.9 
148R-N 3200 3200 42.5 
148R-S 1600 1600 32.0 ± 2.0 
 
Figure 4.9: Comparison of optimal seeding densities and doubling times in A2780 and 148R clones. Cells 
were plated as per Figure 4.8. Graphs were generated using GraphPad Prism 6 for the over-lay of optimal 
seeding densities established in Figure 4.8. Table summarises the doubling times of A2780 and 148R 
clones over 96-hour drug treatment window when plated at their optimal seeding densities. Data points 
represent the mean ± SD from one representative experiment. n = 3 (A2780), 2 (148R-K and S) or 1 (148R-
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4.2.6. Determination of resistance to AT13148 and cross-resistance profiling in 
selected 148R clones 
During the initial cross-resistance profiling, 148R clones were cultured in the absence of 
AT13148 (Figure 4.2-Figure 4.5). Since selected 148R clones were subsequently cultured 
in the maintenance dose of AT13148 (5.2 µM) it was necessary to re-validate AT13148 
resistance and cross-resistance profiling, as continuous culture in the presence of 
AT13148 may influence the results originally obtained.  
Figure 4.10A shows that selected 148R clones all had statistically significant resistance 
to AT13148; A2780 had a GI50 of 0.16 µM compared to GI50 values of 1.65 µM, 1.49 µM 
and 1.46 µM for 148R-K, N and S respectively. This resulted in an RF of ~9 for 148R-N 
and 148R-S, and ~10 for 148R-K (Figure 4.10A). For A2780, 148R-N and 148R-S these 
results were relatively consistent with the previous results obtained in Figure 4.2, but 
this was not the case for 148R-K. In Figure 4.2 the GI50 for 148R-K against AT13148 was 
0.76 µM, ~2-fold lower than the GI50 obtained in Figure 4.10A, 1.49 µM, equating to RF 
of ~3. This could be due to inter-assay variation but may indicate that some of the 
resistance to AT13148 in 148R-K is transient and dependent on chronic exposure to 
AT13148.  
Upon closer inspection of the AT13148 data it appeared that the non-linear regression 
curve did not fit the data for 148R-N as well as it did for A2780, 148R-K and 148R-S 
(Figure 4.10A). This appeared to cause an underestimation of the GI50 for 148R-N. 
Analysis of the R2 values for the non-linear regression curves confirmed this; 148R-N had 
an R2 of 0.84 which was lower than what was seen in A2780, 148R-K and 148R-S (R2 > 
0.90, Figure 4.10A). The AT13148 data for 148R-N was therefore re-analysed by joining 
the datapoints ‘dot to dot’ and calculating the GI50 by using linear regression between 
the data points before and after 50% viability (Figure 4.10B). Figure 4.10B shows that 
the re-analysed GI50 for 148R-N was 3.25 µM, which was statistically significant when 
compared to A2780 and gave an RF of ~20, the greatest seen amongst 148R clones. 
Analysing the data in this manner also highlighted that 148R-N exhibited a distinctive 
response to AT13148. The inhibition of cell viability occurred in two distinct linear 
phases; the 1st at concentrations up to 3.3 µM, where viability gradually decreased, and 
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the 2nd between 3.3 µM and 10.0 µM, where there was sharp decrease in cell viability. 
Taken together, these data validated resistance to AT13148 in 148R-K, N & S, but again 
showed that there was diversity in the response to AT13148 amongst 148R clones, 
particularly 148R-N. 
  












Cell line GI50 (µM) RF R2 
A2780 0.16 ± 0.05 N/A 0.97 ± 0.02 
148R-K 1.65 ± 0.81*** 10.31 0.95 ± 0.03 
148R-N 1.49 ± 0.51*** 9.31 0.84 ± 0.05 











Cell line GI50 (µM) RF 
A2780 0.16 ± 0.05 N/A 
148R-K 1.65 ± 0.81*** 10.31 
148R-N 3.25 ± 0.65*** 20.31 
148R-S 1.46 ± 0.53*** 9.13 
 
Figure 4.10: Dose-response curves and GI50 determinations for AT13148 in A2780 and selected 148R 
clones. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard growth 
conditions for 48 hours. They were then treated with a serial dilution of AT13148 for 96-hours, prior to 
being analysed by SRB assay. Dose-response graphs were generated using GraphPad Prism 6. Dotted line 
marks 50% viability on the y-axis. Data points represent the mean ± SD from one representative 
experiment. Tables summarise AT13148 GI50 and RF, GI50 data points depict the mean ± SD of all 
experiments conducted. (A) GI50 was calculated with GraphPad Prism 6 using non-linear regression for all 
cell lines. (B) GI50 calculated with GraphPad Prism 6 using linear regression for 148R-N and non-linear 
regression for all other cell lines. Statistical significance was calculated using a student’s t-test, *** p ≤ 
0.001. n = 8 independent experiments. 
A 
B 
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As was seen previously (Figure 4.3) the selected 148R clones were again shown to have 
a high degree of cross-resistance to the ROCK inhibitor GSK269962 which was 
statistically significant (Figure 4.11). A2780 had a GI50 of 0.028 µM against GSK269962 
whereas 148R-K, N and S had GI50 values of 3.032 µM (RF = 108.29), 2.180 µM (RF = 
77.86) and 3.385 µM (RF = 117.32) respectively (Figure 4.11). The GI50 for 148R-K against 
GSK269962 was ~3-fold higher than was seen during initial cross-resistance profiling 
(Figure 4.3), which was interesting considering the parallel increase in AT13148 GI50 for 
148R-K shown in Figure 4.10. This provides further evidence of the intimate link between 
the level of AT13148 resistance and cross-resistance to GSK269962. 
Figure 4.11 also shows that none of the selected 148R clones had sensitivity to the IGF-
1R inhibitor NVP-AEW541. The GI50 for 148R-K and 148R-S against NVP-AEW541 was 
1.34 µM and 1.35 µM respectively, only marginally lower than the GI50 of A2780: 1.41 
µM (Figure 4.11). This gave RF values for 148R-K and 148R-S of just under 1, 0.95 & 0.96 
respectively (Figure 4.11). It should be noted that 148R-S was previously shown to be 
sensitive to NVP-AEW541, but only to a minimal extent (Figure 4.4), therefore, the lack 
of sensitivity in Figure 4.11 does not represent a significant shift and is likely due to inter-
assay variation. In contrast, 148R-N had low-level cross-resistance to NVP-AEW541 (GI50: 
2.98 µM, RF = 2.12), which was statistically significant, consistent with the previous 
result shown in Figure 4.4 (Figure 4.11). 
In addition, Figure 4.11 shows that there was large degree of sensitivity to the FGFR 
inhibitor AZD4547 in 148R-K and 148R-S; 148R-K and 148R-S had GI50 values of 0.011 µM 
and 0.008 µM respectively (Figure 4.11). This corresponded to ~15-fold sensitivity for 
148R-K (RF = 0.06) and ~21-fold sensitivity for 148R-K (RF = 0.05), when compared to 
A2780 which had a GI50 of 0.170 µM, and was shown to be statistically significant (Figure 
4.11). It should be noted that that the sensitivity displayed against AZD4547, by 148R-K 
and 148R-S, was slightly lower than was previously seen in Figure 4.5, but nonetheless 
substantial. Conversely, 148R-N had statistically significant cross-resistance against 
AZD4547; 148R-N had a GI50 of 0.969 µM which corresponded to an RF of 5.70 (Figure 
4.11). Taken together, these data show that the selected 148R clones were all cross-
resistant to GSK269962, that 148R-K and 148R-S were highly sensitive to AZD4547, and 
that 148R-N was cross-resistant to NVP-AEW541 and AZD4547. 







GSK269962 (ROCK) NVP-AEW541 (IGF-1R) AZD4547 (FGFR) 
Cell line GI50 (µM) RF GI50 (µM) RF GI50 (µM) RF 
A2780 0.028 ± 0.010 N/A 1.41 ± 0.67 N/A 0.170 ± 0.104 N/A 
148R-K 3.032 ± 1.959* 108.29 1.34 ± 0.40 0.95 0.011 ± 0.012* 0.06 
148R-N 2.180 ± 0.931** 77.86 2.98 ± 1.17*** 2.12 0.969 ± 0.408** 5.70 
148R-S 3.285 ± 0.750** 117.32 1.35 ± 0.65 0.96 0.008 ± 0.002* 0.05 
 
Figure 4.11: Dose-response curves and GI50 determinations for GSK269962, NVP-AEW541 and AZD4547 
in A2780 and selected 148R clones. Cells were plated in triplicate in a 96-well plate and allowed to grow 
under standard growth conditions for 48 hours. They were then treated with a serial dilution of 
GSK269962, NVP-AEW541 or AZD4547 for 96-hours, prior to being analysed by SRB assay. Dose-response 
graphs and non-linear regression curve fits were generated using GraphPad Prism 6. Dotted line marks 
50% viability on the y-axis. Data points represent the mean ± SD from one representative experiment. 
Table summarises GI50 and RF, GI50 data points depict the mean ± SD of all experiments conducted. 
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4.2.7. Analysis of basal signalling in selected 148R clones 
The analysis of basal signalling was also repeated in selected 148R clones to ensure that 
this had not been altered by continuous culture in AT13148. As was seen previously 
(Figure 4.6), selected 148R clones were all shown to have a strong over-expression of 
IGF-1R when compared to A2780, which was most notable in 148R-S which had the 
highest expression of IGF-1R (Figure 4.12A). Since this was not seen previously; IGF-1R 
expression was equal amongst 148R-K, N and S in Figure 4.6; this perhaps suggests that 
there was an induction of IGF-1R expression in 148R-S upon continuous AT13148 
treatment. However, a more thorough investigation would be required to ascertain this.  
The activation of the PAM pathway was also investigated by western blotting for AKT 
and two AKT substrates (GSK3β and PRAS40), as well S6RP to assess downstream 
activation of the PAM pathway. Figure 4.12A shows that there was an increase in the 
phosphorylation of S473 AKT and S9 GSK3β in 148R-N, when compared to A2780, but 
no difference in the phosphorylation of T246 PRAS40. This differs from Figure 4.6, where 
T246 PRAS40 phosphorylation was shown to be increased in 148R-N. In contrast, the 
phosphorylation of S9 GSK3β was unchanged in 148R-K and 148R-S, as was the 
phosphorylation of T246 PRAS40 (Figure 4.12A). The phosphorylation of S473 AKT also 
appeared to be slightly increased in 148R-S, inconsistent with Figure 4.6 and the lack of 
increase in AKT substrate phosphorylation in Figure 4.12A. However, the total 
expression of AKT was slightly increased in all 148R clones, suggesting that the increase 
in AKT phosphorylation within 148R-S might be due to over-loading. The total protein 
expression of PRAS40 and GSK3β was consistent amongst A2780 and the selected 148R 
clones (Figure 4.12A).  Interestingly, as was seen in Figure 4.6, the phosphorylation of 
S325/236 S6RP was decreased in all 148R clones, especially in 148R-K and 148R-N, with 
total S6RP expression unchanged (Figure 4.12A).  
The selected 148R clones were also western blotted for MYPT1 as a readout of the 
activity of the ROCK pathway. The phosphorylation of T696 MYPT1 and MYPT1 total 
expression were unaltered across A2780 and all selected 148R clones (Figure 4.12B). In 
addition, the expression of FGFR2 was also assessed to investigate the sensitivity to 
FGFR inhibition amongst 148R clones. The expression of FGFR2 was shown to be 
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identical to A2780 in 148R-K and 148R-S, however it was much lower in 148R-N (Figure 
4.12B). This was interesting as 148R-N was the only 148R clone not to display cross-



























Figure 4.12: Analysis of the basal expression of IGF-1R, FGFR2 and markers of the PAM and ROCK 
pathways in selected 148R clones. (A, B) Cells were plated at either 0.5 x 106 (A2780) or 1 x 106 (A2780-
148R and 148R clones) cells per 10 cm dish and allowed to grow for 48 hours under standard growth 
conditions. Cells were then lysed prior to western blot analysis. Western blot membranes were probed 
with antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total proteins and 
loading control (β-Actin). A2780 and selected 148R clones are highlighted in red in (B). Data are 
representative of five independent experiments. 
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4.2.8. Cross-resistance of 148R clones to AKT and p70S6K inhibition  
As shown previously in Figure 4.3 & Figure 4.11, one of the defining features of 148R 
clones (and A2780-148R) was their strong cross-resistance to the ROCK inhibitor 
GSK269962. Since ROCK1 and 2 are both targets of AT13148, it was considered that 148R 
clones may also possess cross-resistance to inhibition of other AT13148 targets. To this 
end, SRB cell viability assays were performed on 148R clones using MK2206, an allosteric 
AKT inhibitor, and PF4708671, a p70S6K inhibitor (Hirai et al., 2010; Pearce et al., 
2010b).  
Remarkably, as shown in Figure 4.13, all 148R clones were shown to have statistically 
significant cross-resistance to MK2206; A2780 had a GI50 of 0.08 µM against MK2206 
compared to 0.35 µM, 2.17 µM, 0.50 µM in 148R-K, N and S respectively (Figure 4.13). 
This equated to an RF of 4.38 and 6.25 in 148R-K and 148R-S, indicating a moderate level 
of cross-resistance, and an RF of 27.13 in 148R-N, indicating a strong degree of cross-
resistance to MK2206 (Figure 4.13). There was also some cross-resistance to PF4708671; 
A2780 had a GI50 of 8.78 µM compared to 25.81 µM, 15.37 µM and 20.82 µM in 148R-
K, N and S respectively (Figure 4.13). This was statistically significant (in all 148R clones) 
and equated to an RF of ~2-3 in 148R clones, demonstrating low-level cross-resistance 
(Figure 4.13). Taken together, these data showed that 148R clones had cross-resistance 
to AKT and p70S6K inhibition, key targets of AT13148.  
  

























Figure 4.13: Dose-response curves and GI50 determinations for MK2206 and PF4708671 in A2780 and 
148R clones. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard growth 
conditions for 48 hours. They were then treated with a serial dilution of MK2206 or PF4708671 for 96-
hours, prior to being analysed by SRB assay. Dose-response graphs and non-linear regression curve fits 
were generated using GraphPad Prism 6. Dotted line marks 50% viability on the y-axis. Data points 
represent the mean ± SD from one representative experiment. Table summarises GI50 and RF, GI50 data 
points depict the mean ± SD of all experiments conducted. Statistical significance was calculated using a 




MK2206 (AKT) PF4708671 (p70S6K) 
Cell line GI50 (µM) RF GI50 (µM) RF 
A2780 0.08 ± 0.04 N/A 8.78 ± 3.04 N/A 
148R-K 0.35 ± 0.11** 4.38 25.81 ± 7.00** 2.94 
148R-N 2.17 ± 0.85* 27.13 15.37 ± 0.65* 1.75 
148R-S 0.50 ± 0.19* 6.25 20.82 ± 8.09* 2.37 
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4.2.9. Response of signalling pathways to AT13148 treatment in 148R clones 
4.2.9.1. Markers of PAM signalling 
The previously described cross-resistance to selective inhibitors of AKT and p70S6K, two 
targets of AT13148, may indicate that the mechanism of resistance to AT13148 is 
proximal to the PAM pathway. To investigate this A2780 and 148R clones were treated 
with AT13148 for 4 hours and then analysed by western blot for markers of PAM 
pathway signalling. Figure 4.14 shows that T246 PRAS40 phosphorylation, a marker of 
AKT inhibition, was partially refractory to AT13148 in all 148R clones; 5 µM of AT13148 
was able to abolish T246 PRAS40 phosphorylation in A2780, but this was not the case in 
148R clones. In 148R-K and 148R-S, 5 µM of AT13148 did cause a slight decrease in T246 
PRAS40 phosphorylation, with 10 µM causing a further reduction without completely 
abolishing the phosphorylation of T246 PRAS40 (Figure 4.14). This was similar in 148R-
N, but T246 PRAS40 phosphorylation was maintained to a greater extent than in 148R-
K and 148R-S (Figure 4.14). The total protein expression of PRAS40 was consistent across 
all cell lines and was unaffected by AT13148 treatment (Figure 4.14). 
As with PRAS40 phosphorylation, the phosphorylation of S235/236 S6RP was also 
partially refractory to AT13148 (Figure 4.14). In A2780, S235/236 S6RP phosphorylation 
was strongly inhibited with 0.5 µM AT13148 and completely abolished at ≥ 1 µM (Figure 
4.14). In contrast, there was only a small decrease in S235/236 S6RP phosphorylation 
with 0.5 µM AT13148 in 148R clones, and ≥ 5 µM was required to completely abolish 
the phosphorylation of S235/236 S6RP (Figure 4.14). Despite some changes in 148R-N, 
in response to AT13148, total S6RP expression was mostly unaffected by AT13148 
treatment and was consistent across all cell lines (Figure 4.14). Taken together, these 
data suggest that PAM pathway was partially refractory to AT13148 inhibition in 148R 
clones, this could play a role in AT13148 resistance and warrants further investigation. 
  






Figure 4.14: Analysis of the response of the PAM pathway to AT13148 in 148R clones. Cells were plated 
at either 0.5 x 106 (A2780) or 1 x 106 (148R clones) cells per 10 cm dish and allowed to grow for 48 hours 
under standard growth conditions. Cells were then treated with AT13148, as shown, or D: DMSO vehicle 
control for 4 hours, prior to being lysed for western blot analysis. Western blot membranes were probed 
with antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total proteins or 
loading control (GAPDH). Data are representative of three (PRAS40) or four (S6RP) independent 
experiments. 
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4.2.9.2. Markers of ROCK signalling 
Since 148R clones all had a strong level of cross-resistance to ROCK inhibition, A2780 
cells and 148R clones were also treated with AT13148 to investigate if AT13148 
resistance was proximal to the ROCK pathway. The phosphorylation of T696 MYPT1, a 
substrate of ROCK1 and 2, was used as marker of the inhibition of the ROCK pathway by 
AT13148. Figure 4.15 shows that in both A2780 and 148R clones 1 µM of AT13148 
caused a sharp decrease in the phosphorylation of T696 MYPT1. In 148R-S there was 
also a sharp decrease in MYPT1 T696 phosphorylation at 0.1 µM AT13148, but at 0.5 µM 
AT13148 MYPT1 T696 phosphorylation was similar to the DMSO vehicle control for 
148R-S (Figure 4.15). An unusual response was also seen in A2780 and 148R-K where 
there was a slight rebound in T696 MYPT1 phosphorylation with 5-10 µM AT13148 
(Figure 4.15). However, this was very slight and only seen with a long film exposure, and 
therefore perhaps caused by subtle differences in loading (Figure 4.15). The expression 
of total MYPT1 was unaffected by AT13148 in A2780 and 148R-K, but in 148R-N and 
148R-S, when used at 1-10 µM, AT13148 did cause a decrease in the total expression of 
MYPT1, particularly in 148R-S (Figure 4.15). It should be noted that this was not seen in 
other biological replicates and was thus most likely caused by an experimental artefact. 
In summary, there were some differences in the response of the ROCK pathway to 
AT13148 in A2780 and 148R clones, but in the context of AT13148 resistance, these did 
not appear sufficient to contribute towards resistance. These differences in response, 
amongst A2780 and 148R clones, likely reflects the promiscuous nature of MYPT1 
phosphorylation (as discussed in section 3.3).  
  






Figure 4.15: Analysis of the response of the ROCK pathway to AT13148 in A2780 and 148R clones. Cells 
were plated at either 0.5 x 106 (A2780) or 1 x 106 (A2780-148R) cells per 10 cm dish and allowed to grow 
for 48 hours under standard growth conditions. Cells were then treated with AT13148, as shown, or D: 
DMSO vehicle control for 4 hours prior to being lysed for western blot analysis. Western blot membranes 
were probed with antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total 
proteins or loading control (β-Actin). (S): short exposure to hyperfilm, (L): long exposure to hyperfilm. 
Data are representative three independent experiments. 
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4.2.10. Response of the PAM pathway to MK2206 in A2780 and 148R clones 
The response of the PAM pathway to MK2206 was also examined, as 148R clones, 
particularly 148R-N, had displayed cross-resistance to MK2206. In addition, since the 
PAM pathway was partially refractory to AT13148, the response to MK2206 may enable 
the contribution of AKT towards this to be dissected. Figure 4.16 shows that MK2206 
potently inhibited the phosphorylation of S473 AKT across A2780 and 148R clones in a 
similar manner; 0.01 µM caused a sharp decrease in S473 AKT phosphorylation and ≥ 
0.1 µM MK2206 abolished phosphorylation. However, there were some differences in 
the response of the AKT substrates GSK3β and PRAS40 to MK2206 amongst A2780 and 
148R clones. In A2780 and 148R-S the phosphorylation of S9 GSK3β and T246 PRAS40 
was substantially reduced with 1 µM MK2206, the maximum concentration used, with 
PRAS40 T246 phosphorylation also exhibiting this response in 148R-N (Figure 4.16). But 
in contrast, in 148R-N S9 GSK3β phosphorylation was partially refractory; whilst 1 µM of 
MK2206 caused a decrease in GSK3β S9 phosphorylation, this was to a much lesser 
extent than in A2780 and 148R-S (Figure 4.16) 
A similar phenomenon was also seen with S235/236 S6RP phosphorylation, whereby 0.1 
µM MK2206 caused a sharp decrease in S6RP phosphorylation in A2780 and 148R-S but 
did not do so in 148R-N (Figure 4.16). However, in 148R-N, 1 µM MK2206 did cause 
substantial decrease in S236/236 S6RP phosphorylation, indiscernible from A2780 and 
148R-S, thus indicating that S235/236 S6RP phosphorylation was only partially 
refractory to MK2206 in 148R-N (Figure 4.16). Since AKT was equally inhibited by 
MK2206 in A2780 and 148R clones, as shown by a comparable decrease in AKT 
phosphorylation, the maintenance in the phosphorylation of substrates downstream of 
AKT in 148R-N would seem to occur in an AKT-independent manner. Taken together, 
these data suggest that some of the PAM pathway is partially refractory to AKT inhibition 
in 148R-N, and that this seems to independent of AKT activation.  
  









Figure 4.16: Analysis of the response of PAM pathway to MK2206 in A2780 and 148R clones. Cells were 
plated at either 5 x 105 (A2780) or 7.5 x 105 (148R clones) cells per 7 cm dish and allowed to grow for 48 
hours under standard growth conditions. Cells were then treated with MK2206, as shown, or D: DMSO 
vehicle control for 4 hours prior to being lysed for western blot analysis. Western blot membranes were 
probed with antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total 
proteins or loading control (β-Actin) Data are representative of two (GSK3β) or three (AKT, PRAS40 and 
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4.2.11. Analysis of markers of the MAPK pathway in A2780 and 148R clones 
The work presented thus far in this chapter has shown that the PAM pathway was less 
responsive to AT13148 in 148R clones. This could be caused by changes to AKT and 
p70S6K, e.g. mutation or increased expression, but alternatively could be caused by 
changes in another pathway which interacts with the PAM pathway. One such pathway 
is the MAPK pathway which is known to interact with the PAM pathway on several 
levels, and was shown in chapter 3 to be altered in A2780-148R (Mendoza et al., 2011., 
Figure 3.11). Therefore, markers of the MAPK pathway were analysed in A2780 and 148R 
clones by western blotting. 
Figure 4.17 shows that there was a striking increase in the phosphorylation of 
Thr202/Tyr204 ERK 1/2 in all 148R clones when compared to A2780. This was highest in 
148R-S followed by 148R-K and then 148R-N (Figure 4.17). Contrary to what one might 
expect, there was a decrease in the phosphorylation of S217/221 MEK 1/2 in all 148R 
clones (Figure 4.17), with this being greatest in 148R-N. This paradoxical increase in ERK 
1/2 phosphorylation coupled with a decrease in MEK 1/2 phosphorylation was also seen 
in A2780-148R in chapter 3 (Figure 3.11), but the increase/decrease was considerably 
more marked in 148R clones. As discussed in section 3.3, this dichotomy, between ERK 
1/2 and MEK 1/2 phosphorylation, could be due to an increase in negative feedback 
caused by increased phosphorylation of ERK 1/2. 
The phosphorylation of two ERK 1/2 substrates, ETS Like-1 protein (Elk-1) and p90 
ribosomal S6 kinase (RSK), was also examined to see whether they exhibited a parallel 
increase in their phosphorylation, in line with increased ERK 1/2 phosphorylation. There 
were three bands detected for S383 Elk-1 phosphorylation, which was not anticipated 
as S383 Elk-1 was supposed to be detected as singular band (Figure 4.17). However, the 
band with lowest molecular weight matched the single band detected for total Elk-1 
expression and corresponded to the molecular weight predicted by the antibody 
manufacturer (62 kDa) for Elk-1, so was therefore determined to be the band 
representing S383 Elk-1 phosphorylation. Taking this into account, there was a strong 
increase in the phosphorylation of S383 Elk-1 phosphorylation in 148R-K and 148R-S 
when compared to A2780, but a decrease in 148R-N (Figure 4.17). In contrast, the 
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phosphorylation of T359 RSK was slightly lower in all 148R clones, perhaps suggesting 
that S383 Elk-1 phosphorylation may be a better readout of ERK activity, at least in 148R-
K and 148R-S (Figure 4.17). Taken together, these data suggest that the MAPK pathway 
was altered in 148R clones but not uniformly. This warrants further investigation into 
how it may contribute towards AT13148 resistance, and as to whether 148R clones have 
an increased dependency on the MAPK pathway for growth and survival, which could 
































Figure 4.17: Analysis of the basal expression of markers of the MAPK pathway in A2780 and 148R clones. 
Cells were plated at either 0.5 x 106 (A2780) or 1 x 106 (148R clones) cells per 10 cm dish and allowed to 
grow for 48 hours under standard growth conditions. Cells were then lysed prior to western blot analysis. 
Western blot membranes were probed with antibodies for phospho-proteins, stripped, and then re-
probed with antibodies for total proteins and loading control (β-Actin). Red arrow highlights band 
corresponding to pS383 Elk-1. Data are representative of five independent experiments. 
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4.3. Discussion  
4.3.1. Clone screening and selection   
The primary aim of this chapter was to derive isogenic sub-clones from A2780-148R and 
characterise them in order to identify putative drivers of resistance to AT13148. As has 
been described in this chapter, 148R clones initially went through two phases of 
screening, both of which were based upon SRB cell viability assays determining the 
response to AT13148, GSK269962, NVP-AEW541 and AZD4547, as well as western blot 
analysis of the basal expression of markers of the PAM and ROCK pathways. The first 
phase (Figure 4.2-Figure 4.6) was performed on all isolated 148R clones and the second 
phase (Figure 4.7-Figure 4.12) on three 148R clones; 148R-K, N & S, selected based on 
the results from phase one. Since phase two was conducted with 148R clones cultured 
in the presence of AT13148, with optimal seeding densities determined via growth 
assays, it is likely to be a more accurate representation of 148R clones. However, both 
were able gain insight into resistance against AT13148.  
Prior to getting into a more detailed discussion over the results of the screening of 148R 
clones it is worth mentioning that the over-arching observation that one can take from 
this screening is the sheer variability amongst 148R clones. This was most notable in SRB 
cell viability assays, for example, the RF value for AT13148 in 148R clones ranged from 
1.86 to 20.31 (Figure 4.2 & Figure 4.10). A careful interpretation is required in terms of 
what this means for AT13148 resistance in A2780-148R. This variability could be 
interpreted as showing that A2780-148R has a high degree of heterogeneity, with 
several unique sub-populations likely to have distinct mechanisms of resistance to 
AT13148. However, an equally likely explanation is that this variation is an effect of 
isolation itself being a stimulus for the production of new phenotypes (Heppner, 1984). 
Indeed, it has been shown, due to the inherent genetic instability of many cancers, that 
isolated cancer cells can quickly evolve into a genetically heterogenous population, 
distinct from the cell lines from which they were derived (Ben-David et al., 2018).  
Nonetheless, screening provided evidence that resistance against AT13148 in 148R 
clones was, for the most part, stable. As mentioned, during the 1st phase of screening, 
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which took place over a 2-month period, 148R clones were not cultured in the presence 
of AT13148. Despite this, all but one 148R clone (148R-I) was shown to have > 2-fold 
resistance to AT13148, thus indicating that resistance was stable (Figure 4.2). This was 
further validated by the second phase of screening, which showed that routine sub-
culture in the presence of AT13148 did not substantially increase resistance to AT13148 
(Figure 4.10). 148R-K was an exception to this; there was a ~3-fold increase in AT13148 
resistance in phase two of screening. This could of course be caused by inter-assay 
variation but might also be indicative of transient resistance to AT13148. Whilst most 
resistance phenotypes tend be stable, the acquisition of transient resistant phenotypes 
is not uncommon. For example, Stottrup and colleagues (Stottrup et al., 2016) 
generated resistance against the AKT inhibitor MK2206 in breast cancer cell lines and 
demonstrated that resistant cells could be partially re-sensitized to MK2206 upon drug 
withdrawal over a three week period. A similar approach could be employed to ascertain 
if 148R-K exhibited transient resistance; 148R-K cells could be released from AT13148 
for various time points and compared to 148R-K continuously cultured in the presence 
of AT13148. 
Screening 148R clones for their response to AT13148 not only revealed differences in 
GI50 and RF values, but also distinct dose-response curves (Figure 4.10). A2780, 148R-K 
and 148R-S had typical dose-response curves, that were sigmoidal adhering to the 
threshold model; whereby, at lower doses, drugs elicit no biological effect until a 
threshold is met (target inhibition), inhibition then proceeds in linear fashion until target 
saturation (Reynolds, 2010). The dose-response curve for 148R-N did not adhere to this 
model; AT13148 appeared to inhibit the viability of 148R-N in two distinct linear phases; 
at low concentrations there was an incremental decrease in viability, a shallow gradient, 
followed by a sharp decrease at higher concentrations. This could possibly be due to the 
broad inhibition elicited by AT13148; the inhibition of high potency targets (e.g. ROCK1 
& 2) at low concentrations of AT13148 could cause a small incremental decrease in 
148R-N viability, and the additional inhibition of lower potency targets (e.g. AKT) at 
higher concentrations, could cause the sharp decrease in viability (highlighted in Figure 
4.18). However, there are other possible explanations for the distinctive dose-response 
curve of 148R-N. Fallahi-Sichani and colleagues (Fallahi-Sichani et al., 2013) showed that 
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PAM pathway inhibitors, such as the mTOR inhibitor PP242, which had dose-response 
curves with a low hill-slope (as does 148R-N), correlated with a high-level of cell-cell 
variability of the PAM pathway response to inhibition, demonstrated by 
immunofluorescence staining of the mTORC1 substrate 4EBP1 and cell cycle marker 
retinoblastoma protein (Rb). They postulated that this was due to stochastic fluctuations 
(e.g. in drug target or negative feedback regulation) rather than the presence of distinct 
genetic sub-populations (Fallahi-Sichani et al., 2013). Since the response of 148R-N to 
AT13148, up to ~ 3 µM, exhibits a shallow dose-response curve, cell to cell variation 
(non-genetic) in response to AT13148 could be a possible explanation. Furthermore, 
AT13148 differentially eliciting cytostatic and cytotoxic effects in 148R-N at different 
AT13148 concentrations, and 148R-N exhibiting unique growth kinetics (Figure 4.8 & 
Figure 4.9), could also explain why 148R-N had a distinctive dose-response curve to 
AT13148. Whatever the exact mechanism, it can be said with certainty, that 148R-N 
responds to AT13148 in a distinctive manner, which could suggest that 148R-N has a 








Figure 4.18: Potential influence of AT13148 target inhibition on response of 148R-N to AT13148. Graph 
shows the response of 148R-N and 148R-S to AT13148 (taken from Figure 4.10B) and the hypothetical 
inhibition of AT13148 targets at different concentrations of AT13148. 
As has been mentioned, the screening of 148R clones revealed a substantial degree of 
variation. This can especially be seen in response to the ROCK inhibitor GSK269962, 
where all 148R clones demonstrated cross-resistance, but the extent of this varied 
considerably (RF 11.42 – 168.77, Figure 4.3). Interestingly, it was shown that there was 
significant correlation between AT13148 resistance and GSK269962 cross-resistance 
(Figure 4.3). This would suggest that in order to become resistant to AT13148, cells must 
find a way of overcoming the inhibition of ROCK1 & 2 by AT13148, the extent of which 
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determines the magnitude of resistance to AT13148. Of course, it is possible that there 
is not a direct causal link between AT13148 resistance and GSK269962 cross-resistance, 
but the strong level of correlation between the two, coupled with the potent inhibition 
of ROCK 1 and 2 by AT13148, would seem to make a causal link likely.  
Another interesting finding of the initial screening was the loss of sensitivity to the IGF-
1R inhibitor NVP-AEW541 in 148R clones (Figure 4.4 & Figure 4.11). This was 
independent of AT13148 exposure; as the second phase of screening on selected 148R 
clones, which were maintained in AT13148, did not re-establish NVP-AEW541 
sensitivity. A2780-148R cells were also shown to have lost their sensitivity to NVP-
AEW541, with sensitivity decreasing over the period of time that 148R clones were 
isolated and expanded (Figure 4.4C). It is therefore likely that the loss of sensitivity in 
148R clones was also due to a loss of sensitivity over time, rather than as an artefact of 
the isolation process. 
Remarkably, despite the loss of NVP-AEW541 sensitivity, 148R clones and A2780-148R 
cells were still shown to over-express IGF-1R, albeit to varying extents (Figure 4.6 & 
Figure 4.12). Furthermore, unpublished data from the Garrett lab has shown that an IGF-
1R expressing sub-population can be selected from AT13148 sensitive parental A2780 
cells, when cultured in the presence of 5.2 µM AT13148 (maintenance dose of AT13148; 
data not shown). This might suggest that during the generation of resistance to AT13148 
in parental A2780 cells, an IGF-1R expressing sub-population of A2780 was initially 
selected for that conferred a dependency on IGF-1R signalling and a survival advantage 
in the presence of AT13148. However, over time, with dose-escalation and prolonged 
AT13148 exposure, additional changes occurred/were selected for driving AT13148 
resistance to the level seen in A2780-148R and 148R clones, reducing the dependency 
on IGF-1R signalling for survival. Evidence for this can be seen as despite the loss of NVP-
AEW541 sensitivity, and thus IGF-1R dependency, AT13148 resistance was still retained 
in A2780-148R and 148R clones. 
The loss of NVP-AEW541 sensitivity, combined with the previous work conducted 
investigating IGF-1R as a driver of resistance (Akan, 2015), would seem to exclude IGF-
1R over-expression from either driving resistance or being a therapeutic target in 
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AT13148 resistance. However, further work should be conducted to ascertain the 
importance of IGF-1R over-expression and dependency as an early driver of AT13148 
resistance. If this is validated, then combining AT13148 with an IGF-1R inhibitor could 
be a therapeutic strategy to prevent the acquisition of AT13148 resistance or prolong 
the response to AT13148. 
In contrast, sensitivity to the FGFR inhibitor AZD4547 was retained in most 148R clones 
as well as in A2780-148R (Figure 4.5 & Figure 4.11). Of the 148R clones that were 
selected for further analysis, 148R-K and 148R-S both showed ~20-fold sensitivity (Figure 
4.11). The exception to this was 148R-N which was cross-resistant to AZD4547, as well 
as NVP-AEW541, again, highlighting that 148R-N appears to be distinct from other 148R 
clones. It was interesting to see that 148R-N also had decreased expression of FGFR2, 
which may explain why it was cross-resistant, but the expression of FGFR2 was 
unchanged in 148R-K and 148R-S (Figure 4.12). This is problematic, as the inhibition of 
FGFR could be a potential therapeutic strategy in AT13148 resistant patients, but this 
would be difficult without identifying a biomarker of sensitivity. As discussed in section 
3.3, other isoforms of FGFR (1,3 & 4) exist, of which FGFR 1 & 3 are also targeted by 
AZD4547 (in addition to FGFR2), and have been shown to contribute towards resistance 
to cancer therapies (Yadav et al., 2012; Daly et al., 2017). It would be prudent to 
investigate the expression and phosphorylation of these FGFRs to try and identify a 
biomarker of FGFR sensitivity. Sensitivity to FGFR inhibition should also be validated by 
the use of additional FGFR inhibitors such as BGJ398 and JNJ-42756493, both which have 
progressed to clinical trials (Desai and Adjei, 2016). 
In addition to SRB cell viability assays, 148R clones were also screened by performing 
western blots investigating the basal expression of markers of the PAM and ROCK 
pathways, two key AT13148 targets. Again, these assays revealed that 148R-N appeared 
to be distinct from other 148R clones; 148R-N exhibited increased phosphorylation of 
AKT substrates (PRAS40 and GSK3β) as well as AKT itself, which was not seen in 148R-K 
or 148R-S (Figure 4.6 & Figure 4.12). However, it should be noted that there was some 
discrepancy in the phosphorylation of PRAS40 in 148R-N; PRAS40 phosphorylation was 
shown to be increased in Figure 4.6 but was unchanged in Figure 4.12. Nonetheless, 
since AT13148 inhibits AKT1 & 3, changes to AKT and AKT substrate 
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phosphorylation/expression has the capacity to contribute towards resistance to 
AT13148, this has been observed in other AKT inhibitors. For example, Stottrup and 
colleagues (Stottrup et al., 2016) demonstrated that increased expression of AKT3 can 
drive resistance to the allosteric AKT inhibitor MK2206 in resistant breast cancer cell 
lines.  
It should also be noted that in 148R-K and 148R-N there was decreased phosphorylation 
of S6RP at a basal level. However, this was not seen in any of the subsequent dose-
response western blots (e.g. Figure 4.14), where S6RP phosphorylation was shown to be 
unchanged at a basal level, so would appear to be caused by variation, either stochastic 
or experimental, not AT13148 resistance. Nonetheless, the lack of increase in S6RP 
phosphorylation suggested that the apparent increase in AKT activation in 148R-N does 
not transmit to the downstream components of the PAM pathway, proximal to mTORC1 
and p70S6K. 
4.3.2. The role of PAM and ROCK signalling in AT13148 resistance 
To investigate the potential consequences of altered AKT signalling, SRB assays were 
performed using MK2206, a potent and selective allosteric inhibitor of all three AKT 
isoforms (Hirai et al., 2010; Figure 4.13). 148R-N was shown to be remarkably cross-
resistant to MK2206, with an RF value of ~27, but rather unexpectedly, due to lack 
alterations in the PAM pathway at the basal level, 148R-K and 148R-S also displayed 
cross-resistance, albeit to a lesser extent (RF ~4-6). Western blotting of PAM pathway 
markers in response to MK2206 revealed a potential mechanism for cross-resistance in 
148R-N; AKT substrate phosphorylation was partially refractory to MK2206, however, 
this was only seen with GSK3β and not PRAS40 (Figure 4.16). This was not seen in 148R-
S. 
Since MK2206 is an allosteric inhibitor of AKT, the phosphorylation of AKT was used as 
a direct marker of inhibition of AKT by MK2206. AKT was inhibited by MK2206 to a near-
identical extent across A2780, 148R-N and 148R-S, which suggests, in 148R-N, that the 
maintenance of GSK3β phosphorylation in response to MK2206 was independent of 
AKT. In addition, S6RP phosphorylation was also shown to be partially refractory to 
MK2206 in 148R-N. Considering PRAS40 phosphorylation was not maintained in 148R-
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N, and that PRAS40 is an upstream regulator of mTORC1, therefore PAM pathway 
substrates downstream of mTORC1, such as S6RP, the maintenance of S6RP might be 
due to changes proximal to mTORC1 and p70S6K. Since the PAM pathway was equally 
responsive to MK2206 in A2780 and 148R-S, it would seem likely that MK2206 cross-
resistance is caused by changes outside the PAM pathway in 148R-S 
With regards to 148R-N, despite the maintenance of GSK3β phosphorylation appearing 
to be independent of AKT, it may still be dependent upon PI3K. Indeed, there is 
increasing evidence to suggest that AKT is not the only effector of PI3K, and that some 
tumours are PI3K dependent but AKT independent. Gagliardi and colleagues (Gagliardi 
et al., 2012) demonstrated that the knockdown of PDK1 caused a loss of malignant 
phenotype in breast cancer cells harbouring PIK3CA mutations, which could not be 
recovered by the expression of constitutively active AKT. In a similar study, Vasudevan 
and colleagues (Vasudevan et al., 2009) identified that cancer cell lines that were driven 
by activating PIK3CA mutations, but AKT independent, were dependent upon SGK3.  
As discussed in section 1.5, SGK3 is one of three isoforms of SGK (SGK1, 2 & 3) which, 
like AKT, are members of the AGC family of protein kinases and share significant 
homology with one another and AKT (Bruhn et al., 2010). All isoforms of SGK have been 
shown to act as AKT independent effectors of PI3K; they are activated in a PI3K/PDK1 
dependent manner, with some evidence that they also depend upon mTORC2 for their 
activation (Bruhn et al., 2010, 2013). Furthermore, SGK isoforms have overlapping 
substrate specificity with AKT (Bruhn et al., 2013). Shared substrates between AKT and 
SGK include GSK3β, FOXO3a, TSC2 and BAD, with SGK isoforms shown to either 
phosphorylate the same residue as AKT (e.g. S9 GSK3β) or a different residue (e.g. S315 
FoXO3a) (Brunet et al., 2001; Bruhn et al., 2010).  
Therefore, in 148R-N an increase in SGK expression or activation could explain the 
maintenance of GSK3β phosphorylation, that was seen in response to MK2206, which 
may also occur in response to other AKT inhibitors, such as AT13148 (Figure 4.19). 
Alternatively, alterations in upstream regulators of SGK activation, such as PI3K, PTEN, 
PDK1 and RTK’s could enable the by-pass of AKT via SGK (Figure 4.19). This perhaps 
might be more likely a mechanism in 148R-N, since the phosphorylation of AKT was 
increased at a basal level, indicating that there may be changes upstream of AKT and 
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SGK. However, it should be considered that AT13148 can inhibit SGK3, so SGK1 and 2 
might be more likely involved in AT13148 resistance. Interestingly, it has been shown 
that elevated SGK1 expression can predict resistance to AKT inhibition in breast cancer 
cell lines, thus highlighting the potential of SGK to overcome AKT inhibition  (Sommer et 
al., 2013).  
It is also worth noting that there are several additional kinases, not regulated by PI3K 
and PDK1, that can also phosphorylate GSK3β, including RSK, ERK and PKA (Mendoza et 
al., 2011; Beurel et al., 2015). These should also be considered as contributing to the 
maintenance of GSK3β phosphorylation in response to AKT inhibition. A more 
comprehensive investigation of the response of AKT substrates to MK2206 would gain 
some mechanistic insight; if the phosphorylation of several shared AKT and SGK 
substrates is maintained in response to MK2206 it would make it likely that this is SGK 
dependent. However, caution would be required when interpreting these results, as 
some of the aforementioned kinases can also phosphorylate AKT/SGK substrates; e.g. 
ERK and RSK can phosphorylate TSC2 (Mendoza et al., 2011). Analysis of the 
phosphorylation of a specific SGK substrate, such as N-Myc downstream regulated 
(NDRG) 1 and 2, would provide more conclusive evidence of the contribution of SGK 
isoforms; e.g. increased NDRG phosphorylation would suggest an SGK dependent 
mechanism (Murray et al., 2004).  
Figure 4.19: Potential by-pass of AKT inhibition via SGK in 148R-N. SGK and AKT share the same upstream 
activation (PI3K/PDK1 dependent) and have overlapping substrate specificities. Increased activation or 
expression of SGK might enable the maintenance of GSK3β phosphorylation in the presence of AKT 
inhibition. This could also enable the maintenance of other shared AKT/SGK substrates. Alternatively, 
hyperactivation of upstream regulators of AKT and SGK (highlighted with yellow stars, e.g. PDK1), may 
enable the by-pass of AKT inhibition via SGK.  
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Investigating the response of the PAM pathway to AT13148 also provided insight into 
AT13148 resistance (Figure 4.14). Remarkably, the phosphorylation of the AKT substrate 
PRAS40 and the p70S6K substrate S6RP were both partially refractory to AT13148 in 
148R-K, N & S. This suggests that the re-activation of substrates downstream of the 
AT13148 targets AKT and p70S6K could be a potential mechanism of AT13148 resistance 
in 148R clones. Interestingly, as previously mentioned PRAS40 phosphorylation was not 
refractory to MK2206 in 148R-N or 148R-S, nor was S6RP phosphorylation in 148R-S. 
This would therefore suggest that the maintenance of PRAS40 phosphorylation in 
response to AT13148 was independent of AKT in 148R-N and 148R-S, and that in 148R-
S, the maintenance of S6RP phosphorylation in response to AT13148 was also 
independent of AKT. In 148R-N, since S6RP phosphorylation was maintained in response 
to both MK2206 and AT13148, the mechanism outlined in Figure 4.19 could be 
contributing to both. In hindsight, it would have been prudent to also assess the 
phosphorylation of GSK3β in response to AT13148, to determine if the mechanism 
highlighted in Figure 4.19, which appears specific to 148R-N, also exists in response to 
AT13148. The maintenance of S6RP phosphorylation, may also explain why there was 
low-level cross-resistance in all 148R clones to the p70S6K inhibitor PF4708671 (Figure 
4.13). 
In contrast to the response of the PAM pathway, the ROCK pathway responded in a 
similar manner in A2780 and 148R clones in response to AT13148 (Figure 4.15). This was 
ascertained by using the phosphorylation of the ROCK substrate T696 MYPT1 as a 
marker of ROCK inhibition.  However, as discussed in section 3.3 there are limitations in 
using T696 MYPT1 phosphorylation as a marker of ROCK inhibition; it can be 
phosphorylated by other kinases, which causes an incomplete response to ROCK 
inhibition. Additionally, the decrease of T696 MYPT phosphorylation in response to 
AT13148 did not proceed in a linear fashion in A2780 or 148R clones, the extent and 
magnitude of which varied across biological replicates (data not shown). This further 
questions the validity of using T696 MYPT1 phosphorylation, alone, as a marker of ROCK 
pathway inhibition in response to AT13148. Therefore, whilst it appears that the ROCK 
pathway is equally responsive to AT13148 in A2780, A2780-148R and 148R clones, this 
should be interpreted with caution. In light of the aforementioned intimate link between 
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AT13148 resistance and ROCK cross-resistance, which was highlighted in Figure 4.3, it 
will be important to determine the mechanism in which A2780-148R and 148R clones 
have overcome ROCK inhibition, as this is likely to contribute towards AT13148 
resistance. To this end, it would be worthwhile to use additional substrates of ROCK and 
other markers of the ROCK pathway to comprehensively assess the response of the 
ROCK pathway to AT13148. 
4.3.3. Alterations in the MAPK pathway in 148R clones 
One of the most striking results of chapter 4 was the increase in the phosphorylation of 
ERK 1/2 at a basal level that was seen in 148R clones, most notably in 148R-S (Figure 
4.17). Whilst this was observed within A2780-148R in chapter 3, the extent of the 
increase was far more dramatic in 148R clones. As discussed in section 3.3, the 
magnitude of the increase in ERK 1/2 phosphorylation in A2780-148R did appear to be 
quite variable, possibly suggesting the existence of sub-populations with high ERK 1/2 
phosphorylation within A2780-148R, that were selected for over time and under 
different culture/experimental conditions. The identification of 148R clones that have 
an increased level of phosphorylated ERK 1/2 gives additional credence to this. Since 
ERK 1/2 is a major regulator of growth, proliferation and survival, its increased activation 
alone has the capacity to contribute to AT13148 resistance. In addition, the MAPK 
pathway can interact with the PAM pathway at multiple levels, so increased ERK 1/2 
phosphorylation could be contributing to the maintenance of the PAM pathway in 
response to AT13148 (Figure 4.14), as discussed in section 4.3.2 (Mendoza, Er and Blenis, 
2011). 
Paradoxically, the phosphorylation of MEK 1/2 was decreased in all 148R clones. Again, 
in chapter 3, A2780-148R was also shown to have a decrease in the phosphorylation of 
MEK 1/2, but to a much lesser extent. Interestingly, the decrease in the phosphorylation 
of MEK 1/2 was inversely related to the phosphorylation of ERK 1/2, with the exception 
to this being 148R-N, which had the lowest phosphorylation of both ERK 1/2 and MEK 
1/2 amongst 148R clones. This inverse relationship between ERK 1/2 and MEK 1/2 
phosphorylation might be explained by the extensive negative feedback regulation of 
the MAPK pathway, the vast majority of which emanates from ERK 1/2. For example, 
ERK 1/2 can phosphorylate MEK 1/2, BRAF and CRAF negatively regulating their activity 
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(Eblen et al., 2004; Dougherty et al., 2005; Ritt et al., 2010). This likely explains how an 
increase in ERK 1/2 could co-exist with decreased MEK 1/2 phosphorylation; as ERK 1/2 
phosphorylation increased, so would ERK 1/2 mediated negative feedback, which in turn 
would decrease MEK 1/2 phosphorylation. However, negative feedback via ERK 1/2 
ultimately functions to decrease the phosphorylation of ERK 1/2 itself; this has obviously 
been disrupted in 148R clones. Therefore, a mechanism must exist within 148R clones 
that enables a sustained increase in the phosphorylation of ERK 1/2 in the absence of 
increased MEK 1/2 activation, which warrants further investigation  
In addition, the increased activation of ERK 1/2 in 148R clones was not reflected in RSK, 
an ERK 1/2 substrate, which was shown to have decreased phosphorylation in all 148R 
clones (Figure 4.17). However, the phosphorylation and activation of many ERK 1/2 
substrates is under tight regulatory control, which may explain why RSK phosphorylation 
was decreased in all 148R clones. For example, upon full activation RSK undergoes 
autophosphorylation at S732 in its D-domain, an ERK 1/2 binding site. The effect of this 
differs depending on which RSK isoform this takes place, of which there are four (RSK1-
4). In RSK1 & 2 this causes ERK 1/2 to dissociate from RSK, which enables the 
engagement of a wider range of RSK substrates, but at the cost of a rapid RSK 
inactivation (Roux et al., 2003; Kidger and Cook, 2018). But in RSK3, ERK 1/2 does not 
dissociate which enables a more sustained activation of RSK3 (Roux et al., 2003). 
Therefore, depending on the prevalence of RSK isoforms, RSK may not be a good 
biomarker of sustained ERK 1/2 activation.  
In contrast, the phosphorylation of Elk-1, a nuclear substrate of ERK 1/2, was increased 
in both 148R-K and 148R-S (Figure 4.17). Elk-1 is a transcription factor, a member of the 
ternary complex factor (TCF) sub-family of ETS-domain transcription factors (Yoon and 
Seger, 2006). Phosphorylation of Elk-1, by ERK 1/2, causes its activation which enables 
the rapid transcription of immediate early genes (IEG’s) such as c-fos (Yoon and Seger, 
2006). c-fos and c-Jun (another IEG) form the activator protein 1 (AP-1) transcriptional 
complex, which in turn promotes the transcription of late response genes promoting 
proliferation and cell survival (Yoon and Seger, 2006; Mendoza et al., 2011). 
Interestingly, c-fos is an unstable protein and requires phosphorylation by ERK 1/2 and 
RSK to prevent its degradation (Yoon and Seger, 2006; Anjum and Blenis, 2008). It would 
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therefore be interesting target to look at in 148R clones to investigate if sustained ERK 
1/2 activation, in the absence of sustained RSK activation, can lead to a stable increase 
in the expression downstream transcriptional regulators (Figure 4.20). This might be 














Figure 4.20: Status of the MAPK pathway in 148R-K and 148R-S. In 148R-K and 148R-S there is an increase 
in the phosphorylation of ERK 1/2 but a decrease in MEK 1/2 phosphorylation, possibly via ERK 1/2 
mediated negative feedback. Of the two ERK 1/2 substrates analysed, Elk-1 phosphorylation was 
increased but RSK phosphorylation was decreased. Increased Elk-1 phosphorylation is likely to lead to an 
increase in the expression of its transcriptional targets, such as c-fos, which drives cell cycle progression 
and proliferation. RSK, which translocates to the nucleus upon activation, and ERK both phosphorylate c-
fos to prevent its degradation. The lack of RSK activation could limit the expression of c-fos, therefore 
proliferation and cell survival and perhaps the ability of ERK 1/2 to contribute to AT13148 resistance. 
Contrary to 148R-K and 148R-S, there was a substantial decrease in Elk-1 
phosphorylation in 148R-N. This means there is no evidence that increased ERK 1/2 
activation causes a sustained activation of ERK 1/2 substrates in 148R-N. However, 160 
substrates of ERK 1/2 have been identified, the phosphorylation of which are dependent 
on the abundance of scaffold proteins and other regulatory mechanisms (Yoon and 
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Seger, 2006). It’s quite possible that a subset of these are regulated by increased ERK 
1/2 phosphorylation in 148R-N, but as of yet have not been identified. 
In summary, in this chapter isogenic 148R clones have been derived from A2780-148R 
cells, of which three; 148R-K, N & S, were selected for further characterisation. Of these 
three, 148R-N appeared the most distinct lacking sensitivity to the FGFR inhibitor 
AZD4547 and having changes within the PAM pathway proximal to AKT. Interestingly, in 
all three 148R clones, the PAM pathway was shown partially refractory to AT13148. 
Since AT13148 targets the PAM pathway, via AKT and p70S6K inhibition, the reactivation 
of the PAM pathway in response to AT13148 could be contributing to AT13148 
resistance. In addition, 148R-K, N and S were shown to have increased phosphorylation 
of ERK 1/2, which has the potential to act as a driver of AT13148 resistance. Subsequent 
chapters will focus on investigating the contribution of PAM pathway re-activation and 
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5. Investigating ERK 1/2 as a driver of AT13148 resistance 
5.1. Introduction  
One of the key findings of previous chapters has been the identification of increased ERK 
1/2 phosphorylation in both A2780-148R and 148R clones.  It was reasoned, that since 
ERK 1/2 is a major regulator of cell growth, proliferation and survival, that increased 
phosphorylation of ERK 1/2 had the potential to act as a driver of resistance to AT13148. 
Indeed, ERK 1/2 has frequently been associated with resistance to numerous cancer 
therapies, either directly through alterations to ERK 1/2, or indirectly through changes 
in upstream components of the MAPK pathway. For example, Ercan and colleagues 
(Ercan et al., 2012) generated resistance in an EGFR (T790M) mutant NSCLC cell line 
against WZ4002, a 3rd generation EGFR inhibitor with activity against T790M mutant 
EGFR, and found that the MAPK1 gene, which encodes ERK2, was amplified, rendering 
ERK 1/2 phosphorylation refractory to WZ4002. Subsequently, inhibition of ERK and 
MEK were shown to overcome resistance, restoring sensitivity to WZ4002. In addition, 
the MAPK pathway is frequently mutated to overcome BRAF (V600E) inhibition in 
melanoma (as discussed in section 1.6.2.1), for example via activating mutations in NRAS 
and MEK1 (Nazarian et al., 2010; Wagle et al., 2011).  
However, the aforementioned examples of MAPK pathway driven resistance are against 
therapies which directly target the MAPK pathway, and in which resistance is generated 
via mechanisms that reactivate the MAPK pathway. Since AT13148 is not known to 
directly inhibit the MAPK pathway, increased activation of ERK 1/2 is unlikely to generate 
resistance to AT13148 in this manner. One way in which increased ERK 1/2 activation 
might drive AT13148 resistance is by facilitating the by-pass of AT13148 targets, such as 
the PAM pathway, which AT13148 targets via its inhibition of AKT and p70S6K. Increased 
ERK 1/2 activation might enable this as the MAPK and PAM pathways are both major 
growth factor pathways, and as such display some redundancy, converging on many of 
the same functional outputs, such as cell cycle progression and survival. For example, 
both ERK 1/2 and AKT regulate the expression of cyclin D1, albeit via different 
mechanisms, which promotes cell cycle progression. ERK 1/2 increases the transcription 
of cyclin D1 via the transcription of c-fos (shown in Figure 4.20), which in turn promotes 
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cyclin D1 expression; AKT promotes cyclin D1 stability by phosphorylating GSK3β, which 
inhibits its activity, preventing GSK3β from phosphorylating cyclin D1 and promoting its 
degradation (Chang et al., 2003; Torii et al., 2006). Furthermore, in regards to pro-
survival signalling, the MAPK and PAM pathway are both known to negatively regulate 
many of the same pro-apoptotic proteins including BAD, BIM and FOXO3a, thus 
promoting cell survival (Chang et al., 2003; Qi et al., 2006; O’Reilly et al., 2009).  
As well the MAPK pathway converging upon the same functional outputs of the PAM 
pathway, the MAPK pathway is also known to cross-activate the PAM pathway at several 
levels (Mendoza et al., 2011). For example, ERK 1/2 and RSK, an ERK 1/2 substrate, are 
known to phosphorylate TSC2 in a similar manner to AKT, inhibiting its GAP function and 
promoting mTORC1 activity (Mendoza et al., 2011). In addition, ERK 1/2 and RSK can 
also phosphorylate RAPTOR (regulatory associated protein of mTOR), a subunit of 
mTORC1, which promotes the phosphorylation of 4E-BP1 by mTORC1 (Mendoza et al., 
2011). It is therefore possible that increased ERK 1/2 phosphorylation could also 
promote AT13148 resistance by cross activating the PAM pathway, maintaining its 
activation in the presence of AT13148. 
As one might expect, due to the intimate link between the PAM and MAPK pathways, 
both pathways have been shown to compensate for one another in therapy resistance. 
Villanueva and colleagues (Villanueva et al., 2010) generated resistance to BRAF 
inhibition, in BRAF V600E mutant melanoma cells, and identified that persistent IGF-1R 
signalling induced PI3K/AKT activation. This cooperated with RAF isoform switching to 
drive resistance to BRAF inhibition, in part, by maintaining the expression of myeloid cell 
leukaemia 1 (Mcl-1), a pro-survival factor jointly regulated by the PAM and MAPK 
pathway (Villanueva et al., 2010). Furthermore, increased IGF-1R expression and AKT 
phosphorylation were found in post-relapse patient samples, in the absence of MAPK 
pathway mutations, highlighting the clinical relevance of PAM pathway activation in 
BRAF inhibitor resistance (Villanueva et al., 2010).  The inverse (MAPK pathway 
compensation for PAM pathway inhibition) has also been observed in HER2 over-
expressing breast cancer cells, albeit in an intrinsic resistance setting, where PI3K 
inhibition has been shown to induce the phosphorylation of ERK 1/2, attenuating the 
response to PI3K inhibition, despite robust inhibition of the PAM pathway (Serra et al., 
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2011). Subsequently, co-inhibition of PI3K and MEK was found to cause a much greater 
reduction in cell proliferation and increased apoptosis, when compared to single agent 
alone (Serra et al., 2011).  
For the reasons outlined, the aim of this chapter was to investigate the ability of 
increased ERK 1/2 phosphorylation in 148R clones to act as a driver of AT13148 
resistance. Initially, the response of 148R clones to single agent MEK and ERK inhibition 
was assessed, to ascertain if there was any sensitivity or cross-resistance and to gain 
insight into the regulation of the MAPK pathway in 148R clones. Subsequently, ERK 1/2 
was validated as a driver of AT13148 resistance in 148R clones by performing 
combination SRB cell viability assays with AT13148 and ERK inhibitors.  
  




5.2.1. Response of A2780 and 148R clones to MEK and ERK inhibitors 
Having detected altered MAPK signalling in all three 148R clones, as shown in Figure 
4.17, the response to MEK and ERK inhibitors (inhibitors of the MAPK pathway) was 
studied in A2780 and 148R-K, N & S. Figure 5.1A shows the response and GI50 
determinations for A2780 and 148R clones against the allosteric MEK inhibitors 
PD0325901 and selumetinib (AZD6244; Yeh et al., 2007; Barrett et al., 2008; Wu and 
Park, 2015). A2780 had a GI50 of 0.027 µM against PD0325901 and a GI50 of 0.68 µM 
against selumetinib (Figure 5.1A). Strikingly, there was a statistically significant increase 
in the GI50 for PD0325901 in both 148R-K and 148R-S, which had GI50 values of 0.139 µM 
and 0.072 µM respectively (Figure 5.1A). This equated to an RF of 5.15 for 148R-K and 
2.67 for 148R-S, indicating cross-resistance to PD0325901 (Figure 5.1A). This was also 
the case for selumetinib; 148R-K had a GI50 of 3.51 µM, representing an RF of 5.16, and 
148R-S had a GI50 of 1.25 µM, an RF of 1.84 (Figure 5.1A). However, cross-resistance 
against selumetinib was only statistically significant in 148R-K (Figure 5.1A). In contrast, 
148R-N had low-level sensitivity to PD0325901 and selumetinib (Figure 5.1A). The GI50 
for 148R-N was 0.015 µM against PD0325901 and 0.19 µM against selumetinib, this 
equated to an RF of 0.56 (1.8-fold sensitivity) and 0.28 (3.6-fold sensitivity) respectively 
(Figure 5.1A). However, this sensitivity was not shown to be statistically significant.  
Unlike the response to MEK inhibitors, 148R clones and parental A2780 cells did not 
show any substantial differences (cross-resistance or sensitivity) in response to the ATP-
competitive ERK inhibitors GDC-0994 and SCH772984 (Morris et al., 2013; Blake et al., 
2016; Kidger et al., 2018) (Figure 5.1B). Against GDC-0994, A2780 had a GI50 of 0.93 µM 
compared to 0.79 µM for 148R-K, 0.87 µM for 148R-N and 1.18 µM for 148R-S, which 
equated to RF values of 0.85, 0.94 and 1.27 respectively (Figure 5.1B). This was similar 
for SCH772984; A2780 had a GI50 of 0.071 µM compared to 0.064 µM for 148R-K, 0.062 
µM for 148R-N, and 0.048 µM for 148R-S, which represented RF values of 0.90, 0.87 and 
0.68 respectively (Figure 5.1B). Taken together, these data show that 148R-K and 148R-
 5. Investigating ERK 1/2 as a driver of AT13148 resistance 
166 
 
S, particularly 148R-K, are cross-resistant to MEK inhibition, but that 148R clones 

























Figure 5.1: Dose-response curves and GI50 determinations for MEK and ERK inhibitors in A2780 and 148R 
clones. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard growth 
conditions for 48 hours. They were then treated with a serial dilution of (A) PD0325901 or selumetinib, or 
(B) GDC-0994 or SCH772984 for 96-hours, prior to being analysed by SRB assay. Dose-response graphs 
and non-linear regression curve fits were generated using GraphPad Prism 6. Dotted lines mark 50% 
viability on the y-axis. Data points represent the mean ± SD from one representative experiment. Tables 
summarise GI50 and RF values, GI50 data points depict the mean ± SD of all experiments conducted. 
Statistical significance was calculated using a student’s t-test, n = 3 (SCH772984), 5 (GDC-0994 & 
selumetinib) or 9 (PD0325901) independent experiments. 
 
PD0325901 (MEK) Selumetinib (MEK) 
Cell line GI50 (µM) RF GI50 (µM) RF 
A2780 0.027 ± 0.014 N/A 0.68 ± 0.42 N/A 
148R-K 0.139 ± 0.091** 5.15 3.51 ± 1.60* 5.16 
148R-N 0.015 ± 0.009 0.56 0.19 ± 0.08 0.28 
148R-S 0.072 ± 0.030** 2.67 1.25 ± 0.52 1.84 
 
GDC-0994 (ERK) SCH772984 (ERK) 
Cell line GI50 (µM) RF GI50 (µM) RF 
A2780 0.93 ± 0.39 N/A 0.071 ± 0.023 N/A 
148R-K 0.79 ± 0.13  0.85 0.064 ± 0.012 0.90 
148R-N 0.87 ± 0.28 0.94 0.062 ± 0.035 0.87 
148R-S 1.18 ± 0.35 1.27 0.048 ± 0.008 0.68 
A 
B 
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5.2.2. Response of MAPK pathway to MEK inhibition in A2780 and 148R clones  
To further investigate cross-resistance to MEK inhibition, the phosphorylation of ERK 1/2 
was analysed in parental A2780 cells and 148R clones after treatment with the MEK 
inhibitor PD0325901. The phosphorylation of Thr202/Tyr204 ERK 1/2 was potently 
inhibited in parental A2780 cells at 5-10 nM of PD0325901 (Figure 5.2).  In contrast, 5-
10 nM PD0325901 only caused a slight decrease in Thr202/Tyr204 ERK 1/2 
phosphorylation in 148R clones, much less so than what was seen in A2780 (Figure 5.2). 
However, 50-100 nM PD0325901 did cause an additional decrease in Thr202/Tyr204 ERK 
1/2 phosphorylation in all 148R clones, particularly in 148R-N but to a lesser extent in 
148R-K and 148R-S. (Figure 5.2). Total ERK 1/2 expression was mostly the same between 
cell lines and in response to PD0325901, but appeared to be slightly lower in 148R-N 
and 148R-S, when compared to parental A2780 cells (Figure 5.2). Taken together, these 
data suggest that ERK 1/2 phosphorylation was partially refractory to the MEK inhibitor 
PD0325901 in 148R clones; this could explain why some 148R clones are cross-resistant 
to MEK inhibition.  
  












Figure 5.2: Response of the MAPK pathway to PD0325901 in A2780 and 148R clones. Cells were plated 
at either 5 x 105 (A2780) or 7.5 x 105 (148R clones) cells per 7 cm dish and allowed to grow for 48 hours 
under standard growth conditions. Cells were then treated with PD0325901, as shown, or D: DMSO 
vehicle control for 4 hours prior to being lysed for western blot analysis. Western blot membranes were 
probed with antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total 
proteins or loading control (GAPDH). (S): short exposure to hyperfilm, (L): long exposure to hyperfilm. 
Data are representative of four experiments. 
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5.2.3. Response of MAPK pathway to ERK inhibition in A2780 and 148R clones 
The response of the MAPK pathway to ERK inhibition was also examined in order to 
investigate why the response of 148R clones to ERK inhibition did not mirror that of MEK 
inhibition (cross-resistance or sensitivity, Figure 5.1). Figure 5.3 shows the response of 
A2780 and 148R clones to the ERK inhibitor GDC-0994, using phosphorylation of Elk-1, 
an ERK 1/2 substrate, as a biomarker of ERK inhibition. In parental A2780 cells, 0.1-0.2 
µM of GDC-0994 was required to cause a significant reduction in the phosphorylation of 
S383 Elk-1, and despite a much lower basal phosphorylation of S383 Elk-1, 148R-N 
responded in a similar manner (Figure 5.3). In contrast, S383 Elk-1 phosphorylation was 
maintained in 148R-K and 148R-S; whilst S383 Elk-1 phosphorylation still decreased at 
0.1-0.2 µM GDC-0994 in 148R-K and 148R-S, this was to a much lesser extent than in 
A2780 and 148R-N, with Elk-1 phosphorylation still detectable at 1 µM, most notably in 
148R-K (Figure 5.3). This was especially interesting considering 148R-K and 148R-S had 
not been shown to be cross-resistant to ERK inhibition (Figure 5.1).  The expression of 
total Elk-1 was mostly consistent across A2780 and 148R clones and unaffected by GDC-
0994 (Figure 5.1). 
The response of MEK 1/2 phosphorylation to GDC-0994 was also studied to investigate 
if the decrease in MEK 1/2 phosphorylation in 148R clones, shown in Figure 4.17, was 
caused by an increase in negative feedback from ERK 1/2; i.e. If the decrease in MEK 1/2 
phosphorylation was caused by ERK 1/2 negative feedback, then one would expect 
inhibition of ERK to relieve this and cause an increase in MEK 1/2 phosphorylation. 
Figure 5.3 shows that this response was exhibited in both A2780 and 148R clones, but 
the magnitude and dynamics of the response differed. In parental A2780 cells, there was 
a strong increase in S217/221 MEK 1/2 phosphorylation at 0.05 µM GDC-0994, followed 
by incremental increases between 0.1 µM and 1 µM (Figure 5.3). This response was 
mirrored in 148R-N, but the magnitude of the response was much lower (Figure 5.3). 
148R-K and 148R-S had a different response; 0.01 µM and 0.05 µM GDC-0994 only 
caused a subtle increase in S217/221 MEK 1/2 phosphorylation, but there was a more 
notable increase at 0.1 µM followed by successive strong increases at 0.2 µM and 1 µM 
(Figure 5.3). The total expression of MEK 1/2 was unaffected by GDC-0994 in all cell lines, 
but did appear to be slightly lower in 148R-S, compared to parental A2780 cells (Figure 
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5.3). Taken together, these data provided evidence that ERK 1/2 mediated negative 
feedback was responsible for decreased MEK 1/2 phosphorylation, particularly in 148R-











































Figure 5.3: Response of the MAPK pathway to GDC-0994 in A2780 and 148R clones. Cells were plated at 
either 5 x 105 (A2780) or 7.5 x 105 (148R clones) cells per 7 cm dish and allowed to grow for 48 hours under 
standard growth conditions. Cells were then treated with GDC-0994, as shown, or D: DMSO vehicle control 
for 4 hours prior to being lysed for western blot analysis. Western blot membranes were probed with 
antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total proteins or 
loading control (β-Actin). Red arrow highlights band corresponding to pS383 Elk-1. Data are 
representative of three experiments. 
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5.2.4. Response of the MAPK pathway to AT13148 in A2780 and 148R clones 
The data thus far presented in this chapter does not suggest increased ERK 1/2 
phosphorylation causes an increased dependency on the MAPK pathway for cell growth 
and survival in 148R clones, as shown by the lack of sensitivity to ERK inhibition (Figure 
5.1) However, increased phosphorylation of ERK 1/2 may still contribute towards 
AT13148 resistance; 148R clones might only become dependent upon the MAPK 
pathway when in the presence of AT13148. This could be through additional changes 
induced in the MAPK pathway by AT13148, as was demonstrated in Figure 3.13, 
whereby AT13148 increased ERK 1/2 phosphorylation when used at 5 & 10 µM in A2780-
148R cells. To investigate this, 148R clones were treated with AT13148 and western blot 
analysis performed for detection of Thr202/Tyr204 ERK 1/2 phosphorylation as a 
biomarker of MAPK pathway activation.  
In A2780, higher concentrations of AT13148 (5 and 10 µM) caused a striking increase in 
the phosphorylation of Thr202/Tyr204 ERK 1/2, but the phosphorylation was mostly 
unchanged at lower concentrations, except for a notable decrease below the DMSO 
vehicle control at 1 µM AT13148 (Figure 5.4). The response in 148R clones was 
remarkable; increasing the concentration of AT13148 mostly led to successive increases 
in Thr202/Tyr204 ERK 1/2 phosphorylation, with phosphorylation peaking at 10 µM 
AT13148, the highest concentration used, in all 148R clones (Figure 5.4). However, there 
were some exceptions; 1 µM of AT13148 in 148R-K and 5 µM in 148R-N did not cause 
an increase in Thr202/Tyr204 ERK 1/2 phosphorylation above that of the previous 
concentrations, 0.5 µM and 1 µM respectively, but phosphorylation was still greater 
than their respective DMSO vehicle controls (Figure 5.4). The total expression of ERK 1/2 
did not appear to be greatly affected by AT13148, but was lower in 148R clones, 
compared to A2780, particularly in 148R-K and 148R-S (Figure 5.4).  
Taken together, AT13148 increased the phosphorylation of ERK 1/2 in 148R clones, 
which when combined with elevated basal phosphorylation of ERK 1/2 in 148R clones, 
enabled ERK 1/2 phosphorylation to be vastly greater across all concentrations of 
AT13148 in 148R clones, when compared to parental A2780 cells. This warrants further 
investigation as to whether this might contribute to AT13148 resistance in 148R clones.  









Figure 5.4: Response of the MAPK pathway to AT13148 in A2780 and 148R clones. Cells were plated at 
either 5 x 105 (A2780) or 7.5 x 105 (148R clones) cells per 7 cm dish and allowed to grow for 48 hours under 
standard growth conditions. Cells were then treated with AT13148, as shown, or D: DMSO vehicle control 
for 4 hours prior to being lysed for western blot analysis. Western blot membranes were probed with 
antibodies for phospho-proteins, stripped, and then re-probed with antibodies for total proteins or 
loading control (β-Actin). (S): short exposure to hyperfilm, (L): long exposure to hyperfilm. Data are 
representative of four experiments. 
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5.2.5. Response of A2780 and 148R clones to the combination of AT13148 and GDC-
0994 
5.2.5.1. GI50 determinations and Bliss independence synergy scores 
To investigate the potential contribution of ERK 1/2 towards AT13148 resistance, single 
doses of the ERK inhibitor GDC-0994 were combined with a standard titration of 
AT13148 in a 6-day SRB cell viability assay. If ERK 1/2 was contributing towards AT13148 
resistance, one would expect that ERK inhibition would re-sensitize 148R clones to 
AT13148. GDC-0994 was used at concentrations that corresponded to the GI05, GI10, GI20 
values for each respective cell line. These values were calculated from the data 
presented in Figure 5.1 and are highlighted in Table 5.1, most of which were shown to 
cause ERK inhibition in Figure 5.3. In addition, low concentrations of GDC-0994 (GI05 – 
GI20) were used to mitigate any off-target effects caused by GDC-0994, so that one could 
be confident that any effect of combination was due to ERK inhibition alone. 
Table 5.1: Summary table of GI05, GI10 and GI20 values for GDC-0094 in A2780 and 148R clones. Table 
summarises the concentrations of GDC-0994 used in combination with AT13148. GI values were 
calculated using CalcuSyn software using data presented in Figure 5.1. Data points represent the mean ± 
SD, n = 5 independent experiments.  
  
A2780 148R-K 148R-N 148R-S 
GDC-0994 GI05 (µM) 0.054 ± 0.054 0.023 ± 0.015 0.007 ± 0.006 0.054 ± 0.026 
GDC-0994 GI10 (µM) 0.083 ± 0.055 0.052 ± 0.032 0.014 ± 0.007 0.118 ± 0.057 
GDC-0994 GI20 (µM) 0.228 ± 0.131 0.149 ± 0.062 0.035 ± 0.003 0.341 ± 0.175 
 
Figure 5.5 shows the response of A2780 and 148R clones to the combination of AT13148 
and GDC-0994. In both 148R-K and 148R-S, GDC-0094 caused a striking shift left in their 
dose-response curves to AT13148 indicating that there was a degree of re-sensitisation 
to AT13148 (Figure 5.5B, D). This was reflected in the GI50 determinations for AT13148, 
particularly when in combination with GI20 GDC-0994; the GI50 against AT13148 alone 
was 1.396 µM for 148R-K and 1.408 µM for 148R-S, but when combined with GI20 GDC-
0994, GI50 values for 148R-K and 148R-S were 0.210 µM and 0.198 µM respectively 
(Figure 5.5E, F). This represented a 6.65-fold decrease for 148R-K and 7.11-fold decrease 
for 148R-S, when compared to respective AT13148 alone GI50 values, which were both 
statistically significant, remarkably lowering the GI50 against AT3148 to that of A2780 
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(A2780, AT13148 alone: 0.171 µM; Figure 5.5E, F). The GI05 and GI10 GDC-0994 
combinations also caused a ~2-3-fold shift in AT13148 GI50, of which there was statistical 
significance for GI05 and GI10 GDC-0994 in 148R-S and GI10 GDC-0994 in 148R-K (Figure 
5.5E, F). It should be noted that whilst combination with GDC-0994 did shift the GI50 
against AT13148 in 148R-K and 148R-S, the effect of combination became more 
attenuated at higher concentrations of AT13148 (> 1 µM; Figure 5.5).  
In stark contrast to 148R-K and 148R-S, GDC-0994 did not appear to cause re-
sensitisation to AT13148 in 148R-N (Figure 5.5C). The combination of AT13148 with GI20 
GDC-0994 did cause a slight decrease in the GI50 against AT13148 in 148R-N (AT13148 
alone: 3.664 µM vs GI20 GDC-0994: 2.197 µM), that was statistically significant, but this 
only represented a 1.67-fold decrease and was still substantially greater than the GI50 of 
A2780 (A2780, AT13148 alone: 0.171 µM, Figure 5.5E, F). The GI05 and GI10 GDC-0994 
combinations had even less of an effect on the GI50 of 148R-N against AT13148, only 
causing a 1.07 and 1.10-fold decrease respectively (Figure 5.5E, F).  
Interestingly, A2780 was also sensitized to AT13148 by combination with GDC-0994, 
with the greatest effect seen by combination with GI20 GDC-0994 (Figure 5.5A). In A2780, 
the GI50 against AT13148 in combination with GI20 GDC-0994 was 0.033 µM, which was 
5.18-fold lower than the GI50 of AT13148 alone: 0.171 µM, and statistically significant 
(Figure 5.5E, F). The combination of AT13148 with GI05 and GI10  GDC-0994 also caused a 
~2-3-fold decrease in the GI50 against AT13148, which was also shown to be statistically 
significant (Figure 5.5E, F). Taken together, these data show that A2780, 148R-K and 
148R-S can be sensitised to AT13148 by combination with low concentrations of GDC-
0994, further implicating ERK 1/2 as contributing towards AT13148 resistance, both 
intrinsic and acquired. 
The level of synergistic growth inhibition, for the combinations of AT13148 with GDC-
0994, was also calculated using the Bliss independence model. Synergy can be defined 
as when the combination of two drugs has an effect greater than the expected additive 
effect of the two drugs (i.e. the combined effect is greater than the sum of its individual 
components). The inverse of this is antagonism in which the combination of two drugs 
has an effect less than the expected additive effect of the two drugs (i.e. the combined 
effect is less than the sum of its individual components). However, when determining 
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synergy/antagonism, one must be able to statistically define the expected combined 
effect of two drugs (the additive effect). There are numerous methods to predict the 
combined effect of two drugs, but for the purposes of this study the Bliss independence 
model was used. Foucquier and Guedi (Foucquier and Guedj, 2015) state that “the Bliss 
Independence model is based on the principle that drug effects are outcomes of 
probabilistic processes and assumes that drugs act independently in such a manner that 
neither of them interferes with the other (different sites of action), but each contributes 
to a common result”. The expected additive effect of the combination of two drugs can 
be calculated as follows when using the Bliss independence model: ET = EA × EB, where 
ET: combined effect, and EA and EB: individual effects of drugs A and B, with each effect 
(E) expressed as fractional activity relative to control between 0 (100% inhibition) and 1 
(0% inhibition). By subtracting the actual effect of a combination from the predicted 
additive effect it can be ascertained if the combination was synergistic > 0, additive = 0 
or antagonistic < 0, with the calculated value representing the excess above or below 
Bliss. For example, if two drugs each caused a 50% inhibition in cell viability, the 
predicted additive response for combination would be 25%, as 0.5 × 0.5 = 0.25. If the 
actual effect of combination was 10% then it would be 0.15 (15%) in excess above bliss, 
as 0.25 – 0.10 = 0.15, and therefore indicative of synergy.  
The tables in Figure 5.6 show the excess above Bliss for the combination of GDC-0994 
(GI05, GI10, GI20) with the serially diluted range of AT13148 concentrations. In 148R-K and 
148R-S, in line with the shift in dose-response described in Figure 5.5, there was a degree 
of synergy with combinations of AT13148 and GDC-0994 (Figure 5.6). This was strongest 
when 0.123 - 1.111 µM AT13148 was combined with GI20 GDC-0994; at these 
combinations the combined effect was 0.09-0.13 in excess of Bliss in 148R-K and 0.11 - 
0.14 in excess of Bliss in 148R-S, indicating synergy. There was also synergy when 
AT13148 was combined with GI05 and GI10 GDC-0994, but to a lesser extent (0 - 0.10 in 
excess of Bliss, Figure 5.6). Synergy was also seen in A2780 but was strongest when 0.041 
- 0.370 µM AT13148 was combined with GI10 GDC-0994; at these combinations the 
combined effect was 0.12 - 0.15 in excess of Bliss (Figure 5.6). These concentrations of 
AT13148 also had synergy with GI05 GDC-0994 (0.04 – 0.10 in excess of Bliss) and GI20 
GDC-0994 (0.07 – 0.12 in excess of Bliss, Figure 5.6). In contrast, 148R-N did not show 
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any synergy, with most combinations of AT13148 and GDC-0994 displaying an additive 
or weakly antagonistic effect. Taken together, these data suggest that AT13148 and 
GDC-0994 interact in a synergistic manner when combined in A2780, 148R-K and 148R-











Figure 5.5: Dose-response curves and GI50 determinations for AT13148 and GDC-0994 combination in A2780 and 148R clones. Cells were plated in triplicate in a 96-well plate and 
allowed to grow under standard growth conditions for 48 hours. They were then treated with a serial dilution of AT13148 alone, or in combination with GDC-0994, as shown, for 96-
hours prior to being analysed by SRB assay. (A-D) Dose-response graphs and non-linear regression curve fits were generated using GraphPad Prism 6 (148R-N as described in Fig 
Figure 4.10). Dotted lines mark 50% viability on the y-axis. Data points represent the mean ± SD from one representative experiment. (E & F) GI50 summary graph and table, bars and 
data points represent the mean ± SD of all experiments conducted, red line highlights A2780 GI50 against AT13148 alone. Statistical significance and fold-diff (difference) compare 
AT13148 alone to respective GDC-0994 combinations within each cell line. Statistical significance was calculated using a student’s t-test, n ≥ 3 independent experiments.
 
A2780 148R-K 148R-N 148R-S 
















AT13148 alone 0.171 ± 
0.036 
N/A 1.396 ± 
0.454 
N/A 3.664 ± 
0.254 







2.11 0.808 ± 
0.230 
1.73 3.427 ± 
0.238 







2.59 0.573 ± 
0.462* 
2.44 3.322 ± 
0.412 







5.18 0.210 ± 
0.141** 
6.65 2.197 ± 
0.494* 
1.67 0.198 ± 
0.089*** 
7.11 










  A2780 
  AT13148 (µM) 









GI05 0.00 0.00 0.01 0.04 0.10 0.09 0.03 0.03 
GI10 0.00 0.00 0.01 0.12 0.13 0.15 0.10 0.04 
GI20 0.00 0.00 0.01 0.07 0.12 0.11 0.04 0.00 
 
  148R-K 
  AT13148 (µM) 









GI05 0.00 0.04 0.05 0.03 0.03 -0.06 -0.03 -0.02 
GI10 0.00 0.05 0.10 0.08 0.09 0.01 0.01 0.01 
GI20 0.00 0.06 0.12 0.09 0.13 0.01 0.03 0.04 
 
  148R-N 
  AT13148 (µM) 









GI05 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.03 
GI10 0.00 0.01 -0.03 -0.03 -0.01 0.00 -0.04 -0.01 
GI20 -0.01 0.01 -0.02 -0.01 0.01 -0.01 -0.01 -0.02 
 
  148R-S 
  AT13148 (µM) 








GI05 0.00 0.01 0.02 0.04 0.08 0.04 0.00 -0.02 
GI10 -0.01 0.05 0.07 0.06 0.07 -0.03 -0.06 -0.02 
GI20 -0.01 0.06 0.11 0.11 0.14 0.07 0.00 -0.04 
 
Key (excess above bliss): 
≥ 0.00 0.10 0.20 0.30 0.40 0.50 
 
Figure 5.6: Determination of synergy with the combination of AT13148 and GDC-0994 in A2780 and 
148R clones. Tables summarise the synergy of AT13148 and GDC-0994 in A2780 and 148R clones for the 
assays conducted in Figure 5.5. Synergy was calculated using the Bliss independence model, where values 
> 0, highlighted in red, show an effect greater than the combined fractional inhibition of single agents, 
indicating synergy. Data points in tables represent the mean Bliss independence score for designated 
combinations, n ≥ 3 independent experiments   
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5.2.5.2. Analysis of AT13148 and GDC-0994 biomarkers 
To validate the target inhibition of AT13148 and GDC-0994 at the concentrations used 
in Figure 5.5 & Figure 5.6, as well as investigate the mechanism(s) in which GDC-0994 
sensitises cells to AT13148, a combination western blot was performed. Parental A2780 
cells and 148R clones were treated with AT13148, at either 0.2 µM or 1 µM, GDC-0994, 
at GI20 concentrations for each respective cell line, or combinations of AT13148 and 
GDC-0994, for four hours, prior to western blotting for biomarkers of AT13148 
(phosphorylation of S6RP) and GDC-0994 (phosphorylation of Elk-1). The GI20 
concentrations of GDC-0994 were used as these caused the greatest sensitisation to 
AT13148 and synergy in Figure 5.5 & Figure 5.6.  
Figure 5.7 shows that GDC-0994 alone was able to cause a reduction in the 
phosphorylation of S383 Elk-1 phosphorylation in A2780, 148R-K and 148R-S, indicating 
the inhibition or ERK 1/2. However, GDC-0994 did not decrease S383 Elk-1 
phosphorylation in 148R-N, but it should be noted that some biological replicates did 
show a slight reduction in S383 Elk-1 phosphorylation (data not shown). Perhaps this 
variability suggests that the inhibition of ERK 1/2 is on the limit of detection at the GI20 
concentration of GDC-0994 in 148R-N. 
Interestingly, in 148R-S 1 µM of AT13148 alone was able to cause a slight increase in 
S383 Elk-1 phosphorylation, but this was overcome when AT13148 was combined with 
GDC-0994; S383 Elk-1 phosphorylation was decreased to the level seen with GDC-0994 
alone (Figure 5.7). This increase, in S383 Elk-1 phosphorylation in response to 1 µM 
AT13148, was also seen in 148R-N, however, whilst the combination of AT13148 and 
GDC-0994 also decreased S383 Elk-1 phosphorylation, as in 148R-S, in 148R-N S383 Elk-
1 phosphorylation was decreased below the level seen in with GDC-0994 alone (Figure 
5.7). In contrast, AT13148 alone did not increase S383 Elk-1 phosphorylation in 148R-K, 
with S383 Elk-1 phosphorylation still retained below the level seen in the DMSO control 
when AT13148, both at 0.2 µM and 1 µM, was combined with GDC-0994, but it should 
be noted that S383 Elk-1 phosphorylation was elevated above the level seen with GDC-
0994 alone when 1 µM AT13148 was combined with GDC-0994 in 148R-K (Figure 5.7). 
The phosphorylation of S383 Elk-1 was mostly unaffected by AT13148 in parental A2780 
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cells, with the level of S383 Elk-1 phosphorylation identical to the decrease caused by 
GDC-0994 alone, when used in combination (Figure 5.7). The total expression of Elk-1 
was similar across all cell lines and conditions used (Figure 5.7). 
In both A2780 and 148R clones the phosphorylation of S235/236 S6RP was unaffected 
by GDC-0994 alone, and AT13148 was able to decrease S235/236 S6RP phosphorylation 
in a manner consistent with Figure 4.14; S235/236 S6RP phosphorylation was potently 
inhibited in A2780 but was partially refractory in 148R clones (Figure 5.7). However, 
remarkably, the combination of AT13148 and GDC-0994 potentiated the decrease in 
S6RP phosphorylation caused by AT13148 alone (Figure 5.7). This was seen in all 148R 
clones where the combination of 1 µM of AT13148 with GDC-0994 caused a greater 
decrease in S235/236 S6RP phosphorylation than 1 µM AT13148 alone (Figure 5.7). In 
parental A2780 cells a similar affect was also observed with 0.2 µM AT13148 and 1 µM 
AT13148 when used in combination with GDC-0994, although this was clearer with a 
longer hyperfilm exposure (data not shown; Figure 5.7). Total S6RP expression was 
similar across A2780 and 148R clones and was not greatly affected by the conditions 
used (Figure 5.7) 
Taken together, these data show that the combination of GDC-0994 with AT13148 was 
able to potentiate the decrease in S6RP phosphorylation caused by AT13148 in A2780 
and 148R clones. This could, in part, explain why GDC-0994 sensitised cells to AT13148 
and suggests that the refractory response of S6RP phosphorylation in 148R clones, 
shown in Figure 4.14, is dependent on ERK 1/2 activation, again, implicating ERK 1/2 in 
AT13148 resistance.  
  

















































Figure 5.7: AT13148 and GDC-0994 biomarker response to AT13148 and GDC-0994 combination in 
A2780 and 148R clones. Cells were plated at either 5 x 105 (A2780) or 7.5 x 105 (148R clones) cells per 7 
cm dish and allowed to grow for 48 hours under standard growth conditions. Cells were then treated with 
AT13148 at 0.2 µM (AT0.2) or 1 µM (AT1); GDC-0994 at its GI20 concentration (G), as shown in Table 5.1; 
a combination of AT13148 and GDC-0994; or DMSO vehicle control (D), for 4 hours prior to being lysed 
for western blot analysis. Western blot membranes were probed with antibodies for phospho-proteins, 
stripped, and then re-probed with antibodies for total proteins or loading control (β-Actin). Data are 
representative of three experiments. 
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5.2.6. Response of A2780 and 148R clones to the combination of AT13148 and 
SCH772984 
To further validate the contribution of ERK 1/2 towards AT13148 resistance, additional 
combination assays were performed using SCH772984, an ERK inhibitor with a different 
mechanism of action to GDC-0994; SCH772984 has a dual-mechanism of action 
decreasing the phosphorylation of ERK 1/2, as well as ERK 1/2 substrates (Morris et al., 
2013; Blake et al., 2016; Kidger et al., 2018). Just as with GDC-0994, low concentrations 
of SCH772984 were used (1 nM, 5 nM and 10 nM), so as to mitigate any off-targets 
effects. The effect of these concentrations on cell viability, when used as single agents, 
is highlighted in Table 5.2. In addition, the assays were focused on 148R-S and A2780, 
since GDC-0994 was shown to cause the greatest sensitisation to AT13148 in 148R-S 
(Figure 5.5).  
Table 5.2: Effect of SCH772984 on cell viability in A2780 and 148R-S when used as a single agent. Table 
summarises the effect of SCH772984 on cell viability when used as a single agent at the concentrations 
used in combination assays with AT13148. Each SCH772984 concentration was plated in triplicate in 
parrallel with combination assays (Figure 5.8) and cell viability was determined in a standard 6-day SRB 
cell viability assay. Data points represent the mean ± SD, n ≥ 2 independent experiments.  
 
Cell viability (%) 
SCH772984 (nM) A2780 148R-S 
5 93.1 ± 1.7 94.5 ± 8.7 
10 98.4 ± 0.4 104.0 ± 2.0 
20 85.2 ± 6.5 77.9 ± 0.8 
 
As expected, Figure 5.8B  shows that 148R-S was sensitised to AT13148 by combination 
with SCH772984. This was most dramatic when AT13148 was combined with 20 nM 
SCH772984 in 148R-S; the AT13148 GI50 for this combination was 0.202 µM which was 
15.66-fold lower than the GI50 of AT13148 alone in 148R-S: 3.163 µM, and statisitcally 
significant (Figure 5.8C, D). In addition, this combination lowered the GI50 against 
AT13148 below that of A2780 (A2780, AT13148 alone: 0.389 µM), indicating 148R-S had 
been re-sensitised to AT13148 (Figure 5.8C, D). Combination of AT13148 with 1 nM and 
5 nM SCH772984 also sensitsed 148R-S cells to AT13148 by ~2-fold, but this was only 
statistically significant with the combination of 1 nM SCH772984 (Figure 5.8C, D). Whilst 
this was not as substantial as the sensitisation caused by 20 nM SCH772984, it was 
nonetheless remarkable, considering that these concentrations of SCH772984 had little 
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to no effect on cell viability when used as single agents (Table 5.2). Furthermore, 
parental A2780 cells were also sensitised to AT13148 by SCH772984, albeit to a much 
lesser extent when compared to 148R-S cells (Figure 5.8A). Only combination with 20 
nM SCH772984 was able to cause a statistically signficant sensitation to AT13148; in 
A2780 the GI50 for AT13148 in combination with 20 nM SCH772984 was 0.117 µM which 
was 3.32-fold less than AT13148 alone: 0.389 µM (Figure 5.8C, D). Combination with 
5nM and 10nM SCH772984 caused a < 2-fold sensitisation to AT13148, neither of which 
were statistically significant (Figure 5.8C, D) 
The sensitiation caused by SCH772984 to AT13148 was also reflected when calculating 
the level of synergy of the combinations of AT13148 and SCH772984. Figure 5.8E shows 
that all concentrations of SCH772984 displayed synergy across a wide range of AT13148 
concentrations in 148R-S. The peak of this was when 10 nM or 20 nM of SCH772984 was 
combined with 0.041 – 1.111 µM AT13148; these combinations were between 0.17 and 
0.25 in excess of Bliss, thus indicating synergy (Figure 5.8E). In contrast, whilst there was 
synergy in A2780 it was lower and confined to much narrower set of concentrations. 
Synergy appeared to be at it highest, in A2780, when concentrations of SCH772984 were 
combined with 0.370 µM and 0.123 µM AT13148, a peak of 0.19 in excess of Bliss was 
observed when 20 nM SCH772984 was combined with 0.123 µM AT13148 (Figure 5.8E). 
Outside of this narrow range, combinations displayed a mostly additive or weakly 
synergistic response in parental A2780 cells (Figure 5.8E).  
Taken together, these data show that SCH772984 was able to senisitise A2780 and 148R-
S cells to AT13148, and that combination of SCH772984 and AT13148 displayed synergy. 
Interestingly, the level of sensitisation and synergy by SCH772984 appeared far greater 
in 148R-S than A2780, and in 148R-S greater than that seen when GDC-0994 was 
combined with AT13148 (Figure 5.5 & Figure 5.6). These data add further evidence of 
the contribution of ERK 1/2 to AT13148 resistance and the possibility of co-targetting 

























Figure 5.8: Dose-response curves and determination of GI50 and synergy for the 
combination of AT13148 with SCH772984 in A2780 and 148R-S. Cells were plated in triplicate 
in a 96-well plate and allowed to grow under standard growth conditions for 48 hours. They 
were then treated with a serial dilution of AT13148 alone or in combination with SCH772984, 
as shown, for 96-hours prior to being analysed by SRB assay. (A-B) As per Figure 5.5A-D, (C-
D) As per Figure 5.5E-F, (E) As per Figure 5.6, n ≥ 2 independent experiments. 
   
  A2780 
  AT13148 (µM) 







5 0.00 0.00 0.02 0.09 0.08 0.04 0.01 0.01 
10 0.00 0.00 0.02 0.11 0.14 0.00 -0.02 -0.01 
20 0.00 0.00 0.03 0.13 0.19 0.07 0.04 0.02 
 
A2780 148R-S 
Combination GI50 (µM) Fold-diff GI50 (µM) Fold-diff 
AT13148 alone 0.389 ± 0.110 N/A 3.163 ± 0.573 N/A 
+ 5nM SCH772984 0.233 ± 0.110 1.67 1.534 ± 0.185* 2.06 
+ 10nM SCH772984  0.246 ± 0.034 1.58 1.447 ± 0.539 2.19 
+ 20nM SCH772984  0.117 ± 0.062* 3.32 0.202 ± 0.013** 15.66 
  148R-S 
  AT13148 (µM) 







5 0.03 0.14 0.12 0.12 0.10 0.07 0.14 0.08 
10 0.04 0.18 0.23 0.25 0.17 0.21 0.18 0.14 
20 0.04 0.16 0.20 0.22 0.24 0.22 0.19 0.11 
A B C 
D E 
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5.2.7. Response of A2780 and 148R clones to the combination AT13148 and 
PD0325901 
Combination assays were also performed with the MEK inhibitor PD0325901 to 
investigate if inhibition of MEK could also sensitise cells to AT13148. As with GDC-0994 
and SCH772984, low concentrations of PD0325901 were used to alleviate any off-target 
effects. Most of the PD0325901 concentrations used had been previously shown to 
inhibit MEK 1/2 in A2780 and 148R-S in Figure 5.2. The effect on cell viability when the 
PD0325901 concentrations, used in combination, were used as single agents is shown in 
Table 5.3.  
Table 5.3: Effect of PD0325901 on cell viability in A2780 and 148R-S when used as a single agent. Table 
summarises the effect of PD0325901 on cell viability when used as a single agent at the concentrations 
used in combination assays with AT13148. Each PD0325901 concentration was plated in triplicate in 
parrallel with combination assays (Figure 5.9) and cell viability was determined in a standard 96-hour SRB 
cell viability assay. Data points represent the mean ± SD, n ≥ 2 independent experiments.  
 
Cell viability (%) 
PD0325901 (nM) A2780 148R-S 
1 94.7 ± 1.6 95.0 ± 1.2 
5 81.1 ± 19.0 76.9 ± 0.2 
10 66.9 ± 14.4 70.2 ± 2.2 
 
Figure 5.9B-D shows that all concentrations of PD0325901 were able to cause a 
statistically significant sensitisation to AT13148 in 148R-S cells. This was most dramatic 
when AT13148 was used in combination with 5 nM and 10 nM of PD0325901 (Figure 
5.9B-D). Both these concentrations of PD0325901 were able to lower the GI50 against 
AT13148 in 148R-S below that of A2780 (A2780, AT13148 alone GI50: 0.389 µM); 5 nM 
PD0325901 in combination with AT13148 had a GI50 of 0.313 µM and 10 nM PD0325901 
a GI50 0.112 µM (Figure 5.9B-D). These GI50 values were respectively 10.11 and 28.24-
fold lower than the GI50 for AT13148 alone in 148R-S: 3.163 µM (Figure 5.9B-D). 1 nM 
PD0325901 caused a more modest, but statistically significant, 2.51-fold decrease in the 
GI50 of 148R-S against AT13148, which was nonetheless impressive considering the 
minimal effect on cell viability when 1nM PD0325901 was used as a single agent (Figure 
5.9B-D & Table 5.3). A2780 was also sensitised to AT13148 by PD0325901, which whilst 
to a lesser extent than 148R-S was still considerable, particularly with 5 nM and 10 nM 
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of PD0325901 (Figure 5.9A). In A2780, combination with 5 nM PD0325901 lowered the 
GI50 against AT13148 by 5.40-fold to 0.072 µM and combination with 10 nM lowered the 
GI50 by 11.79-fold to 0.033 µM, both of which were statistically significant, when 
compared to AT13148 alone (Figure 5.9C, D). Combination of 1 nM PD0325901 with 
AT13148 only caused a 1.77-fold decrease in AT13148 GI50 in A2780 and was not shown 
to be statistically significant (Figure 5.9C, D).  
To further investigate the sensitisation caused by PD0325901 to AT13148, synergy 
between the two drugs in combination was determined. In 148R-S, as was seen with 
SCH772984, there was synergy to all PD0325901 concentrations across a wide range of 
AT13148 concentrations (Figure 5.9E). Whilst synergy was seen across a broad range of 
concentrations, the level of synergy was at its greatest when PD0325901 was combined 
with 0.123 – 1.111 µM AT13148 (Figure 5.9E). The excess above bliss at these 
concentrations was 0.11 – 0.20 with 1 nM PD0325901; 0.19 – 0.21 with 5 nM PD0325901 
and 0.22 – 0.25 with 10nM PD0325901 (Figure 5.9E). This broad range synergy between 
PD0325901 and AT13148 was also observed in A2780, however the peak in synergy 
occurred between 0.041 µM and 0.370 µM AT13148 (Figure 5.9E). At these 
concentrations the excess above Bliss was 0.10 – 0.20 with 1 nM PD0325901; 0.21 – 0.30 
with 5 nM PD0325901 and 0.19 – 0.26 with 10 nM PD0325901 (Figure 5.9E).  
Taken together, these data show that AT13148 and PD0325901 interact in a synergistic 
manner in 148R-S and A2780, and that PD0325901 can sensitise 148R-S and A2780 to 
AT13148. Therefore, in addition to ERK inhibitors, the combination of AT13148 with MEK 


















   
 
 
Figure 5.9: Dose-response curves and determination of GI50 and synergy for the combination 
of AT13148 with PD0325901 in A2780 and 148R-S. Cells were plated in triplicate in a 96-well 
plate and allowed to grow under standard growth conditions for 48 hours. They were then 
treated with a serial dilution of AT13148 alone or in combination with PD0325901, as shown, 
for 96-hours prior to being analysed by SRB assay. (A-B) As per Figure 5.5A-D, (C-D) As per 
Figure 5.5E-F, (E) As per Figure 5.6, n ≥ 2 independent experiments. 
 
A2780 148R-S 
Combination GI50 (µM) Fold-diff GI50 (µM) Fold-diff 
AT13148 alone 0.389 ± 0.110 N/A 3.163 ± 0.573 N/A 
+ 1nM PD0325901 0.220 ± 0.105 1.77 1.258 ± 0.262** 2.51 
+ 5nM PD0325901 0.072 ± 0.072* 5.40 0.313 ± 0.136*** 10.11 
+ 10nM PD0325901 0.033 ± 0.031** 11.79 0.112 ± 0.027** 28.24 
  A2780 
  AT13148 (µM) 






) 1 0.00 0.02 0.04 0.10 0.16 0.20 0.10 0.12 
5 0.00 0.03 0.09 0.21 0.30 0.21 0.17 0.14 
10 0.00 0.02 0.06 0.19 0.26 0.19 0.11 0.10 
  148R-S 
  AT13148 (µM) 






) 1 0.01 0.08 0.18 0.11 0.20 0.15 0.11 0.09 
5 0.05 0.16 0.21 0.17 0.19 0.14 0.02 0.06 
10 0.04 0.16 0.25 0.22 0.23 0.15 0.00 0.06 





5.3. Discussion  
The aim of this chapter was to investigate the contribution of ERK 1/2 to AT13148 
resistance. Initially, the response of 148R clones to ERK and MEK inhibition was assessed, 
as it was thought that increased ERK 1/2 phosphorylation, seen in 148R clones, might 
correspond with an increased dependency on the MAPK pathway for survival, therefore 
sensitivity to MAPK pathway inhibitors. It has been shown that an increased MAPK 
transcriptional signature, which one might expect with increased ERK 1/2 
phosphorylation in 148R clones, correlates with increased sensitivity to MAPK pathway 
inhibition (Wagle et al., 2018). However, despite increased phosphorylation of ERK 1/2, 
148R clones did not appear to have an increased dependency on the MAPK pathway for 
their survival; 148R clones did not display any substantial sensitivity to ERK or MEK 
inhibition (Figure 5.1A, B). Indeed, 148R-K and 148R-S displayed some cross-resistance 
to MEK inhibition (Figure 5.1A). Furthermore, it was revealed that ERK 1/2 
phosphorylation was refractory to the MEK inhibitor PD0325901 in 148R-K and 148R-S, 
providing a mechanistic explanation for MEK cross-resistance (Figure 5.2). In 148R-N, 
which did not display cross-resistance to MEK inhibition, ERK 1/2 phosphorylation was 
also refractory to PD0325901, albeit to a lesser extent than in 148R-K and 148R-S (Figure 
5.2). This perhaps indicates that there is a threshold of ERK 1/2 phosphorylation 
maintenance, which is required in order to achieve discernible MEK inhibitor cross-
resistance in 148R clones (Figure 5.2). 
In addition, the maintenance of ERK 1/2 phosphorylation in response to MEK inhibition, 
provides further evidence that ERK 1/2 phosphorylation has become less dependent 
upon MEK 1/2 activation. From this we can begin to speculate what might be causing an 
increase in ERK 1/2 phosphorylation. In general, when there is an increase in the 
phosphorylation of a protein this can either be caused by an increase in the 
expression/activation of its kinase, or the loss of expression/activation of its 
phosphatase. Since MEK 1/2 is the only known kinase responsible for ERK 1/2 
phosphorylation and has been shown to have decreased phosphorylation in 148R 
clones, it would seem likely that the loss of expression/function of an ERK 1/2 
phosphatase is responsible for increased ERK 1/2 phosphorylation. One possible 
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candidate is dual-specificity MAPK phosphatases (MKP’s or DUSP’s), a subfamily of 
protein kinases that can de-phosphorylate both the threonine (Thr202) and tyrosine 
(Tyr204) residues found in the T-X-Y motif of ERK 1/2 (Kidger and Keyse, 2016, 






Figure 5.10: Potential mechanism of increased ERK 1/2 phosphorylation in 148R clones. The level of ERK 
1/2 phosphorylation is dependent upon the equilibrium between MEK 1/2 activity and the activity of 
negative regulators such as DUSPs. The loss of expression/function of DUSPs might enable an increase in 
ERK 1/2 phosphorylation sufficient enough to cause a sustained increase in ERK 1/2 phosphorylation, 
despite a decrease in MEK 1/2 phosphorylation. 
One of the most interesting findings in previous chapters has been the seemingly 
paradoxical relationship between ERK 1/2 and MEK 1/2 phosphorylation in both A2780-
148R and 148R clones; increased ERK 1/2 phosphorylation co-exists with decreased MEK 
1/2 phosphorylation (Figure 3.12 & Figure 4.17). A possible explanation for this, that has 
been proffered in previous chapters, is that MEK 1/2 phosphorylation was decreased 
due to ERK 1/2 mediated negative feedback. Indeed, the data presented in this chapter 
has provided evidence of this; the ERK inhibitor GDC-0994 was able to cause a dose-
dependent increase in MEK 1/2 phosphorylation in all 148R clones, as well parental 
A2780 cells (Figure 5.3). This would suggest that the MAPK pathway is under powerful 
negative feedback control in both A2780 and 148R clones. Therefore, an increase in ERK 
1/2 phosphorylation in 148R clones would increase ERK 1/2 mediated negative 
feedback, reducing the activation of upstream components of the MAPK pathway, such 
as MEK 1/2 (Figure 5.11A). In contrast, the inhibition of ERK 1/2 in 148R clones relieves 
negative feedback mediated by increased ERK 1/2 phosphorylation, thus causing an 
increase in MEK 1/2 phosphorylation (Figure 5.11B).  
 




Figure 5.11: ERK 1/2 mediated negative feedback in 148R clones. (A) 148R clones have increased 
activation of ERK 1/2, which in turn causes an increase in ERK 1/2 mediated negative feedback, decreasing 
MEK 1/2 phosphorylation. (B) When ERK 1/2 is inhibited in 148R clones, by GDC-0994, ERK 1/2 mediated 
negative feedback is attenuated causing an increase in MEK 1/2 phosphorylation. 
Since there is direct evidence that MEK 1/2 phosphorylation was decreased due to ERK 
1/2 mediated negative feedback, it is worth considering the mechanisms in which this 
may occur. For example, Eblen and colleagues (Eblen et al., 2004) demonstrated that 
ERK2 can directly phosphorylate MEK1 at T292, which whilst not directly effecting MEK 
1 activity, prevents the phosphorylation of MEK 1 at S298 by p21 activated kinase (PAK), 
which is required for required for adhesion-induced MEK1 activation by RAF. However, 
it not clear whether this ERK-mediated negative feedback applies in other circumstances 
in which MEK activation is not adhesion-induced, e.g. growth factor stimulation. In 
addition, BRAF and CRAF are both phosphorylated by ERK 1/2 at multiple sites, which in 
turn inhibits binding to activate RAS, decreasing the activation of BRAF and CRAF 
(Dougherty et al., 2005; Ritt et al., 2010). Furthermore, ERK 1/2 can impart inhibitory 
phosphorylations on several MAPK pathway regulators upstream from RAF and MEK 
including several RTKs, such as EGFR and FGFR1; the RAS guanine exchange factor (GEF) 
son of sevenless 1 (SOS1); and adaptor proteins such as FGF receptor substrate 2 (FRS2) 
(Lake et al., 2016). It should also be noted that ERK 1/2  can mediate negative feedback 
via the transcriptional induction of several negative feedback regulators, such as sprouty 
(SPRY) proteins, which can negatively regulate the MAPK pathway at several levels, for 
example by interacting with CRAF and BRAF and the adaptor proteins growth factor 
A B 
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receptor bound protein 2 (GRB2) and FRS2 (Mason et al., 2006; Lake et al., 2016). In 
148R clones, increased ERK 1/2 phosphorylation may induce a decrease in MEK 1/2 
phosphorylation by the interaction of several of the aforementioned mechanisms, or 
one may predominate. 
Whilst the use of MAPK pathway inhibitors did help gain some mechanistic insight into 
the regulation of the MAPK pathway within 148R clones, the lack of sensitivity to 
inhibitors of the MAPK pathway did create some difficulties in linking increased ERK 1/2 
phosphorylation to AT13148 resistance. As discussed, it was initially thought that 
increased ERK 1/2 phosphorylation may cause increased dependency upon the MAPK 
pathway for growth and survival, potentially enabling the by-pass of AT13148 targets. 
The lack of sensitivity to ERK inhibition seemed to suggest that this was not the case. It 
was also considered that increased ERK 1/2 phosphorylation might drive resistance by 
maintaining the phosphorylation and activation of constituents of the PAM pathway 
(e.g. S6RP and PRAS40) in response to AT13148, as was shown in Figure 4.14. This was 
considered because ERK 1/2 is known to cross-talk with the PAM pathway at multiple 
levels both directly and indirectly (Mendoza et al., 2011). But if this was the case, one 
would have expected to have also seen the maintenance of PRAS40 and S6RP 
phosphorylation in response to AKT inhibition by MK2206 in 148R-S (Figure 4.16). 
However, 148R clones were also shown to have a dramatic dose-dependent increase in 
ERK 1/2 phosphorylation in response to AT13148 (Figure 5.4). This was seen to a lesser 
extent in A2780-148R in chapter 3 in which the potential mechanisms of this response 
were discussed (Figure 3.13 and section 3.3). This response may in part provide an 
explanation for the role of ERK 1/2 in AT13148 resistance; the basal increase of ERK 1/2 
phosphorylation alone is not sufficient to either by-pass AT13148 targets, or directly 
compensate for AT13148 inhibition by direct pathway re-activation; but that additional 
increases in ERK 1/2 phosphorylation caused by AT13148 are, and this drives AT13148 
resistance.  
To test this hypothesis combination assays were performed with AT13148 and the ERK 
inhibitor GDC-0994. GDC-0994 was able to re-sensitise 148R-K and 148R-S to AT13148, 
with the combination shown to be weakly synergistic at several combinations (Figure 
5.6 & Figure 5.7). The concentration of GDC-0994 (GI20) that caused the greatest 
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sensitisation to AT13148 was shown to decrease the phosphorylation of the ERK 1/2 
substrate Elk-1 to the same level seen in A2780 in 148R-K, or slightly below in 148R-S 
(Figure 5.7). This indicated that ERK 1/2 had been sufficiently inhibited, and that ERK 1/2 
activation pheno-copied that of A2780. Therefore, the sensitisation to AT13148 caused 
by GDC-0994 provides evidence that ERK 1/2 is acting as a driver of AT13148 resistance 
in 148R-K and 148R-S. However, it should be noted that the sensitisation caused by GDC-
0994 was incomplete, which could be seen as sensitisation was attenuated it higher 
concentrations of AT13148. It may be that other changes beyond increased ERK 1/2 
phosphorylation also contribute towards AT13148 resistance. Alternatively, this could 
be caused by the limitations of the experimental set-up, i.e. GDC-0994 may not cause a 
sustained inhibition of ERK 1/2 over the course of a 6-day SRB assay. Indeed, the 
phosphorylation of Elk-1 was only assessed over a 4-hour treatment with GDC-0994. 
Western blot analysis also showed that the combination of AT13148 and GDC-0994 
enhanced the loss of S6RP phosphorylation in 148R clones, i.e. combination of GDC-0994 
and AT13148 caused a greater decrease in S6RP phosphorylation than AT13148 alone. 
This, in part, validates the hypothesis suggested earlier that ERK 1/2 contributes to 
AT13148 resistance by maintaining the phosphorylation of AT13148 targets, as S6RP is 
a substrate of the AT13148 target p70S6K. Furthermore, in A2780 the combination of 
AT13148 and GDC-0994 also caused a greater decrease in S6RP phosphorylation than 
AT13148 alone and sensitised parental A2780 cells to AT13148. This suggests that ERK 
1/2 may also contribute to intrinsic AT13148 resistance.  
It is worth considering that there are several ways in which ERK 1/2 could contribute 
towards the maintenance of S6RP phosphorylation in the presence of AT13148. ERK 1/2 
can phosphorylate RSK causing its activation, which can in turn directly phosphorylate 
S6RP at S235/236 (Anjum and Blenis, 2008; Mendoza et al., 2011). Whilst RSK 
phosphorylation was shown to be decreased at a basal level in Figure 4.17, the increase 
in ERK 1/2 phosphorylation induced by AT13148 may also cause an increase in RSK 
phosphorylation, thus maintaining phosphorylation of S6RP in the presence of AT13148 
(Figure 5.12). Therefore, the phosphorylation of RSK in response to AT13148 should be 
investigated. Alternatively, ERK 1/2 can phosphorylate the AKT substrate TSC2 inhibiting 
its GAP (GTPase activating protein) activity, which increases the abundance of RHEB-GTP 
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(Ras homolog enriched in brain), an activator of mTORC1 (Mendoza et al., 2011). 
mTORC1 activates p70S6K (targeted by AT13148) which phosphorylates S6RP, therefore 
increased ERK 1/2 could lead to an increased activation of p70S6K to the extent in which 
it was refractory to AT13148 and could maintain S6RP phosphorylation (Figure 5.12). 
Interestingly, both RSK and p70S6K phosphorylate S6RP at S235/236, but p70S6K can 
also phosphorylate at S6RP at S240/244 (Mendoza et al., 2011). With this in mind, 
interrogation of the S240/244 phospho-site may help identify the kinase downstream of 















Figure 5.12: Potential mechanisms of ERK 1/2 mediated S6RP phosphorylation and AT13148 resistance 
in 148R clones. S6RP is refractory to AT13148 in 148R clones but this can be overcome with combined 
ERK inhibition, which also sensitises 148R clones to AT13148. ERK 1/2 may maintain S6RP phosphorylation 
via its activation of RSK, which can phosphorylate S6RP at S235/236. Alternatively, ERK 1/2 can impart an 
inhibitory phosphorylation on TSC2, which in turn, via mTORC1, may increase the activation of p70S6K, 
overcoming inhibition by AT13148 and maintaining the phosphorylation of S6RP at S235/236 as well as 
S240/244.  
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In addition to S6RP, there is extensive crosstalk and convergence between the MAPK 
and PAM pathways (Mendoza et al., 2011). Therefore, increased ERK 1/2 
phosphorylation in 148R-K and 148R-S has the capacity to compensate for the inhibition 
of the PAM pathway by AT13148 at several levels. For example, both AKT and ERK 1/2 
phosphorylate the transcription factor FoXO3a at distinct sites, which either causes its 
exclusion from the nucleus (AKT mediated phosphorylation) or degradation (ERK 1/2 
mediated phosphorylation) (Wang et al., 2017). Both mechanisms act to negatively 
regulate FoXO3a, preventing its positive regulation of apoptosis and cell cycle arrest 
(Wang et al., 2017). Thus, inhibition of AKT by AT13148 and subsequent loss of negative 
regulation of FOXO3a, could be compensated by increased ERK 1/2 activation. 
Therefore, the effect of the combination of AT13148 and GDC-0994 should be evaluated 
throughout the PAM pathway, to investigate the ability of ERK 1/2 to compensate for 
AT13148 mediated inhibition.  
In contrast to 148R-K and 148R-S, 148R-N was not sensitised to AT13148 by combination 
with GDC-0994 (Figure 5.5 & Figure 5.6). This might be caused by the lack of ERK 
inhibition at the concentrations of GDC-0994 used in 148R-N. This could be seen as the 
GI20 concentration of GDC-0994 was unable to cause a decrease in Elk-1 
phosphorylation, an ERK 1/2 substrate, in 148R-N (Figure 5.7). But there are some 
difficulties in interpreting this data as Elk-1 phosphorylation does not correspond with 
increased ERK 1/2 phosphorylation in 148R-N and is thus likely to be a poor biomarker 
of ERK inhibition in 148R-N (Figure 4.17). Indeed, as was seen in 148R-K and 148R-S, in 
148R-N the combination of AT13148 and GDC-0994 also enhanced the reduction in S6RP 
phosphorylation (Figure 5.7). This itself could be a biomarker of ERK inhibition and 
suggests that ERK 1/2 also has the capacity to maintain the phosphorylation of 
substrates downstream of AT13148 targets in 148R-N (at least downstream of p70S6K). 
However, as mentioned, the inhibition of ERK 1/2 is insufficient to sensitise 148R-N to 
AT13148, despite the effect of the combination on S6RP phosphorylation. It is therefore 
likely that other mechanisms exist to drive AT13148 resistance in 148R-N in addition to 
increased ERK 1/2 phosphorylation. The AKT independent mechanism highlighted in 
Figure 4.19 is a possible candidate.  
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Whilst ERK 1/2 did not appear to contribute towards AT13148 resistance in 148R-N, the 
ability of ERK 1/2 to act as a driver of resistance in 148R-S was further validated; 148R-S 
cells were also sensitised to AT13148 by combination with an additional ERK inhibitor, 
SCH772984 (Figure 5.8). Together, this meant that two ERK inhibitors, GDC-0994 and 
SCH772984 had been able to re-sensitise 148R-S to AT13148. Interestingly, SCH772984 
preferentially sensitised 148R-S over A2780, and sensitised 148R-S cells to a much 
greater extent than was seen with GDC-0994, with a greater level of synergy. This was 
probably due to the different mechanisms of ERK inhibition by GDC-0994 and 
SCH772984. GDC-0994 acts as a classical type I kinase inhibitor of ERK 1/2, binding to 
ERK 1/2 in its phosphorylated/active confirmation and functioning in an ATP-
competitive manner inhibiting catalytic activity. In contrast, SCH772984 is said to have 
a ‘dual-mechanism’ of action; whilst also acting in an ATP-competitive manner inhibiting 
ERK 1/2 catalytic activity, SCH772984 additionally locks ERK 1/2 in its 
inactive/unphosphorylated state preventing phosphorylation by MEK 1/2 (Kidger et al., 
2018).  
Due to the relief of negative feedback inhibition during ERK inhibition, GDC-0994 can 
induce ERK 1/2 hyperphosphorylation, whilst still retaining its catalytic inhibition (Kidger 
et al., 2018). Consequently, upon GDC-0994 degradation during the course of a 6-day 
SRB assay, hyperphosphorylated ERK 1/2 would be primed for re-activation, potentially 
attenuating its ability to sensitise 148R clones to AT13148 (Kidger et al., 2018). In 
addition, hyperphosphorylated ERK 1/2, induced by GDC-0994, may accumulate in the 
nucleus where it can cause cell cycle progression in a kinase independent manner, which 
may also attenuate the ability of GDC-0994 to sensitise 148R clones to AT13148 
(Rodríguez et al., 2010). Since SCH772984 retains ERK 1/2 in its inactive state, inhibition 
of ERK 1/2 by SCH772984 would neither prime ERK 1/2 for activation nor cause its 
nuclear accumulation. Therefore, SCH772984 may have increased efficacy as an ERK 
inhibitor, and thus be better at overcoming ERK 1/2 driven resistance, such as that seen 
in 148R-S. It would be interesting to investigate if the combination of AT13148 and 
SCH72984 causes a greater reduction in S6RP phosphorylation than that caused by the 
combination of GDC-0994 and AT13148. Nonetheless, regardless of mechanism of 
action, the data presented in this chapter suggests that combination of an ERK inhibitor 
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with AT13148 could be an effective therapeutic strategy to overcome AT13148 
resistance, should it emerge in the clinic.  
Interestingly both A2780 and 148R-S were also sensitised to AT13148 by combination 
with the MEK inhibitor PD0325901 (Figure 5.9). Whilst this was unexpected in 148R-S, 
due to ERK 1/2 phosphorylation being refractory to MEK inhibition, this is of therapeutic 
interest, as several MEK inhibitors, such as trametinib and cobimetinib, are currently 
used clinically (Cheng and Tian, 2017). Since ERK inhibitors have not yet progressed 
beyond clinical trials, co-targeting MEK 1/2 to overcome AT13148 resistance has more 
potential as a therapeutic strategy. It would therefore be prudent to investigate if a 
clinically approved MEK inhibitor could also sensitise 148R clones to AT13148. 
In summary, the data in this chapter has implicated ERK 1/2 as a driver of AT13148 
resistance in 148R-K and 148R-S. This has been validated using ERK inhibitors, which 
were shown to act synergistically with AT13148 and sensitise 148R-K and 148R-S to 
AT13148. However, the exact mechanism of how ERK 1/2 contributes to AT13148 
resistance is not fully understood, but ERK 1/2 has been shown to be responsible for the 
refractory response of S6RP phosphorylation to AT13148 in 148R clones. In contrast, 
148R-N lacked sensitisation to AT13148 caused by ERK Inhibition and is likely to have a 
distinct mechanism of resistance from 148R-K and 148R-S. The mechanism of how ERK 
1/2 phosphorylation has been increased in 148R clones would appear to be due to a loss 
of a negative ERK 1/2 regulator, such as DUSPs, the investigation of which will be focus 
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6. Investigation into loss of DUSP6 as a mechanism of AT13148 
resistance 
6.1. Introduction 
The work presented thus far in this thesis implicates increased ERK 1/2 phosphorylation 
as a driver of acquired resistance to AT13148 in 148R clones (148R-K and 148R-S). This 
has been validated by combination assays in which inhibition of ERK was shown to re-
sensitise 148R-K and 148R-S to AT13148 (Figure 5.5 & Figure 5.8). However, the 
mechanism(s) by which ERK 1/2 phosphorylation is increased has not been elucidated. 
As previously discussed, the decrease in MEK 1/2 phosphorylation, suggests that the 
increase in ERK 1/2 phosphorylation is caused by loss of expression/function of an ERK 
1/2 phosphatase. There are several protein phosphatases that are known to de-
phosphorylate ERK 1/2 but the most well characterised of these is the dual-specificity 
MAPK phosphatase (DUSPs or MKP’s) sub-family (Keyse, 2000; Lake et al., 2016).  
The DUSP sub-family of protein phosphatases is unique among ERK 1/2 phosphatases 
due to the ability of DUSPs to de-phosphorylate both the threonine (Thr202) and 
tyrosine (Tyr204) residues of the T-X-Y motif found in the activation loop of ERK 1/2 
(Kidger and Keyse, 2016). This motif is also found in the related stress-activated protein 
kinases, c-Jun amino terminal kinase (JNK) and p38 MAPK, which can also be 
dephosphorylated by some DUSPs (Kidger and Keyse, 2016). Currently, 10 DUSPs have 
been identified, which can be categorised into three groups based upon their selectivity 
and sub-cellular localisation. The 1st group comprises the inducible nuclear DUSPs: 
DUSP1, DUSP2, DUSP4 and DUSP5; the 2nd, cytoplasmic DUSPs: DUSP6, DUSP7 and 
DUSP9; and the 3rd contains DUSPs which are specific for stress-activated protein 
kinases: DUSP8, DUSP10 and DUSP16 (Kidger and Keyse, 2016; Lake et al., 2016). The 
specificity of nuclear inducible and cytoplasmic DUSPs is varied; some are specific to ERK 
1/2 (DUSP5, DUSP6 and DUSP7), whereas others, whilst de-phosphorylating ERK 1/2, 
can also de-phosphorylate p38 MAPK and JNK (DUSP1, DUSP2, DUSP4 and DUSP9) 
(Kidger and Keyse, 2016). DUSP6 is a focus of this introduction due to its ERK 1/2 
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specificity, and association with resistance to several cancer therapies (Kidger and 
Keyse, 2016).  
Figure 6.1 shows the domain structure of DUSP6, similar amongst all DUSPs, consisting 
of a non-catalytic N-terminal domain and catalytic C-terminal domain, which contains a 
conserved protein tyrosine phosphatase (PTPase) active site consensus sequence 
(Kidger and Keyse, 2016). The non-catalytic domain contains a nuclear export sequence 
(NES), which is responsible for the cytoplasmic localisation of DUSP6, and as such, is also 
present in other cytoplasmic DUSPs (Dickinson and Keyse, 2006). The non-catalytic 
domain also contains two regions which have sequence homology with the catalytic 
domain of cdc25 phosphatases (Dickinson and Keyse, 2006). This is found in all DUSPs 
and reflects a common evolutionary origin for this domain in the rhodanese family of 
sulphotransferases (Dickinson and Keyse, 2006). In addition, the non-catalytic domain 
contains a kinase interaction motif (KIM) which facilitates  the binding of DUSP6 to ERK 
1/2 (Kidger and Keyse, 2016). Specifically, the KIM contains a D-domain, a domain 
commonly found on ERK 1/2 binding partners, which binds to the common docking (CD) 
region of ERK 1/2, a site used by ERK 1/2 to bind its substrates (Yoon and Seger, 2006). 
This interaction is crucial, since unbound DUSP6  is catalytically inactive but becomes 
active upon binding ERK 1/2, due an allosteric rearrangement within the active site of 
its catalytic domain (Kidger and Keyse, 2016). It is this interaction that enables DUSP6 to 
specifically dephosphorylate ERK 1/2. Interestingly, since DUSP6 can bind both inactive 
and active ERK 1/2, it has also been shown to act as a cytoplasmic anchor of ERK 1/2 
(Karlsson et al., 2004; Kidger and Keyse, 2016).  
 
Figure 6.1: Domain structure of DUSP6. Schematic diagram highlighting the domain structure of DUSP6. 
The C-terminal domain contains a PTPase active site consensus sequence responsible for ERK 1/2 
dephosphorylation. The N-terminal non-catalytic domain regulates the cytoplasmic localisation of DUSP6, 
via NES, and its binding to ERK 1/2, via KIM. Image adapted from Kidger and Keyse, 2016. 
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The expression of DUSP6 is inducible by ERK 1/2, i.e. activation of ERK 1/2 drives the 
expression of DUSP6. This is thought to be largely regulated at the transcriptional level 
by the ERK 1/2 targets ETS-1 and ETS-2 (ETS proto-oncogene 1 & 2), transcription factors 
of the ETS (E26 transformation specific) family, that are phosphorylated by ERK 1/2 
(Yang et al., 1996; Ekerot et al., 2008; Zhang et al., 2010). Upon phosphorylation by ERK 
1/2, ETS-1 & 2 bind to transcriptional co-activators, such as CREB binding protein (CBP) 
or p300, causing an increase in the expression of target genes, such as DUSP6 (Nelson 
et al., 2010; Tetsu and McCormick, 2017). The ERK 1/2 inducible expression of DUSP6 
enables DUSP6 to act as a classical negative feedback regulator of the MAPK pathway 
(Figure 6.2). In addition, ERK 1/2 has been shown to phosphorylate DUSP6 at two serine 
sites (S159 and S197) which promotes the proteasomal degradation of DUSP6 
(Marchetti et al., 2005). This, in contrast, creates a positive feedback loop between ERK 
1/2 and DUSP6; ERK 1/2 activation can decrease DUSP6 expression, which in turn, 
further increases ERK 1/2 activation (Figure 6.2). This dual regulation of DUSP6 
expression by ERK 1/2 enables DUSP6 to finely tune the magnitude and duration of ERK 
1/2 activation, although DUSP6 has been predominantly associated as a negative 













Figure 6.2: ERK 1/2 mediated regulation of DUSP6 expression facilitates positive and negative feedback 
regulation of ERK 1/2. Upon activation ERK 1/2 can translocate to the nucleus and activate ETS-1 & 2, 
regulating DUSP6 transcription. DUSP6 can then translocate to the cytoplasm and dephosphorylate ERK 
1/2, thus enabling DUSP6 to act as a classical negative feedback regulator. Alternatively, ERK 1/2 can 
directly phosphorylate DUSP6, inducing DUSP6 proteasomal degradation, enabling DUSP6 to act as a 
positive feedback regulator.  
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As one might expect, due the negative regulation of ERK 1/2 by DUSP6, DUSP6 has often 
been found to act as a tumour suppressor. Furukawa and colleagues (Furukawa et al., 
2003), using immunohistochemistry on patient samples, showed that DUSP6 expression 
was decreased in advanced/invasive PDAC but increased in primary (in-situ) PDAC 
tissues, when compared to normal pancreatic tissue. Since the majority of PDAC cells 
harbour gain-of function KRAS mutations, they hypothesised that in primary PDAC 
tissues the effects of hyperactivated KRAS can be dampened by increased expression of 
DUSP6 (via ERK 1/2 mediated negative feedback), which in turn decreases ERK 1/2 
phosphorylation causing a more attenuated phenotype, thus DUSP6 acts as tumour 
suppressor (Figure 6.3A). However, in advanced PDAC cells DUSP6 is lost, further 
increasing ERK 1/2 phosphorylation, enabling a more invasive/aggressive phenotype 
(Figure 6.3B). Furthermore, they also demonstrated that DUSP6 expression was lost in 
7 out of 8 PDAC cell lines tested; the re-expression of DUSP6 in these cell lines led to a 
decrease in the phosphorylation of ERK 1/2 and induced strong growth suppression and 
apoptosis, giving further evidence to the role of DUSP6 as a tumour suppressor in PDAC 
(Furukawa et al., 2003). DUSP6 has also been shown to act in a similar manner (as a 
tumour suppressor) in KRAS-mutant lung cancer, where it has been shown that DUSP6 
expression is inversely related to both growth activity and histological grade (Okudela 
et al., 2009; Kidger and Keyse, 2016).  
In contrast, whilst DUSP6 has been shown to act as a tumour suppressor, there is some 
evidence to suggest that DUSP6 may also function in a pro-oncogenic manner (Kidger 
and Keyse, 2016). Shojaee and colleagues (Shojaee et al., 2015) showed that the acute 
activation of oncogenes (BCR-ABL, NRASG12D) induced cell death in the vast majority of 
human pre-B cells,  but that the small fraction of cells that survived, and eventually gave 
rise to malignant transformation, had high expression of DUSP6 and other negative 
regulators of the MAPK pathway. Primary samples from patients with pre-B cell acute 
lymphoblastic leukaemia (ALL) were also shown to have a greater expression of DUSP6 
than bone marrow pre-B cells (Shojaee et al., 2015). These data suggested that the high 
expression of DUSP6 appeared to provide a survival advantage to pre-B cells following 
oncogenic transformation. Additionally, a potential pro-oncogenic role for DUSP6 has 
also been identified in melanoma (Wittig-Blaich et al., 2017). Wittig-Blaich and 
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colleagues (Wittig-Blaich et al., 2017), found that DUSP6 mRNA expression was 
consistently elevated in melanoma samples from patients and melanoma cell lines. They 
hypothesised that high DUSP6 expression may compensate for excessive MAPK pathway 
activation caused by BRAF V600E in melanoma (Wittig-Blaich et al., 2017). Indeed, it was 
shown in BRAF V600E melanoma cells, where DUSP6 expression and MAPK activation 
were high, that DUSP6 KD (knockdown) caused cell death via induction of apoptosis, 
thus indicating a pro-oncogenic role for DUSP6 (Wittig-Blaich et al., 2017). However, in 
contrast, in BRAF WT melanoma cells where DUSP6 expression and MAPK pathway 
activation were lower, it was shown that DUSP6 KD caused either no effect or promoted 
growth, as would be expected for a tumour suppressor (Wittig-Blaich et al., 2017). This 
eloquently highlights how DUSP6 can either act in a pro-oncogenic manner or as tumour 
suppressor in a context dependent fashion.  
Figure 6.3: DUSP6 acts as tumour suppressor in PDAC. KRAS is mutated in the majority PDAC (indicated 
with red star). (A) In primary PDAC tissues this only leads to a slight increase in ERK 1/2 phosphorylation 
(or no increase at all) due to negative feedback elicited by DUSP6, therefore a less aggressive/invasive 
phenotype. (B) In advanced/invasive PDAC, DUSP6 expression is decreased/lost, which facilitates a 
greater increase in ERK 1/2 phosphorylation, and therefore a more aggressive/invasive phenotype. 
On reflection, the exact role of DUSP6, pro-oncogenic or tumour suppressor, would 
appear to be determined via the level of ERK 1/2 phosphorylation present within cells. 
In cells where ERK 1/2 phosphorylation is at low/normal physiological levels (e.g. BRAF 
WT melanoma), DUSP6 acts as a tumour suppressor; the loss of DUSP6 causes an 
increase in ERK 1/2 phosphorylation to a level in which it can promote oncogenic growth 
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and survival. However, in cells where ERK 1/2 phosphorylation is high, and already 
driving oncogenic growth and survival (e.g. BRAF V600E melanoma), DUSP6 effectively 
acts in an oncogenic manner; acting as a buffer to prevent the phosphorylation of ERK 
1/2 from reaching a lethal signalling threshold (Unni et al., 2018). In these 
circumstances, the loss of DUSP6 causes the phosphorylation of ERK 1/2 to go beyond a 
lethal signalling threshold, thus inducing cell death or senescence (Unni et al., 2018).  
Due to the intimate regulation of ERK 1/2 phosphorylation by DUSP6, it is not surprising 
that DUSP6 has been implicated in resistance to cancer therapies, particularly to 
tyrosine kinase inhibitor (TKI) therapies (Kidger and Keyse, 2016). In NSCLC, 14% of 
patients harbour mutations in EGFR, however, only 5% of patients achieve tumour 
reduction > 90% when treated with EGFR TKI’s, such as erlotinib (Phuchareon et al., 
2015). Phuchareon and colleagues (Phuchareon et al., 2015), investigated the 
mechanisms of intrinsic EGFR TKI resistance in NSCLC using gefitinib (EGFR TKI) and 
HCC827, an EGFR mutant NSCLC cell line insensitive to EGFR TKI. They identified that 
whilst gefitinib inhibited ERK 1/2 phosphorylation at 1 hour in HCC827 cells, ERK 1/2 
phosphorylation was reactivated after 6-24 hours of gefitinib treatment. They also 
showed that DUSP6 expression decreased in response to gefitinib treatment and that 
ectopically expressing DUSP6 in HCC827 cells completely inhibited gefitinib induced ERK 
1/2 re-activation. Whilst they didn’t investigate if ectopic DUSP6 expression sensitised 
HCC827 cells to gefitinib, the aforementioned inhibition of gefitinib induced ERK 1/2 re-
activation by ectopic DUSP6 expression, suggests that DUSP6 may contribute to intrinsic 
gefitinib resistance in NSCLC.  
The loss of DUSP6 expression has also been implicated in acquired resistance to ALK 
inhibition in ALK fusion-positive (ALK+) lung adenocarcinoma cells (Hrustanovic et al., 
2015). Hrustanovic and collagues (Hrustanovic et al., 2015) generated resistance against 
the ALK inhibitors crizotinib and ceritinib in the ALK+ cell line H3122. All resistant sub-
clones generated were shown to have ERK 1/2 phosphorylation that was refractory to 
ALK inhibition. Interestingly, two resistant sub-clones were shown to have a marked 
reduction in the expression of DUSP6, and thus the loss of DUSP6 expression was 
hypothesised to cause resistance to ALK inhibition. The re-expression of DUSP6 in these 
sub-clones re-established the inhibition of ERK 1/2 phosphorylation by ALK inhibition, 
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therefore restoring sensitivity to ALK inhibitors. Conversely, the shRNA (short hairpin 
RNA) mediated KD of DUSP6 in parental H3122 cells, made ERK 1/2 phosphorylation 
refractory to ALK inhibition, driving ALK inhibitor resistance. Together, these data 
showed that loss of DUSP6 expression can drive acquired resistance to ALK inhibition in 
ALK+ lung adenocarcinoma cells. This was also validated clinically in patient tumour 
samples; DUSP6 expression was decreased in post ALK-inhibitor-resistance tumour 
samples compared to pre-treatment samples. A similar mechanism of resistance has 
been identified to pazopanib, a TKI that targets several RTK’s, in synovial sarcoma (SS) 
cells (Yokoyama et al., 2017). Yokohama and colleagues (Yokoyama et al., 2017) 
generated resistance to pazopanib in SS cells and found that ERK 1/2 phosphorylation 
was refractory to pazopanib in resistant cells. Again, DUSP6 expression was shown to be 
decreased in resistant cells and DUSP6 KD in parental SS cells was able to recapitulate 
the resistant phenotype.  
In summary, DUSP6 is a critical regulator of ERK 1/2 phosphorylation and loss of 
expression is associated with therapy resistance. Therefore, the aim of this chapter was 
to investigate the loss of the expression/function of DUSP6, and other DUSPs, in 148R 
clones, as a mechanism of increased ERK 1/2 phosphorylation, and thus AT13148 
resistance. Initially the expression of several DUSPs was assessed in A2780 and 148R 
clones using western blotting. The contribution of the altered expression of DUSP6 to 
AT13148 resistance was subsequently investigated using pharmacological inhibition, 
siRNA KD and a lentivirus expressing DUSP6.  
  




6.2.1. Expression of DUSPs in A2780, A2780-148R and 148R clones 
The expression of DUSP6 was initially assessed at a basal level in A2780 and 148R clones 
(K, N & S). Figure 6.4A shows that there was a remarkable loss in the expression of DUSP6 
in 148R-K, N & S, when compared to parental A2780 cells. Even with a long hyperfilm 
exposure (as is shown in Figure 6.4A) only a very faint signal for DUSP6 could be detected 
in 148R-S, and in 148R-K and 148R-N DUSP6 was undetected (Figure 6.4A). This was in 
stark contrast to parental A2780 cells, where a strong and robust signal for DUSP6 was 
detected (Figure 6.4A). Of note, DUSP6 was detected as a doublet, consistent with what 
has been previously described (Dowd et al., 1998; Zhang et al., 2010). The two bands 
correspond to two translational products initiating at the first ATG and an internal ATG 
(Met14)(Dowd et al., 1998; Zhang et al., 2010). The phosphorylation of Thr202/Tyr204 
ERK 1/2 was increased in 148R-N, K & S, consistent with what was previously described 
in chapter 4 (Figure 6.4A & Figure 4.17).  
In addition, the expression of DUSP4 and DUSP5 was also assessed, as they both de-
phosphorylate ERK 1/2 and have been associated with resistance to cancer therapies 
(Menyhart et al., 2017; Liu et al., 2018). In contrast to DUSP6, DUSP4 and DUSP5 did not 
show any substantial difference in expression amongst A2780 and 148R clones, but 
DUSP5 did appear slightly increased in 148R-S, when compared to parental A2780 cells 
(Figure 6.4A). DUSP5 was also detected as a doublet, again, this was consistent with 
previous results, and is thought to be caused by ERK 1/2 dependent phosphorylation of 
DUSP5 causing a gel mobility shift (Kucharska et al., 2009).  
Since DUSP6 expression was shown to be downregulated in 148R-K, N and S (clones that 
were selected for further characterisation in chapter 4), the expression of DUSP6 was 
also evaluated in A2780-148R. Interestingly, DUSP6 was shown to be downregulated in 
A2780-148R, but to a much lesser extent than was seen in 148R-K, N, and S (Figure 6.4B). 
Figure 6.4B also shows the expression of DUSP6 in 148R-J and 148R-P (two clones not 
selected for further characterisation in chapter 4). Whilst DUSP6 was decreased in 148R-
P, to a similar extent as in 148R-K, N & S, DUSP6 expression was unchanged in 148R-J 
(Figure 6.4A, B). 
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Taken together, these data show that there was a loss of DUSP6 expression in 148R-K, 
148R-N and 148R-S, compared to parental A2780 cells. This warrants further 
investigation into the contribution of DUSP6 loss to increased ERK 1/2 phosphorylation 
and thus AT13148 resistance in 148R clones.  
 
 



















Figure 6.4: Expression of DUSPs in A2780, A2780-148R and 148R clones. (A, B) Cells were plated at either 
5 x 105 (A2780) or 7.5 x 105 (A2780-148R & 148R clones) cells per 7 cm dish and allowed to grow for 48 
hours under standard growth conditions. Cells were then lysed prior to western blot analysis. Western 
blot membranes were probed with antibodies for phospho-proteins, stripped, and then re-probed with 
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6.2.2. Response of DUSP6 expression to AT13148 in A2780 and 148R clones 
The expression of DUSP6 in A2780, 148R-N and 148R-S, was also evaluated in response 
to AT13148. Figure 6.5 shows that AT13148 did not alter the expression of DUSP6 in 
parental A2780 cells. The effect of AT13148 on DUSP6 expression in 148R-N could not 
be determined as DUSP6 was undetected, despite a prolonged hyperfilm exposure (as 
shown by the over-exposed DUSP6 signal for A2780, Figure 6.5). In 148R-S, there did 
appear to be some response in the expression of DUSP6 to AT13148; 1 µM was able to 
cause a slight reduction in the expression of DUSP6, however, DUSP6 expression was 
unchaged with 0.1 µM and 10 µM AT13148 (Figure 6.5). Taken together, DUSP6 








Figure 6.5: Response of DUSP6 expression to AT13148 in A2780 and 148R clones. Cells were plated at 
either 5 x 105 (A2780) or 7.5 x 105 (148R clones) cells per 7 cm dish and allowed to grow for 48 hours under 
standard growth conditions. Cells were then treated with AT13148, at the concentrations shown, or D: 
DMSO vehicle control for 4 hours prior to being lysed for western blot analysis. Western blot membranes 
were probed with an antibody for DUSP6, stripped, and then re-probed with loading control antibody 
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6.2.3. The effect of DUSP6 inhibition on ERK 1/2 phosphorylation and AT13148 
resistance 
6.2.3.1. Response of ERK 1/2 phosphorylation to BCI in A2780 
As previously mentioned, loss of DUSP6 in 148R clones may contribute to the increase 
seen in ERK 1/2 phosphorylation (Figure 6.4). To investigate this, the effects of BCI (2-
benzylidene-3-(cyclohexylamino)-1-indanone hydrochloride), a small molecule 
allosteric inhibitor of DUSP6, which also has activity against DUSP1, were initially 
examined on ERK 1/2 phosphorylation in parental A2780 cells (Molina et al., 2009). 
These cells were treated with 0.01 µM – 1.00 µM of BCI for 4 hours, and western blots 
conducted to assess ERK 1/2 phosphorylation, compared to a 148R-S untreated sample. 
Figure 6.6 shows that BCI caused a dose-dependent increase in the phosphorylation of 
Thr202/Tyr204 ERK 1/2. However, an exception to this was 0.05 µM BCI which 
unexpectedly caused a decrease in ERK 1/2 Thr202/Tyr204 phosphorylation (Figure 6.6). 
Interestingly, at 1 µM BCI the level of Thr202/Tyr204 ERK 1/2 phosphorylation, in 
parental A2780 cells, was approximately equal to that of the 148R-S untreated control 
(Figure 6.6). Total ERK 1/2 expression was consistent across all BCI concentrations and 
the DMSO vehicle control in A2780 but did appear to be lower in the 148R-S untreated 
control (Figure 6.6). Together, these data show that inhibition of DUSP6 (and DUSP1), 
by BCI, was able to recapitulate the increase in ERK 1/2 phosphorylation seen in 148R-S 
and other 148R clones. This provided evidence of a link between DUSP6 loss in 148R 






Figure 6.6: The effect of BCI on ERK 1/2 phosphorylation in A2780 cells. Cells were plated at either 5 x 
105 (A2780) or 7.5 x 105 (148R-S) cells per 7 cm dish and allowed to grow for 48 hours under standard 
growth conditions. Cells were then treated with BCI, at the concentrations shown, or D: DMSO vehicle 
control for 4 hours prior to being lysed for western blot analysis. 148R-S ctrl was also treated with DMSO 
vehicle control. Western blot membranes were probed with antibodies for phospho-proteins, stripped, 
and then re-probed with antibodies for total proteins or loading control (β-Actin). Data are representative 
of four independent experiments. 
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6.2.3.2. Response of A2780 and 148R clones to BCI 
The loss of DUSP6 may have affected how 148R clones responded to BCI. Therefore, the 
response of A2780 and 148R clones to BCI was assessed over the course of a standard 
6-day SRB cell viability assay. Figure 6.7 shows that A2780 had GI50 of 0.76 µM against 
BCI, but that 148R-K and 148R-N had GI50 values of 1.14 µM and 1.50 µM, respectively 
(Figure 6.7). This equated to an RF value of 1.50 for 148R-K and 1.97 for 148R-N, 
indicating slight cross-resistance to BCI, but this was only statistically significant in 148R-
K (Figure 6.7). In contrast, 148R-S had a GI50 against BCI of 0.50 µM, which was lower 
than that of A2780, representing an RF value of 0.66, but this was not statistically 
significant (Figure 6.7). In summary, these data do not show any substantial difference 















Figure 6.7: Dose-response curves and GI50 determinations for BCI in A2780 and 148R clones. Cells were 
plated in triplicate in a 96-well plate and allowed to grow under standard growth conditions for 48 hours. 
Cells were then treated with a serial dilution of BCI for 96-hours, prior to being analysed by SRB assay. 
Dose-response graphs and non-linear regression curve fits were generated using GraphPad Prism 6. 
Dotted line marks 50% viability on the y-axis. Data points represent the mean ± SD from one 
representative experiment. Table summarises GI50 and RF values; GI50 data points represent the mean ± 
SD of all experiments conducted. Statistical significance was calculated using a student’s t-test, * p ≤ 0.05, 
n ≥ 4 independent experiments. 
 
BCI 
Cell line GI50 (µM) RF 
A2780 0.76 ± 0.24 N/A 
148R-K 1.14 ± 0.12* 1.50 
148R-N 1.50 ± 0.41 1.97 
148R-S 0.50 ± 0.09 0.66 
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6.2.3.3. Response of A2780 cells to the combination of AT13148 and BCI 
Since BCI was able to cause an increase in ERK 1/2 phosphorylation in A2780, it was 
thought that BCI could mimic the loss of DUSP6 seen in 148R clones and therefore be 
used as a tool to validate DUSP6 loss as a mechanism of AT13148 resistance. To this end, 
A2780 cells were treated with a combination of AT13148 and BCI over the course of a 
standard 6-day SRB cell viability assay, to investigate if inhibition of DUSP6 by BCI could 
induce resistance to AT13148. The concentrations of BCI that were used in combination 
with AT13148 were selected as they had been shown to increase the phosphorylation 
of ERK 1/2 and have minimal toxicity (Figure 6.6 & Figure 6.7).  
Figure 6.7 shows the response of A2780 cells to the combination of AT13148 and BCI. 
As expected, BCI had a minimal effect on cell viability when used as a single agent at 
concentrations used in combination with AT13148; respectively, cell viability was 
104.7% and 93.8% for 0.01 µM and 0.10 µM BCI (Figure 6.8). However, the combination 
did not seem to greatly affect the response to AT13148; the GI50 against AT13148 alone 
was 0.20 µM compared to 0.17 µM when used in combination with 0.01 µM BCI and 
0.14 µM in combination with 0.10 µM BCI. Contrary to what was anticipated, this 
represented a 1.18 and 1.43-fold decrease in AT13148 GI50, when AT13148 was 
combined with 0.01 µM and 0.10 µM BCI respectively (Figure 6.8). This was not shown 
to be statistically significant (Figure 6.8). Taken together, these data show that the 
combination of BCI with AT13148 in parental A2780 cells does not recapitulate the 
resistance to AT13148 seen in 148R clones. Due to the limitations of the use of BCI to 
mimic DUSP6 loss in A2780 (e.g. co-inhibition of DUSP1), the loss of DUSP6 as a 
mechanism of AT13148 resistance was further examined using alternative techniques.  
  















Figure 6.8: Dose-response curve and GI50 determinations for the combination of AT13148 and BCI in 
A2780. Cells were plated in triplicate in a 96-well plate and allowed to grow under standard growth 
conditions for 48 hours. They were then treated with single agent BCI or a serial dilution of AT13148 alone, 
or in combination with BCI, for 96-hours, prior to being analysed by SRB assay. Dose-response graph and 
non-linear regression curve fits were generated using GraphPad Prism 6. Dotted line marks 50% viability 
on the y-axis. Data points represent the mean ± SD from one representative experiment. Table 
summarises GI50, fold-difference (fold-diff) and % viability for single agent BCI. GI50 and viability data points 
represent the mean ± SD of all experiments conducted. Statistical significance was calculated using a 






Combination Viability (%) GI50 (µM) Fold-diff 
AT13148 alone N/A 0.20 ± 0.04 N/A 
+ 0.01 µM BCI 104.7 ± 1.1 0.17 ± 0.02 1.18 
+ 0.10 µM BCI 93.8 ± 3.3 0.14 ± 0.04 1.43 
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6.2.4. Investigation of DUSP6 loss as a mechanism of resistance using RNA 
interference 
RNA interference has been used previously to successfully validate loss of DUSP6 as a 
mechanism of resistance to pazopanib and ALK inhibitors in synovial sarcoma and ALK+ 
lung adenocarcinoma respectively (Hrustanovic et al., 2015; Yokoyama et al., 2017). 
Therefore, loss of DUSP6 alone, as a mechanism of resistance to AT13148, was 
investigated using siRNA mediated KD of DUSP6 expression. To this end, DUSP6 siRNA 
KD was performed in A2780 parental cells, to see if the phenotype in 148R clones could 
be recapitulated; increased phosphorylation of ERK 1/2 and resistance to AT13148. 
6.2.4.1. Optimisation of siRNA transfection conditions  
Initially, siRNA transfection conditions were optimised for the use of Lipofectamine 
2000, a cationic lipid-based transfection reagent, to identify those that enabled the 
greatest transfection efficiency and lowest transfection reagent toxicity. Briefly, A2780 
cells were plated at 5,000 – 10,000 cells per well in a 96-well plate and reverse 
transfected with 0.05 – 0.20% Lipofectamine 2000 combined with non-targeting siRNA 
(NT) or death control siRNA (a pooled blend of siRNA’s that target genes essential for 
cell survival). A mock transfection control was also used which just contained 
Lipofectamine 2000 and no siRNA. Mock and NT were used to assess transfection 
reagent toxicity, and death control siRNA was used to assess transfection efficiency. 
After reverse transfection, cells were left to grow in standard growth conditions for 4-
days and cell viability assessed by SRB assay.  
Figure 6.9A shows that death control siRNA reduced cell viability in a Lipofectamine 2000 
concentration dependent manner at all cell densities. This indicated that Lipofectamine 
2000 was able to successfully transfect siRNA into A2780 cells. The concentration of 
death control siRNA used (either 5 nM or 25 nM), did not appear to cause a great 
difference in the reduction of cell viability (Figure 6.9A). However, the mock and NT 
controls also caused a concentration dependent reduction in cell viability, indicating that 
there was some transfection reagent toxicity (Figure 6.9A). Both transfection efficiency 
and transfection reagent toxicity were also affected by cell density; the higher the cell 
density the more Lipofectamine 2000 needed for transfection efficiency and 
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transfection reagent toxicity (Figure 6.9A). Taking all these factors into account it was 
determined that 0.15% Lipofectamine 2000 and plating density of 10,000 cells/well were 
optimal for siRNA transfection in parental A2780 cells (Figure 6.9A). Under these 
conditions there was the greatest window between transfection efficiency and 
transfection reagent toxicity. In addition, growth characterisation assays were 
performed, which demonstrated that parental A2780 cells were in log-phase over the 
course of a 4-day SRB cell viability assay when plated at 10,000 cells/well (Figure 6.9B). 
  




Figure 6.9: Optimisation of Lipofectamine 2000 siRNA transfection in A2780 cells. (A) A2780 cells were 
reverse transfected in duplicate, at the plating densities shown, with Lipofectamine 2000, at the 
concentrations indicated, in a total volume of 160 µl/well in a 96-well plate. This was either alone (mock), 
with 25 nM non-targeting Allstars negative control siRNA (NT) or Allstars cell death control siRNA (Death, 
5 nM or 25nM). Cells were then incubated for 24 hours under standard growth conditions, prior to the 
addition of 40 µl/well of complete DMEM, followed by an additional 72 hours of incubation under 
standard growth conditions. Cells were then analysed by an SRB assay. Graphs were generated using 
GraphPad Prism 6, data points on graphs represent the mean ± SD from one representative experiment 
and are normalised to mock untransfected (0% lipofectamine 2000) control. Data points highlighted in 
red indicate the optimal transfection conditions identified. n ≥ 2 independent experiments. (B) Growth 









 6. Investigation into loss of DUSP6 as a mechanism of AT13148 resistance 
215 
 
6.2.4.2. Knockdown of DUSP6 using pooled DUSP6 siRNA 
After the optimal siRNA transfection conditions were identified, DUSP6 siRNA KD was 
performed in parental A2780 cells to investigate if loss of DUSP6 alone could act as 
mechanism of resistance to AT13148. Initially, this was performed using pooled DUSP6 
siRNA, which contained 4 siRNA duplexes targeting DUSP6 mRNA at distinct sites. Since 
siRNA KD is transient, and therefore lost over time, an adapted 4-day SRB cell viability 
assay was performed to maximise the time in which DUSP6 expression would be 
decreased. Briefly, parental A2780 cells were reverse transfected with DUSP6 siRNA 
(and controls) in a 96-well plate, left to incubate for 24 hours prior to the addition of a 
serial dilution of AT13148. They were than left to incubate for a further 72 hours prior 
to analysis via an SRB assay. In parallel to this, A2780 cells were reverse transfected with 
DUSP6 siRNA (and transfection controls) in 6-well plates, using conditions appropriately 
scaled from Figure 6.9. These were then lysed for western blot analysis, in order to 
monitor the expression of DUSP6 and phosphorylation of ERK 1/2 over the time course 
of a 4-day SRB cell viability assay. 
Figure 6.10 shows that all concentrations of pooled DUSP6 siRNA caused a decrease in 
the expression of DUSP6 across all timepoints, when compared to transfection controls 
(untransfected, mock and NT), i.e. pooled DUSP6 siRNA caused KD of DUSP6. The level 
of DUSP6 KD seemed to peak at 24 hours (which corresponds to when AT13148 was 
added in 4-day SRB cell viability assay), followed a slight decrease at 48 hours (Figure 
6.10). Whilst there was still some noticeable DUSP6 KD at 96 hours (which corresponds 
to the end of a 4-day SRB cell viability assay), this was to a much lesser extent than was 
seen at 24 and 48 hours (Figure 6.10). The level of DUSP6 KD was not particularly 
affected by the concentration of pooled DUSP6 siRNA (5, 10 & 25 nM), but 25 nM did 
cause a greater level of DUSP6 KD at 48 hours and 96 hours (Figure 6.10). Of note, even 
when DUSP6 KD was at its greatest, at 24 hours with 10 or 25 nM pooled DUSP6 siRNA, 
the expression of DUSP6 was still above that of the 148R-K control (Figure 6.10). 
However, this should be interpreted with some caution, as the 148R-K control was 
obtained from a previous experiment, and thus would have been grown under different 
conditions.  
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The level of ERK 1/2 phosphorylation appeared to correlate with the level of DUSP6 KD 
(Figure 6.10). At 24 hours, where DUSP6 KD was at its greatest, there was a small, but 
notable increase in Thr202/Tyr204 ERK 1/2 phosphorylation, when compared to 
transfection controls (Figure 6.10). In addition, at 24 hours, 25 nM pooled DUSP6 siRNA 
appeared to cause a slightly greater increase in ERK 1/2 phosphorylation, when 
compared to 5 or 10 nM pooled DUSP6 siRNA (Figure 6.10). This increase in 
Thr202/Tyr204 ERK 1/2 phosphorylation was not seen at 48 hours and 96 hours, possibly 
due to the decrease in the level of DUSP6 KD seen at these timepoints (Figure 6.10). It 
should be noted, that at 96 hours, ERK 1/2 phosphorylation was inconsistent amongst 
siRNA controls, making it difficult to determine if ERK 1/2 phosphorylation was altered 
in response to pooled DUSP6 siRNA (Figure 6.10). The total expression of ERK 1/2 was 
consistent within each timepoint, across all transfection controls and concentrations of 
pooled DUSP6 siRNA (Figure 6.10).  
 
Figure 6.10: Knockdown of DUSP6 in A2780 cells using pooled DUSP6 siRNA. A2780 cells were reverse 
transfected in 6-well plates, at 1 x 105 cells/well, with 0.15% Lipofectamine 2000 and pooled DUSP6 siRNA, 
at the concentrations indicated, or 25 nM non-targeting Allstars negative control siRNA (NT). Cells were 
then incubated under standard growth conditions for 24, 48 or 96 hours prior to lysis and western blot 
analysis, alongside a 148R-K lysate from a previous experiment, as described in Figure 6.4. UT: un-
transfected, M: mock transfected. Data are representative of 2 independent experiments 
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Figure 6.11 shows the effect of pooled DUSP6 siRNA KD on the sensitivity to AT13148 in 
parental A2780 cells, over the course of a 4-day SRB cell viability assay. As previously 
mentioned, this was to determine if loss of DUSP6 expression could act as mechanism 
of resistance to AT13148. The KD of DUSP6 using pooled DUSP6 siRNA was unable to 
induce resistance to AT13148 in parental A2780 cells (Figure 6.11A, B, D). The GI50 
against AT13148 for pooled DUSP6 siRNA KD was 0.28 µM, which was near identical to 
the GI50 for mock transfection and NT siRNA, 0.30 µM and 0.25 µM respectively (Figure 
6.11A, B, D). This equated to an RF value of 0.93, which was not statistically significant 
(Figure 6.11A, B, D). In addition, pooled DUSP6 siRNA did not affect the viability of 
untreated parental A2780 cells; the viability for parental A2780 cells transfected with 
pooled DUSP6 siRNA was 102.5% (Figure 6.11C, D).  
Taken together, these data (Figure 6.10 & Figure 6.11) show that that KD of DUSP6 using 
pooled DUSP6 siRNA was unable to recapitulate the phenotype seen in 148R clones: 
sustained increase in ERK 1/2 phosphorylation and AT13148 resistance. However, the 
strength and duration of DUSP6 KD caused by pooled DUSP6 siRNA did not match what 
was seen in 148R clones and may explain why pooled DUSP6 siRNA did not recapitulate 
the resistance phenotype in parental A2780 cells.  
  














Transfection condition Viability (%) GI50 (µM) RF 
Mock 100.0 ± 0.0 0.30 ± 0.17 N/A 
NT 100.9 ± 9.7 0.25 ± 0.15 0.83 
DUSP 6 102.5 ± 13.6 0.28 ± 0.13 0.93 
 
Figure 6.11: Effect of pooled DUSP6 siRNA knockdown on sensitivity to AT13148 in A2780 cells. A2780 
cells were reverse transfected in triplicate in 96-well plates, at 10,000 cells/well, with 0.15% Lipofectamine 
2000 and 25 nM pooled DUSP6 siRNA, or 25 nM non-targeting Allstars negative control siRNA (NT). Cells 
were also mock transfected with Lipofectamine 2000 alone. They were then left to incubate under 
standard growth conditions for 24 hours, prior to the addition of a serial dilution of AT13148 and a further 
incubation for 72 hours, under standard growth conditions. Cells were then analysed by SRB assay. Data 
was normalised to untreated control for each respective transfection condition unless otherwise stated 
(A) Dose-response graph was generated as previously described in Figure 6.7, data points represent the 
mean ± SD from one representative experiment (B-D) Graphs and table summarise GI50, RF (relative to 
mock transfected) and cell viability (normalised to mock untreated control) of untreated AT13148 controls 
for each respective transfection condition. Data points and bars represent the mean ± SD of all 
experiments conducted. Dotted red line on GI50 graph highlights the mock GI50. Statistical significance, 
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6.2.4.3. Knockdown of DUSP6 using individual DUSP6 siRNAs 
One of the limitations of using siRNA to KD gene expression, is that siRNA’s may cross-
react with non-targeted mRNAs, even those with limited sequence similarity, decreasing 
the expression of non-targeted genes, thus producing off-target effects (Jackson et al., 
2003). The use of pooled DUSP6 siRNA (Figure 6.10 & Figure 6.11), a combination of 
siRNAs that target different sequences within DUSP6 mRNA, may amplify the number of 
off-target effects, making it difficult to interpret any phenotypes observed (or lack 
thereof). In addition, pooled DUSP6 siRNA may contain siRNAs with limited efficacy in 
the KD of DUSP6, which may compete and interfere with higher efficacy siRNAs within 
the pool. Therefore, the individual DUSP6 siRNAs, which comprised the pool used in 
Figure 6.10 & Figure 6.11, were used to KD DUSP6 expression in parental A2780 cells.  
Figure 6.12 shows the expression of DUSP6 in response to KD by DUSP6 siRNAs (D6-01, 
D6-03, D6-04 & D6-05) in parental A2780 cells, 24 hours post siRNA transfection. All of 
the DUSP6 siRNAs were able to decrease DUSP6 expression, but the extent of this varied 
quite drastically (Figure 6.12). The decrease in DUSP6 expression caused by D6-05, when 
compared to mock and NT controls, was marginal, but other DUSP6 siRNAs caused a 
much more notable decrease (Figure 6.12). In particular, D6-03 caused the strongest 
decrease in DUSP6 expression; the expression of DUSP6 was only just detectable with a 
long hyperfilm exposure (Figure 6.12). In parallel to this, D6-03 caused the greatest 
increase in Thr202/Tyr204 ERK 1/2 phosphorylation (Figure 6.12). Other DUSP6 siRNAs 
also caused an increase in Thr202/Tyr204 ERK 1/2 phosphorylation, but to a lesser 
extent (Figure 6.12). Interestingly, despite near identical KD of DUSP6 caused by D6-01 
and D6-04, D6-01 caused a greater increase in Thr202/Tyr204 ERK 1/2 phosphorylation 
than D6-04 (Figure 6.12). Furthermore, D6-05 was still able to increase Thr202/Tyr204 
ERK 1/2 phosphorylation, despite only causing a marginal decrease in DUSP6 expression 
(Figure 6.12). There also appeared to be a slight increase in total ERK 1/2 expression in 
D6-01, D6-03 and D6-04, but this did not appear to account for the aforementioned 
increase in ERK 1/2 phosphorylation (Figure 6.12).  
Taken together these data show that individual DUSP6 siRNAs are an effective strategy 
for the KD of DUSP6 expression in parental A2780 cells. The variability in DUSP6 KD by 
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individual DUSP6 siRNAs suggests that they may have improved efficacy over pooled 







Figure 6.12: Knockdown of DUSP6 in A2780 cells using individual DUSP6 siRNAs. A2780 cells were 
reverse transfected in 6-well plates, at 1 x 105 cells/well, with 0.15% Lipofectamine 2000 and 10 nM of 
DUSP6 siRNA’s (D6-01, D6-03, D6-04 or D6- 05) or 10 nM non-targeting Allstars negative control siRNA 
(NT). Cells were then incubated under standard growth conditions for 24 hours prior to lysis and western 
blot analysis, as described in Figure 6.4. M: mock transfected. Data are representative of 2 independent 
experiments 
To this end, based upon their KD of DUSP6 expression and increase in ERK 1/2 
phosphorylation, D6-01 and D6-03 were selected for use in additional experiments, to 
determine if loss of DUSP6 alone in parental A2780 cells could act as mechanism of 
resistance to AT13148. Based on the experience with pooled DUSP6 siRNA, i.e. limited 
duration of DUSP6 KD, it was decided to perform a 2-day SRB cell viability assay. Cells 
were reverse transfected and incubated for 4 hours prior to the addition of AT13148, 
followed by a further 48 hours incubation and analysis via an SRB assay. As before, 
western blot analysis was performed in parallel with SRB cell viability assays, across the 
2-day time course. However, to ensure a more accurate depiction DUSP6 expression 
during an SRB cell viability assay, cells were plated in a 24-well plate for both SRB cell 
viability assays and western blot analysis.  
Figure 6.13 shows the expression of DUSP6 in parental A2780 cells over a 2-day time 
course, following transfection of individual DUSP6 siRNA’s (D6-01 and D6-03). Control 
lysates for A2780 and 148R-S from a previous experiment were also analysed, so as to 
assess if siRNA KD of DUSP6, in parental A2780 cells, was able to recapitulate the loss of 
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DUSP6 seen in 148R-S (Figure 6.4). Remarkably, D6-01 and D6-03 were able to decrease 
the expression of DUSP6 4 hours post-transfection, when compared to mock and NT 
controls, which was also seen at 28 hours but to a greater extent. A decrease in DUSP6 
expression was also caused by D6-01 and D6-03 at 52 hours post-transfection, when 
compared to mock and NT controls, but this appeared to be to a lesser extent than was 
seen at 28 hours (Figure 6.13). However, it was difficult to accurately compare the level 
of DUSP6 KD at 28 hours and 52 hours, since the expression of DUSP6 in mock and NT 
controls had also increased between these timepoints (Figure 6.13). Nonetheless, whilst 
D6-01 and D6-03 decreased the expression of DUSP6 in A2780 cells across all timepoints, 
this was not to the same extent as was seen in the 148R-S control (Figure 6.13). 
Interestingly, despite the incomplete KD of DUSP6, D6-01 and D6-03 caused an increase 
in Thr202/Tyr204 ERK 1/2 phosphorylation at both 4 and 28 hours, compared to mock 
and NT controls (Figure 6.13). The increase in Thr202/Tyr204 ERK 1/2 phosphorylation 
appeared to be similar to the increase seen in the 148R-S control (when compared to 
the A2780 control), particularly at 28 hours (Figure 6.13). However, this increase in 
Thr202/Tyr204 ERK 1/2 phosphorylation was lost at 52 hours (Figure 6.13). The total 
expression of ERK 1/2 was consistent across all timepoints and the A2780 control but 









Figure 6.13: Knockdown of DUSP6 over a 2-day time course in A2780 cells using individual DUSP6 
siRNAs. A2780 cells were reverse transfected in 24-well plates, at 2.5 x 104 cells/well, with 0.15% 
Lipofectamine 2000 and 10 nM of DUSP6 siRNA (D6-01 or D6-03) or 10 nM non-targeting Allstars negative 
control siRNA (NT). Cells were then incubated under standard growth conditions for 4, 24 or 52 hours 
prior to lysis and western blot analysis, alongside an A2780 and 148R-S lysate from a previous experiment, 
as described in Figure 6.4. M: mock transfected. Data are representative of 4 independent experiments.  
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As mentioned, the effect of DUSP6 KD, using individual siRNA’s (D6-01 & D6-03), on the 
response of parental A2780 cells to AT13148 was also assessed in parallel with the 2-
day western blot time course. Due to being performed in a 24-well plate format the 
number of AT13148 concentrations used was reduced from 8, the number of 
concentrations in standard SRB cell viability assay, to 5. Figure 6.14A shows that the 
viability of A2780 cells transfected with D6-03 was greater than mock and NT controls 
at every concentration of AT13148 tested, except 10 µM (Figure 6.14A). However, this 
difference was small and only statistically significant at 0.5 µM AT13148, where the % 
viability of D6-03 was 62.5% ± 5.4, compared to 54.1% ± 4.3 in the mock control (Figure 
6.14A, E). The viability of A2780 cells transfected with D6-01 was mostly 
indistinguishable from the mock and NT controls, across all AT13148 concentrations 
(Figure 6.14A).  
Despite the limited number of AT13148 concentrations used, the GI50 against AT13148 
was still able to be accurately determined. Transfection of A2780 parental cells with D6-
03 also increased the GI50 against AT13148; D6-03 GI50 was 1.15 µM compared to 0.74 
µM in the mock control, a statistically significant difference, which equated to an RF 
value of 1.55, relative to the mock control (Figure 6.14B, C, E). The GI50 for A2780 cells 
transfected with D6-01 was 0.95 µM, which was also above that of the mock control, 
but the GI50 for A2780 cells transfected with NT siRNA was very similar, 0.89 µM, thus 
indicating that the increase in GI50 caused by D6-01 was likely due to a generic effect of 
siRNA transfection (Figure 6.14B, C, E). Interestingly, untreated parental A2780 cells 
transfected with D6-01 and D6-03 had decreased viability compared to mock control, a 
12.5% and 9.0% decrease respectively, which was statistically significant in D6-01 (Figure 
6.14D, E). However, the viability of parental A2780 cells transfected with NT was also 
reduced by a similar amount (7.4%) and shown to be statistically significant, which again 
suggests a generic effect caused by siRNA transfection (Figure 6.14D, E).  
Taken together, these data (Figure 6.13 & Figure 6.14) show that knockdown of DUSP6 
using individual DUSP6 siRNAs was unable to cause a sustained increase in ERK 1/2 
phosphorylation or sufficiently increase viability or GI50 against AT13148. However, just 
as with pooled DUSP6 siRNA, the KD of DUSP6 by D6-01 and D6-03 siRNA did not match 
the loss of expression seen in 148R clones. This could explain the inability to recapitulate 
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the resistance phenotype. Therefore, the loss of DUSP6 alone, as mechanism of AT13148 








Figure 6.14: Effect of individual DUSP6 siRNA knockdown on sensitivity to AT13148 in A2780 cells. A2780 
cells were reverse transfected in duplicate in 24-well plates, at 2.5 x 104 cells/well, with 0.15% 
Lipofectamine 2000 and 10 nM DUSP6 siRNA (D6-01 or D6-03), or 10 nM non-targeting Allstars negative 
control siRNA (NT). Cells were also mock transfected with 0.15% Lipofectamine 2000 alone. Cells were 
then left to incubate under standard growth conditions for 4 hours, prior to the addition of AT13148, at 
the concentrations shown, followed by a further incubation for 48 hours under standard growth 
conditions. Cells were then analysed by SRB assay. Data was normalised to untreated control for each 
respective transfection condition, unless otherwise stated. (A) Graph summarises the effect of AT13148 
on cell viability, data points represent the mean ± SD from all experiments conducted. (B) Dose-response 
graph was generated as previously described in Figure 6.7; data points represent the mean ± SD from one 
representative experiment. (C-E) Graphs and table summarise GI50, RF (relative to mock transfected) and 
cell viability (normalised to mock untreated control) of untreated AT13148 controls for each respective 
transfection condition. Data points and bars represent the mean ± SD of all experiments conducted. 
Dotted red line on GI50  graph highlights the mock GI50. Statistical significance, relative to mock transfected, 
was calculated using a student’s t-test, * p ≥ 0.05, n ≥ 3 independent experiments.  
 
  
Transfection conditions Viability (%) GI50 (µM) RF 
Mock 100.0 ± 0.0 0.74 ± 0.23 N/A 
NT 92.6 ± 1.3* 0.89 ± 0.20 1.20 
D6-01 87.5 ± 2.0* 0.95 ± 0.13 1.28 
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6.2.5. Ectopic re-expression of DUSP6 in 148R-S cells using a lentiviral strategy 
6.2.5.1. Un-purified DUSP6 expressing lentivirus 
In addition to DUSP6 siRNA KD in parental A2780 cells an alternative strategy was 
employed, whereby DUSP6 was ectopically re-expressed in 148R-S cells to see if this 
could re-sensitise 148R-S to AT13148. 148R-S cells were selected as they had the highest 
phosphorylation of ERK 1/2 and exhibited the greatest sensitivity to the combination of 
AT13148 with an ERK inhibitor (Figure 6.4 & Figure 5.5). In contrast to siRNA KD 
experiments, which attempted to answer whether loss of DUSP6 alone was sufficient 
for resistance, the ectopic re-expression of DUSP6 attempted to answer if loss of DUSP6 
expression was necessary for AT13148 resistance. To this end, 148R-S cells were 
infected with a lentivirus expressing Myc and FLAG-tagged DUSP6 (henceforth referred 
to as DUSP6 lentivirus) and subsequently analysed to see if this could abolish the 
resistance phenotype: increased ERK 1/2 phosphorylation and AT13148 resistance. The 
presence of a Myc and FLAG tag enabled ectopic DUSP6 to be distinguished from 
endogenous DUSP6 via a gel mobility shift (i.e. higher molecular weight). It should also 
be noted that ectopic re-expression was only transient, as DUSP6 lentivirus did not 
contain a selectable marker for expression in mammalian cells 
Initially, un-purified DUSP6 lentivirus was used; lentivirus obtained directly from the 
media of HEK293T cells that had been co-transfected with lentiviral plasmids. 148R-S 
cells were infected with un-purified DUSP6 lentivirus at 1-500 µl/ml, to identify 
conditions that optimally re-established DUSP6 expression. Figure 6.15 shows the 
expression of DUSP6 48 hours post-infection with DUSP6 lentivirus. DUSP6 was only re-
expressed in 148R-S cells when DUSP6 lentivirus was used at 500 µl/ml, the maximum 
concentration used (Figure 6.15). However, whilst the level of ectopically expressed 
DUSP6 was stronger than endogenous DUSP6 in 148R-S cells infected with 500 µl/ml 
DUSP6 lentivirus, it was still dramatically below the expression of DUSP6 in parental 
A2780 cells. These data show that un-purified DUSP6 lentivirus was able to induce 
ectopic expression of DUSP6 in 148R-S cells but was unable to re-express DUSP6 at the 
level seen in parental A2780 cells. 
  





Figure 6.15: Ectopic re-expression of DUSP6 in 148R-S cells using un-purified lentivirus. Cells were plated 
in 6-well plates at 5 x 105 cells/well and left to incubate overnight under standard growth conditions. 
Subsequently, media was replenished with complete DMEM containing 5 µg/ml polybrene and a lentivirus 
expressing Myc and FLAG-tagged DUSP6 at the concentrations shown. A2780 and 148R-S control cells 
(ctrl) were not infected with lentivirus. Cells were then incubated for 24 hours under standard growth 
conditions, prior to media, containing lentivirus, being replaced with complete DMEM and a further 
incubation for 24 hours under standard growth conditions. Cells were subsequently lysed for western blot 
analysis, as described in Figure 6.4. n = 1 experiment. 
Despite being unable to re-express DUSP6 in 148R-S cells at the level seen in A2780 
parental cells, un-purified DUSP6 lentivirus was used in 148R-S cells to investigate if re-
expression of DUSP6 could decrease ERK 1/2 phosphorylation and re-sensitise 148R-S to 
AT13148. Since the ectopic expression of DUSP6 using DUSP6 lentivirus was transient, a 
4-day SRB assay was used in a 96-well plate format (as previously described in section 
6.2.4.2). In parallel to this, cells were plated in 6-well plates, to evaluate the expression 
of DUSP6 and ERK 1/2 phosphorylation over the time-course of a 4-day SRB cell viability 
assay. In addition, to maximise the expression of DUSP6, un-purified DUSP6 lentivirus 
was used undiluted, as well as at 500 µl/ml, and with 10 µg/ml polybrene, as well as 5 
µg/ml polybrene which was used in Figure 6.15. Polybrene (Hexadimethrine Bromide) is 
a cationic polymer which reduces the charge repulsion between cell membranes and 
lentivirus, facilitating greater lentiviral adsorption; increasing polybrene concentration 
may improve lentiviral transduction efficiency (Davis et al., 2004). 
Figure 6.16 shows the expression of DUSP6 in 148R-S over a time-course following 
infection with un-purified DUSP6 lentivirus. The 48-hour and 120-hour post-infection 
timepoints respectively correspond to the addition of AT13148 during a 4-day SRB cell 
viability assay and its end. At both timepoints, using un-purified DUSP6 lentivirus 
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undiluted improved the ectopic expression of DUSP6, when compared to 500 µl/ml, but 
the concentration of polybrene (5 or 10 µg/ml) seemed to have a limited effect on the 
ectopic expression of DUSP6 (Figure 6.16). Unfortunately, despite improved ectopic 
DUSP6 expression, DUSP6 expression in 148R-S cells was still much lower than the level 
seen in parental A2780 cells (Figure 6.16). Moreover, ectopic DUSP6 expression 
decreased at 120 hours post-infection, when compared to 48 hours post-infection, 
under all lentiviral conditions used (Figure 6.15). Thus, further compounding the ability 
of un-purified DUSP6 lentivirus to sufficiently re-express DUSP6 (Figure 6.16).  
Interestingly, at 48 hours post-infection, undiluted un-purified DUSP6 lentivirus caused 
a decrease in the phosphorylation of Thr202/Tyr204 ERK 1/2 in 148R-S cells, when 
compared to 148R-S control. This decrease lowered Thr202/Tyr204 ERK 1/2 
phosphorylation to approximately the same level as in parental A2780 cells (Figure 
6.16). However, the decrease in ERK 1/2 phosphorylation coincided with a decrease in 
total ERK 1/2 expression, which may therefore, in part, explain the decrease in ERK 1/2 
phosphorylation (Figure 6.16). Furthermore, Thr202/Tyr204 ERK 1/2 phosphorylation 
was not decreased at 120 hours post-infection, under all lentiviral conditions used 
(Figure 6.16). Total ERK 1/2 expression appeared to be mostly consistent within each 
timepoint, apart from the aforementioned decrease (Figure 6.16).  
In summary, these data showed that using un-purified DUSP6 lentivirus undiluted can 
increase the ectopic expression of DUSP6 in 148R-S cells. However, the expression does 
not match that of parental A2780 cells, is not durable across the time-course of 4-day 
SRB cell viability assay and does not cause a sustained decrease in ERK 1/2 
phosphorylation. 
  




Figure 6.16: Time-course of DUSP6 re-expression in 148R-S cells using an un-purified lentivirus. Cells 
were plated in 6-well plates at 5 x 105 cells/well and left to incubate overnight under standard growth 
conditions. Subsequently, media was replenished with complete DMEM containing 5 or 10 µg/ml 
polybrene (indicated by 5 µg or 10 µg) and un-purified lentivirus expressing Myc and FLAG-tagged DUSP6, 
at the concentrations shown. A2780 and 148R-S control cells (ctrl) were not treated with lentivirus. Cells 
were then incubated for 24 hours under standard growth conditions, prior to being split into a new 6-well 
dish at either 5 x 105 cells/well (48 hours post-infection timepoint) or 1 x 105 cells/well (120-hours infection 
timepoint). Cells were than incubated for an additional 24 or 96-hours, according to timepoint, under 
standard growth conditions, prior to lysis and western blot analysis, as described in Figure 6.4. Data are 
representative of 2 (controls and 500 µl/ml with 5µg/ml polybrene) or 1 (all other conditions) independent 
experiment. 
Whilst the ectopic expression of DUSP6 in 148R-S cells was insufficient, even when un-
purified DUSP6 lentivirus was used undiluted, SRB celll viability assays were still 
conducted, as ectopic expression of DUSP6 was above the level of endogenous DUSP6 
expression in 148R-S cells, so therefore might be able to cause some sensitisaion to 
AT13148 (Figure 6.15 & Figure 6.16). However, Figure 6.17 shows that ectopic 
expression of DUSP6, via un-purified DUSP6 lentivirus, was unable to re-sensitise 148R-
S cells to AT13148. In a 4-day SRB cell viability assay with AT13148, A2780 (A2780 ctrl) 
was shown to have a GI50 of 0.27 µM compared to 2.49 µM in un-infected 148R-S control 
cells (148R-S ctrl), a statistically significant difference equating to an RF value of 9.22, 
consistent with previous results (Figure 6.17, previous result Figure 4.10). Unexpectedly, 
there was a small increase in the GI50 against AT13148 in 148R-S cells infected with un-
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purified DUSP6 lentivirus at 500 µl/ml, when compared to 148R-S control cells; the GI50 
was 3.00 µM with 5 µg/ml polybrene and 3.12 µM with 10 µg/ml polybrene, equating 
to RF values of 11.11 and 11.56 respectively (Figure 6.17). But these were not shown to 
be statistically significant when compared to AT13148 GI50 values for A2780 and 148R-S 
control cells (Figure 6.17). However, whilst not statistically significant, there was a 
decrease in the GI50 against AT13148 in 148R-S cells infected with undiluted un-purified 
DUSP6 lentivirus; the GI50 was 1.94 µM with 5 µg/ml polybrene and 2.23 µM with 10 
µg/ml polybrene, equating to an RF value of 7.19 and 8.26 respectively (Figure 6.17). 
Whilst this was a small decrease in AT13148 GI50, undiluted un-purified DUSP6 lentivirus 
was unable to completely re-establish DUSP6 expression (as shown in Figure 6.16). 
Therefore, this may suggest that further increasing the level of DUSP6 re-expression in 











Figure 6.17: Effect of ectopic DUSP6 re-expression in 148R-S cells, using un-purified DUSP6 lentivirus, 
on response to AT13148. Cells were plated in 6-well plates at 5 x 105 cells/well and left to incubate 
overnight under standard growth conditions. Subsequently, media was replenished with complete DMEM 
containing 5 or 10 µg/ml polybrene (indicated by 5 µg or 10 µg) and lentivirus expressing Myc and FLAG-
tagged DUSP6, at the concentrations shown. A2780 and 148R-S control cells (ctrl) were not infected with 
lentivirus. Cells were then incubated for 24 hours under standard growth conditions, prior to being split 
into a 96-well plate at 1 x 104 cells/well, followed by an additional 24 hours incubation under standard 
growth conditions. AT13148 was then added at the concentrations indicated and cells incubated for 72 
hours under standard growth conditions, followed by SRB assay analysis. Graph and table were generated 
as described previously in Figure 6.7. Statistical significance, relative to A2780 (^) or 148R-S (*) ctrl, was 
calculated using a student’s t-test, ^ or * p ≤ 0.05, n = 4 (control cells), 2 (500 µl/ml with 5µg/ml polybrene) 
or 1 (all other conditions) independent experiment(s). 
Cell line/condition GI50 (µM) RF 
A2780 ctrl 0.27 ± 0.05* N/A 
148R-S ctrl 2.49 ± 0.81^ 9.22 
148R-S, 500 µl/ml (5 µg) 3.00 ± 0.97 11.11 
148R-S, 500 µl/ml (10 µg) 3.12 11.56 
148R-S, undiluted (5µg) 1.94 7.19 
148R-S, undiluted (10µg) 2.23 8.26 
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6.2.5.2.  Purified DUSP6 expressing lentivirus  
In the work presented thus far, DUSP6 was re-expressed using un-purified/un-
concentrated DUSP6 lentivirus. As has been mentioned, even when used undiluted, un-
purified DUSP6 lentivirus could not sufficiently re-express DUSP6 in 148R-S cells and this 
may explain why re-expression of DUSP6 did not re-sensitise 148R-S cells to AT13148 
(Figure 6.17). To overcome this, DUSP6 lentivirus was purified using PEG 6000 
precipitation, to increase the concentration of DUSP6 lentivirus, thus the ectopic 
expression of DUSP6 in 148R-S cells. Following this, the assays conducted in Figure 6.16 
& Figure 6.17 were repeated using purified/concentrated DUSP6 lentivirus. 
Figure 6.18 shows the expression of DUSP6 in 148R-S over a time-course, parallel to a 4-
day SRB cell viability assay, following infection with purified DUSP6 lentivirus. At 48-
hours post-infection, when purified DUSP6 lentivirus was used at 50 and 100 µl/ml the 
ectopic expression of DUSP6 in 148R-S cells at least equalled the level of DUSP6 
expression in parental A2780 cells (Figure 6.18). In fact, when purified DUSP6 lentivirus 
was used at 100 µl/ml, where ectopic expression of DUSP6 was at its greatest, ectopic 
expression of DUSP6 in 148R-S was slightly above the level of DUSP6 expression seen in 
parental A2780 cells (Figure 6.18). Just as was seen previously (Figure 6.16), the ectopic 
expression of DUSP6 decreased at 120-hours post-infection, when compared to 48-
hours, with both 50 and 100 µl/ml of purified DUSP6 lentivirus (Figure 6.18). 
Unfortunately, this meant that the ectopic expression of DUSP6 in 148R-S cells was 
below the level of DUSP6 expression in parental A2780 cells at this timepoint. However, 
the ectopic expression was still strong at 120-hours, particularly with 100 µl/ml purified 
DUSP6 lentivirus, where ectopic DUSP6 expression was only slightly lower than DUSP6 
expression in parental A2780 cells (Figure 6.18).  
Interestingly, at 48-hours, when purified DUSP6 lentivirus was used at 50 and 100 µl/ml, 
the ectopic expression of DUSP6 caused a dramatic reduction in Thr202/Tyr204 ERK 1/2 
phosphorylation in 148R-S cells. At these concentrations, Thr202/Tyr204 ERK 1/2 
phosphorylation was approximately the same level as was seen in parental A2780 cells 
(Figure 6.18). Thr202/Tyr204 ERK 1/2 phosphorylation was also decreased by ectopic 
DUSP6 expression at 120-hours, with both 50 and 100 µl/ml purified DUSP6 lentivirus, 
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however, this was to a much lesser extent, with ERK 1/2 phosphorylation being above 
the level seen in parental A2780 cells at this timepoint (Figure 6.18). It should be noted, 
that in the repeat of this assay (data not shown), ectopic DUSP6 expression did not cause 
a decrease in Thr202/Tyr204 ERK 1/2 phosphorylation at 120-hours, indicating a degree 
of inter-assay variation. The phosphorylation of the ERK 1/2 substrate Elk-1, at S383, 
was also assessed and corresponded to ERK 1/2 phosphorylation; decreased at 48-hours 
but this was lost at 120-hours (Figure 6.18). Total expression of ERK 1/2 and Elk-1 was 
consistent within each timepoint (Figure 6.18) 
In addition, the phosphorylation of MEK 1/2 was also evaluated to ascertain if ectopic 
expression of DUSP6, and subsequent decrease in ERK 1/2 phosphorylation, might 
restore the phosphorylation of MEK 1/2 in 148R-S. MEK 1/2 phosphorylation was 
previously shown to be decreased in 148R clones, due to negative feedback mediated 
by increased ERK 1/2 phosphorylation (Figure 4.17 & Figure 5.3). Figure 6.18 shows that 
S217/221 MEK 1/2 phosphorylation increased in 148R-S cells in response to ectopic 
expression DUSP6, in both timepoints. This, in part, seemed to be dependent upon the 
level of DUSP6 expression; within each timepoint as the level of ectopic DUSP6 
expression increased so did S217/221 MEK 1/2 phosphorylation. Therefore, in both 
timepoints S217/221 MEK 1/2 phosphorylation peaked with 100 µl/ml purified DUSP6 
lentivirus, where ectopic DUSP6 expression was at its greatest (Figure 6.18). 
Furthermore, this increase in S217/221 MEK 1/2 phosphorylation seemed strongest at 
120 hours (Figure 6.18). This may, in part, explain why the decrease in ERK 1/2 
phosphorylation was not sustained at 120 hours. However, even at its peak, S217/221 
MEK 1/2 phosphorylation was still below the level seen in parental A2780 cells (Figure 
6.18). Total expression of MEK 1/2 was consistent within each time point (Figure 6.18) 
Taken together, these data show that purified DUSP6 lentivirus can restore DUSP6 
expression to the same level seen in A2780 parental cells. However, this expression was 
lost over time, therefore purified DUSP6 lentivirus was unable to maintain DUSP6 
expression during the time-course of a 4-day SRB assay. Additionally, ectopic expression 
of DUSP6, via purified DUSP6 lentivirus, was shown to abolish the MAPK pathway 
alterations seen in 148R-S: increased ERK 1/2 and Elk-1 phosphorylation, and decreased 
MEK 1/2 phosphorylation; particularly at 48 hours. 




Figure 6.18: Time-course of ectopic DUSP6 re-expression in 148R-S cells using purified lentivirus. Cells 
were plated in 6-well plates at 5 x 105 cells/well and left to incubate overnight under standard growth 
conditions. Subsequently, media was replenished with complete DMEM containing 10 µg/ml polybrene 
and a purified lentivirus expressing Myc and FLAG-tagged DUSP6, at the concentrations shown. A2780 
and 148R-S control cells (ctrl) were not infected with lentivirus. Cells were then incubated for 24 hours 
under standard growth conditions, prior to being split into a new 6-well dish at either 5 x 105 cells/well 
(48 hours post-infection timepoint) or 1 x 105 cells/well (120-hours infection timepoint). Cells were than 
incubated for an additional 24 or 96 hours, according to timepoint, under standard growth conditions, 
prior to lysis and western blot analysis, as described in Figure 6.4. Red arrow highlights band 
corresponding to pS383 Elk-1. Data are representative of 2 independent experiment. 
Whilst purified DUSP6 lentivirus did not optimally re-express DUSP6, it was an 
improvement upon what was achieved with un-purified DUSP6 lentivirus and was able 
to appropriately alter the MAPK pathway (e.g. decreased ERK 1/2 phosphorylation), 
albeit only temporarily (Figure 6.18). Therefore, purified DUSP6 lentivirus was used in 
an SRB cell viability assay to evaluate if DUSP6 re-expression could re-sensitise 148R-S 
cells to AT13148. Figure 6.19 shows the response of 148R-S cells ectopically expressing 
DUSP6, via purified DUSP6 lentivirus, to AT13148 over the course of a 4-day SRB cell 
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viability assay. Interestingly, the GI50 of 148R-S cells ectopically expressing DUSP6 against 
AT13148 was lower than 148R-S control cells (uninfected); the GI50 for 148R-S cells 
infected with 50 and 100 µl/ml purified DUSP6 lentivirus was 1.44 µM and 1.83 µM 
respectively, compared to 2.49 µM in 148R-S control cells (Figure 6.19). However, these 
differences only represented a < 2-fold difference and were not shown to be statistically 
significant, compared to 148R-S control cells. In addition, the GI50 of 148R-S cells 
ectopically expressing DUSP6 was still substantially greater than the GI50 of A2780 cells 
for AT13148: 0.27 µM (Figure 6.19). Therefore, 148R-S cells ectopically expressing 
DUSP6 still had RF values of 5.33 and 6.77, for 50 and 100 µl/ml purified DUSP6 lentivirus 
respectively, only slightly below the RF value for 148R-S control cells: 9.22 (Figure 6.19). 
It should also be noted that the GI50 against AT13148 for 148R-S control cells and 148R-
S cells infected with 50 µl/ml purified DUSP6 lentivirus was shown to be statistically 
significant, when compared to parental A2780 cells (Figure 6.19).  
In summary, these data show that ectopic expression of DUSP6, via purified DUSP6 
lentivirus, does not re-sensitise 148R-S cells to AT13148. However, this might be 
explained by the loss of ectopic DUSP6 expression over the time course a 4-day SRB cell 
viability assay, as shown in Figure 6.18.  
  














Figure 6.19: Effect of ectopic DUSP6 re-expression in 148R-S cells, using a purified DUSP6 lentivirus, on 
response to AT13148.  Cells were plated in 6-well plates at 5 x 105 cells/well and left to incubate overnight 
under standard growth conditions. Subsequently media was replenished with fresh complete DMEM 
containing 10 µg/ml polybrene and a purified lentivirus expressing Myc and FLAG-tagged DUSP6, at the 
concentrations shown. A2780 and 148R-S control cells (ctrl) were not infected with lentivirus. Cells were 
then incubated for 24 hours under standard growth conditions, prior to being split into a 96-well plate at 
1 x 104 cells/well, followed by an additional 24 hours incubation under standard growth conditions. 
Subsequently AT13148 was added at the concentrations indicated and cells were incubated for 72 hours 
under standard growth conditions, followed by SRB assay analysis. Graph and table were generated as 
described previously in Figure 6.7. Statistical significance, relative to A2780 (^) or 148R-S (*) ctrl, was 
calculated using a student’s t-test, ^ or * p ≤ 0.05, n = 2 (50 & 100 µl/ml lentivirus) or 4 (controls cells) 





Cell line/condition GI50 (µM) RF 
A2780 ctrl 0.27 ± 0.05* N/A 
148R-S ctrl 2.49 ± 0.81^ 9.22 
148R-S, 50 µl/ml, purified 1.44 ± 0.11^ 5.33 
148R-S, 100 µl/ml, purified  1.83 ± 0.30 6.77 
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6.2.5.3. Summary of the response of 148R-S cells ectopically re-expressing 
DUSP6 to AT13148 
The response of 148R-S cells ectopically re-expressing DUSP6 across all DUSP6 lentiviral 
conditions used is summarised in Figure 6.20. In summary, there did seem to be a trend; 
as conditions became more optimal for strong and durable ectopic expression of DUSP6 
(e.g. via lentivirus purification/concentration) the GI50 against AT13148 decreased 
(Figure 6.20). However, none of the conditions used, to ectopically express DUSP6, were 
able to significantly re-sensitise 148R-S cells to AT13148 (Figure 6.20). As was 
mentioned, even with purified DUSP6 lentivirus the ectopic expression of DUSP6 was 
not durable over the course of a 4-day SRB cell viability assay. In addition, Figure 6.20 
highlights that due to time constraints only 1-2 independent experiments were 
conducted for each lentiviral condition. Therefore, the ability of DUSP6 re-expression to 
abolish the resistance phenotype in 148R-S cells warrants a more thorough 
investigation. 
  




























Figure 6.20: Summary of AT13148 GI50 and RF in 148R-S cells ectopically expressing DUSP6 via lentivirus. 
Graph and table summarise the data shown in Figure 6.17 & Figure 6.19. Data points and bars represent 
the mean ± SD of all experiments conducted. Red line highlights the GI50 of A2780 control. Unless 
otherwise stated (5 µg or 10 µg), 10 µg/ml polybrene was used. Statistical significance, relative to A2780 
(^) or 148R-S (*) ctrl, was calculated using a student’s t-test, ^ or * p ≤ 0.05, number of independent 






Cell line/condition GI50 (µM) RF n 
A2780 ctrl 0.27 ± 0.05* N/A 4 
148R-S ctrl 2.49 ± 0.81^ 9.22 4 
148R-S, 500 µl/ml (5 µg) 3.00 ± 0.97 11.11 2 
148R-S, 500 µl/ml (10 µg) 3.12 11.56 1 
148R-S, undiluted (5µg) 1.94 7.19 1 
148R-S, undiluted (10µg) 2.23 8.26 1 
148R-S, 50 µl/ml, purified 1.44 ± 0.11^ 5.33 2 
148R-S, 100 µl/ml, purified  1.83 ± 0.30 6.77 2 
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6.2.6. Response of MAPK pathway to FGFR inhibition in A2780 and 148R clones 
Whilst the experiments presented in this chapter have not definitively excluded loss of 
DUSP6 alone as a mechanism of resistance to AT13148, it seems likely that other factors 
may also contribute. Specifically, other factors may be required for a sustained increase 
in ERK 1/2 phosphorylation, a driver of AT13148 resistance. Evidence for this can be seen 
as KD of DUSP6 in parental A2780 cells and ectopic DUSP6 expression in 148R-S cells 
only caused a temporary respective increase or decrease in ERK 1/2 phosphorylation 
(Figure 6.13 & Figure 6.18). One possible candidate for regulation of increased ERK 1/2 
phosphorylation is FGFR signalling, as FGFR’s are known to regulate MAPK pathway 
activation, therefore ERK 1/2 phosphorylation, and most 148R clones had been shown 
to be sensitive to FGFR inhibition  (Desai and Adjei, 2016., Figure 4.5 & Figure 4.9).   
To investigate this A2780, 148R-N and 148R-S cells, were treated with the FGFR inhibitor 
AZD4547, and western blotted for markers of the MAPK pathway. 148R-N and 148R-S 
were selected as they were respectively shown to be cross-resistant or sensitive to 
AZD4547 (Figure 4.11). The phosphorylation of Thr202/Tyr204 ERK 1/2 and S217/221 
MEK 1/2 appeared to be refractory to AZD4547 in A2780 and 148R-N (Figure 6.21). It 
should be noted that there was a slight decrease in ERK 1/2 and MEK 1/2 
phosphorylation with 0.1 µM AZD4547 in parental A2780 cells, but this did not occur 
with 0.01 µM or 1 µM AZD4547 (Figure 6.21). In contrast, the MAPK pathway exhibited 
a strong response to AZD4547 in 148R-S cells; at 0.01 µM there was a slight increase in 
ERK 1/2 phosphorylation, whilst MEK 1/2 phosphorylation was unchanged, followed by 
consecutive decreases in both ERK 1/2 and MEK 1/2 phosphorylation at 0.1 µM and 1 
µM AZD4547 (Figure 6.21). The decrease in ERK 1/2 phosphorylation appeared to be 
much more marked than the decrease in MEK 1/2 phosphorylation (Figure 6.21). The 
total expression of ERK 1/2 and MEK 1/2 was mostly consistent across all cell lines and 
AZD4547 concentrations 
Since FGFR can also regulate the activation of the PAM pathway the phosphorylation of 
AKT was also evaluated (Desai and Adjei, 2016). Phosphorylation of S473 AKT was shown 
to be refractory to AZD4547 in both A2780 and 148R-N (Figure 6.21). However, AZD4547 
was able to decrease S473 AKT phosphorylation in 148R-S, albeit to a small extent and 
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only at 1 µM, the maximum AZD4547 concentration used (Figure 6.21). The total 
expression of AKT appeared to be consistent across all cell lines and concentrations of 
AZD4547 (Figure 6.21).  
Taken together, these data show the MAPK pathway is responsive to FGFR inhibition in 
148R-S cells but is not in 148R-N or parental A2780 cells. This may explain why 148R-S 
is sensitive to FGFR inhibition by AZD4547, and suggests that FGFR signalling may also 
contribute to the increased phosphorylation of ERK 1/2 seen in 148R-S. Therefore, FGFR 
signalling and its contribution to increased ERK 1/2 phosphorylation, thus AT13148 
resistance, warrants further investigation.  
 
Figure 6.21: Response of AKT phosphorylation and MAPK pathway to AZD4547 in A2780 and 148R 
clones. Cells were plated at either 5 x 105 (A2780) or 7.5 x 105 (148R clones) cells per 7 cm dish and allowed 
to grow for 48 hours under standard growth conditions. Cells were then treated with AZD4547, as shown, 
or D: DMSO vehicle control, for 9 hours prior to being lysed for western blot analysis. Western blot 
membranes were probed with antibodies for phospho-proteins, stripped, and then re-probed with 
antibodies for total proteins and loading control (β-Actin). (S): short exposure to hyperfilm, (L): long 
exposure to hyperfilm. Data are representative of 3 independent experiments. 
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6.3. Discussion  
6.3.1. Potential mechanisms of DUSP6 loss 
The aim of this chapter was to investigate the contribution of DUSP6, and other DUSPs, 
to increased ERK 1/2 phosphorylation and AT13148 resistance. In order to do this a 
candidate approach was used, in which the expression of selected DUSPs, that could 
dephosphorylate ERK 1/2 and had been associated with resistance to cancer therapies, 
were assessed using western blot analysis. This was a successful approach as it was 
shown that 148R-K, N & S all had a drastic decrease in the expression of DUSP6 (Figure 
6.4A). In contrast, DUSP4 and DUSP5 did not show any substantial differences amongst 
parental A2780 cells and 148R clones. The expression of DUSP6 was also investigated in 
148R-J and 148R-P, two 148R clones that were discontinued from further investigation 
in chapter 4, where it was shown that DUSP6 was also lost in 148R-P but not in 148R-J 
(Figure 6.4B). This may suggest that A2780-148R contained sub-populations with 
differential expression of DUSP6 (high vs low). Indeed, further evidence of this was seen 
as A2780-148R was only shown to have a slight reduction in DUSP6 expression, much 
less so than was seen in 148R-K, N, P & S (Figure 6.4B).  
Interestingly, amongst 148R clones where DUSP6 expression was decreased, there was 
variation in the expression of DUSP6; DUSP6 expression was greatest in 148R-S, followed 
by 148R-K, and 148R-N, where DUSP6 expression was never detected (data not shown). 
This could indicate that 148R clones have lost DUSP6 expression via distinct 
mechanisms. Whilst not investigated here, it is worth considering the mechanisms in 
which DUSP6 expression could have been lost and how this could be investigated in 
future.  
One way to interrogate regulation of DUSP6 expression would be by performing reverse 
transcriptase quantitative polymerase chain reaction (RT-Q-PCR) assays, to assess the 
expression of DUSP6 at the mRNA level. If DUSP6 mRNA was unchanged between 
parental A2780 cells and 148R clones, this would suggest that the loss of DUSP6 
expression was post-transcriptional. As was discussed in section 6.1, DUSP6 is known to 
undergo proteasomal degradation, if this process was to become enhanced then DUSP6 
expression would be decreased at the protein level but not at the mRNA level (Marchetti 
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et al., 2005). 148R clones could be treated with a proteasome inhibitor, such as 
bortezomib, to see if this restored DUSP6 expression, or alternatively, treated with a 
protein translation inhibitor, such as tetracycline, to see if DUSP6 protein had a 
decreased half-life in 148R clones compared to parental A2780 cells.  
If DUSP6 mRNA was decreased in 148R clones, this would suggest that the loss of DUSP6 
expression occurred at the genetic, epigenetic or transcriptional level, which could be 
further investigated. At the transcriptional level this could be caused by the loss of 
expression/function of a DUSP6 transcriptional activator. As well as being 
transcriptionally regulated by ETS-1 and ETS-2, DUSP6 can also be transcriptionally 
regulated by p53 (Ekerot et al., 2008; Piya et al., 2012). In addition, the DUSP6 promoter 
region has also been shown to contain putative binding sites for a number of 
transcription factors including NF-kB and FoxO transcription factors (Ekerot et al., 2008). 
Global gene expression could be analysed (e.g. via microarray analysis), to assess if 148R 
clones have a gene signature indicative of a deficiency in the aforementioned 
transcription factors. At the epigenetic level, DUSP6 expression could be lost via 
hypermethylation of the DUSP6 promoter, which has been previously characterised in 
advanced PDAC (Xu et al., 2005). 148R clones could be treated with a DNA methyl 
transferase inhibitor, such as 5-azacytidine, to see if this restored DUSP6 expression, 
which would indicate hypermethylation of the DUSP6 promoter as a mechanism of 
DUSP6 loss. Finally, at the genetic level copy number variations in the DUSP6 gene or 
mutations that cause a truncated DUSP6 protein, could cause a decrease in the 
expression of DUSP6. This could be investigated by Sanger DNA sequencing of the DUSP6 
gene and FISH (fluorescence in situ hybridisation) assays.  
6.3.2. Inhibition of DUSP6 via BCI 
Whatever the mechanism of the loss of DUSP6 expression in 148R clones, its 
contribution to increased ERK phosphorylation and therefore AT13148 resistance, was 
worthy of extensive investigation. Initially, DUSP6 was manipulated in parental A2780 
cells, to investigate if the loss of DUSP6 alone could recapitulate the AT13148 resistance 
phenotype, i.e. is DUSP6 loss alone sufficient to drive AT13148 resistance. Parental 
A2780 cells were treated with the dual DUSP1 and DUSP6 inhibitor BCI, to mimic the 
 6. Investigation into loss of DUSP6 as a mechanism of AT13148 resistance 
240 
 
loss of DUSP6 in 148R clones (Molina et al., 2009). BCI was able to increase ERK 1/2 
phosphorylation in a dose-dependent manner, thus highlighting the intimate link 
between DUSP6 and ERK 1/2 phosphorylation in parental A2780 cells (Figure 6.6). There 
was an exception to this; low concentrations of BCI (0.05 µM) paradoxically caused a 
decrease in ERK 1/2 phosphorylation. Unni and colleagues (Unni et al., 2018), saw a 
similar phenomenon in the lung adenocarcinoma cell line A549, whereby a decrease in 
ERK 1/2 phosphorylation was seen with lower concentrations of BCI, but higher 
concentrations increased ERK 1/2 phosphorylation. This could perhaps be explained by 
the interplay between the increase in ERK 1/2 phosphorylation and subsequent increase 
in ERK 1/2 mediated negative feedback that would occur in response to DUSP6 inhibition 
by BCI.  
Despite BCI increasing ERK 1/2 phosphorylation in parental A2780 cells, the combination 
of BCI with AT13148 did not generate resistance against AT13148 (Figure 6.8). However, 
this was not unexpected as there were a number of limitations in using BCI to mimic 
DUSP6 loss in parental A2780 cells; the most obvious being that BCI can also inhibit 
DUSP1 (Molina et al., 2009; Korotchenko et al., 2014). DUSP1 is exclusively localised in 
the nucleus and can also de-phosphorylate JNK and p38 MAPK, as well as ERK 1/2 (Kidger 
and Keyse, 2016). It’s therefore likely that the phosphorylation of JNK and p38 MAPK 
was increased in parental A2780 cells treated with BCI. Indeed, Shojaee and colleagues 
(Shojaee et al., 2015) showed that both JNK and p38 MAPK phosphorylation, as well as 
ERK 1/2 phosphorylation, increased in response to BCI in human pre-B ALL cells. In 
general, JNK and p38 MAPK are phosphorylated/activated in response to environmental 
stresses, and induce apoptosis upon activation (Morrison, 2012). Therefore, any survival 
advantage against AT13148, conferred by increased ERK 1/2 phosphorylation in BCI 
treated A2780 cells, might be offset by an increase in the phosphorylation of JNK and 
p38 MAPK.  
It should also be taken into consideration that BCI has been shown to cause whole 
organism toxicity in a Zebrafish model, when used at concentrations approximately the 
same as the BCI IC50, as determined by biochemical assays, for DUSP1 and DUSP6 
(Korotchenko et al., 2014). Since toxicity has not been observed in DUSP1 and DUSP6 
knock-out mice, it seems likely that whole organism toxicity is caused by off-target 
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effects of BCI (Wu et al., 2006; Maillet et al., 2008). Furthermore, shojaee and colleagues 
(Shojaee et al., 2015) demonstrated that that BCI caused a global reduction in cellular 
phospho-tyrosine in human pre-B ALL cells, giving further evidence of the off-target 
effects of BCI. Indeed, 0.10 µM BCI, when used as a single agent, did cause a slight 
reduction in the viability of parental A2780 cells (Figure 6.8). Therefore, any survival 
advantage gained from increased ERK 1/2 phosphorylation, might be overcome by BCI 
associated off-target effects. 
6.3.3. Knockdown of DUSP6 using siRNA  
The ability of DUSP6 loss alone to recapitulate the resistance phenotype in parental 
A2780 cells was also investigated using siRNA mediated KD of DUSP6. Initially, pooled 
siRNA was used to KD DUSP6, in a 4-day SRB cell viability assay, but this did not confer 
resistance against AT13148 (Figure 6.11). However, when using pooled DUSP6 siRNA, 
DUSP6 KD did not last over the course of a 4-day SRB cell viability assay (Figure 6.10). 
Furthermore, even when DUSP6 KD was at its peak, pooled DUSP6 siRNA failed to reduce 
DUSP6 expression to the level seen in 148R clones. Therefore, a 2-day SRB cell viability 
assay was performed, to compensate for the limited duration of DUSP6 KD. Additionally, 
individual DUSP6 siRNAs were used, to improve DUSP6 KD efficiency, and minimize off-
targets effects (as discussed in section 6.2.4.3). Despite the KD of DUSP6 being more 
effectively maintained over the course of a 2-day SRB assay (Figure 6.13), DUSP6 KD via 
individual siRNAs did not generate resistance against AT13148 either (Figure 6.14). 
However, as with pooled DUSP6 siRNA, individual DUSP6 siRNAs were unable to 
decrease DUSP6 expression to the level seen in 148R clones, even when DUSP6 KD was 
at its peak. Consequently, the inability of DUSP6 KD, using both pooled and individual 
siRNA, to generate AT13148 resistance in parental A2780 cells, might be explained by 
experimental limitations: i.e. the inability of siRNA KD to cause a sufficient and sustained 
decrease in DUSP6 expression. It is worth considering the reasons for these 
experimental limitations, so that they might be overcome in future.  
One such reason is that the conditions for siRNA transfection were not optimal. The 
conditions selected for siRNA KD were identified via a series of siRNA optimisation assay, 
however, under these conditions there was still some residual cell viability (~10%) in 
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cells transfected with death control siRNA, indicating incomplete siRNA transfection 
efficiency (Figure 6.9). This may, in part, explain why DUSP6 KD was insufficient in 
strength and duration. Since Lipofectamine 2000 was the only transfection reagent 
assessed in siRNA optimisation assays, a broader range of siRNA transfection reagents 
should also be evaluated to identify the most optimal siRNA transfection conditions, 
thus improving the KD of DUSP6 in parental A2780 cells.  
It should also be considered that DUSP6 has several attributes which make its expression 
difficult to manipulate using siRNA. The half-life of both DUSP6 mRNA and protein is 
incredibly short at ~30 minutes and ~60 minutes respectively (Marchetti et al., 2005; 
Blüthgen et al., 2009). Larsson and colleagues (Larsson et al., 2010) have shown that 
mRNA’s with short half-life’s, thus a high rate of turnover, are inherently resistant to KD 
with siRNA. Under these circumstances, mRNA that is degraded by siRNA can quickly be 
replaced. This therefore may explain why is was difficult to cause a strong and durable 
KD of DUSP6 using siRNA. In addition, the ERK 1/2 inducible expression of DUSP6 may 
make it difficult to KD with siRNA (Unni et al., 2018). This is because as the expression 
of DUSP6 is decreased by siRNA there is an increase in ERK 1/2 activation, this in turn 
induces the transcription of DUSP6 mRNA, which can overcome the effects of DUSP6 
siRNA, causing a re-bound in DUSP6 expression.  
As has been discussed, the experimental limitations of siRNA KD may explain why 
resistance against AT13148 was not generated in parental A2780 cells by DUSP6 siRNA 
KD. However, there was some evidence to suggest that this may be because the loss of 
DUSP6 alone was not sufficient to drive resistance to AT13148 in parental A2780 cells. 
This can be seen as DUSP6 KD, using either individual or pooled siRNA, despite not 
decreasing DUSP6 expression to the level seen in 148R clones, was able cause an 
increase in ERK 1/2 phosphorylation in parental A2780 cells, up to 24-28 hours post-
transfection, similar to the level seen in 148R clones (Figure 6.10 & Figure 6.13). But this 
increase was lost at ≥ 48 hours post-transfection, which may, in part, be due to the 
aforementioned loss of DUSP6 KD over time. This was certainly the case 96-hours post 
transfection with pooled DUSP6 siRNA, where there was substantial loss of in the level 
of DUSP6 KD (Figure 6.10). However, there was not much difference, if any, between 
the level of DUSP6 KD at 24/28 hours and 48/52 hours post-transfection, and yet, ERK 
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1/2 phosphorylation was only increased at 24/28 hours post-transfection (highlighted in 
Figure 6.22). Furthermore, individual DUSP6 siRNA was able to cause an increase in ERK 
1/2 phosphorylation at 4 hours post transfection, despite the level of DUSP6 KD being 
less than it was at 52 hours, where phosphorylation of ERK 1/2 was unchanged 
(highlighted in Figure 6.22). What this might suggest is that KD of DUSP6 alone did not 
induce resistance to AT13148 as it only caused a temporary increase in the 
phosphorylation of ERK 1/2, rather than the sustained increase required for AT13148 
resistance. The inefficiencies in DUSP6 siRNA KD cannot entirely explain this, it’s possible 
that other factors are required for a sustained increase in ERK 1/2 phosphorylation to 









Figure 6.22: Discrepancy between the level of siRNA mediated DUSP6 KD and ERK 1/2 phosphorylation. 
Diagram is a graphical representation of DUSP6 expression and ERK 1/2 phosphorylation over a time-
course, in response to KD of DUSP6 using individual siRNA’s, as shown in Figure 6.13. Times shown indicate 
hours post-transfection. Phosphorylation of ERK 1/2 at 52 hours post-transfection was unchanged despite 
the level of DUSP6 KD being greater than what was seen at 4 hours post-transfection, where ERK 1/2 
phosphorylation was increased. It’s possible that other factors, other than loss of DUSP6, are required to 
cause sustained increase in ERK 1/2 phosphorylation, driving resistance against AT13148 
Since ERK 1/2 is under tight regulatory control, the initial increase in ERK 1/2 
phosphorylation in response to DUSP6 KD may lead to a compensatory increase in other 
negative feedback regulators of ERK 1/2, preventing a sustained increase in ERK 1/2 
phosphorylation. This may be mediated by other DUSP proteins, as many of them are 
also inducible by ERK 1/2 activation, such as DUSP5 and DUSP7 (Kidger and Keyse, 2016., 
highlighted in Figure 6.23). Indeed, it has been observed that siRNA KD of DUSP proteins 
can cause compensatory increases in other DUSPs. Buffet and colleagues (Buffet et al., 
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2017) showed that there was an increase in DUSP6 expression in response to the siRNA 
mediated KD of DUSP5 in the human thyroid cancer cell line 8505c. Additionally, Caunt 
and colleagues (Caunt et al., 2008) demonstrated in Hela cells stimulated with PDBu, 
phorbol 12,12-dibutyrate, that siRNA KD of DUSP1 and DUSP2 caused a respective 
compensatory increase in DUSP2 and DUSP1 mRNA. Alternatively, upon DUSP6 KD ERK 
1/2 mediated feedback could act upstream of the MAPK pathway, e.g. via ERK 1/2 
mediated inhibitory phosphorylation of MEK 1/2, BRAF & CRAF, to overcome the initial 
increase in ERK 1/2 phosphorylation caused by DUSP6 KD (Eblen et al., 2004; Dougherty 
et al., 2005; Ritt et al., 2010., highlighted in Figure 6.23). Disruption of these negative 
feedback loops, in addition to loss of DUSP6, may also be required to cause a sustained 
increase in ERK 1/2 phosphorylation, to drive resistance against AT13148. This could be 
investigated by analysing MEK 1/2 phosphorylation and the expression of inducible 
DUSPs in response to DUSP6 siRNA KD in parental A2780 cells. Furthermore, DUSP6 
expression should be manipulated in A2780 cells using alternative techniques, such as 
CRISPR (clustered regularly interspaced short palindromic repeats)-mediated knock-out 
or shRNA, to cause a sufficient and durable decrease in DUSP6 expression, so that it can 
be definitively shown that DUSP6 loss alone is not sufficient to drive AT13148 resistance.  
 
Figure 6.23: Potential increase in ERK 1/2 mediated negative feedback in response to individual DUSP6 
siRNA KD. In A2780 cells, at 4 and 28-hours post-transfection DUSP6 KD causes an increase in ERK 1/2 
phosphorylation, but this is lost at 52 hours post-transfection (shown in Figure 6.13). As shown in Figure 
6.22, this cannot entirely be explained by the difference in the level of DUSP6 KD across these timepoints. 
It may be explained by ERK 1/2 mediated negative feedback; at 4 and 28-hours negative feedback is low 
and cannot not overcome the increase in ERK 1/2 phosphorylation caused by DUSP6 KD, but at 52 hours 
negative feedback has increased and overcome the initial increase in ERK 1/2 phosphorylation caused by 
DUSP6 KD. ERK 1/2 mediated negative feedback may work on two levels; increased expression of inducible 
DUSPs (e.g. DUSP5) or increased inhibitory phosphorylation of upstream components of the MAPK 
pathway (e.g. MEK 1/2). 
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6.3.4. Lentiviral mediated ectopic re-expression of DUSP6 
To investigate if loss of DUSP6 was necessary, if not sufficient, for AT13148 resistance, 
DUSP6 was transiently re-expressed using a DUSP6 lentivirus in 148R-S cells, to assess if 
this could re-sensitise cells to AT13148. For the purposes of this discussion, results 
obtained using purified DUSP6 lentivirus will be focused on, as this caused the strongest 
and most durable re-expression of DUSP6. Whilst purified DUSP6 lentivirus did cause a 
decrease in the GI50 of 148R-S cells against AT13148, this was a < 2-fold decrease, and 
still represented an RF of > 5 (Figure 6.17). It should be noted, that the DUSP6 lentiviral 
experiments should be interpreted with some caution, as a limited number of 
independent experiments were performed. Additional biological replicates may have 
enabled greater statistical significance to be demonstrated, but it’s likely that that 
magnitude of the effect would still be marginal.  
However, as with DUSP6 siRNA KD, the ectopic re-expression in 148R-S cells was not 
sustained over the course of a 4-day SRB cell viability assay; at 48 hours post infection, 
ectopic DUSP6 expression matched the expression of DUSP6 in parental A2780 cells, but 
was decreased, compared to A2780 cells, at 120 hours post-infection (Figure 6.18). This 
could explain why the re-expression of DUSP6 did not re-sensitise 148R-S cells to 
AT13148. It is worth noting that it was always going to be difficult to transiently re-
express DUSP6 at a sufficient level, due to its short half-life (Marchetti et al., 2005). For 
this reason, a lentivirus was used rather than a standard mammalian expression vector 
(e.g. pcDNA3); lentiviral DNA integrates into the host genome, whereas a standard 
mammalian expression vector does not. Therefore, with a standard mammalian 
expression vector transgene DNA is not passed on to daughter cells, thus the expression 
of a protein with short half-life, such as DUSP6, would be rapidly lost. In contrast, since 
lentiviral DNA is passed on to daughter cells, assuming a high infection efficiency, the 
expression of a transgene, even one with short half-life, should be much more durable. 
However, even under optimised conditions, lentiviral infection efficiency is never 100%, 
and transient expression is lost over time, as was seen with ectopic expression of DUSP6 
in 148R-S cells. This could be overcome by using a mammalian expression vector (viral 
or plasmid), which contains selectable marker for expression in mammalian cells, such 
as neomycin resistance, to generate 148R-S cells which stably re-express DUSP6. 
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Furthermore, DUSP6 should be under the control of an inducible promoter (e.g. Tet-on 
system), so that the expression of DUSP6 can be finely controlled. 
Additional evidence as to why ectopic re-expression of DUSP6 did not re-sensitise 148R-
S cells to AT13148, can be seen by looking at ERK 1/2 phosphorylation; re-expression of 
DUSP6 did not cause a sustained decrease in ERK 1/2 phosphorylation (Figure 6.18). At 
48 hours post infection DUSP6 re-expression decreased the phosphorylation of ERK 1/2 
to the level seen in parental A2780 cells, but at 120 hours post infection, whilst the 
phosphorylation of ERK 1/2 was still below that of 148R-S control cells, it was above the 
level seen in parental A2780 cells. A similar pattern was also seen in the phosphorylation 
of the ERK 1/2 substrate Elk-1 (Figure 6.18). This may be explained by the decrease in 
DUSP6 expression over this time period, i.e. the re-expression of DUSP6 was not 
sufficiently maintained to cause a sustained decrease in ERK 1/2 phosphorylation. But 
in parallel to this, there was an increase in MEK 1/2 phosphorylation, which peaked at 
120 hours post-infection. What this might suggest is that in response to DUSP6 re-
expression there was an initial decrease in ERK 1/2 phosphorylation, however, over-time 
there was an increase in MEK 1/2 phosphorylation, likely due to relief of ERK 1/2 
mediated negative feedback, which prevented DUSP6 re-expression from causing a 
sustained decrease in ERK 1/2 phosphorylation, thus 148R-S cells were not re-sensitised 
to AT13148. Interestingly, a similar phenomenon has been observed by McCormick and 
colleagues (Phuchareon et al., 2015), whereby ectopic expression of DUSP6 caused an 
increase in the phosphorylation of MEK 1/2 in HCC827 cells.  
6.3.5. Contribution of FGFR signalling to AT13148 resistance 
In many ways the results obtained from DUSP6 siRNA KD in parental A2780 cells and 
ectopic DUSP6 expression in 148R-S cells were similar; neither were able to generate 
the hypothesised phenotype: respectively, to re-capitulate or abolish AT13148 
resistance. In addition, both suffered experimental limitations (e.g. duration of DUSP6 
KD or re-expression), which may in part explain why the appropriate alteration to ERK 
1/2 phosphorylation was not sustained over the course of an SRB cell viability assay, 
thus the hypothesised phenotype not generated. However, as discussed, there was also 
evidence suggesting that experimental limitations alone did not explain the inability to 
 6. Investigation into loss of DUSP6 as a mechanism of AT13148 resistance 
247 
 
cause a sustained increase or decrease in ERK 1/2 phosphorylation. Therefore, whilst 
the role of DUSP6 in AT13148 resistance cannot be dismissed, it was deemed likely that 
other factors contributed to ERK 1/2 phosphorylation and AT13148 resistance.  
With this in mind, and due to the sensitivity to FGFR inhibition exhibited by most 148R 
clones (Figure 4.5 & Figure 4.11), the contribution of FGFR signalling to MAPK signalling 
was investigated, by assessing the MAPK pathway response to AZD4547, an FGFR 
inhibitor. Remarkably, there was a strong decrease in MEK 1/2 and ERK 1/2 
phosphorylation in 148R-S, but not in A2780 and 148R-N (Figure 6.21). Interestingly, it 
also appeared that FGFR signalling preferentially activated the MAPK pathway over the 
PAM pathway within 148R-S cells, as AZD4547 only had a minimal effect upon AKT 
phosphorylation. This is consistent with what has been previously reported, as it has 
been shown that hyperactivation of FGFR signalling and FGFR inhibitor sensitivity are 
associated with a MAPK pathway gene signature (Nakanishi, Akiyama, et al., 2015; 
Nakanishi, Mizuno, et al., 2015).  
It would therefore seem that the MAPK pathway has an increased dependency on FGFR 
signalling in 148R-S cells. This likely explains why 148R-S cells were much more sensitive 
to FGFR inhibition than A2780 and 148R-N cells (Figure 4.11). It may also explain why 
DUSP6 siRNA KD in parental A2780 cells did not generate AT13148 resistance; perhaps 
an increase in FGFR signalling is also required for a sustained increase in ERK 1/2 
phosphorylation. It is well established that DUSP6 is an important negative feedback 
regulator of FGFR signalling. For example, DUSP6 knock-out mice exhibit phenotypes 
consistent with hyperactive FGFR signalling, and the DUSP6 inhibitor BCI was discovered 
as part of a screen to identify compounds that could hyperactivate FGFR signalling (Li et 
al., 2007; Molina et al., 2009). Therefore, a sustained increase in ERK 1/2 
phosphorylation may not be mediated by increased FGFR signalling alone due DUSP6 
mediated negative feedback, and as discussed, loss of DUSP6 alone might be unable to 
cause a sustained increase due to increased ERK 1/2 mediated negative feedback 
upstream the MAPK pathway (Figure 6.24A, B). However, together, whilst there would 
still be ERK 1/2 mediated negative feedback (exemplified by the decrease in MEK 1/2 
phosphorylation in 148R-S; Figure 4.17), in the absence of DUSP6, this might be 
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sufficient to cause a sustained increase in ERK 1/2 phosphorylation, driving AT13148 
resistance (Figure 6.24C).  
 
Figure 6.24: Potential cooperation of FGFR signalling and DUSP6 loss to generate AT13148 resistance. 
Diagram highlights how increased FGFR signalling (e.g. via mutation or increased expression of FGFR’s) 
and DUSP6 loss might cooperate to increase ERK 1/2 phosphorylation and drive AT13148 resistance. (A) 
Increased FGFR signalling alone might increase activation of upstream components of the MAPK pathway 
but not ERK 1/2 due to negative feedback regulation by DUSP6. (B) Any initial increase in ERK 1/2 
phosphorylation caused by loss of DUSP6 alone, may be overcome by ERK 1/2 mediated negative feedback 
on upstream components of the MAPK pathway. (C) Together, increased FGFR signalling and DUSP6 loss 
might cooperate to cause a sustained increase in ERK 1/2 phosphorylation, driving AT13148 resistance. In 
this scenario, ERK 1/2 mediated negative feedback would still exist, but be sufficiently overcome. 
For the reasons outlined above, the contribution of FGFR signalling to AT13148 
resistance, either alone or in combination with DUSP6 loss, warrants further 
investigation. Combination SRB cell viability assays should be conducted in 148R-S cells, 
in which low concentrations of AZD4547 are combined with a standard titration of 
AT13148. If AZD4547 sensitised 148R-S cells to AT13148 this would suggest that FGFR is 
driving resistance. Interestingly, preliminary combination assays, as described, have 
been performed, and have shown some re-sensitisation to AT13148 caused by AZD4547 
(data not shown). If the resistance mechanism shown in Figure 6.24C is correct, and 
DUSP6 re-expression is also required for sensitisation, it may be necessary to ectopically 
express DUSP6 during these combination assays to fully re-sensitise 148R-S cells to 
AT13148. Furthermore, FGFR signalling could be activated in parental A2780 cells to 
assess if this alone, or in combination with DUSP6 siRNA KD, could generate resistance 
A B C 
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against AT13148. Since the exact mechanism by which 148R-S cells have acquired an 
increased dependency on FGFR is unknown (e.g. increased FGFR expression), this could 
be undertaken by using an FGF ligand, such as FGF2. This approach was used by Yadav 
and colleagues (Yadav et al., 2012), with great success, to validate hyperactive FGFR 
signalling as a resistance mechanism to vemurafenib in BRAF V600E mutant melanoma.  
In summary, the data in this chapter showed there was a dramatic decrease in the 
expression of DUSP6 in 148R-K, N & S. The loss of DUSP6 expression was subsequently 
hypothesised as a mechanism of increased ERK 1/2 phosphorylation, thus AT13148 
resistance. This was investigated by siRNA KD of DUSP6 in parental A2780 cells and 
transient ectopic expression of DUSP6 in 148R-S cells, of which neither were able to 
respectively re-capitulate or abolish the resistance phenotype. These results may, in 
part, be explained by experimental limitations of these techniques, but it is likely that 
other factors may be required for AT13148 resistance. To this end, 148R-S cells were 
found to have an increased dependency on FGFR signalling for MAPK pathway 
activation. Therefore, the contribution of FGFR signalling to AT13148 resistance, alone 
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7. General discussion  
7.1. Introduction   
The AGC family of protein kinases regulate growth, proliferation, survival and migration, 
and as such, AGC kinases are often deregulated in cancer, driving oncogenesis. Due to 
their role in oncogenesis there are a number of agents that are currently in clinical 
development targeting AGC kinases, the majority of which are AKT inhibitors (Prêtre and 
Wicki, 2018). AT13148 was discovered as part of a drug discovery programme between 
the ICR and Astex Pharmaceuticals, to identify potent and selective AKT inhibitors (Yap 
et al., 2012). However, whilst inhibiting AKT1 and AKT3, AT13148 was also shown to 
inhibit other AGC kinases: PKA, ROCK1, ROCK2, p70S6K, SGK3 and RSK1, of which PKA, 
p70S6K and ROCK1/2, were inhibited more potently than AKT (Yap et al., 2012). Most 
inhibitors targeting kinases within the AGC family (e.g. AKT inhibitors), that are currently 
in clinical development, show a much greater degree of selectivity, versus AT13148, but 
have been shown to have limited efficacy when used as a monotherapy (Prêtre and 
Wicki, 2018). It was hoped that by targeting several AGC kinases, both within and 
outside the PAM pathway, AT13148 might have an improved efficacy, when compared 
to more selective AKT inhibitors and other inhibitors of AGC kinases. For example, as 
discussed in section 1.5, by inhibiting several kinases of the PAM pathway (AKT, p70S6K 
and SGK3), AT13148 may provide a more robust inhibition of the pathway, thus have a 
greater efficacy in treating PAM pathway dysregulated cancers. For these reasons, 
AT13148 progressed to clinical development; AT13148 has recently completed a phase 
1 clinical trial, the results of which are yet to be published (clinicaltrials.gov – identifier: 
NCT01585701). However, acquired drug resistance is a major obstacle in the success of 
many targeted cancer therapies, and likely to occur to AT13148, despite the predicted 
improved efficacy afforded by targeting several AGC kinases simultaneously.  
Pre-clinical studies of acquired drug resistance are effective at identifying drivers and 
mechanisms of resistance, often with clinical relevance, providing a means of accurately 
studying acquired resistance whilst a drug is in clinical development (Garraway and 
Jänne, 2012). In doing so, these studies can help identify therapeutic strategies to 
overcome acquired resistance, and facilitate the stratification of patients based on 
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predicted drug sensitivity (Garraway and Jänne, 2012). Currently, there are no 
publications that report the identification of acquired mechanisms of resistance to 
AT13148. Therefore, the primary aim of this thesis was to identify and validate acquired 
mechanisms of resistance to AT13148 using pre-clinical cell line models. The work 
presented in this thesis identified ERK 1/2 as a driver of AT13148 resistance and several 
therapeutic strategies to potentially overcome AT13148 resistance. These findings may 
assist in the future clinical development of AT13148 and potentially improve the efficacy 
of AT13148 treatment, should AT13148 progress to new drug approval.  
This chapter discusses the main findings of this thesis, their implications to the future 
clinical development of AT13148, and how future work might best be conducted to 
further our understanding of AT13148 resistance, to improve the efficacy of AT13148 in 
the clinic.  
7.2. Summary of main findings and future work 
7.2.1. Increased ERK 1/2 phosphorylation as a driver of AT13148 resistance  
In chapter 3, it was first shown in A2780-148R cells that there was increased 
phosphorylation of ERK 1/2 in parallel with a decrease in the phosphorylation of MEK 
1/2. However, the magnitude of the increase in ERK 1/2 phosphorylation did vary across 
experiments; in basal western blot experiments there was only a slight increase, but in 
dose-response western blots, in untreated A2780-148R cells, there was a much more 
substantial increase in ERK 1/2 phosphorylation (Figure 3.11, Figure 3.13 & Figure 3.15). 
This suggested that there might be distinct sub-populations cells of within the A2780-
148R population, with differing levels of ERK 1/2 phosphorylation, that were selected 
for over-time/under different experimental conditions.  
Indeed, in chapter 4, several isogenic sub-clones: 148R-K, N & S, derived from A2780-
148R cells, exhibited a marked increase in ERK 1/2 phosphorylation, much more so than 
was seen in A2780-148R, and with a greater degree of consistency across experiments 
(Figure 4.17). This increase in ERK 1/2 phosphorylation in 148R clones was greatest in 
148R-S, followed by 148R-K, then 148R-N (Figure 4.17). As with A2780-148R, increased 
ERK 1/2 phosphorylation was seen in parallel with a decrease in MEK 1/2 
phosphorylation in 148R clones, but again, this was to a much greater extent than was 
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seen in A2780-148R (Figure 4.17). Moreover, in 148R-K and 148R-S, increased ERK 1/2 
phosphorylation corresponded with an increase in the phosphorylation of Elk-1, an ERK 
1/2 substrate, which therefore could be used as a biomarker of ERK 1/2 activation in 
148R-K and 148R-S (Figure 4.17). 
In addition to ERK 1/2 phosphorylation being increased at a basal level, ERK 1/2 
phosphorylation also exhibited a response to AT13148 in A2780-148R and 148R clones, 
as well as in parental A2780 cells (Figure 3.13 & Figure 5.4). Whilst there were some 
inconsistencies between datasets, in A2780 cells ERK 1/2 phosphorylation was increased 
at higher concentrations of AT13148 but was either decreased or unchanged at lower 
concentrations; whereas in A2780-148R and 148R clones, the phosphorylation of ERK 
1/2 tended to progressively increase with increasing concentrations of AT13148 (Figure 
3.13 & Figure 5.4). This response was much more notable in 148R clones, particularly 
148R-S. Since AT13148 is not known to directly target the MAPK pathway, it is currently 
unknown how AT13148 may elicit this response. However, as highlighted in Figure 3.17A 
& B, targets of AT13148 are known to regulate the MAPK pathway, the inhibition of 
which could be responsible for the response of ERK 1/2 phosphorylation to AT13148. A 
greater understanding of how AT13148 regulates ERK 1/2 phosphorylation could aid the 
clinical development of AT13148 and should therefore be further investigated in future 
work. For example, PKA and AKT impart an inhibitory phosphorylation on CRAF at S259, 
of which there are commercial antibodies available for detection by western blot 
analysis (Zimmermann and Moelling, 1999; Pursiheimo et al., 2002; Dumaz et al., 2006). 
It would be interesting to see if there was a reduction in S259 CRAF phosphorylation in 
response to AT13148; if this was the case, it would suggest that the inhibition of PKA 
and/or AKT by AT13148, and subsequent decrease in inhibitory phosphorylation of 
CRAF, is responsible for the AT13148 mediated increase in ERK 1/2 phosphorylation 
















Figure 7.1: Relief of CRAF inhibition as a mechanism of increased ERK 1/2 phosphorylation in response 
to AT13148. (A) In untreated cells, AKT and PKA can phosphorylate CRAF at S259, inhibiting CRAF 
activation and activation of downstream components of the MAPK pathway. (B) The inhibition of AKT and 
PKA by AT13148 might cause a decrease in S259 CRAF phosphorylation, increasing the activation of CRAF 
and downstream components of the MAPK pathway, such as ERK 1/2. 
Nonetheless, the consequence of increased basal ERK 1/2 phosphorylation, combined 
with the aforementioned ERK 1/2 response to AT13148, was that ERK 1/2 
phosphorylation was much greater in A2780-148R and 148R clones, across all 
concentrations of AT13148 used.  It was therefore reasoned that ERK 1/2 might act as a 
driver of resistance to AT13148. Indeed, in chapter 5, the combination of AT13148 with 
the ERK inhibitor GDC-0994 demonstrated synergistic growth inhibition in 148R-K and 
148R-S cells, re-sensitising 148R-K and 148R-S to AT13148 (Figure 5.5 & Figure 5.6). In 
both 148R-K and 148R-S, the greatest re-sensitisation was seen when AT13148 was 
combined with respective GI20 concentrations of GDC-0994, where the combination 
lowered the GI50 against AT13148 ~7-fold, to approximately the same GI50 value shown 
by A2780 to AT13148 (Figure 5.5). Western blot analysis showed that respective GI20 
concentrations of GDC-0994 decreased Elk-1 phosphorylation in 148R-K and 148R-S, to 
approximately the same level as parental A2780 cells, if not slightly below (Figure 5.7). 
Therefore, the re-sensitisation and synergy caused by the combination of AT13148 and 
GDC-0994, provided evidence that increased activation of ERK 1/2 was acting as a driver 
of AT13148 resistance in 148R-K and 148R-S. This was further validated in 148R-S, as an 
A B 
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additional ERK inhibitor, SCH772984, also demonstrated synergy with AT13148 and re-
sensitised 148R-S cells (Figure 5.8). Interestingly, parental A2780 cells were also 
sensitised to AT13148 by the synergistic combination with GDC-0994 or SCH772984, 
suggesting that the response of ERK 1/2 phosphorylation in A2780 cells (in response to 
AT13148), may cause a level of intrinsic resistance to AT13148 (Figure 5.5, Figure 5.6 & 
Figure 5.8). 
It should be noted that the sensitisation to AT13148 caused by ERK inhibition was 
attenuated at higher concentrations of AT13148 in A2780, 148R-K and 148R-S (Figure 
5.5, Figure 5.6 & Figure 5.8). This could be due to the experimental set-up; ERK inhibitors 
may be unable to sufficiently inhibit ERK 1/2 over the 96-hour drug treatment during a 
standard SRB cell viability assay, which in turn attenuated sensitisation to AT13148 at 
higher concentrations. Western blot analysis only assessed the inhibition of ERK 1/2 by 
GDC-0994 at 4 hours, therefore combination assays should be repeated to assess ERK 
inhibition at additional time points to ensure ERK inhibition is durable (Figure 5.7). 
Alternatively, if inhibition of ERK was shown to be sustained, it’s possible that other 
drivers of AT13148 resistance may co-exist with ERK 1/2, the inhibition of which may 
also be required to fully re-sensitise cells to AT13148.  
Combinations assays also provided evidence of how ERK 1/2 may contribute to AT13148 
resistance. In 148R clones, the combination of AT13148 and GDC-0994 was able to cause 
a greater decrease in S6RP phosphorylation than that seen with AT13148 alone (Figure 
5.7). In chapter 4, S6RP phosphorylation was shown to be refractory to inhibition by 
AT13148 in 148R clones (Figure 4.14). Therefore, ERK 1/2 might act as driver of AT13148 
resistance, at least in part, by maintaining phosphorylation of S6RP. To be more precise, 
in 148R clones, it would seem that ERK 1/2 can compensate for the AT13148 mediated 
inhibition of p70S6K, by maintaining the phosphorylation of S6RP. The potential 
mechanisms of how ERK 1/2 might facilitate the maintenance of S6RP phosphorylation 
were discussed in section 5.3 and highlighted in Figure 5.12.  
The maintenance of S6RP phosphorylation alone might make a significant contribution 
to AT13148 resistance, due to regulation of protein synthesis driven through S6RP, a 
process that cancer cells are often dependent upon for their growth and survival (Grzmil 
and Hemmings, 2012). However, it should also be considered that PRAS40 
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phosphorylation was also maintained in response to AT13148 in 148R clones, and that 
ERK 1/2, either directly or via its substrate RSK, can phosphorylate several substrates of 
the AT13148 targets AKT and p70S6K, many of which are highlighted in Figure 7.2 (Figure 
4.14; Mendoza, Er and Blenis, 2011). Consequently, in 148R-K and 148R-S, ERK 1/2 could 
potentially drive AT13148 resistance by maintaining the phosphorylation of several 
substrates of AKT and p70S6K, including S6RP, rendering the PAM pathway refractory 
to AT13148, driving growth and survival. Therefore, in future, western blot analysis 
should be conducted to evaluate if the phosphorylation of other AKT and p70S6K 
substrates is also maintained in response to AT13148, and if so, whether ERK inhibition 
can overcome this. Alternatively, global gene expression could be analysed (e.g. by using 
gene microarray analysis or RNA sequencing) in A2780 and 148R clones, both untreated 
and treated with AT13148, to investigate if a PAM pathway gene signature could be 








Figure 7.2: Model to show how ERK 1/2 may compensate for the inhibition of AKT and p70S6K by 
AT13148. Diagram highlights how ERK 1/2, either directly or via RSK, might compensate for the inhibition 
of AKT and p70S6K by AT13148. ERK 1/2 and RSK share many of the same substrates as AKT and p70S6K, 
therefore increased activation of ERK 1/2, either at a basal level or in response to AT13148, could enable 
the phosphorylation of AKT and p70S6K substrates to be maintained in response to AT13148. This has 
been shown with the p70S6K substrate S6RP, as combining AT13148 with an ERK inhibitor was able to 
overcome refractory S6RP phosphorylation in response to AT13148 in 148R clones (Figure 5.7).  
Interestingly, 148R-K and 148R-S were also shown to have low-level cross-resistance to 
the allosteric AKT inhibitor MK2206, exhibiting RF values of ~4 and ~6 respectively 
(Figure 4.13). However, in contrast to AT13148, in 148R-S cells (148R-K was not 
assessed) western blot analysis did not reveal any maintenance in the phosphorylation 
of components of the PAM pathway (S6RP, PRAS40 & GSK3β) in response to the MK2206 
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(Figure 4.16). If the basal increase in ERK 1/2 phosphorylation alone was responsible for 
the maintenance of S6RP phosphorylation in response to AT13148, and potentially other 
PAM pathway components, then one would have also expected to see this response to 
MK2206.  
This suggests that the maintenance of S6RP phosphorylation, and possibly other PAM 
pathway components, could be unique to AT13148 and not seen with other inhibitors 
of the PAM pathway, such as MK2206. This might be due to the further induction of ERK 
1/2 phosphorylation mediated by AT13148 in 148R clones (Figure 5.4). However, since 
AKT can cross-inhibit the MAPK pathway, future studies should investigate if MK2206 
can also increase ERK 1/2 phosphorylation (Zimmermann and Moelling, 1999; Guan et 
al., 2000). If MK2206 was shown not to increase ERK 1/2 phosphorylation, it would 
suggest that the maintenance of S6RP phosphorylation in response to AT13148 was 
dependent upon the induction of ERK 1/2 phosphorylation. In addition, combination SRB 
cell viability assays should be performed with MK2206 and ERK inhibitors, to assess the 
contribution of ERK 1/2 to MK2206 cross-resistance. Despite, the lack of PAM pathway 
maintenance, ERK 1/2 could still contribute to MK2206 via an alternative mechanism, 
such as enabling a functional by-pass of the PAM pathway (e.g. maintenance of cell cycle 
progression), which could also be relevant to AT13148 resistance.  
In summary, increased basal ERK 1/2 phosphorylation appeared to act as a driver of 
acquired AT13148 resistance in 148R-K and 148R-S, although other unidentified drivers 
may also exist. ERK 1/2 phosphorylation was also further enhanced upon AT13148 
exposure, which is likely to be important for AT13148 resistance. ERK 1/2 may act as 
driver of AT13148 resistance by maintaining the phosphorylation of S6RP, and 
potentially other components of the PAM pathway, in the presence of AT13148. 
7.2.2. Cross-resistance to ROCK inhibition  
Another major finding presented in this thesis was cross-resistance to ROCK inhibition. 
This was initially observed in chapter 3, where A2780-148R cells were shown to be cross-
resistant to the ROCK inhibitors GSK429286A and GSK269962 (Figure 3.5). The cross-
resistance to these ROCK inhibitors, exhibited by A2780-148R, was quite substantial, 
particularly against GSK269962, which had the greatest potency against ROCK1 and 2, 
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where A2780-148R was shown to have an RF value of 86.00 (Figure 3.5; Lotz-Jenne et 
al., 2016). Cross-resistance to GSK269962 was also seen in 148R clones, which had RF 
values between 11.42 and 168.77 (Figure 4.3). Furthermore, across A2780, A2780-148R 
and 148R clones, the GI50 values for GSK269962 showed strong positive correlation with 
AT13148 GI50 values (Figure 4.3). Due to the potent inhibition of ROCK1 & 2 by AT13148, 
this suggests that for AT13148 resistance to develop the inhibition of ROCK1 & 2 must 
be overcome.  
The exact mechanism(s) by which ROCK1 & 2 inhibition has been overcome, has not 
been elucidated. In both A2780-148R and 148R clones, the ROCK pathway seemed to be 
equally inhibited in response to AT13148, when compared to parental A2780 cells, as 
indicated by a decrease in the phosphorylation of the ROCK substrate MYPT1 (Figure 
3.12 & Figure 4.15). This data alone would suggest that the ROCK pathway has been by-
passed in A2780-148R and 148R clones; i.e. A2780-148R and 148R clones have activated 
another signalling pathway, to drive growth and survival in the presence of ROCK 
inhibition. However, as discussed in section 3.3, there are issues with using the 
phosphorylation of MYPT1, alone, as a readout of ROCK pathway inhibition, mostly 
concerning the phosphorylation of MYPT1 by alternative kinases, such as MRCK 
(Wilkinson et al., 2005). Consequently, the response of MYPT1 phosphorylation to 
AT13148 may be misleading; not giving an accurate reflection of the response of the 
ROCK pathway to AT13148. Other ROCK substrates are also phosphorylated by 
alternative kinases and so would present a similar issue when used as a biomarker of 
ROCK inhibition (Kümper et al., 2016). Therefore, the response of a range of ROCK 
pathway substrates; such as MLC, LIMK and cofilin, to AT13148, should be investigated 
in future, in order to more accurately determine the response of the ROCK pathway to 
AT13148, to determine how ROCK inhibition has been overcome in AT13148 resistance.  
Since ERK 1/2 was the only driver of AT13148 resistance identified in the work presented 
in this thesis, it should be considered that ERK 1/2 may also contribute to cross-
resistance to ROCK inhibition. Indeed, this may be in part how ERK 1/2 contributes to 
AT13148 resistance. Interestingly, ERK 1/2 is known to phosphorylate and activate 
myosin light chain kinase (MLCK), which in turn can phosphorylate the ROCK substrate 
MLC2 (Klemke et al., 1997). Therefore, increased ERK 1/2 phosphorylation could 
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contribute to ROCK cross-resistance, and AT13148 resistance, by activating MLCK, 
rendering MLC2 phosphorylation refractory to ROCK inhibition (Figure 7.3). 
Maintenance of phosphorylated MLC2 might be important for ROCK cross-
resistance/AT13148 resistance, as MLC2 positively regulates actin-myosin contractility, 
which is required for cell cycle progression by providing the contractile strength for 
cytokinesis (Matsumura, 2005). However, phosphorylation and activation of MLCK by 









Figure 7.3: Potential contribution of ERK 1/2 to ROCK cross-resistance. Diagram shows that ERK 1/2 can 
activate MLCK, which in turn can phosphorylate the ROCK substrate MLC2.  Therefore, increased ERK 1/2 
phosphorylation, in 148R clones, might render MLC2 phosphorylation refractory to ROCK inhibition, thus 
facilitate actin-myosin contractility and cell cycle progression in the presence of a ROCK inhibitor.  
Cell viability assays, in which GSK269962 is combined with an ERK inhibitor, would 
enable the contribution of ERK 1/2 activity to ROCK cross-resistance to be determined. 
If ERK inhibition was able to re-sensitise 148R clones to GSK269962 it would suggest that 
increased ERK 1/2 phosphorylation was responsible for ROCK cross-resistance. 
Furthermore, it would suggest that ERK 1/2 acts as a driver of AT13148 resistance, in 
148R clones, by overcoming ROCK inhibition by AT13148. This should be an immediate 
focus of any future work, as a lack of understanding of the mechanism of ROCK cross-
resistance, and its relevance to AT13148 resistance, is a limitation in the work presented 
in this thesis. Moreover, since AT13148 could potentially be used in the clinic as a ROCK 
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inhibitor (e.g. in pancreatic cancer), understanding ROCK cross-resistance may have 
clinical relevance (Rath et al., 2018). 
7.2.3. Loss of DUSP6 as a mechanism of AT13148 resistance  
Due to the identification of increased ERK 1/2 phosphorylation as a driver of acquired 
AT13148 resistance, the focus of chapter 6 was to investigate the mechanism by which 
ERK 1/2 phosphorylation had been upregulated. For the following reasons a candidate 
approach was undertaken, focusing on the DUSP sub-family of ERK 1/2 phosphatases: 
1) in 148R clones, increased ERK 1/2 phosphorylation existed in parallel with a reduction 
in  phosphorylation of MEK 1/2; 2) the phosphorylation of ERK 1/2 was refractory to 
MEK inhibition in 148R clones (Figure 4.17 & Figure 5.2). Therefore, since MEK 1/2 is the 
only known kinase responsible for ERK 1/2 phosphorylation, it was deemed likely that 
the loss of an ERK 1/2 phosphatase, of which the DUSP sub-family is the most well 
characterised, was responsible for the increase in ERK 1/2 phosphorylation observed in 
148R clones.  
Indeed, this proved to be a successful approach, as it was shown that there was a drastic 
loss of DUSP6 expression in 148R-K, N & S (Figure 6.4). Subsequently, DUSP6 siRNA KD 
was performed in parental A2780 cells, to see if this caused a sustained increase in ERK 
1/2 phosphorylation and AT13148 resistance. Conversely, a DUSP6 lentivirus was used 
to ectopically re-express DUSP6 in 148R-S cells, to see if this restored ERK 1/2 
phosphorylation to the level seen in parental A2780 cells and re-sensitised 148R-S to 
AT13148. Neither of these experiments achieved their desired outcome; DUSP6 siRNA 
KD did not induce AT13148 resistance in parental A2780 cells, nor did ectopic re-
expression of DUSP6 sensitise 148R-S cells to AT13148 (Figure 6.14 & Figure 6.20). 
Furthermore, both experiments only caused a temporary respective increase or 
decrease in ERK 1/2 phosphorylation, which was lost at later timepoints (Figure 6.10, 
Figure 6.13 & Figure 6.18). This may be due to both experiments failing to cause a 
sustained manipulation to DUSP6 expression, as was discussed in sections 6.3.3 & 6.3.4 
(Figure 6.10, Figure 6.13 & Figure 6.18). Therefore, in order to definitively exclude loss 
of DUSP6 alone as a mechanism of AT13148 resistance, these experiments should be 
repeated using alternative techniques, to cause a more sustained decrease or increase 
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in DUSP6 expression. CRISPR could be used to cause a stable knockout of DUSP6 in 
parental A2780 cells and DUSP6 could be stably re-expressed in 148R-S cells, by using 
an expression vector containing a selectable marker for expression in mammalian cells.  
However, despite the limitations of these experiments, there was evidence to suggest 
that the loss of DUSP6 alone might not be sufficient for AT13148 resistance, which was 
discussed at length in sections 6.3.3 & 6.3.4. It would appear that other factors, in 
addition to DUSP6 loss, are required to cause a sustained increase in ERK 1/2 
phosphorylation, thus generating AT13148 resistance. This is likely due to the powerful 
negative feedback control of the MAPK pathway in parental A2780 cells and 148R 
clones. Evidence for this can be seen as the inhibition of ERK, by GDC-0994, was able to 
cause a substantial increase in MEK 1/2 phosphorylation, in both A2780 and 148R clones 
(Figure 5.3). This might explain why DUSP6 KD, in parental A2780 cells, only caused a 
temporary increase in ERK 1/2 phosphorylation, as this could be overcome by increased 
ERK 1/2 mediated negative feedback, and why DUSP6 re-expression, in 148R-S cells, only 
caused a temporary decrease in ERK 1/2 phosphorylation, as this could be overcome by 
a relief in ERK 1/2 mediated negative feedback. Direct evidence of this can be seen as 
ectopic expression of DUSP6 in 148R-S cells caused an increase in MEK 1/2 
phosphorylation, which was likely the reason why increased ERK 1/2 phosphorylation 
was not sustained (Figure 6.18).  
7.2.4. FGFR signalling and AT13148 resistance 
It was reasoned that FGFR signalling could potentially play a role in causing a sustained 
increase in ERK 1/2 phosphorylation, thus AT13148 resistance, due to the sensitivity to 
AZD4547, an FGFR inhibitor, that had been observed in A2780-148R and most 148R 
clones (Figure 3.6, Figure 4.5 & Figure 4.11). Furthermore, it was shown that AZD4547 
was able to cause a decrease in MEK 1/2 and ERK 1/2 phosphorylation in 148R-S cells, 
but not in parental A2780 cells or 148R-N, which was cross-resistant to AZ4547 (Figure 
6.21). This suggested that in 148R-S cells ERK 1/2 phosphorylation was dependent on 
FGFR signalling. Taking this into account, a new putative mechanism of AT13148 
resistance was established, in which increased FGFR signalling, yet to be defined, and 
loss of DUSP6 combine to cause a sustained increase in ERK 1/2 phosphorylation, driving 
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AT13148 resistance in 148R clones, such as 148R-S. As highlighted in Figure 6.24, these 
two changes could cooperate to cause a sustained increase in ERK 1/2 phosphorylation, 
by compensating for the increase in ERK 1/2 mediated negative feedback that would be 
caused by either change alone. The investigation of this putative mechanism of 
resistance should be focused upon in future work, which was discussed in section 6.3.5. 
For example, by performing cell viability combination assays, with AT13148 and 
AZD4547, on 148R-S cells that ectopically re-express DUSP6.  
7.2.5. Alternative mechanism of AT13148 resistance in 148R-N cells 
Throughout this thesis 148R-N cells appeared to have a distinctive phenotype, when 
compared to other 148R clones. For example, 148R-N had the greatest level of 
resistance to AT13148 with an RF value of 20.31, ~2-fold greater than 148R-K and 148R-
S (Figure 4.10). Not only did 148R-N have the greatest resistance, but also responded to 
AT13148 in a distinctive manner, so much so that the GI50 of AT13148 could not be 
determined accurately by non-linear regression, as was discussed in section 4.3.1 (Figure 
4.10). In addition, unlike other 148R clones, 148R-N lacked any sensitivity to the FGFR 
inhibitor AZD4547, in fact, 148R-N displayed cross-resistance to AZD4547 (Figures 4.5 & 
4.11). Most importantly, in contrast to 148R-K and 148R-S, 148R-N was not re-sensitised 
to AT13148 by the ERK inhibitor GDC-0994, despite 148R-N also exhibiting increased ERK 
1/2 phosphorylation (Figure 4.17 & Figure 5.5). Together, this suggests that there is an 
alternative driver/mechanism of resistance to AT13148 in 148R-N.  
An alternative driver of AT13148 resistance is yet to elucidated for 148R-N, but there is 
evidence to suggest that it may be proximal to AKT. 148R-N exhibited increased 
phosphorylation of AKT and GSK3β, an AKT substrate, as well as ~27-fold cross-
resistance to the AKT inhibitor MK2206, versus parental A2780 cells, much greater than 
the level of MK2206 cross-resistance seen in 148R-K and 148R-S (Figure 4.12 & Figure 
4.13). Furthermore, the phosphorylation of GSK3β was partially refractory to MK2206 in 
148R-N (Figure 4.16). However, AKT phosphorylation was equally inhibited by MK2206, 
when compared to parental A2780 cells, which suggested that GSK3β phosphorylation 
was maintained independently of AKT (Figure 4.16). This might be via the increased 
activation or expression of SGK, since as discussed in section 4.3.2, AKT and SGK have 
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overlapping substrate specificities, including GSK3β (Bruhn et al., 2010, 2013; Figure 
7.4). Therefore, an increased activation/expression of SGK could enable AKT inhibition 
to be overcome, driving MK2206 cross-resistance, and possibly contributing to AT13148 
resistance in 148R-N cells (Figure 7.4). It should be noted that there are three isoforms 
of SGK, of which SGK3 is known to be inhibited by AT13148, thus inhibition of AKT is 
more likely be by-passed by increased activation/expression of SGK1 and SGK2. The 
mechanisms by which SGK activation may be increased are highlighted in Figure 4.19 & 
Figure 7.4 and include increased activation of upstream regulators such as PI3K.  
 
Figure 7.4: Summary of the potential mechanisms of AT13148 resistance in 148R-N. Diagram depicts 
how SGK could contribute to AT13148 resistance by enabling the by-pass of AKT inhibition. This could be 
caused by increased expression or activation of SGK (marked with a star), or alterations in the upstream 
regulators of SGK activation (also marked with a star). This may act alone, or combination with increased 
ERK 1/2 phosphorylation, to drive AT13148 resistance in 148R-N cells. The contribution of SGK to AT13148 
resistance could evaluated by using the SGK inhibitor GSK650394 in combination with AT13148.  
Aside from western blotting for additional AKT and SGK substrates, as discussed in 
section 4.3.2, the role of SGK in AT13148 resistance could be investigated by performing 
combination assays with AT13148 and an SGK inhibitor. If SGK inhibition was able to 
sensitise 148R-N cells to AT13148, it would suggest that SGK is contributing to AT13148 
resistance. Currently, there are no selective SGK inhibitors in clinical development, 
however a tool compound, GSK650394, is available, which inhibits SGK1 and SGK2, 
displaying a ~30-fold selectivity over AKT (Sherk et al., 2008). In addition, the role of ERK 
1/2 in AT13148 resistance in 148R-N cells should not be entirely discounted, as despite 
the lack of sensitisation to AT13148 caused by ERK inhibition, the combination of 
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AT13148 and GDC-0994 was shown to potentiate the decrease in S6RP phosphorylation 
in 148R-N, as seen in 148R-K and 148R-S (Figure 5.7). Therefore, if ERK 1/2 is also linked 
to the maintenance of S6RP phosphorylation in 148R-N cells, it is unclear why ERK 1/2 
inhibition did not sensitise 148R-N cells to AT13148. In 148R-N cells, it could be possible 
that both ERK 1/2 and SGK (directly or via upstream regulators) act as drivers of AT13148 
resistance, and that inhibition of both ERK 1/2 and SGK is required to sensitise 148R-N 
cells to AT13148 (Figure 7.4). This should be considered when interpreting the results of 
combination assays with AT13148 and an SGK inhibitor, such as GSK650394.  
7.3. Future studies  
Much of the future work discussed thus far in this chapter, has been focused on 
answering questions that have arisen during this PhD project, that as of yet, have not 
been satisfactorily answered, e.g. what is the mechanism of ROCK cross-resistance and 
its relevance to AT13148 resistance? Whilst these questions will be important to answer, 
they are mostly confined within the narrow focus of this project, i.e. investigating 
AT13148 resistance using A2780-148R and 148R clones, alone, as a model. Any future 
studies should also focus upon asking, and attempting to answer, new questions 
regarding AT13148 resistance and its future clinical use, thus further facilitating the 
clinical development of AT13148 
One such question that is immediately prompted by the work presented in this thesis is: 
are the findings of this thesis, regarding AT13148 resistance, relevant to other cell line 
models/tissue types, i.e. is AT13148 resistance always driven, in part, by increased 
activation of ERK 1/2? To answer this question, acquired resistance to AT13148 would 
have to be generated in other cell line models representing different tissue types. Since 
it has been suggested that AT13148 could be used as an adjuvant therapy in pancreatic 
cancer, it would prudent to generate and investigate AT13148 resistance in PDAC cell 
lines, such as PANC-1 and Bx-PC3 (Deer et al., 2010; Rath et al., 2018). Furthermore, 
AT13148 may have a clinical use in the treatment of RCC, since ROCK inhibition has been 
shown to be synthetically lethal with VHL loss in RCC (Thompson et al., 2017). Therefore, 
AT13148 resistance should also be generated and investigated in VHL-null RCC cell lines, 
such as RCC4 and 786-O (Thompson et al., 2017). Investigating resistance in these cell 
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lines would gain insight into the potential use, and resistance, of AT13148 in cancers in 
which the PAM pathway is not dysregulated.  
When investigating resistance in these cell lines, a candidate approach should initially 
be undertaken, based on the findings of this thesis. Initially, the basal expression of 
markers of the MAPK pathway should be assessed, such as ERK 1/2 phosphorylation. If 
ERK 1/2 phosphorylation is also increased in these resistant cell lines, ERK 1/2 should be 
validated as a driver of AT13148 resistance by using combination assays with AT13148 
and an ERK inhibitor, as shown in Figure 5.5 & Figure 5.8. If increased ERK 1/2 
phosphorylation is shown to be acting as a driver of AT13148 resistance, then the 
expression of DUSP6, as well as the response of ERK 1/2 phosphorylation to FGFR 
inhibition, should also be evaluated. 
However, if ERK 1/2 was not shown to be a driver of AT13148 resistance in these 
resistant cell lines, then unbiased approaches such as global genomic analysis could be 
used to identify candidate drivers of resistance. For example, whole exome sequencing 
could be used to compare resistant cell lines to their respective parental counterparts, 
from which they were derived, to identify resistance conferring mutations. In addition, 
RNA sequencing could be used to compare gene expression profiles, and identify altered 
gene expression, which might gain insight into AT13148 resistance. 
In the above examples of how resistance should be investigated, it has been assumed a 
similar approach, to the one presented in this thesis, will be undertaken, whereby 
AT13148 resistance is studied by using resistant cell lines generated by dose-escalation. 
However, alternative approaches should also be considered to model AT13148 
resistance in future studies, such as the use of functional genetic screens. In these 
screens, parental cell lines would be submitted to systematic loss-of-function (e.g. by 
RNA interference) or gain-of-function (e.g. by lentiviral open reading frame [ORF] 
libraries) of the entire genome, to identify genes associated with AT13148 resistance 
(Garraway and Jänne, 2012). Using these approaches offers several advantages as they 
are unbiased, high-throughput and may enable the identification of several mechanisms 
of resistance to a single therapy (Garraway and Jänne, 2012). For example, Wilson and 
colleagues (Wilson et al., 2015) used a lentiviral ORF library to identify several drivers of 
ALK inhibitor resistance in NSCLC, including several previously established resistance 
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drivers such as KRAS and COT, as well novel drivers, such as the P2Y subfamily of P2 
purinergic receptors. 
In addition, one the limitations of the work presented in this thesis, due to the potent 
inhibition of PKA by AT13148, is the lack of understanding of the status of PKA signalling 
in A2780, A2780-148R and 148R clones. As discussed in section 3.3, an attempt was 
made to determine the phosphorylation level of VASP, a PKA substrate, via western 
blotting, so as to have a biological readout of PKA activation in A2780 and A2780-148R 
cells, but VASP was undetectable. Furthermore, it was also considered that a PKA 
inhibitor could be used in cross-resistance profiling, however, there aren’t many 
marketed PKA inhibitors that are commercially available, and the PKA inhibitors that are 
most frequently used for research, H 89 and KT 5720, have been shown to lack selectivity 
for PKA, inhibiting several other kinases more potently (Davies et al., 2000; Lochner and 
Moolman, 2006; Murray, 2008).  
In future studies, the use of functional genetic screens may also be able to elucidate the 
role of PKA, if any, in AT13148 resistance. This approach was used by Johannessen and 
colleagues (Johannessen et al., 2013), where a functional genetic screen identified that 
PRKACA, a catalytic subunit of PKA, could convey resistance against MAPK pathway 
inhibitors in BRAF mutant melanoma. Alternatively, a candidate approach could be 
undertaken; cell-permeable cAMP derivatives, such as bucladesine and 8-Br-cAMP, or 
the adenylate cyclase stimulator forskolin, could be used to increase PKA activation in 
A2780 cells (and other AT13148 sensitive parental cell lines), to evaluate if this could 
recapitulate the resistance phenotype. 
Future studies should also focus on investigating the clinical relevance of the insight 
gained into AT13148 resistance, presented in this thesis. This would be undertaken by 
using patient data and tumour biopsies obtained from clinical trials conducted on 
AT13148. Currently, only one phase 1 clinical trial has been completed for AT13148, of 
which the results have not been fully published; only an abstract from the ASCO annual 
meeting is publicly available (Papadatos-Pastos et al., 2015). Therefore, patient data and 
samples might be limited and difficult to gain access to. However, the inclusion criteria 
from the phase 1 clinical trial, states that paraffin embedded tumour tissue from 
patients must be available (clinicaltrials.gov – identifier: NCT01585701). Therefore, one 
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could envisage a future study in which immunohistochemical staining is used to detect 
ERK 1/2 phosphorylation and DUSP6 expression, in tumour samples from patients that 
took part in the phase 1 clinical trial for AT13148. The data from this could be compared 
to the response evaluation criteria in solid tumours (RECIST) from patients, to see if 
phosphorylation of ERK 1/2 or DUSP6 expression correlated with a lack of response to 
AT13148. Alternatively, if more clinical trials are conducted, it might be possible obtain 
pre-treatment and post-relapse samples from AT13148 treated patients, and again, 
investigate the phosphorylation of ERK 1/2 and DUSP6 using immunohistochemistry. A 
similar approach was used by Hrustanovic and colleagues (Hrustanovic et al., 2015), 
where it was demonstrated that DUSP6 expression was lower in post-ALK inhibitor-
resistance tumour samples vs treatment naïve samples, validating their in vitro findings 
of loss of DUSP6 expression as a mechanism of acquired resistance to ALK inhibitors in 
NSCLC. 
7.4. Potential therapeutic strategies to treat AT13148 resistance 
As well as gaining insight into the drivers and mechanisms of AT13148 resistance, the 
work presented in this thesis has also identified several potential therapeutic strategies 
to overcome AT13148 resistance, should it emerge in the clinic. As has been discussed, 
the combination of AT13148 with ERK inhibitors was synergistic and was able to re-
sensitise 148R-K and 148R-S to AT13148 (Figure 5.5, Figure 5.6 & Figure 5.8). Since 
several ERK inhibitors are currently in clinical trials, including GDC-0994 and SCH772984, 
AT13148 resistance could potentially be treated by the combination of AT13148 and, for 
example, GDC-0994. The efficacy of this combination would be based upon increased 
ERK 1/2 phosphorylation driving AT13148 resistance, therefore, increased ERK 1/2 
phosphorylation could be used as a potential biomarker when selecting patients that 
would best benefit from this combination. However, it should also be considered that 
increased ERK 1/2 phosphorylation didn’t always correlated with the efficacy of this 
combination, as shown by the lack of response in 148R-N (Figure 4.17 & Figure 5.5). 
In addition, AT13148 resistant patients might also benefit from the combination of 
AT13148 and a MEK inhibitor, since the combination of AT13148 and PD0325901 (MEK 
inhibitor), was also shown to be synergistic and re-sensitised 148R-S cells to AT13148 
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(Figure 5.9). This might be more immediately applicable to AT13148 resistant patients, 
since several MEK inhibitors are clinically approved, such as trametinib and cobimetinib 
(Cheng and Tian, 2017). However, unacceptable toxicities might develop when using 
AT13148 in combination with a MEK inhibitor in patients, due the inhibition of AKT by 
AT13148, as the combination of MEK and AKT inhibitors has been shown to be 
prohibitively toxic in several clinical trials (Chung et al., 2017; Cao et al., 2019).  
It should also be considered that the combination of AT13148 with a MEK or ERK 
inhibitor, might have improved efficacy in treatment-naïve patients, when compared to 
AT13148 monotherapy. This is because the combination of AT13148 with a MEK or ERK 
inhibitor was also shown to sensitise parental A2780 cells to AT13148, in a synergistic 
manner (Figure 5.5, Figure 5.6, Figure 5.8 & Figure 5.9). The sensitivity to these 
combinations was likely due to the response of ERK phosphorylation to AT13148, which 
upon review of the literature published on AT13148, has only been described in this 
thesis. The ERK 1/2 response to AT13148 would therefore need be validated in 
additional cell lines/tissue types, before the combination of AT13148 with MAPK 
pathway inhibitors could be considered as a genuine therapeutic option in treatment 
naïve patients.  
Another potential therapeutic option for AT13148 resistant patients would be to treat 
them with an FGFR inhibitor, as A2780-148R and all 148R clones, with the exception of 
148R-N, were shown to be highly sensitive to the FGFR inhibitor AZD4547 (Figure 3.7, 
Figure 4.5 & Figure 4.11). Furthermore, there are several FGFR inhibitors currently in 
clinical development, including AZD4547 in which a phase 1/2 clinical trial was recently 
completed (Dai et al., 2019; clinicaltrials.gov – identifier: NCT02824133). Therefore, 
targeting FGFR in AT13148 resistant patients may be a realistic option in the future. 
However, a biomarker of FGFR inhibitor sensitivity was not identified in this thesis, which 
would therefore make it difficult to select AT13148 resistant patients that would most 
benefit from FGFR inhibitor treatment. Accordingly, the identification of a biomarker of 
FGFR sensitivity should be a focus of any future work conducted. In doing so, it will be 
important to assess the expression and phosphorylation of FGFR1-4, which might be 
best achieved by using a phospho-RTK array. The discovery of a biomarker of FGFR 
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sensitivity might also help further understand the role of FGFR signalling in AT13148 
resistance, as previously discussed in section 7.2.3. 
7.5. Concluding remarks 
The AGC family of serine/threonine kinases contains multiple members that can drive 
cancer progression and survival and are therefore attractive therapeutic targets. In 
targeting multiple AGC kinases, AT13148 represents a novel therapeutic strategy, that 
may provide improved efficacy over other, more selective inhibitors of AGC kinases. For 
these reasons, AT13148 is currently in clinical development having recently completed 
a phase 1 clinical trial. However, the acquisition of drug resistance to targeted agents is 
a frequent problem encountered in the clinic, and likely to occur with AT13148.  
In this thesis, acquired resistance to AT13148 was generated in the A2780 human 
ovarian carcinoma cell line and it was demonstrated that upregulated ERK 1/2 
phosphorylation could act as a driver of AT13148 resistance. It is likely that the ability of 
ERK 1/2 to act as a key signalling node, with over 160 recognised substrates, enables the 
compensation of the inhibition of several targets of AT13148, either via direct pathway 
reactivation, as was shown with the AT13148 target p70S6K, or pathway bypass. It was 
also shown that other drivers of AT13148 resistance are likely to exist, which appear 
proximal to the PAM pathway but independent of AKT, which warrants further 
investigation. The exact mechanism(s) by which ERK 1/2 phosphorylation had been 
increased was not identified, but was linked, in part, to a loss of DUSP6 expression. 
Nonetheless, the clinical relevance of increased ERK 1/2 phosphorylation to AT13148 
resistance should be the subject of future studies.  
In conclusion, the work presented in this thesis has gained invaluable insight into 
acquired AT13148 resistance. This has provided a firm foundation on which future 
studies will be conducted and identified therapeutic strategies to improve the efficacy 
of AT13148 treatment and overcome AT13148 resistance. Therefore, the work 
presented in this thesis, will aid the future clinical development of AT13148, and should 
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